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ABSTRACT 
Background and Aims: Knowledge on several key aspects of the neurogenic bladder (NGB) 
patient journey remain unknown. Accordingly, the aim of this research was to conduct an 
in-depth analysis of the prominent NGB clinical guidelines (CGs) and characterise the 
descriptive epidemiology and healthcare resource utilisation (HRU) of NGB in the UK. 
Methods: (1) The AGREE II tool was used to appraise the quality of the National Institute 
for Health and Care Excellence (NICE), European Association of Urology (EAU) and 
International Consultation on Incontinence (ICI) CGs for NGB and the concordance of their 
recommendations were assessed. (2) Adults (≥19 years) with a definitive or probable 
diagnosis of NGB between 1st January 2004 and 31st December 2016 were included into a 
study using the Clinical Practice Research Datalink (CPRD) GOLD and Hospital Episode 
Statistics (HES) databases in order to determine their real-world patient characteristics and 
drug utilisation patterns. Furthermore, the level of HRU over 12 months and associated 
costs were calculated via a bottom-up approach (ISAC protocol number 17_207RMn). 
Results: NICE scored 92%, the EAU scored 83% and the ICI scored 75% in the AGREE II 
appraisal. The CGs place differing emphasis on costs and expert opinion, which translated 
in notably different recommendations. Amongst many important findings, the CPRD study 
revealed evidence of diagnosis error in NGB, a high level of comorbidities 8.6 (SD,7.6), 
polypharmacy 5.2 (SD,4.8), an Anticholinergic Cognitive Burden (ACB) score of 6.6 (SD,5.9), 
and substantial HRU (overall costs £2,395 per annum). 
Conclusions: Improving the applicability and incorporation of comparative effectiveness 
research (CER) is crucial to ensure uptake of CGs and efficiency in clinical practice. It is also 
imperative that the underlying evidence base is strengthened, and cross-speciality 
interactions enhanced in order to guide more robust and consistent recommendations in 
future publications. Furthermore, policy makers should be aware of the substantial burden 
of complications, polypharmacy, comorbidity, anticholinergic burden and HRU associated 
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with NGB, and modifications to CGs should be introduced to aid in optimal management of 
these issues.  
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1) Chapter One - Background to the Study  
1.1  Neurogenic Bladder 
Neurological disorders are caused by damage or dysfunction to the central nervous system 
(CNS). They can cause major disability, premature death and cost a monumental amount 
to the healthcare system (Raggi and Leonardi, 2015; Thornton, 2018). Some of the common 
disorders and the typical phenotypic manifestations are described in Table 1.1. There is a 
great deal of heterogeneity within each disease, owing to differences in patient 
characteristics and varying disease stages and severity. 
 
Table 1.1 Common neurological conditions and the typical symptoms  
Neurological disorder Symptoms  
Parkinson’s disease Tremor, rigidity, bradykinesia, (slowness of movement), 
hypokinesia (decreased body movement), and akinesia (impaired 
unconscious movement). 
Multiple sclerosis  Weakness, sensory loss, ataxia (voluntary coordination of muscle 
movements) 
Stroke Hemiparesis (numbness on one side of the body), confusion, speech 
problems, trouble walking, severe headache, sight problems 
Spinal cord injury Pain, fatigue, weakness or total paralysis of arms and/or legs 
Spina bifida Weakness or total paralysis of the legs 
Adapted from (Dauer and Przedborski, 2003; Ben-Zacharia, 2011; Centre for Disease Control, 2018; 
Jensen et al., 2007) 
 
Normal micturition involves a process of passive, low pressure filling of the bladder during 
the urine storage phase, whilst voiding necessitates bladder contraction. The process is 
fundamentally dependent upon the hierarchical neural circuitry, involving interaction 
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between the sympathetic, parasympathetic and somatic nervous systems. The neural 
signalling pathway mediating this process can become dysfunctional due to neurological 
diseases, such as those listed in Table 1.1; this is termed neurogenic bladder (NGB) (or 
neurogenic lower urinary tract dysfunction (NLUTD)) (Dorsher and McIntosh, 2012). NGB 
also occurs in numerous other neurological conditions including dementia, cerebral palsy 
and multiple system atrophy (MSA), amongst others (Bloc et al., 2017). The concept of NGB 
is relatively new, being known to medical professionals for around thirty years and 
consequently, knowledge in this field is constantly evolving (Persu, 2014). 
Although NGB patients share the same diagnosis, they are notably unique in their urological 
symptoms and risk profiles because of differences in their underlying condition, location of 
neurological lesion, and stage and severity of disease (Apostolidis et al., 2017). Symptoms 
of NGB result from a complex interplay of pathophysiological features. The main 
manifestations include neurogenic detrusor overactivity (NDO), where individuals 
experience increased frequency of micturition, urinary urgency and urinary incontinence. 
This is usually the result of spastic, unexpected bladder contractions occurring through a 
lack of inhibition of the motor pathway or augmentation of sensory input and/or motor 
output (Cocos and Przydacz, 2018). Alternatively, the bladder may become flaccid and 
distended, ceasing to contract fully. In this case, patients experience problems in voiding, 
with symptoms including hesitancy, a slow urinary stream, straining and urinary retention. 
In some instances, both retention and voiding symptoms can arise in combination 
(Ginsberg, 2013). 
1.1.1 Impact of Neurogenic Bladder to Patients and the Healthcare System 
The multi-faceted and disabling nature of NGB has far-reaching effects, impacting many 
aspects of patient life. Serious systemic illnesses such as hydronephrosis (blockage of the 
renal collection system causing distention of the renal calyces), renal failure and 
septicaemia are amongst the multiple detrimental sequela associated with NGB (Patel et 
al., 2015; NHS, 2011; Gormley, 2010). The risk of renal dysfunction has lessened since the 
1940’s and 50’s, however a recent study found that the incidence of chronic kidney disease 
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(CKD) was still three times higher in NGB patients in comparison to their healthy 
counterparts (Sung, 2016). This reveals that despite recent advances in medical care, 
serious complications remain an ominous threat to patients’ health.   
Bladder symptoms can be embarrassing and isolating, which has a substantial impact on 
health-related quality of life (HRQoL). Patients with multiple sclerosis (MS), spinal cord 
injuries (SCI), and Parkinson’s disease (PD) have reported negative effects in physical 
function, emotional well-being and social relationships (Tapia et al., 2013). Furthermore, 
the symptoms and associated complications poses an economic burden across all realms 
of the healthcare sector; at an individual level and in primary, specialist, hospital and social 
care (Davis et al., 2016; Flack and Powell, 2015). 
1.2 Clinical Guidelines in Neurogenic Bladder 
The National Academy of Medicine (NAM) (formerly known as the Institute of Medicine 
(IOM)) was founded in 1970, under the charter of the National Academy of Sciences. The 
organisation comprises of 80 prominent members in the field of medicine and related 
disciplines (IOM, 2011). The NAM defined clinical guidelines (CGs) in 2011 as: 
Statements that include recommendations intended to optimise patient care that are 
informed by a systematic review of evidence and an assessment of the benefits and harms 
of alternative care options (Sox, 2014: 200).  
Evidence-based medicine (EBM) involves the conscientious and reasonable application of 
the best modern evidence in clinical decisions. CGs are an important vehicle to introducing 
and establishing up-to-date EBM in clinical practice as well as reducing unwarranted 
variation in care (Masic et al., 2008). Accordingly, CGs are used by clinicians to keep abreast 
of new scientific advances and devise optimal management strategies for patients. They 
are also useful in empowering patients to upkeep their own health by allowing them to 
enhance their understanding of available treatments and the associated harms (Fearns et 
al., 2016).   
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Most CGs for NGB are developed by special interest groups for neurological conditions, for 
example those developed in the UK by Abrams et al (2008) for patients with SCI, and those 
by the Consortium for Spinal Cord Medicine (CFSCM) in the USA (CFSCM, 2006). 
Recommendations have also featured in scientific journal publications, such as the UK 
recommendations for NGB secondary to MS (Fowler, 2011). The most prominent and most 
utilised NGB CGs are those by the National Institute of Clinical Excellence (NICE) (NICE, 
2012), the European Association of Urology (EAU) (Bloc et al., 2017), and the International 
Consultation on Incontinence (ICI) (Apostolidis et al., 2017) (Table 1.2). These CGs cover all 
types of underlying neurological conditions; therefore, can be applied in a wide range of 
clinical circumstances. 
 
Table 1.2 Clinical guidelines for neurogenic bladder 
Guideline Title Institution Year Region 
Neurologic Urinary and 
Faecal Incontinence 
 
International 
Consultation on 
Incontinence (ICI) 
2017 International scope 
Clinical Guidelines on 
Neuro-Urology 
 
 
European Association 
of Urology (EAU) 
2017 European scope 
 Urinary Incontinence in 
Neurological Disease: 
Management of Lower 
Urinary Tract 
Dysfunction in 
Neurological Disease 
National Institute for 
Health and Care 
Excellence (NICE) 
2012 National scope (United 
Kingdom) 
Developed from: NICE, 2012; Bloc, 2017; Apostolidis, 2017 
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In order to derive the most benefit for stakeholders and reduce the chances of harm to 
patients, it is important to appraise CGs to ensure they meet the key characteristics of what 
constitutes ‘high quality’. In particular, assessing the comprehensiveness of the underlying 
evidence base, the process by which recommendations are created, and the feasibility of 
applying them to clinical practice is essential (Brouwers et al., 2010).  
1.3 The Evidence Gap in Neurogenic Bladder  
Randomised controlled trials (RCTs) are considered the gold standard for testing the 
efficacy of interventions because special effort is made to reduce multiple forms of 
confounding and bias. This means they are highly internally valid and allow for the sole 
investigation of the cause-effect relationship (Akobeng, 2005; Spieth et al., 2016). A recent 
systematic review (SR) showed a very low number of RCTs conducted from 1976 (earliest 
recorded NGB RCT) to 2014, furthermore, the studies were too heterogenous to derive 
solid conclusions on optimal management practices (Persu, 2014) (Section 4.7.1).  
Despite the merits, RCTs also beset with a number of problems, one of the principal issues 
being their low external validity (generalisability outside of the study setting), arising as a 
result of the constricted patient inclusion criteria and artificial study settings (Jones et al., 
2017). As CGs are designed to be applied in real-world practice, it has been argued that the 
concern for external validity should be equally as great as that for internal validity. 
Therefore, real world evidence (RWE) (observational data), which represents the reality of 
healthcare delivery should be given elevated importance when formulating 
recommendations (Rosner, 2012). Accordingly, in order to strengthen the 
recommendations that appear in the NGB CGs, increased research effort should be focused 
on generating knowledge beyond the traditional sphere of RCTs. This is especially apt in 
this disease area, where there are obstacles to conducting RCTs because of the vulnerable 
patient populations, for example, children, the elderly and patients with cognitive deficits 
and comorbidities (Apostolidis et al., 2017; Denys et al., 2006).  
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Descriptive epidemiological studies, a particular type of RWE, are an important gateway 
into more hypothesis driven real-world research in a disease area where little evidence 
exists. They also provide initial insights into how the management of the disease can be 
improved. Descriptive epidemiology includes prevalence estimates and frequency counts, 
which demonstrate the scale of the disease and can guide efforts towards supply 
management, and the targeting of education regarding diagnosis and treatment of 
urological complications (Gomelsky et al., 2018). Drug treatment patterns provide an 
insight into the care and attention physicians give to a particular group, acting as an 
indicator of physician attitudes towards the disease. They are also important in 
understanding how well recommendations are implemented in real world practice and 
thus, how CGs could potentially be improved. Furthermore, highlighting the current burden 
of disease (including rates of healthcare resource utilisation (HRU), complications and 
associated costs) aids in quantifying the magnitude of burden in NGB. This information can 
enlighten policy-makers on the resource intensive aspects of the disease, helping them to 
consider how healthcare budgets could be allocated efficiently and equitably to avoid 
unnecessary costs and ensure optimal outcomes for patients. Unfortunately, the only truly 
large-scale epidemiological study focusing on the NGB population was conducted in the 
USA, using data between 2002-2007 (Manack et al., 2011) (Section 4.7.1). 
The comprehensiveness of the underlying evidence base is instrumental to the formation 
of high-quality recommendations; however, this chapter has established that there is a 
paucity of research conducted in NGB, both from a clinical and epidemiological research 
point of view. Consequently, the question arises as to whether this translates in 
implications for the quality of the current CGs. Many other factors also dictate whether CGs 
can be reliably applied in clinical practice, including the rigour of development, whether 
relevant stakeholders were involved in their creation and the clarity with which 
recommendations and supporting evidence is presented. A quality appraisal of NGB CGs 
has never been conducted, thus their potential value and effectiveness in current clinical 
practice remain unknown. Two previous studies have assessed the quality of similar CGs in 
the area of urology, however they exclude NGB, which has a distinct evidence base. There 
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may also be possible differences in development, and a calculation of interclass correlation, 
which is important to assess the level of agreement between appraisers, is not included. 
With all of this in mind, this thesis will assess the quality of current NGB CGs to elucidate 
how well-equipped clinicians are to manage patients. A descriptive epidemiological study 
will also be carried out as the first step to characterising the UK NGB population. Through 
this research potential areas of improvements in the CGs and treatment pathway can be 
identified, which can incentivise further research, enhance health outcomes and introduce 
improved economic efficiencies in this critical patient group. 
1.4 Aims of Research 
There are two main aims to the proposed research, where the ultimate goal is to improve 
the awareness and understanding of this currently under-researched population and 
advance patient management through making recommendations for alterations to CGs and 
treatment practices.  
Primary aim: Enhance the understanding of the current treatment landscape in NGB 
through the following objectives: 
1. To critically appraise NGB CGs developed by NICE, EAU and ICI, using the 
Appraisal of CGs for Research and Evaluation (AGREE) II instrument (a specific 
tool designed to assess the quality of CGs). 
2. To compare the treatment recommendations in NGB CGs in order to uncover 
the similarities and differences between the three institutions. 
3. To undertake a SR to describe and characterise the treatment patterns and 
management strategies of NGB in real-world settings. 
4. Conduct an epidemiological study using the UK Clinical Practice Research 
Datalink (CPRD) to describe the NGB patient demographics, comorbidities, 
complications, current patterns of drug use over 12 months. 
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Secondary aim: Enhance the understanding of current burden of disease of the NGB 
population through the following objectives: 
1. To undertake a literature review to describe the HRU of NGB related to the 
symptomology, secondary complications of disease and management strategies.  
2. Conduct an epidemiological study using the UK CPRD database to describe NGB 
related HRU and costs over 12 months.  
1.5 Thesis Overview 
Chapter 1 discussed the current gaps in knowledge in the NGB disease area. This included 
highlighting the impetus for quality appraisal of the current prominent CGs and a discussion 
of the dearth of clinical and epidemiological research. Accordingly, the aims of the research 
related to these topics were outlined.  
 
Chapter 2 provides a detailed overview of NGB. The chapter begins by presenting 
prevalence estimates from around the world. It then proceeds to review the clinical 
classifications of NGB followed by complications related to the condition. Next, the 
particular importance of anticholinergic burden in patients with neurological conditions is 
discussed at length. The concepts of drug utilisation research (DUR) and HRU are 
introduced, as well as presenting a literature review of HRU in NGB.  
 
Chapter 3 first includes an overview of CGs and their importance in clinical practice, and 
then presents a completely novel critical quality appraisal of the three most prominent CGs 
available for NGB (NICE, EAU and ICI) using the AGREE II instrument. 
 
Chapter 4 compares and contrasts the treatment recommendations in the NICE, EAU and 
ICI NGB CGs and provides in-depth discussion around the evidence gap that currently exists 
in this disease area. 
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Chapter 5 presents a SR describing the real-world treatment patterns of NGB. The aim of 
this SR is to determine changes in practices over time, as well as compare the results to the 
recommendations in the current NICE, EAU and ICI CGs.  
 
Chapter 6 presents the methodology for a descriptive epidemiological study using the CPRD 
database. This study aims to elucidate the patient characteristics, drug utilisation patterns 
and HRU in a UK patient population.  
 
Chapter 7 exclusively presents the results from the CPRD study.  
 
Chapter 8 discusses the findings from the CPRD study, particularly in the context of similar 
research and considers the strengths and limitations of the research. 
 
Chapter 9 contains the summary, recommendations for future research and conclusions 
taking into account all of the research presented in this thesis.  
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2) Chapter Two - Background to the Disease Area 
2.1 Introduction  
The main objective of this thesis is to develop a comprehensive picture of the neurogenic 
bladder (NGB) population. In line with this, the following chapter gives a concise overview 
of several relevant aspects of NGB. Firstly, prevalence estimates from the literature are 
reported. Secondly, the clinical features and classifications are discussed; in particular, the 
most renowned classification system by the International Continence Society (ICS) is 
described in detail. Third, the major clinical complications related to NGB are described. 
Fourth, a brief overview of the impact NGB has on health-related quality of life (HRQoL) is 
presented. Fifth, the use of bladder muscarinic drugs as first-line treatment of NGB are 
discussed along with an assessment of risks and benefits of their use. Sixth, the concept of 
healthcare resource utilisation (HRU) is introduced and a literature review of the HRU and 
economic burden of NGB is presented. Lastly, the concept of drug utilisation research (DUR), 
a prominent theme in this thesis, is introduced. 
2.2 Prevalence of Neurogenic Bladder  
2.2.1 Definition and Importance  
Prevalence is defined as:  
The proportion of persons in a population who have a particular disease or attribute at a 
specified point in time or over a specified period of time (Centre for Disease Control [CDC], 
2012: online). 
This is distinct from the incidence rate, which only provides information on the number of 
new diseases or attributable cases (CDC, 2012). Chronic conditions such as NGB are best 
described using prevalence figures, as incidence underestimates the magnitude of the 
problem (Yamamoto, 2003). 
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Although it is true that estimates of the scale of disease can never directly equate to need, 
they are crudely but inexorably linked to issues connected with funding and effective 
healthcare planning (Ward, 2013). There is normally a relationship between the size of a 
population and the demand for healthcare, for this reason prevalence estimates are useful 
for defining actual or potential markets for the delivery of pharmaceuticals and healthcare 
services (Morris et al., 2007). Demographic descriptions of a population also can aid in 
market segmentation. For example, in the case of NGB stratifying the population by age, 
sex, and underlying neurological condition would be useful for targeting delivery of 
healthcare services accordingly, given the differing needs between these populations. 
2.2.2 Prevalence of Neurogenic Bladder 
The global aging population means that there is an increasing number of people living well 
into their 70s and beyond. In the UK, the population aged 85 and over has increased by 31% 
since mid-2005 (Henderson and Thilagarjah, 2016).  
Despite the advancements in modern medicine, as population age increases the number of 
chronic conditions also continues to surge. According to the World Health Organisation 
(WHO), chronic diseases have surpassed infectious and parasitic diseases in becoming the 
leading cause of mortality and morbidity worldwide (a phenomenon known as the 
epidemiological transition) (McKeown, 2009). Over the years, we will continue to witness 
an increase in neurological conditions such as Parkinson’s disease (PD), multiple sclerosis 
(MS), and stroke, and the rate of NGB will follow suit. The scale of elderly patients with 
multiple chronic conditions requiring long-term care will challenge healthcare systems 
across the globe, putting invariable pressure on budgets and resources. Accordingly, 
economic analyses of interventions and careful allocation of resources will become 
increasingly crucial as time goes on (MacLeod et al., 2017).  
Neurological conditions currently account for between 4.5 to 11% of global disease burden. 
A lack of large-scale epidemiological research means that the overall prevalence of NGB 
within that population remains poorly understood (Ruffion et al., 2013). The small number 
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of estimates that do exist are highly variable, which is likely a reflection of a mix of limiting 
factors, such as the difference in populations sampled (different geographical areas) and 
the heterogeneity of patient samples (including variations in age, sex, disease severity etc.). 
The only large-scale real-world study conducted to address the epidemiology of NGB was 
in 2011 (study period between 2002-07), using a US claims database, containing over 30 
million patient records. The researchers observed 46,271 patients with NGB and of those 
patients 9,315 patients had MS and 4,168 had spinal cord injuries (SCI) (Manack et al., 2011). 
The absence of data on the UK NGB population highlights the need for epidemiological 
research using data from a UK electronic healthcare record (EHR).  
Rather than overall estimates, several epidemiological studies have reported the 
prevalence of NGB within specific neurological conditions. The studies have been 
conducted over differing periods and geographical regions. The prevalence estimates of 
the main neurological conditions that cause NGB are presented in the following sections 
and summarised in Table 2.1.  
2.2.2.1 Multiple Sclerosis  
The median prevalence of MS is highest in North America (140/100,000 population) and 
Europe (108/100,000), and lowest in East Asia (2.2/100,000), and Sub-Saharan Africa 
(2.1/100,000) (Leray et al., 2016). Estimates are also low in Ecuador, Colombia and Panama 
where 0.75–6.5/100,000 individuals live with MS (Przydacz et al., 2017). Consequently, the 
rate of NGB is also lower in developing nations in comparison to the Western hemisphere.   
A systematic review (SR) conducted in 2007, reported a large variance in the occurrence of 
NGB amongst MS patients (32% to 96.8%). The varying times of examination from onset of 
MS and diagnosis was cited as a reason for the variance (de Seze et al., 2007). A separate 
SR found that prevalence of urinary incontinence (UI) amongst MS patients was 51% 
(Przydacz et al., 2017).  
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2.2.2.2 Parkinson’s Disease 
The prevalence of PD within the UK is 27.4 per 10,000 people, which when applied to the 
UK population as a whole is equivalent to 126,893 individuals (Parkinson's UK, 2009). Like 
MS, the prevalence of PD in developing countries tends to be a lot lower, subsequently, the 
occurrence of NGB will also be lower in these countries. For example, the rate is 16–
27/100,000 in India and 7/100,000 in Nigeria (Przydacz et al., 2017).  
Lower urinary tract dysfunction (LUTD) is present in 27-63.9% of PD individuals worldwide 
(Ruffion et al., 2013). The review also estimates that Multiple System Atrophy (MSA), which 
is often confused for PD in the early stages, has a virtually 100% prevalence rate of UI (Yeo 
et al., 2012). 
2.2.2.3 Stroke 
Stroke is one of the leading causes of adult physical disability worldwide (Murray et al., 
2012). The stroke association estimated that 100,000 strokes occur every year in the UK 
(Stroke Association, 2016) Estimates of stroke in the developing world are scarce; however, 
occurrence is generally thought to be lower than in developed nations (Przydacz et al., 
2017). 
An SR estimated 22-47% of patients had urinary retention within 72 hours of acute stroke 
(Sayed, 2008). It is important to note that the studies included into the SR were 
heterogeneous, and prevalence of bladder dysfunction was dependent on the study group, 
the interval after stroke, and the criteria used to define retention (Sayed, 2008). Another 
SR found that 23.6% individuals that had experienced stroke subsequently developed UI 
(Ruffion et al., 2013).  
2.2.2.4 Dementia  
An SR found a 5%–7% prevalence of dementia in individuals aged 60 or over, in most 
regions of the world. The major anomalies were Latin America (8.5%), and sub-Saharan 
Africa (2%–4%) (Prince et al., 2013). 
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A study including 464 patients with probable Alzheimer’s disease (AD) found a prevalence 
of 24.8% of incontinence in AD and more than 25% in other dementias, namely; Lewy body, 
Normal Pressure Hydrocephalus (NPH), Binswanger, Nasu-Hakola and Pick Disease (Na et 
al., 2015).  
2.2.2.5 Spina Bifida and Spinal Cord Injuries  
The prevalence of those with spina bifida and other congenital disease in the UK is 8-9 cases 
per 10,000 in patients aged between 10-69, with the highest prevalence in those aged 
between 25-29 years (Lawrenson et al., 2000). A cross-sectional study in the Netherlands 
found that 60.9% young adults with spina bifida suffered from UI (Verhoef et al., 2005).  
The prevalence of traumatic SCI in some Asian countries is estimated to be between 236 
and 464/1,000,000 (Przydacz et al., 2017). In the UK, 12–16 per million of the population 
live with SCI (NHS, 2013).  
An SR identified 52.3% of individuals with SCI in the UK suffered from UI (Ruffion et al., 
2013). In a prospective cross-sectional study conducted in India, researchers found the 
prevalence of UI in patients with non-traumatic SCI to be 31.25% (Gupta et al., 2009). 
 
Table 2.1 Prevalence of common neurological disorders and bladder symptoms 
Neurological disorder Prevalence of neurological disorder Prevalence of bladder 
symptoms 
Multiple sclerosis 
 
 
 
 
North America: 140/100,000 population, 
Europe: 108/100,000, East Asia: 
2.2/100,000 population, Sub-Saharan 
Africa: 2.1/100,000, Ecuador, Colombia 
and Panama: 0.75–6.5/100,000 
NGB: 32% to 96.8%, UI: 
52% 
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Parkinson’s disease 
 
UK: 27.4 per 10,000, India: 16–
27/100,000, Nigeria: 7/100,000 
NGB: 27-63.9%, UI: 57-83% 
Multiple System Atrophy - 100% 
Stroke UK: 100,000 strokes per year Urinary retention within 72 
hours of acute stroke: 22-
47%, within this group, 
detrusor areflexia: 75%, 
hyper-flexia: 25%. 
UI: 23.6%  
Dementia 
 
Most countries: 5%–7%, Latin America: 
8.5%, Sub-Saharan Africa: 2%–4% 
UI: 24.8% 
Spina bifida UK: 8-9 cases per 10,000 UI: 60.9% 
Spinal cord injuries UK: 12 – 16 per million 
Some Asian countries: between 236 and 
464/1,000,000 
UI: 52.3% 
India (non-traumatic SCI) 
UI: 31.25% 
UI, urinary incontinence; NGB, neurogenic bladder; SCI, spinal cord injuries 
Adapted from: Leray et al., 2016; Przydacz et al., 2017; de Seze et al., 2007; UK, 2009; Ruffion et al., 
2013; Murray et al., 2012; Stroke Association, 2016; Na et al., 2015; Lawrenson et al., 2000; Gupta et 
al., 2009. 
 
2.3 Clinical Features and Classifications  
A good classification system ensures that patients are diagnosed accurately and therefore 
are recipients of appropriate care. Additionally, classification systems are a valuable tool in 
providing a structured framework for introducing new scientific findings and observations 
into the existing sphere of knowledge (Staskin and Wein, 2017). 
Multiple classification systems exist to describe the distinct manifestations of NGB; some 
are based on urodynamic findings (functional tests that are used to determine the nature 
of LUTD) whilst others are based on neurological criteria. The most utilised and reputable 
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systems include the Krane and Siroky's, Lapide’s, and Maddersbacher’s. All systems come 
with their inherent advantages and disadvantages and at present, no system is advocated 
over another. These systems will continue to evolve and improve as greater evidence is 
generated on the complex interactions of the phases of micturition, bladder physiology and 
neurological processes (Staskin and Wein, 2017). 
The current classification system created by the ICS and used in the International 
Consultation on Incontinence (ICI) clinical guidelines (CGs) focus on the nature of lesion and 
its location (Apostolidis et al., 2017) (Figure 2.1). This classification system provides an 
intuitive way to categorise the various types of NGB. From the descriptions below, it clear 
to see that NGB is a diverse and complicated condition, where symptomology is heavily 
influenced by the lesion of damage. 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Regions of neurological lesion (Adapted from ThinkFirst, 2015) 
 
Supra-Pontine region 
Pontine Region 
Supra-Sacral Region 
Sacral and Subra-
Sacral Region 
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2.3.1 Pontine Region  
Lesions that occur in the pontine region, such as MSA are a rare occurrence. Urological 
dysfunction typically presents as neurogenic detrusor overactivity (NDO), where symptoms 
of frequency, nocturia, urgency and urge incontinence are common, and/or detrusor 
sphincter dyssynergia (DSD), where the urethral sphincter contracts at the same time as 
the bladder. The most frequent symptom is voiding (79%), followed by nocturia (74%), 
urgency (63%), urgency incontinence (63%) and urinary retention (8%) (Ciolli et al., 2014).  
2.3.2 Supra-Pontine Region  
Lesions that occur in the supra-pontine (above the pontine micturition center (PMC) 
located in the brainstem), may be as a result of progressive diseases such as dementia, MS 
and PD or stable conditions such as stroke (Game, 2010; Hashim and Dasgupta, 2017). 
Typically, lesions in this area cause NDO however detrusor underactivity in conjunction 
with NDO has also been reported (Apostolidis et al., 2017). Additionally, older men may 
experience bladder outlet obstruction (BOO) in conjunction with NDO, which 
simultaneously reduces or stops the flow of urine into the urethra (Oelke et al., 2008).  
Urological symptoms are dynamic and tend to worsen with increasing decline in cognition 
and mobility, reflecting the advancing severity of the underlying neurological condition 
(Araki and Kuno, 2000; Game, 2010). For example, in the four stages of dementia, each of 
which represent a distinct decline in cognition, incontinence normally begins to develop in 
the third stage (moderate dementia) (Han, 2008). Relapsing-remitting MS (RRMS) accounts 
for around 85% to 90% of all cases of MS (Canadian Agency for Drugs and Technologies in 
Health, 2013). The pattern of LUTD is different within each period of disease; during periods 
of remission, urinary symptoms may be less severe or completely absent, however during 
a period of relapse, urinary symptoms worsen (Phé et al., 2016). 
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2.3.3 Supra-Sacral Spinal Region  
Lesions which occur in the supra-sacral region, located between the pons and sacral cord 
and panel are either SCI or spina bidifa. Lesions may be either complete (total lack of 
sensory and motor function) or incomplete in nature (Apostolidis et al., 2017). Despite 
abnormal urodynamic tests, because of the lesser severity, patients with incomplete 
lesions tend to experience fewer urinary tract symptoms than individuals with complete 
lesions. 
Complete lesions describe a state when the spinal reflex becomes unmodulated; causing 
NDO (Apostolidis et al., 2017). In conjunction to this, instead of the normal synchronisation 
of sphincter relaxation with bladder contraction, DSD occurs (Lawrenson et al., 2000). 
Bladder contractions are poorly sustained and voluntary control of the micturition reflex is 
lost (Apostolidis et al., 2017). 
Anterior cord syndrome is another condition occurring in this region. It causes reduced or 
absent motor activity. In this type of injury, NDO is most likely to occur, and depending on 
the severity and location of cord injury, DSD may also be present (Apostolidis et al., 2017).  
2.3.4 Sacral and Subra-Sacral Region  
Sacral SCI is caused by lesions at the sacral region. Damage to the parasympathetic system 
is common and results in weak or absent detrusor contraction, known as detrusor areflexia 
(Yoshimura and Chancellor, 2004). Incontinence or stress urinary incontinence (SUI) may 
also result (Madersbacher, 2005; Apostolidis et al., 2017).  
Similar symptoms can be seen when lesions occur in the subra-sacral regions, which include 
cauda equina syndrome or damage to the peripheral nerves as a result of infections such 
as cytomegalovirus and herpes, fractures or surgery. Peripheral neuropathies can occur in 
diabetes, alcohol abuse and Guillain-Barré syndrome and impairment to both the 
parasympathetic and somatic motor function are possible (Apostolidis et al., 2017). 
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2.4 Health Related Quality of Life in Neurogenic Bladder  
HRQoL measures an individual’s perception of their own health in relation to their social, 
psychological and physical well-being (Flokstra-de Blok et al., 2009). Understanding the 
additional dimension of burden that NGB has on several health-related aspects of an 
individual’s life, can aid in devising better management strategies. This is especially 
important in a climate where patient-centred care is accumulating greater weight in 
healthcare decision-making (King and Hoppe, 2013).  
In a study using the Kings Health questionnaire (KHQ) which measures attributes such as 
general health, physical limitations and personal relationships, HRQoL was found to be 
more negatively impacted in individuals with NGB in comparison to the idiopathic OAB 
population. Participants were also asked to complete the Incontinence Quality of Life 
questionnaire (I-QOL), which again demonstrated lower scores for NGB patients. This study 
shows that those with NGB view their LUTD differently to those with idiopathic OAB, hence 
management of these patients should also be distinct (Burks, 2011). A separate study 
showed that incontinence also has a detrimental impact on HRQoL. Incontinent NGB 
patients scored significantly lower on several OAB symptom scales and measures of activity 
impairment in comparison to their continent counterparts (Tang et al., 2014).  
Studies have also demonstrated changes in Quality of Life (QoL) as a result of treatment 
strategies employed. One study showed that bladder augmentation resulted in significant 
improvements in QoL due to the perception of better health and resolution of UI (Lima et 
al., 2015). A separate study demonstrated improvements in QoL scores after intradetrusor 
injections of Onabotulinum-A (Kalsi et al., 2006). 
2.5 The Clinical Burden of Complications of Neurogenic Bladder 
A number of adverse sequelae can occur as a consequence of NGB, either as a result of the 
natural progression of the disease or due to side effects of treatments. The severity and 
nature of complications are often dependent upon the prominence of the underlying 
neurological condition. Complications increase morbidity, lower QoL and represent a 
  
 
 
 
41 
significant economic burden to both the patient and the healthcare provider, thus utmost 
effort should be made to reduce their occurrence and manage them appropriately 
(Gormley, 2010). This section will cover the clinical burden of complications, and the 
economic burden will be addressed separately (Section 2.7.1.4.1).  
Vesicoureteral reflux (VUR) is one of the most frequent complications of NGB, observed in 
20% of cases (Gormley, 2010). The condition is caused by high intravesical pressures as a 
result of the retrograde flow of urine from the bladder to the kidneys, leading to a number 
of further serious complications such as pyelonephritis, urinary tract calculi and 
hydronephrosis (Sillen, 2008; Wu and Franco, 2017). VUR in NGB is less likely to 
spontaneously resolve as it often does in idiopathic cases, therefore, to avoid long-term 
damage, it should be managed by restoring the intravesical pressure early on through 
management methods such as intermittent catheter (IC), anticholinergics or bladder 
augmentation (Santiago-Lastra and Stoffel, 2015; Wu and Franco, 2017). 
Hydronephrosis is another serious complication of NGB, characterised by dilation of the 
renal collecting system that occurs because of a blockage (Groth, 2012). A study of 178 
patients with myelomeningocele found a correlation between hydronephrosis and renal 
deterioration as well as the increased need for surgical intervention (Alpajaro, 2015). 
Chronic urinary tract infections (UTIs) are another significant, and well-documented 
problem in NGB patients. High bladder pressures, immunocompromised status, and 
inadequate management with catheters put patients at particular risk. In the worst-case 
scenario, chronic infections can lead to renal insufficiency (Hsiao et al., 2015). MS patients 
in particular are at increased risk due to the immunosuppressive treatment regime used to 
manage their condition (Palma-Zamora and Atiemo, 2017).  
Chronic UTI can disrupt the detrusor’s normal anti-reflex mechanisms and lead to acute 
pyelonephritis (APN), a severe type of UTI emanating in the kidney (Paz, 2014). 
Complications can often exacerbate one another, and VUR in APN causes the reflux of 
infected urine which increases the risk for permanent renal scarring (Jakobsson et al., 1994; 
Ghoniem, 2006). Raz et al (2003) showed that 46% of women that were hospitalised for 
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APN had evidence of renal scarring. Urolithiasis (stone formation) is also potentiated by 
chronic UTI. Once a kidney stone has developed, the risk of developing a second stone 
within 5-7 years is around 50% (Parmar, 2004). Symptoms include fatigue, dysuria (painful 
micturition) and renal pain (Institute for the Study of Urologic Diseases, N.D.).  
All of the complications described above are risk factors for renal failure (end stage CKD). 
Renal failure was the leading cause of mortality for SCI patients in the 1950’s, when 
treatment and surveillance techniques strategies were less advanced (Donovan, 2007). 
Despite vast improvements in patient management, 3-12% of NGB patients still die from 
renal-related dysfunction. Those at highest risk are individuals with SCI, transverse myelitis, 
spina bifida, and men with MS (Nseyo, 2017).   
Although a relatively rare outcome, the risk of developing bladder cancer is up to 28 times 
higher in individuals with NGB compared to the general population (Kalisvaart et al., 2010). 
In addition to this, malignancy tends to present on average 25 years earlier, and at a more 
advanced pathological stage (Welk et al., 2013). Risk factors include chronic bladder 
infection, long-term use of indwelling catheterisation (IndUC) and urolithiasis (Austin et al., 
2007; Yu et al., 2018).  
2.6 Anticholinergic Burden in Neurogenic Bladder 
Anticholinergics are a class of drugs prescribed to manage numerous conditions including 
PD, depression, certain allergies and chronic obstructive pulmonary disorder (COPD) 
(Ruxton et al., 2015). For a number of years, anticholinergic drugs have also represented 
the mainstay of pharmacological treatment for patients with NDO (henceforth referred to 
as ‘bladder muscarinics’). A systematic review of trials including various bladder 
muscarinics demonstrated favourable patient-reported cure/improvement rates and 
significant reduction of maximum detrusor pressure when compared to placebo 
(Madhuvrata et al, 2012). Various bladder muscarinics are available on the market, with 
the most prominent including oxybutynin, solifenacin, and tolterodine (Abrams and 
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Andersson, 2007). Evidence from clinical trials has not effectively differentiated the these 
drugs in terms of efficacy (Madhuvrata et al, 2012).  
Anticholinergic burden is defined as the cumulative effect of using one or more drugs with 
the potential to cause anticholinergic adverse effects (Chaplin, 2013). The most serious and 
irreversible adverse event culminating from a high anticholinergic burden is dementia 
(Rudolph et al., 2008). Patients with neurological conditions are particularly vulnerable to 
these adverse events given the neuropathological changes that occur in the brain and high 
levels of cognitive and functional dysfunction accompanying their condition (Dauphinot et 
al., 2017).  
This section serves as a useful introduction to anticholinergic burden in neurological 
disorders, which is one of the central themes in this thesis. It discusses the implications of 
and the role of bladder muscarinics in the NGB treatment pathway. This dialogue is 
essential in raising awareness of this issue amongst prescribers and payers and deciphering 
whether modifications to clinical practice may be necessary to ensure optimal patient 
outcomes.  
2.6.1 Propensity of Bladder Muscarinics to Cause Secondary Organ Effects  
The beneficial effects of bladder muscarinics are primarily exerted via the blockade of the 
muscarinic M2 and M3 receptors located on the detrusor muscle. This inhibits binding of 
the primary detrusor contractile neurotransmitter, acetylcholine, decreasing the ability of 
the bladder to contract and therefore alleviating the symptoms of urge and incontinence 
(Athanasopoulos and Giannitsas, 2011). 
Some bladder muscarinics have low muscarinic receptor selectivity, which means that as 
well as binding to the muscarinic receptors on the detrusor, they may indiscriminately bind 
to other muscarinic receptors (M1-M5), which are widely distributed throughout the body. 
This can cause a range of undesirable systemic effects, affecting both cognitive and 
physiological function (Klausner and Steers, 2007).  
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Blockade of M1 and M3 salivary receptors causes significant dry mouth; a particularly 
burdensome symptom extensively reported in the literature. A recent meta-analysis found 
that 25% of subjects taking bladder muscarinics experienced symptoms of dry mouth 
compared to just 5.3% of those receiving placebo. When considering specific drugs, the 
highest rate of dry mouth was in the fesoterodine group (29.45%), followed by solifenacin 
(26.0%), darifenacin (23.8%), and lastly tolterodine ER (6.1%) (Vouri et al., 2017). There is 
also a distinct difference between the rates of dry mouth between immediate-release (IR) 
oxybutynin and extended release (ER) oxybutynin (Appell, 2002).  
Some evidence suggests that interference with cardiac M2 receptor function may be 
associated with electrocardiogram (ECG) changes, such as bradycardia anarrhythmias.  
There is currently a lack of clinical data differentiating the risk profiles of the various 
bladder muscarinics in causing cardiovascular effects (Andersson et al., 2011). 
2.6.2 Propensity of Anticholinergics to Cause Cognitive Impairment  
The blood-brain barrier (BBB) is a diffusion barrier made up of endothelial cells, pericytes, 
and astroglial processes (Pagoria et al., 2011). The main purpose of the BBB is to prevent 
the influx of compounds from the blood to the brain in order to preserve the healthy brain 
microenvironment and normal functioning of the central nervous system (CNS) (Ballabh et 
al., 2004). A number of therapeutic agents are obstructed by the BBB to protect against 
undesirable cognitive side effects; examples include antibiotics, antineoplastic agents and 
neuropeptides. It is however essential that certain drugs are able to enter the brain in order 
to deliver their intended health benefit (Pardridge, 2005). These drugs are carefully 
designed to penetrate the membrane through drug delivery systems such as drug carriers 
(prodrugs), or through cellular mechanisms for drug targeting (Upadhyay, 2014). 
The passage of bladder muscarinics across the BBB is not necessary for their impact on 
bladder function, despite this, many of them possess the ability to pass through into the 
brain. Once there, these drugs can cause a spectrum of CNS adverse events (AEs) such as 
delirium, hallucinations and confusion (Staskin and Zoltan, 2007; Chancellor and Boone, 
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2012). Some anticholinergics for PD, depression and insomnia, are supposed to pass the 
BBB, but nonetheless they can still cause similar undesirable secondary cognitive effects. 
Historically, the general view has been that any impact on cognition was reversible; 
however, a hypothesis has recently emerged connecting the chronic antagonism of 
muscarinic receptors by anticholinergics to the pathogenesis of AD (Carrière et al., 2009; 
Gray et al., 2015). A pivotal study, deemed methodologically superior to similar previous 
studies, uncovered a ten-year dose-response relationship between common 
anticholinergics (tricyclic antidepressants, antihistamines and bladder muscarinics) and AD 
(Gray et al., 2015). The potentiality of dementia is of particular concern considering the 
severity, irreversibility and substantial economic and humanistic burden (Madersbacher, 
2005).  
It is thought that the antagonism of anticholinergics to the M1 and M2 receptors situated 
in the neocortex, hippocampus and neostriatum, which are involved in higher cognitive 
processing, is responsible for CNS AEs (Abrams et al., 2006; Yamamoto et al., 2011). Certain 
pharmacological properties including non-polarity, high lipophilicity, small molecular size, 
lack of efflux-pump affinity and long half-life can enhance the drug’s ability to cross the BBB 
and subsequently increase chances of binding to the muscarinic receptors and causing CNS 
AEs (Kay, 2008) (Table 2.2).   
 
Table 2.2 Pharmacokinetic profile of common bladder muscarinics used in neurogenic 
bladder 
Bladder 
Muscarinic 
M3 Receptor 
Affinity 
Size Lipophilicity  Polarity Efflux Pump Half-Life 
(Hours) 
Oxybutynin Poorly M3 
selective 
357 
kDa 
Lipophilic  Neutral  None 2/13 
Tolderodine Poorly M3 
selective  
475.6 
kDa 
Lipophilic  Positive None 2/8 
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Solifenacin Moderately 
M3 selective  
480.6 
kDa 
Lipophilic  N/A None 45-68  
Darifenacin  M3 selective 507.5 
kDa 
Lipophilic  Positive  P-glycoprotein 12  
Trospium  Poorly M3 
selective 
428 
kDa 
Hydrophilic  Positive P-glycoprotein 20  
kDa, kilodaltons 
Developed from: Abrams and Andersson, 2007; Cetinel and Onal, 2013; Kay, 2008; Klausner and 
Steers, 2007; Pagoria et al., 2011 
 
Amongst the bladder muscarinic agents, oxybutynin (in particular the IR formulation) has 
the highest potential for causing CNS AEs, due to its low M3 muscarinic receptor selectivity 
and other pharmacological properties that increase its ability to cross the BBB. Gray et al 
(2015) demonstrated that the consumption of oxybutynin consecutively for three years 
increased the risk of dementia. No other bladder muscarinic has been exclusively 
implicated in the onset of dementia. Unfortunately, as oxybutynin is the cheapest and the 
oldest drug available, it is one of the most utilised in clinical practice (Donovan, 2007; 
Game, 2010). Other bladder muscarinics have varying degrees of potency, with darifenacin 
considered to be one of the safest drugs due to its favourable pharmacokinetic properties 
and no documented evidence of CNS AEs in trials (Table 2.2) (Zinner, 2007). 
Some of the most potent anticholinergic drugs of other classes are summarised in Table 2.3 
below, although by no means should be considered an exhaustive list. These drugs also 
significantly contribute towards anticholinergic burden and possess an enhanced ability to 
cross the BBB and cause CNS AEs.  
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Table 2.3 Medications with definite anticholinergic activity (potent anticholinergics) 
Class Specific medication 
Antidiarrheals diphenoxylate/atropine. 
Antihistamines cyproheptadine, chlorpheniramine, dexchlorpheniramine, 
hydroxyzine, clemastine, diphenhydramine. 
Antidepressants amitriptyline, amoxapine, clomipramine, doxepin, imipramine, 
mirtazapine, nortriptyline, protriptyline, trazodone, paroxetine 
Antipsychotics chlorpromazine, clozapine, fluphenazine, haloperidol, 
mesoridazine, olanzapine, thioridazine, thiothixene, 
prochlorperazine, promethazine. 
Antiemetics dimenhydrinate, meclizine, prochlorperazine, promethazine, 
trimethobenzamide. 
Anti-Parkinson’s agents amantadine, benztropine, biperiden, trihexyphenidyl, hyoscyamine. 
Antiarrhythmics disopyramide, quinidine, procainamide. 
Cardiovascular agents dipyridamole 
Antispasmotics belladonna alkaloids, clidinium/chlordiazepoxide, dicyclomine, 
flavoxate, hyoscyamine, oxybutynin, propantheline, tolterodine 
Adapted from Lakey et al., 2009 and Campbell et al., 2016 
 
An individual’s overall anticholinergic burden can be calculated using an anticholinergic 
burden scale, where the resulting score gives an indication as to how ‘at risk’ an individual 
is to CNS AEs (Section 6.2.14.1.6 and Section 8.6.3). It is important to note that not only 
‘potent’ anticholinergics can contribute towards anticholinergic burden, in fact most of the 
anticholinergic burden (over 70%) seen in general practice comes from multiple ‘low 
potency’ anticholinergic medications (in particular cardiovascular drugs) (Magin et al., 
2016).  
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2.6.3 Use of Anticholinergic Drugs in Patients with Neurological Conditions 
The pathophysiological changes in the brain that accompany increasing severity of certain 
neurological conditions make these individuals particularly susceptible to the potential CNS 
AEs of anticholinergic drugs (Gao et al., 2017; Spencer et al., 2018). Most studies in the 
literature documenting the effects of anticholinergics on cognition have focused on older 
individuals. It is important that patients with neurological conditions are assessed 
separately, as they represent a younger, clinically distinct patient group and pose unique 
management challenges compared to older individuals. This section aims to summarise 
notable studies that have investigated cognitive impairment and the use of anticholinergic 
drugs in neurological conditions.  
Although PD is predominantly a motor condition, around 20–50% of individuals also 
experience mild cognitive impairment (MCI) (Goldman and Litvan, 2011). MCI includes 
symptoms of memory decline, disorientation, or reduced cognition, which tends to 
increase parallel to neurodegeneration (Meireles and Massano, 2012). MCI is a further risk 
factor for dementia (clinically referred to as Parkinson’s disease dementia (PDD)), which 
affects 30-40% of individuals. PDD significantly contributes towards morbidity and 
mortality (Poewe, 2005; Pandya et al., 2016).    
Anticholinergic drugs have shown to increase the rate of cognitive dysfunction in PD 
(McKenzie, 2017). Importantly, common anti-Parkinson’s drugs consist of anticholinergics, 
consequently putting patients at high risk of exposure (Crispo et al., 2016). The relationship 
between anticholinergic burden and cognition was measured in a community-based cohort 
of patients with PD (n=235) using the mini-mental state examination (MMSE), one of the 
most widely used screening tools for dementia (Ehrt et al., 2010). During an 8-year follow-
up, the cognitive decline was higher in those taking anticholinergic drugs (median decline 
on MMSE 6.5 points) in comparison to those not taking them (median decline 1 point; 
p=0.025). In order to avoid the progression of cognitive decline, the researchers go so far 
as to suggest avoiding anticholinergic drugs in PD patients altogether (Ehrt et al., 2010). 
The impact anticholinergics have on cognition was confirmed in a functional imaging study; 
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Perry et al (2003) found that hallmark signifiers of AD; amyloid plaque and neurofibrillary 
tangle densities were much higher in long-term anticholinergic drug users compared to 
short-term and non-users. These observations provide tangible evidence to suggest that 
anticholinergics contribute towards AD-type pathology in PD.  
In contrast, in a longitudinal observational study by Yarnall et al (2015) demonstrated that 
anticholinergic drug use in PD patients was in fact not associated with a decrease in 
cognitive scores. This result is surprising, as it goes against the broad consensus of other 
studies in this area that suggest the contrary. Despite this, the authors of the study still 
recommend avoiding these drugs in the PD population and warn that the results should be 
interpreted with caution due to a number of intrinsic limitations in the study design, 
including the short follow-up duration and the young average age of participants.  
Like PD, MS is also defined as a neurodegenerative disease (Hague et al., 2005; Gironi et 
al., 2016). Forty to sixty percent of MS patients experience some degree of cognitive 
impairment and in the same manner as PD, the progression seems to be associated with 
advancement of the underlying condition (Rahn et al., 2012; Højsgaard Chow et al., 2018). 
Cognitive impairment is most prevalent and severe in secondary progressive MS (SPMS) 
(Højsgaard Chow et al., 2018). Although the occurrence of dementia is much rarer, it still 
exhibits in 20–30% of individuals, emerging primarily at end stages of disease (Guimaraes 
and Sa, 2012). Cognitive dysfunction in all its forms is an arbiter of large societal burden in 
MS, constituting one of the primary reason’s patients cannot return to employment (Coyne 
et al., 2015). 
There is scarce data on the impact of high anticholinergic burden in MS patients. A small 
observational study including 42 patients revealed that bladder muscarinic drug use 
resulted in consistently lower scores on the two separate cognitive functioning tests; the 
Symbol Digit Modality Test (SDMT) and the Selective Reminding Test (SRT) compared to 
individuals not taking anticholinergics (Cruce et al., 2012). Another study including 70 
patients, covering not only anticholinergics, but also a broad range of CNS active 
medications found that individuals taking these medications experienced greater 
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impairment on measures of processing speed, sustained attention, and fatigue compared 
to non-users (Oken et al., 2006). 
Cognitive impairment is also an issue in stroke patients. The chances of an individual 
becoming cognitively impaired increases threefold after experiencing a stroke. What is 
more alarming is that, 25% of individuals go on to develop dementia (Danovska, 2012). 
Healthcare costs are increased threefold for stroke patients with cognitive impairment, and 
the ability to perform activities of daily living (ADL) is severely diminished (Claesson et al., 
2005).   
As in PD and MS, the use of anticholinergics is directly implicated in exacerbating cognitive 
deficits. A preliminary study found that anticholinergic drugs play a role in the pathogenesis 
of delirium in acute stroke patients (Caeiro et al., 2004). Delirium is characterised by 
reduced ability to focus, sustain, or shift attention and is often accompanied by perceptual 
or cognitive dysfunction (Fong et al., 2009). Although there is some evidence to suggest 
bladder muscarinics do not cause cognitive impairment, the studies are marred with 
limitations such as small cohort numbers and short follow up periods (Park, 2013). 
The literature presented in this section clearly indicates there is an association between 
neurological disorders and the onset of cognitive impairment and dementia, which is 
further exacerbated by high anticholinergic burden. Given the significant level of 
comorbidity, neurological patients tend to be prescribed anticholinergic drugs to manage 
a number of different conditions (Novy and Sander, 2016; McLean et al., 2017) (Section 
8.2.1). In addition, a sizable proportion of patients that suffer from bladder dysfunction will 
be receiving bladder muscarinics as first-line management (Manack et al., 2011) (Section 
2.6 and Section 8.4.1). This puts patients at particularly great risk of exposure. Furthermore, 
due to their pre-existing cognitive impairment as a consequence of their neurological 
condition, subtle changes in cognitive functionality induced by anticholinergics may be 
overlooked. This can be dangerous as the additional anticholinergic load can have a major 
impact on patient’s daily functioning and potentially cause irreversible changes to brain 
structure (Perry et al., 2003).  
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Despite the incentive for further inquiry, much of the research into the impact of using 
anticholinergics in this patient population is preliminary, based on small sample sizes, and 
the results can often be conflicting. Additional research is imperative to extend our 
understanding in this crucial area to prevent avoidable harm to patients. An important first 
step would be to determine the baseline anticholinergic burden in NGB patients. 
2.7 Marketing Authorisation and Reimbursement of Bladder Muscarinics  
The evidence requirements between marketing authorisation (MA) authorities (for 
example, The European Medicines Agency (EMA)) and Health Technology Assessment 
(HTA) bodies (for example, the National Institute for Health and Care Excellence (NICE) in 
the UK) differ. MA authorities are principally concerned with assessing the safety and 
efficacy of a new intervention through rigorously controlled double-blind randomised 
clinical trials (RCTs). All pharmaceutical companies legally require MA for every product 
they wish to distribute (Permanand et al., 2006).  
HTA is defined as:  
a multidisciplinary process that summarises information about the medical, social, 
economic and ethical issues related to the use of a health technology in a systematic, 
transparent, unbiased, robust manner (Sacchini et al., 2009: 453). 
As the remit of HTA bodies is a lot more extensive than MA authorities, companies are 
asked to provide additional evidence requirements, including the presentation of the 
unmet medical needs, the relative effectiveness and safety of the drug, drug price, budget 
impact and cost‐effectiveness (Tafuri et al., 2016). Progressively, MA authorities are also 
becoming more receptive to the holistic effects of interventions. 
Although bladder muscarinics are advocated as first-line management in CGs, their use in 
neurological populations has not been thoroughly assessed. Manufactures have only 
sought MA for idiopathic OAB therefore most use of bladder muscarinics in clinical practice 
is off-label (Cameron, 2016). Subsequently, the efficacy and safety evidence from the 
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idiopathic population tends to be ‘carried over’ to the NGB population (Kennelly and 
Devoe, 2008). The transfer of evidence from OAB to NGB is largely inappropriate, as despite 
similar symptoms, NGB tends to be more diffuse and dynamic than the idiopathic kind 
because severity increases with underlying neurological disease progression (Aharony et 
al., 2017; McDonald et al., 2017). The same also holds true for many other treatments such 
as neuromodulation and the β3-adrenoceptor agonist, mirabegron (these treatment 
options are discussed further in Chapter 4). 
The limited evidence that does exist in the NGB population pertains mostly to adults with 
MS and SCI, and children and young adults with myelodysplasia (Fowler, 2011). Due to the 
magnitude of population diversity, it is difficult to apply evidence across neurological 
conditions; however, it is still common practice to do so given the paucity of adequate 
research. In addition, only the older generation of bladder muscarinics (propiverine, 
trospium, oxybutynin, propantheline and tolterodine) have studies supporting their use, 
which means the use of the newer generation of bladder muscarinic drugs is not evidence-
based (Fowler, 2011). A meta-analysis revealed 'there is still uncertainty about which 
bladder muscarinics are most effective, at which dose, and by which route of 
administration' (Madhuvrata et al., 2012: 823). 
The median cost of RCTs is $3.4 million USD for phase I, $8.6 million for phase II and $21.4 
million for phase III (Martin et al., 2017). Furthermore, applications to the EMA cost 
upwards of €286,900. Therefore, pharmaceutical companies generally do not wish to incur 
the costs of pursuing MA for drugs that are already extensively used in clinical practice 
unless they expect it to encourage further uptake of the drug. In a disease area such as NGB 
where there are no other viable alternatives to idiopathic OAB drugs, the incentive for 
seeking MA approval is very low (Institute of Medicine, 2010). On the other hand, gaining 
reimbursement for use in non-licenced indications is desirable for pharmaceutical 
companies in the UK because once a technology has been recommended by NICE, National 
Health Service (NHS) trusts are ‘legally obliged to fund and resource medicines and 
treatments recommended by NICE’s technology appraisals’, thus encouraging uptake of 
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the intervention (Lawrence, 2016). Furthermore, from a government perspective, in order 
to promote the efficient use of bladder muscarinics, and indeed other forms of 
management in NGB, there needs to be a formal process by which the available treatments 
are assessed for their cost-effectiveness, based upon the value demonstrated in RCTs and 
real-world settings, which should be used by HTA bodies for priority setting.  
2.8 Healthcare Resource Utilisation in Neurogenic Bladder 
2.8.1 Cost of Illness Studies 
Cost-of-illness (COI) studies represent an important preliminary step in lowering the total 
burden of disease by identifying and measuring all of the associated costs. They are 
valuable for policy makers for evidence-based planning of services and the introduction of 
new interventions. One of the most notable COI studies is the ‘Global Burden of Disease’ 
program, launched in 1991 by the WHO, which is the largest of its kind in the world, 
providing information on the burden of a number of diseases, injuries and risk factors 
(Murray and Lopez, 2013). When focusing only on direct medical costs, these studies are 
known as healthcare resource utilisation (HRU) studies. 
Scarcity is intrinsic to the healthcare system therefore there is invariable pressure on 
governments to utilise financial resources as efficiently as possible (de Joncheere, 2003; 
Parkin, 2017). Accordingly, cost-containment strategies are used across jurisdictions to free 
up resources and generate additional benefits to be used elsewhere in the system 
(Almarsdottir and Traulsen, 2005). COI studies are able to highlight the major cost 
components of disease, and hence act as an important tool in demonstrating where cost-
containment policies could have the greatest impact (Jo, 2014; Zannetos et al., 2017). COI 
studies can also be utilised to justify more resources to be devoted to diseases with higher 
economic burden (Drummond, 1992). Whilst both of these uses are valid, in reality, the 
role of COI studies has changed significantly since their inception and early use. Because of 
their descriptive nature, rather than actively directing healthcare decisions, these studies 
have adopted an increasingly complimentary role, mainly in raising the cost-consciousness 
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of consumers. They are typically used as educational tools, in public advocacy, to encourage 
policy debate and evaluation, and contribute towards the planning of services in 
conjunction with more sophisticated measures of healthcare evaluation (Larg and Moss, 
2011).  
The amount of pharmaceutical innovation directly relates to the burden of disease 
(Lichtenberg, 2005). Therefore, as well as being useful for guiding policy decisions, COI 
studies are valuable to pharmaceutical companies in guiding their Research and 
Development (R&D) focus. The target product profile (TPP) is an all-encompassing 
document, outlining the goals and expectations of the drug development process. The 
economic burden of a disease is calculated as part of the initial environmental scanning in 
order to highlight the unmet need and possible areas where cost savings can be made 
through the introduction of new interventions (Tyndall, 2017). Well-differentiated 
products in established disease areas are more likely to be successful (Ahlawat, 2013). It is 
therefore important for pharmaceutical companies to invest resources in elucidating and 
publishing evidence on the burden of disease in order to increase the likelihood commercial 
success.  
2.8.2 Debate on the Use of Cost of Illness Studies 
There is no shortage of debate amongst health economists on the value of COI studies in 
guiding healthcare decisions. Some criticisms relate to the methods involved in calculating 
indirect and productivity costs, however since the research presented in this thesis is only 
concerned with direct medical costs (HRU), other types of costs will not be discussed. This 
section will instead focus on the broad concerns pertaining to flaws in design and rationale 
of use.  
Welfare economists argue that health is a multi-dimensional concept that cannot simply 
be measured in monetary gains and losses. They propose that a patient’s judgement of 
their own health reveals a great deal on the burden of disease, for example the 
psychological distress and social isolation that is not captured in direct or indirect measures 
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of cost (Shiell, 1987). Accordingly, these critics, suggest that the lack of attention given to 
HRQoL is a major limitation of COI studies.  
COI studies are often presented in a way that suggests vast cost savings could be made 
from eradicating the disease in question, however, in reality, few diseases could be 
completely eliminated therefore the costs of treatments presented will not all be saved 
(Byford et al., 2000). In addition, whilst COI studies could indeed reveal that treatment costs 
are high, they often fail to account for the costs of preventing disease, which could also be 
costly, if not more so (Byford et al., 2000). It is therefore important that the conclusions 
derived from COI studies are presented in a way that is purely informative and raises 
awareness of the disease, rather than making bold inferences about cost savings.  
It is evident that the descriptive nature of COI studies, limits their practical use in healthcare 
decision-making (Wiseman and Mooney, 1998). Other, more sophisticated forms of 
economic analyses such as cost-effectiveness analysis (CEA) have considerably more weight 
in priority setting because they make valid comparisons between alternative interventions 
of the cost versus the expected health gain (Hutubessy et al., 2003). However, with limited 
resources for HTA, and almost one novel chemical entity introduced per week, decisions 
need to be made around which disease areas are worth focusing on (Gabbay and Walley, 
2006). This is particularly necessary in low-income countries with a lessened ability to 
conduct expensive assessments of all new interventions (Baltussen et al., 2005; Drummond 
et al., 2011). In this sense, COI studies can help to educate, inform and enlighten HTA bodies 
and policy-makers, and guide the focus onto diseases that are resource intensive, have a 
high rate of complications, and are in need of new cost-effective interventions.  
Furthermore, it is also important to consider that the economic models submitted to HTA 
bodies can only be as reliable as the evidence used to inform their parameters. Outputs 
from COI studies improve the reliability of the underlying evidence in economic models as 
the full disease pathway can be accurately elucidated, including the costs and occurrence 
of iatrogenic and disease related AEs, costs for medical services and, if taking a societal 
perspective, broader parameters such as the level of work absenteeism (Gao et al., 2016).   
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Ultimately, it is inapt to compare COI studies to more sophisticated types of economic 
evaluation as they have their own unique place in healthcare research, representing an 
essential, descriptive type of economic evaluation. They should be used in combination 
with population frequency, morbidity and mortality estimates to derive the best possible 
value. These studies are exceedingly important in the under-researched and unrepresented 
area of NGB, where it is important to raise the profile of the disease and generate further 
hypotheses to encourage more research and innovation.  
2.8.3 Literature Review - Healthcare Resource Utilisation in Neurogenic 
Bladder  
A literature review was conducted to summarise evidence of HRU in NGB. Literature 
reviews differ from systematic literature reviews in that there is no specific question that 
needs to be addressed, rather, the topics covered are general and aim to provide an overall 
summary of the pertinent data in the area. This means that papers are sought through a 
random process, without the use of pre-defined search terms, and without the conduction 
of a pilot study to determine feasibility of article detection (Robinson and Lowe, 2015). 
Furthermore, a quality assessment of individual studies is not conducted. 
NGB is associated with a number of widespread indirect and direct costs, spanning further 
than the resources required to manage the condition. When adopting the perspective of 
the patient and/or their family, costs include trips to hospital appointments, the income 
lost from a partner taking on the role of a carer, and in more advanced stages of disability, 
nursing home and end of life costs (Palma-Zamora and Atiemo, 2017). When considering 
the societal perspective, reduction in work productivity and work absenteeism as a result 
of NGB related morbidity represent a substantial burden (Boccuzzi, 2003).  
Although a number of different costs from various perspectives could be considered, HRU 
(direct medical costs) will be discussed in this section. It is recognised that a number of 
factors dictate the level of HRU and associated costs in NGB including complications, access 
to healthcare, symptomology and management strategies employed, however the 
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economic burden on the healthcare system still remains poorly characterised (Palma-
Zamora and Atiemo, 2017). Most studies in the literature pertain to idiopathic OAB 
patients, and owing to the lack of data, these estimates are often extrapolated to the NGB 
population.  
Across multiple disease areas, significant proportions of healthcare spending are wasted 
on complications that could have been prevented with the right care and planning. A study 
using hospital claims data for California and Maryland in the USA found that 9.63% of all 
hospital spending ($6,504,557,501) was associated with potentially avoidable 
complications (Fuller et al., 2009). In NGB, preventing complications such as those detailed 
in Section 2.3 can help reduce potentially avoidable medical costs and free up resources to 
be used in other parts of the healthcare sector.  
UTI is a common complication of NGB and also one of the most common healthcare 
associated infections (HCAIs), accounting for 17.2% of all cases. In the USA, UTI accounted 
for nearly 7 million office visits, 1 million emergency department (ED) visits, and 100,000 
hospitalisations in 1997, mostly associated to APN (Foxman, 2002). These conditions are 
also expensive, generating medical costs of $1.30 billion USD and $1.6 billion USD per year 
respectively (Brown et al., 2005). Evidence suggests there is a direct relationship between 
the length of time a patient resides in a healthcare setting and their chances of contracting 
a HCAI (Mantle, 2015). The average length of hospital stay is longer for NGB patients in 
comparison to idiopathic OAB patients, consequently putting them at increased risk for 
contracting nosocomial UTIs (Sauerwein, 2002). The risk of infection also increases with the 
duration of catheterisation, and in the UK, around 43%-56% of overall UTI cases are caused 
by IndUC, which stays in the bladder longer than IC (Mantle, 2015; Hallam, 2017). From a 
UK perspective, every catheter associated urinary tract infection (CAUTI) case increases 
hospital stay by 10 days and costs an average of £2523 per patient (Prieto et al., 2015). 
Antibiotics are the mainstay of treatment for UTIs, and currently there are no alternative 
treatments in existence. Worryingly, antimicrobial resistance (AMR) is emerging as a major 
threat to the effectiveness of antibiotics and consequently to global population health. The 
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drugs are slowly proving ineffective against many common strains of bacteria, including 
E.coli, which is responsible for 70-80% of all community acquired infections (McLellan and 
Hunstad, 2016). Unless antibiotic stewardship is adopted across the globe, the possibility 
of a post-antibiotic era may become a reality, and common infections such as UTIs could 
cause much longer duration and severity of illness, and inevitable mortality for a lot more 
people. The WHO predict this will put a much higher economic strain on healthcare 
resources, families and societies (WHO, 2014). An instance of AMR has been estimated to 
cost more than $55,000 USD per patient episode. Furthermore, mortality from infections 
as a result of AMR are predicted to result in a reduction of 2%-3.5% of global gross domestic 
product (GDP) by 2050, equating to around $60-100 trillion USD (Allcock, 2017).  
Renal related complications also pose a large burden on the healthcare system. CKD cost 
the NHS £1.45 billion in 2009-2010, accounting for around 1.3% of all spending that year 
(Kerr, 2012). When considering per-person costs, a study using Medicare data in the USA 
estimated the costs reached up to $12,700 for stage 4 patients (adjusted to 2010 dollars) 
(Honeycutt et al., 2013). Kidney transplantation is more cost effective than dialysis in 
managing CKD, leading to a cost benefit in the second and subsequent years of £25,800 per 
annum, however the lack of organ donation remains a prominent barrier to carrying out 
more transplantations (National Kidney Federation., 2010). VUR, is another common 
complication in NGB and correspondingly the costs are also substantial. A retrospective 
study found that since 2000, hospital charges for inpatient VUR management have 
gradually increased, and in the last year of analysis, charges were $18,798 USD per 
hospitalisation (Spencer et al., 2011).  
The link between incontinence and HRU has been well established in the idiopathic OAB 
population. Two large-scale studies showed average annual per capita costs of $65.7 billion 
in the US and £4.2 billion in the five largest western European countries (Germany, Italy, 
Spain, Sweden, and the UK), spent in managing OAB (Ganz et al., 2010; Reeves et al., 2006). 
Another study conducted from the perspective of a payer in the USA estimated an annual 
cost of $12,357.43 per patient for incontinence related hospitalisations, clinician office 
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visits, outpatient, and emergency department (ED) services (Thom et al., 2005). There is 
also evidence to suggest that NGB patients with NDO are more healthcare resource 
intensive than their continent counterparts. A retrospective, cross-sectional study utilising 
a multinational survey of patient and physician reported data, demonstrated higher rates 
of OAB-related hospitalisations, OAB-related surgery, pad use and bladder muscarinic 
treatment switching amongst incontinent NDO patients in comparison to continent 
patients (Tang et al., 2014). 
A study estimated the overall treatment costs in idiopathic OAB to be $27,98990 USD (Hu 
et al., 2003). Investment of resources and enhancement of initial treatment capabilities 
should theoretically reduce the costs of treating late‐stage disease and the associated 
consequences, therefore justifying initial high treatment costs (Hu et al., 2003). However, 
certain management techniques and situations can prove an unfounded cost burden. A US 
claims database showed that all-cause and OAB-related costs were higher in a treatment-
switch group than persistent patients six months after the index date (all-cause $7,017 vs. 
$8,806, OAB-related $642 vs. $797) (Ivanova, 2014). Therefore, considering that many NGB 
patients do not remain persistent on their first line bladder muscarinic, all of the costs 
associated with bladder muscarinics may not be justified. Better strategies should be 
employed to consider the optimal management method from the onset, in order to avoid 
switching and save costs (Tijnagel et al., 2017). 
A cost analysis in the USA comparing 12 common treatments for idiopathic OAB found that 
costs ranged from $500 USD for oxybutynin to $19,443 for sacral nerve stimulation (SNS). 
The cost for onabotulinumtoxin A was $1892 and was found to be the least costly option 
throughout the duration of the study when compared to SNS and percutaneous tibial nerve 
stimulation (PNS) (Yehoshua, 2018). Although generic bladder muscarinics were the 
cheapest in this study, it is essential to consider the persistence rates and risk of AEs, which 
tend be higher with this form of management (Tijnagel et al., 2017). Accordingly, the choice 
and sequence of treatments are typically guided by cost-effectiveness analysis (CEA), 
where the ratio of costs incurred by the new intervention relative to the comparator to the 
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cost per health benefit gained is used to determine whether the intervention in question is 
cost-effective or not (depending on the available national or local budget) (Giannitsas and 
Athanasopoulos, 2015).  
A CEA comparing onabotulinumtoxin A to best supportive care (BSC) in individuals with MS 
and SCI, resulted in an additional 0.4 Quality Adjusted Life Years (QALYs), at an increased 
cost of £1,689 over 5 years. The authors of the study considered onabotulinumtoxin A to 
be more cost-effective than BSC. Another CEA, projecting the 10-year costs for 
onabotulinumtoxin A, deemed it more cost-effective than clam cystoplasty (Flack and 
Powell, 2015). At present, most CEA has been primarily conducted in the OAB population, 
signifying an unmet need in the NGB population. 
2.8.3.1 Access to Healthcare  
Access to healthcare services is a key attributor towards the health of the NGB population. 
Access is simply defined as the ‘ability to obtain health services when needed’ 
(Bodenheimer, 2012: 17). In many parts of the world, the opportunity to reach services is 
impeded by barriers such as poor healthcare infrastructure, economic deprivation, and 
physical restrictions (Levesque et al., 2013). Delayed or restricted access to services 
ultimately results in higher long-term resource use and costs. 
In countries that lack universal healthcare coverage, the price of services conditions the 
individual’s willingness to pay (WTP) for necessary interventions and consequently, out-of-
pocket payments often inhibits access to healthcare for the poorest in society (Peters et 
al., 2008). When there are high costs attached to lifesaving treatments such as dialysis in 
renal failure, patients may be compelled to forgo treatment and risk increased morbidity 
or even death because of the lack of affordability. Thus, NGB patients with lower ability to 
pay are at risk of being inappropriately managed, consequently increasing their risk of 
further complications, morbidity, morality, and associated costs (Rahmqvist et al., 2016; 
Przydacz et al., 2017). This notion is supported in a retrospective database study in the USA, 
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which found that NGB patients with low annual incomes and without insurance or self-pay 
were more likely to be discharged from hospital earlier (Sood et al., 2017). 
In countries with underdeveloped health infrastructure, the necessary services may be 
entirely absent. Urodynamic testing is often considered essential for diagnosis and guiding 
subsequent treatment choices, however countries in the developing world may lack the 
sophisticated equipment and/or the medical expertise required to carry out these tests 
(Przydacz et al., 2017). Undiagnosed or poorly diagnosed NGB can have devastating 
consequences for healthcare outcomes and costs.  
Even in countries such as the UK with the well-established NHS, barriers to care remain 
persistent. Waiting times are an all-too-familiar problem in publicly funded services (Willis 
et al., 2011). ‘Non-urgent’ patients wait an average of 13 weeks to see a urologist, much 
longer than what is considered clinically reasonable (Witherspoon et al., 2017). Long wait 
times have been proven to lead to poor patient outcomes, increased risk of mortality and 
increased medical costs due to the delay in accurate diagnosis and treatment (Schaafsma, 
2006).  
The cost of incontinence products such as pads and diapers typically represent an ongoing 
out-of-pocket expense for patients even in countries where state funding often covers 
most forms of management. A study demonstrated that absorbent pads represented 
nearly two thirds of the annual per patient costs of idiopathic OAB management in five 
European countries (Reeves et al., 2006). In the UK, provision of these products by the NHS 
depends on criteria set out by local clinical care commissioning groups (CCGs), which can 
introduce inequity in access (Guimaraes and Sa, 2012). In the USA, absorbent products are 
not covered by health plans (Palma-Zamora and Atiemo, 2017). A notable exception to this 
trend is Denmark, where the Danish National Health Service (DNHS) fully reimburses 
incontinence pads and the major manufacturers even send nurses to the patients’ homes 
to help with adjustment (Cornago and Garattini, 2001). 
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2.8.3.2 Conclusions 
It is unmistakable from the evidence presented in this section that NGB represents a large 
economic burden to healthcare systems, which is amplified by multiple barriers to access. 
The literature also revealed that there is a lack of resource use data in the NGB population, 
resulting in the necessary extrapolation of data from the OAB population. Other literature 
reviews into the burden of NGB have resorted to the same extrapolation to make up for 
the dearth of research (Flack and Powell, 2016). Despite the similarity in symptoms, these 
two conditions should be considered as distinct clinical entities due to differences in 
HRQoL, varying patterns of disease, and differences in complications, such as the unique 
occurrence of autonomic dysreflexia in SCI (Tapia et al., 2013; Truzzi et al., 2016). Despite 
this, the use of OAB data is the best available alternative until more research efforts are 
directed towards generating evidence for NGB.  
Most of the estimates retrieved were from non-UK populations, calculated at a national 
level. Therefore, in order to inform prescribers and payers and potentiate informed 
decisions on optimal care in the UK, there is a need to characterise the impact NGB has on 
the NHS, particularly at a patient level.  
2.9 Drug Utilisation Research  
DUR is one of the main themes underpinning the research in this thesis, and this section 
aims to provide an overview of the topic. Narrow definitions define DUR as ‘research or 
studies related to the prescribing, dispensing and ingesting of drugs’ (Brodie, 1971: 1), 
however it is now widely accepted as being a vast, ever-evolving area of research, 
encompassing a breadth of aims and methodologies. A broader and more apt definition 
was coined by the WHO in 1977 describing it as: 
the marketing, distribution, prescription, and use of drugs in a society, with special 
emphasis on the resulting medical, social and economic consequences (WHO, 2003: 33).  
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In this discussion, special attention is placed on descriptive studies, which undeniably do 
not allow causal inferences to be drawn but are exceedingly important for new areas of 
investigation such as NGB, to identify problems which require more in-depth research. 
DUR is an important step in the promotion of rational and effective use of drugs (Shalini, 
2010). It incorporates quantitative methods to describe the current state (cross-sectional) 
and trends of treatment use over time (longitudinal), using retrospective databases or 
prospective studies (Lee, 2012). It is possible to determine utilisation patterns within 
specific sub-groups of patients (for example different neurological populations), and 
stratify according to demographic characteristics (for example, age and sex), to explore 
differences between groups and generate hypotheses. In order to calculate and compare 
use of drugs both nationally and internationally, a standardised classification system in 
which drugs are described and sorted is necessary. Drugs can be classified according to 
their mode of action, indications or chemical structure (WHO, 2003). The reference 
standard for quantitative DUR is the WHO Anatomical Therapeutic Chemical/Defined Daily 
Dose (ATC/DDD) methodology, however, other coding systems also exist, for example 
standard coding in the UK is by the British National Formulary (BNF) (Mittal et al., 2014) 
(Section 6.3.12.1.7). 
There has been a proliferation in DUR since its inception in the 1960s due to the 
intensification of marketing of new drugs, variation in prescribing patterns, differences in 
attitudes towards drugs, and increasing pressure to adopt cost-containment measures 
(Gama, 2008). Approaches to DUR vary according to the purpose and needs of the intended 
user (Lunde and Baksaas, 1988). Perspectives can be of governments, healthcare 
management, economists, the public, and drug manufacturers, amongst others (Lee, 
2012). For example, a single hospital sought to determine whether local CGs were being 
adhered to in their institution, whereas a nationwide study was focused on the differences 
in drug utilisation between males and females (Wettermark, 2016). Other studies place a 
particular focus on identifying inappropriate drug use through validated scales such as the 
anticholinergic cognitive burden (ACB) scale, which identifies high anticholinergic burden 
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whilst others focus on identifying Potentially Inappropriate Medicine (PIM) use by using 
tools such as STOPP/START or the Beer’s Criteria (Campbell et al., 2013; Desnoyer et al., 
2017). PIM incorporates issues such as over-prescriptions, prescriptions of contra-indicated 
medications, or incorrect prescribing of an indicated drug, including duplicates or 
administering an incorrect dose or duration. Inappropriate use of drugs is a public health 
hazard, causing AEs, considerable morbidity, mortality and increased healthcare costs, thus 
it is important to identify and correct (Desnoyer et al., 2017). The DUR in this thesis consists 
of a systematic review (SR) (Chapter 5) which focuses on gathering evidence on real world 
drug utilisation patterns in NGB. Additionally, a retrospective study using the CPRD 
database (Chapters 7 and 8) seeks to describe multiple aspects of NGB drug prescribing 
behaviour in the UK including OAB drug use, polypharmacy and ACB score.  
The vast majority of DUR studies are descriptive; therefore, they are designed to pave the 
way for more focused research and activity such as hypothesis driven 
pharmacoepidemiological research, that can improve the way drugs are utilised in society. 
Alternatively, retrospective data can first be employed to detect problems or notable 
trends in prescribing, then specific patients who are at risk or of interest can be targeted 
for further enquiry through qualitative means (Truter, 2008). The central theme of 
qualitative studies is the ‘appropriateness of drug prescribing’; thence, quite aptly, these 
studies are referred to as ‘drug use evaluation (DUE)’ studies (Lee, 2012). Methods to 
gather data can include in-depth interviews or focus group discussions (Wettermark, 2016). 
Ultimately, DUR can lead to modifications to CGs, changes in health policy, educational 
interventions to improve physician prescribing and patient awareness programmes 
(Wettermark, 2016).  
DUR can also help pharmaceutical companies to demonstrate the value of their product 
compared to routine clinical practice, identify key target subgroups, and aid in the 
evaluation of likely commercial success (Navarro, 2009). Expert opinion is often used to 
construct treatment pathways in economic models for submissions to reimbursement 
agencies, however, this type of evidence is heavily subject to cognitive bias. CGs could be 
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used, however they often represent what clinical practice should look like in an ideal sense, 
thus are an inaccurate reflection of prescribing reality (Tappenden, 2012). Treatment 
pathways derived from large-scale epidemiological studies are a better indicator of how 
patients are being managed in the real world thus; this information can improve the 
reliability and transparency of the economic model, improving chances of reimbursement 
(Nuijten et al., 2011). 
Given that CGs are the main tool by which to promote best practice in and influence 
prescribing choices, analysis of CG development and recommendations are a useful 
supplement to DUR to help contextualise the findings and understand how alterations in 
CG development could improve the treatment landscape.  
2.10  Chapter Summary 
This chapter provided an in-depth overview of many pertinent aspects relating to NGB. The 
prevalence of this chronic condition is high; however, current estimates fall short of 
providing an accurate depiction of real-life rates, especially in a UK population. The clinical 
burden of complications relating to NGB were also elucidated, revealing that secondary 
conditions can be severe, thus optimising management should be a priority. The impact of 
high anticholinergic burden in neurological patients was also discussed at some length. 
From the research presented it is apparent that further evidence needs to be accumulated 
on this topic in order to inform current prescribing practices with anticholinergics. A logical 
first step comes in calculating the ACB score of individuals with NGB. Lastly, HRU and DUR 
were explored in some detail, including a literature review on the economic burden of NGB, 
which revealed a dearth of data in a UK population, especially at a patient level. HRU and 
DUR are important in determining the quality of current management practices and 
highlighting the resource intensive aspects of the condition, demonstrating to payers and 
policy makers where improvements are possible.  
This chapter ultimately revealed that there is a lack of epidemiological data on NGB patients 
in the UK. Accordingly, a UK-wide retrospective study utilising the CPRD database is 
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presented in Chapters 6, 7 and 8 to bridge this evidence gap. The next chapter will focus on 
developing a comprehensive understanding of the current management landscape for NGB 
through a critical appraisal of the NICE, EAU and ICI CGs for NGB, which is a useful precursor 
to conducting DUR.  
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3) Chapter Three - Clinical Guidelines in Neurogenic Bladder – A Critical 
Appraisal  
3.1 Introduction  
High quality clinical guidelines (CGs) influence drug utilisation in clinical practice and 
adherence to recommendations is positively correlated with improvements in health 
outcomes (Murad, 2017). Despite this, the application of neurogenic bladder (NGB) CGs in 
clinical practice remains sub-optimal in the Netherlands, and expert opinion suggests that 
the same trend is replicated in other European countries (Cruce et al., 2012; Drake and de 
Ridder, 2017). Low uptake of CGs is most commonly due to the multifaceted barriers in 
implementation across care practices or inadequacy in the CGs themselves, pertaining to 
the methods of development and content (Spallek et al., 2010). 
It is important to contextualise the prominent NGB CGs, in order to assess their value in the 
current healthcare setting and discover what may be preventing optimal uptake. In keeping 
with the theme of drug utilisation research (DUR), the aim of this chapter is to identify 
potential shortcomings in the CGs and provide suggestions around the means by which 
they can be addressed. Such investigation paves the way for improvements in the 
treatment pathway and delivery of care, with the ultimate aim of enhancing health 
outcomes and introducing increased economic efficiency in the treatment of NGB. 
To achieve this aim, the chapter begins with a discussion on the importance of CGs and the 
impetus for quality assessment. Secondly, the important attributes and activities that steer 
CG development are explored in the context of NGB. Third, a brief history on the evolution 
of the National Institute for Health and Care Excellence (NICE), European Association of 
Urology (EAU) and International Consultation on Incontinence (ICI) CGs is presented. Finally, 
a critical appraisal of the CG development process using the Appraisal of CGs for Research 
and Evaluation (AGREE) II instrument is presented. 
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3.2 Importance of Clinical Guidelines  
With burgeoning healthcare expenditures and public spending budgets becoming 
progressively strained, increasing the value obtained from health care investments has 
become an emerging priority (Clancy and Cronin, 2005). Consequently, evidence-based 
medicine (EBM) has gained a lot of traction over the last 20 years, with increased efforts 
dedicated towards embedding high quality research into clinical decision-making 
(Fernandez et al., 2015). CGs encapsulate the plethora of complex and dynamic evidence 
into easy to follow recommendations, as well as (ideally) considering costs, expert opinion 
and health policy (Oyinlola et al., 2016). Therefore, they represent the model way to 
introduce EBM into clinical practice and improve efficiency. 
The majority of patient care takes place in the primary healthcare setting, where general 
practitioners (GPs) are faced with various treatment options and may be unaware of all of 
the associated side effects or merits. It can be near impossible to keep abreast of all existing 
and new developments in the field of NGB, especially when the body of scientific research 
is vast, ever expanding, and often conflicting. Thus, one of the primary aims and uses of 
CGs is guiding GPs towards optimal treatment choices so that they can rest assured with 
the knowledge that their care decisions are supported by sound evidence (Woolf et al., 
1999). 
Patients with chronic conditions are notoriously non-adherent to their medications (Yeaw 
et al., 2009). In NGB there is a medication continuation rate of only 40% after 12 months 
(Tijnagel et al., 2017). Often, low adherence is the result of a gap that lies between actual 
medical outcomes and patient expectations (Lateef, 2011). In a survey sent out to 
idiopathic overactive bladder (OAB) patients prescribed bladder muscarinics, the 
overwhelming majority (89%) named unmet treatment expectations as the main reason 
for discontinuation (Benner et al., 2010). ‘Consumer’ CGs, such as leaflets and online 
versions in lay language can help patients gain a better understanding of all treatment 
options available to them. Equipped with a better knowledge, patients can feel empowered 
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to upkeep their own health, adhere to their medications and improve communications with 
their doctor (King and Hoppe, 2013; Francke et al., 2008; Woolf et al., 1999).  
Unwarranted variation in care is generally the result of underuse of ‘effective’ care, this is 
problematic because patients in certain geographical areas or particular practices may not 
be deriving the best possible value from the healthcare system (Wennberg, 2011; Woolf et 
al., 1999). In many disease areas, standardisation in the application of CGs has been a 
preeminent step in optimising the efficiency of healthcare resource utilisation (HRU), 
ensuring that services are more equitably distributed, and thus better outcomes are 
possible for the vast majority of patients (Woolf et al., 1999). It is however important to 
consider that complete standardisation is not always desirable due to varying patient 
characteristics and preferences (Buchan et al., 2016; Alexander, 2017). This is especially 
true for NGB patients, who are a notably heterogeneous patient group with varying 
treatment requirements. For example, a young child with spina bifida would require a 
distinctly different treatment regime than an elderly patient with Parkinson’s disease (PD).  
3.3 Quality of Clinical Guidelines 
The AGREE collaboration, a multidisciplinary team of experts formed in 2003 to address the 
variability that exists in CG development, defined good quality CGs as: 
The confidence that the potential biases of guideline development have been addressed 
adequately and that the recommendations are both internally and externally valid, and are 
feasible for practice (AGREE, 2013: online).  
CG quality is essential to derive the best possible benefit for all stakeholders. To this end, 
the AGREE collaboration developed the AGREE II instrument as means to critically appraise 
the transparency and methodological rigour of CG development (Brouwers et al., 2010). 
Some of the pertinent aspects of CG quality they identified relate to the clarity of objectives, 
general presentation, the systematic review (SR) techniques, level of stakeholder 
involvement, conflicts of interest and integration of external review. These attributes are 
explored further in the following sections.  
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3.3.1 Scope and Purpose of Clinical Guidelines 
There should be good rationale for CG creation; ideally, they should fill a gap that exists in 
clinical practice. Often it is necessary to create new CGs because the condition of interest 
lacks evidence-based guidance for healthcare professionals (HCPs). In other instances, 
there may be evidence of inappropriate practice, which the CGs aim to rectify (Rosenfeld 
and Shiffman, 2009).  
The objective of the CGs should specifically describe the overall goals of implementation 
and the performance expectations should be clearly communicated. This can serve as 
criteria against which specific improvements in patient health or clinical care can be 
measured against. 
3.3.2 Systematic Review Techniques and Grading of Evidence  
The most vital aspect in the formation of evidence-based recommendations is a 
comprehensive SR of all available evidence (Semlitsch et al., 2015). In order to be truly 
systematic, reviews should be carried out by experienced researchers, start with clearly 
formulated research questions, appraise the quality of well selected studies and 
adequately summarise the evidence (Khan et al., 2003). Explicit SR methodology such as 
that from the Cochrane collaboration or the Preferred Reporting for Systematic Reviews 
and Meta-Analyses (PRISMA) should be utilised (Moher et al., 2009; Henderson et al., 
2010). 
The EBM hierarchy, conceptualised in 1995, provides guidance around the relative strength 
of difference evidence types (Figure 3.1). Its use ensures the totality of high-quality 
evidence informs recommendations, rather than single studies or expert opinion, which 
are prone to bias (Møller and Myles, 2016). Moving up the hierarchy implies increasing 
validity and applicability in making clinical decisions (Murad et al., 2016). By default, 
randomised controlled trials (RCTs) are ranked as ‘high’ and observational studies are 
ranked as ‘low’.  
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Figure 3.1 The evidence-based medicine hierarchy (Guyatt et al., 1995) 
 
Meta-analyses involve the quantitative aggregation of several high quality and 
homogenous RCTs to provide a precise overall treatment effect; it is therefore considered 
the optimal analytical method to appraise the underlying evidence (Figure 3.1) (Kanters et 
al., 2016; Haidich, 2010). High-quality RCTs should be double blinded, as this prevents 
doctors and patients acting on any preconceived notions they have of the interventions in 
question (Misra, 2012). Other attributes of a well-designed trial include randomisation, 
which reduces selection bias, large sample sizes, which increase the power to detect a 
relevant outcome, and following an intention to treat (ITT) analysis, which reduces the risk 
of breaking the random assignment of patients (Kendall, 2003). Outcomes normally relate 
to proving the efficacy of a new intervention compared to the current standard of care 
(SOC). Safety, patient reported outcomes (PROs), and economic outcomes are often sought 
as secondary outcomes (Revicki and Frank, 1999). Most RCTs compare an active 
intervention to an inert placebo, although in some instances head-to-head trials are also 
conducted (Ioannidis, 2006).   
RCT
Cohort study
Case-control study
Case series
Expert opinion
Meta-
analysis 
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Expert opinion is considered the lowest level of evidence within the EBM hierarchy, due to 
the inability of experts to detach themselves from their personal experiences, thus making 
their opinions subject to cognitive bias (Burns et al., 2011). The excessive use of expert 
opinion in place of scientific research can jeopardise the integrity of the recommendations 
by allowing the experts’ conflict of interest to potentially direct decisions (Eibling et al., 
2014; Grilli et al., 2000). There is however an important distinction between expert opinion 
and expert knowledge (which is not made in the hierarchy), with the latter being grounded 
in extensive and shared experiential knowledge between multiple experts (Fernandez, 
2015). Nevertheless, clinicians need to exercise additional caution when considering 
recommendations not supported by substantial evidence.  
Grading the underlying strength of the body of evidence (the methodological quality) 
allows users to determine how much confidence they can place in the resulting 
recommendation. The strength of the recommendation is determined separately and is not 
solely dependent upon the quality of the underlying evidence base; it necessitates 
multifaceted judgments of the clinical context in combination with the developer’s 
experiential knowledge. If the recommendation is based on high-quality evidence, as 
further evidence accumulates it is unlikely to change, however if it is based on low-quality 
evidence, then it has the potential to change subject to new evidence generation (Guyatt 
et al., 2012). It is therefore important that the strength of evidence is reported 
transparently, so that users are aware of the changeability of recommendations.  
There are a number of evidence appraisal systems available to facilitate grading, the most 
common being the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) and Oxford Centre for Evidence-Based Medicine Levels of Evidence 
(OCEBM 2011). Both are validated and posited as highly credible and reliable systems, 
however based on a recent high-quality SR, the GRADE system was considered the most 
useful, as it goes beyond just rating evidence, providing a framework to guide SR (Atkins et 
al., 2004). Furthermore, it is comprehensive and flexible in nature, and includes all 
consumers’ views and preferences (Johnston and Dijkers, 2012).  
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The notion of the EBM hierarchy is somewhat contentious because CGs are designed to be 
applied in real world practice, thus external validity (highest in observational studies) 
should be of particular importance. This issue is particularly apposite in NGB where there 
is dearth of high-quality research, thus a need for new evidence generation, however RCTs 
are difficult to conduct because of the vulnerability of the patient population (Section 4.7). 
Despite this, the explicit use of grading systems underpinned by the philosophical concept 
of the EBM hierarchy (i.e. the GRADE and OCEBM) garners high marks in the AGREE II 
appraisal. 
3.3.3 Stakeholder Involvement  
A stakeholder is anyone with a legitimate interest in the CG (Cluzeau et al., 2012). The 
involvement of a broad range of stakeholders allows the integration of several unique 
perspectives on optimal healthcare, aids in the prioritisation of important topics, and 
minimises bias towards certain treatment options caused by conflict of interest (Rosenfeld 
and Shiffman, 2009). In order to integrate stakeholder views successfully, their involvement 
needs to be ‘inclusive, equitable, and adequately resourced’ (Cluzeau et al., 2012: 269). 
Experts working in the field of neuro-urology, such as urologists, gynaecologists, urology 
nurses as well as neurologists have superior knowledge of disease pathological processes 
and possess vital experiential knowledge of managing patients in clinical practice. Their 
involvement in the development group is integral, both in assessing objective evidence and 
in providing expert opinion in the absence of high-level evidence (Eibling et al., 2014).  
As the recommendations will ultimately affect patients, it is internationally recognised that 
their involvement is a critical component of CG development (Armstrong et al., 2017; Boivin 
et al., 2010). Active participation of patients encourages public confidence and acceptance, 
which can in turn increase the likelihood of adherence to recommendations. 
There are a number of ways to assimilate the patient voice into recommendations. At the 
macro-level, patients could be involved in topic selection for the CG via passive means such 
as submitting topics for discussion. Alternatively, they may have direct input into the SR, 
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however the relevance of patient involvement is debated due to the scientific complexity 
of the task (van de Bovenkamp and Trappenburg, 2009). At the micro-level, CGs can be 
used to stimulate consideration of individual patient values and preferences during their 
interactions with their healthcare provider (van der Weijden et al., 2010). Out of all 
methods, active involvement in the development team is considered the optimal way to 
integrate the patient voice into CGs (Armstrong and Bloom, 2017).  
Primary care is where the bulk of prescribing normally takes place therefore it is also 
necessary to glean insights from GPs, who are at the forefront of patient care. Limited 
involvement from this stakeholder group can result in a reluctance to utilise the CGs due 
to the inevitable limited applicability in primary care (McKinlay et al., 2004).  
There are some important barriers that must be overcome to ensure the optimal inclusion 
of patients and GPs. This includes reconciling their views with experts, gaining clarity 
around their roles in the development team, and ensuring adequate representation. An 
additional requirement to integrate patients is finding the resources for training to aid 
them in their evaluation (van der Ham et al., 2016).  
3.3.4 Implementation and Dissemination Techniques  
Implementation refers to the promotion of the systematic uptake of EBM into routine 
practice. Dissemination is closely linked, referring to the spread of new practices to target 
audiences through planned strategies (Schillinger, 2010). Even if CGs are created with the 
highest possible scientific and methodological rigour, it is still not possible to ensure the 
translation of EBM into routine practice without superior and targeted implementation and 
dissemination strategies. Unfortunately, many best efforts to improve CG uptake often go 
unfulfilled, with non-compliance reaching as high as 70% across many countries and 
disease areas (Barth et al., 2016). Furthermore, around 30–40% of patients still receive care 
that is not in line with up-to-date research, and more alarmingly, 20-25% receive care that 
is unnecessary or potentially harmful (Fischer et al., 2016). Poor implementation and 
dissemination can also have a negative impact on timely rates of correct diagnosis.  
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Common barriers to uptake of CGs pertain to a lack of available resources, resistance to 
changing long-established clinical practices, and the difficulty of implementing complex 
recommendations. Uptake can be improved through the formulation of tailored 
approaches, based on an assessment of local barriers and available resources (Carey et al., 
2009; Grimshaw et al., 2012). Additionally, interactive education and training for HCPs has 
been found to enhance knowledge, skills, attitudes and clinical behaviour, thus increasing 
chances of them utilising the CGs (Kastner et al., 2015).  
Clinical Decision Support Systems (CDSS) represent a sophisticated computational means 
by which CGs can be fully integrated into clinical practice. CDSS are defined as:  
Software that are designed to be a direct aid to clinical decision-making, in which the 
characteristics of an individual patient are matched to a computerized clinical knowledge 
base and patient-specific assessments or recommendations are then presented to the 
clinician or the patient for a decision (Sim et al., 2001: 528).  
They are flexible enough to provide individual patient-specific advice, whilst allowing the 
clinician to exercise their personal judgement where they feel the recommendation is not 
applicable. Clinicians are able to input reasons for deviation into the system, as well as 
which alternatives were employed instead, adding to the body of knowledge around 
management pathways (Fox et al., 2009). Although CDSS are not the magic bullet to 
implementation, and several challenges in information technology (IT) infrastructure 
impede full success (O’Sullivan et al., 2014), recent meta-analyses have demonstrated 
promising improvements in health outcomes (Bright et al., 2012; Fillmore et al., 2013).  
3.3.4.1 Health Economics  
Burgeoning healthcare expenditure coupled with the expansion of new technologies and 
healthcare innovation means that integration of economic analyses within CGs and 
consideration of the wider impact on population health and inequalities are essential 
(Eccles et al., 2000; Da'ar and Al Shehri, 2015). Healthcare systems, policy makers and 
payers often depend on CGs to maximise the cost-effectiveness of healthcare (Eccles and 
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Mason, 2001). However, despite the proliferation in CGs over the last two decades, 
incorporation of resource implications and costs remains low. A study conducted in the 
USA found that only 26% CGs incorporated at least one economic analysis of above-average 
quality (Wallace et al., 2002). 
Moreover, clinicians are often resistant to the uptake of CGs, and are seldom swayed by 
economic arguments (Tunis et al., 1994; Ramsey, 2002). This is primarily due to a lack of 
understanding around the fundamentals of health economics, and a sense of moral 
responsibility towards their patients, causing them to be less inclined to choose less-
effective, but cheaper interventions (Wailoo et al., 2004).  
Without systematic implementation of cost-effectiveness at a regional or national level, 
clinicians inevitably end up making their own subjective choices on how to best manage 
budgets, which introduces inconsistency and variation across practices. Treatments are 
applied until there is no more health to be gained, which will ultimately lead to the 
exhaustion of resources (Ramsey, 2002). The acceptance of health economics is contingent 
upon training and education; helping clinicians to develop an appreciation for the fine 
balance between the human aspect of healthcare and scarcity of resources (Eddy, 1999; 
Oladokun, 2016). This will encourage both clinicians and budget allocators to accept the 
principle which advocates the application of treatments continually until health returns 
diminish in relation to costs so as to improve the efficiency of care (Oladokun, 2016). 
3.3.5 External Review 
According to Shekelle et al (2012), criticism from external reviewers can enhance CG quality 
in four ways: 
1) Checking the accuracy, comprehensiveness, and balance of the scientific evidence 
2) Checking the validity of the rationale for recommendations 
3) Feedback on the clarity and feasibility of recommendations 
4) Engagement of stakeholders  
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The external reviewers may identify additional studies that were previously overlooked and 
issues with ambiguity or methodological/statistical errors. External review also provides an 
additional opportunity to eliminate any specialty or society bias that may exist (Fulda, 
2014).  
Views can be sought either through invited peer review, where individuals or groups are 
chosen based on their perceived ability to contribute valuable criticism, or they may be 
sought via public consultation, where anyone with an interest in the CGs can provide 
comments (Shekelle et al., 2012).  
3.3.6 Clarity and Presentation  
Recommendations should be easily identifiable, specific and unambiguous. Ease of 
information visualisation is intrinsically linked to the applicability of CGs, thus it is important 
that due attention is given to presentation (Kastner et al., 2015). 
3.3.7 Conflict of Interest and Funding Bias 
In order to preserve the integrity of CGs and ensure confidence in the resulting 
recommendations, organisations should make every effort possible to ensure editorial 
independence. This is only possible with a commitment to openness, transparency and 
communication (Matias-Guiu and Garcia-Ramos, 2010).  
Funding bias refers to the tendency of CGs to support the interests of the financial sponsor. 
Electing unbiased sponsors or erecting a firewall between developers and the sponsor can 
mitigate against this type of bias (Lexchin, 2012).  
Research suggests that CG developers are more likely to positively favour the commercial 
products being evaluated if they have vested financial, personal or family interests with the 
pharmaceutical company responsible for developing the intervention; this is known as 
conflict of interest (Lenzer et al., 2013; Shnier et al., 2016). This can pose an ethical dilemma 
for clinicians who may reluctantly follow recommendations despite the knowledge that 
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they are compromised by conflict of interest, potentially putting patients at undue harm 
(Lenzer, 2013). The way that conflicts are handled is of utmost importance, for example 
individuals with relevant conflicts may not be permitted to participate in the formulation 
of certain recommendations. 
It is perhaps naïve to assume that key opinion leaders (KOLs) can ever be truly free of 
conflict of interest. It has been postulated that even if individuals genuinely do not have 
any conflict, they may be biased by their desire to work in industry in the future, although 
of course this is a type of conflict that cannot be avoided by any measures (Garrison, 2016). 
Some alternative opinion suggests that financial relationships with industry could provide 
unique and important expertise into the input of CG development (Institute of Medicine, 
2009).  
3.4 Evolution of Neurogenic Bladder Clinical Guidelines  
The three most prominent CGs in NGB are those produced by the NICE, EAU and ICI. This 
section will provide background information on the institutions and detail the 
methodological evolution of the CGs. 
The International Consultation on Urologic Disease (ICUD) is a non-governmental 
organisation registered with the World Health Organisation (WHO). The ICI is a sub-
committee of the ICUD, tasked with developing recommendations with worldwide 
relevance for lower urinary tract dysfunction (LUTD) (Khoury et al., 2000).  
Under the initiative of the WHO, the Scientific Committee of the First International 
Consultation on Incontinence gathered in 1998. Based on conclusions drawn at this 
meeting, the ‘neurogenic incontinence’ sub-committee devised the earliest 
recommendations for NGB in 2000, which were published in the Lancet scientific journal 
(ICI, 2000). The recommendations were top level; confined to just initial management in 
exclusively incontinence issues. Only two paragraphs worth of recommendations and one 
treatment algorithm were presented. Although the methodology involved systematic 
reviewing of literature, the recommendations were not graded using a validated system. 
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The second international conference took place a year later and resulted in a more 
comprehensive set of recommendations, published in the form of a book in 2002 (Abrams 
et al., 2002). The CGs tackled a wider range issues not covered in the initial publication; this 
included urinary retention, adverse events (AEs) of treatments, and patient education. This 
demonstrates the increased effort towards better quality CGs, which only enhanced in 
forthcoming years of publication. The committee sought evidence to answer particular 
questions relating to interventions: 
1) How and when to do it? 
2)  Is it effective? 
3) Is it safe? 
4) Is it cost-effective? 
5) Complications and how to treat them  
They also provided conclusions (with levels to signify the strength of underlying evidence), 
as well as graded recommendations (to signify the strength with which the authors 
recommend interventions).  
In the latest CGs, a broad range of urological dysfunctions are covered. Members of the 
working group performed SRs and updates to compile the CGs. The most recent 
recommendations are based on evidence and conclusions drawn in the 2013 meeting in 
Tokyo and were published in 2017 (Apostolidis et al., 2017).  
The EAU is a non-profit organisation that formed in 1973, with the aim of improving 
urological practice, research and education across Europe and beyond. They develop CGs 
on a wide range of urological topics, including in ‘neuro-urology’ (NGB). The first NGB CGs 
were released in 2003, shortly after the second edition of the ICI CGs. Unlike the ICI, who 
explicitly stated their publication is not to be considered as CGs or SOC, the EAU CGs were 
designed to be applied directly in clinical practice. The first edition of the EAU CGs were not 
graded, instead, they reflected the current opinion of experts, rendering them less superior 
in rigour of development than the ICI CGs at this point in time. The most recent edition of 
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the EAU CGs, published in 2017, are of a substantially higher quality, using a validated 
grading system and incorporating comprehensive systematic reviewing techniques. 
NICE was founded in 1999 with the aim of reducing unwarranted variation in care and 
encourage the fast uptake of innovations in clinical practice across the UK (Chalkidou, 
2009). The institute provides evidence-based clinical care guidance for the National Health 
Service (NHS) through multiple initiatives. They pioneered their CG development 
programme in 2002 (NICE, 2018c). The first (and thus far, the only) NICE CGs for NGB 
entitled ‘urinary incontinence (UI) related to neurological disease’ were developed in 2012, 
considerably later than the ICI and EAU. As the name implies, the CGs are only concerned 
with UI, purposefully omitting urinary retention issues. They target both children and adults 
and were specifically designed for application to clinical practice in UK healthcare settings. 
As the field of EBM had made considerable strides by this time, the first NICE NGB CGs were 
significantly more robust than the earlier versions of the ICI and EAU.  
With each new edition of the EAU and ICI CGs, the organisations adopted a more systematic 
and structured processes of development, which has seen the scientific rigour and 
consequently, their credibility also improve. Today, all three CGs have evolved to become 
well-respected and consulted documents for urologists, other HCPs and patients alike. 
Their influence reaches internationally and are often used as the basis for many national 
CGs.  
3.5 Critical Appraisal of the NICE, EAU, and ICI Clinical Guidelines for 
Neurogenic Bladder Using the AGREE II Instrument. 
3.5.1 Introduction 
The development process (Section 3.3) differs between CGs, primarily on account of the 
differing goals and objectives of the institutions, the amount of financial resources available 
and disparate organisation membership. For example, some developers employ rigorous 
SR techniques whilst others weigh more heavily on expert opinion. Another key 
differentiating factor is the weight given to health economics, whereas some CGs include 
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well-integrated economic analysis to determine the most cost-effective management 
strategies, others focus solely on clinical outcomes. Consequently, the quality of resulting 
CGs also varies, which can have implications for clinical practice. 
The history and growth of the NICE, EAU and ICI CGs for NGB was described in Section 3.4. 
In order to determine their current value in clinical practice and decipher where 
improvements are necessary, their quality was assessed using the AGREE II instrument. The 
following section describes the methods utilised and results from the study. 
3.5.2 Aim 
The aim of this study was to critically appraise the quality of three principal CGs for NGB 
using the AGREE II instrument.  
3.5.3 Methods 
3.5.3.1 Instrument Selection  
In order to avoid the duplication of efforts an SR by Siering et al (2013) was the main source 
of information for instrument selection, supplemented by other evidence from the 
literature. Siering et al (2013) identified 40 different appraisal instruments, exemplifying 
the sheer amount of choice researchers are faced with when planning a quality appraisal. 
Options include the AGREE II instrument, the Deutsches Instrument zur methodischen 
Leitlinien-Bewertung (DELBI) and GuideLine Implementability Appraisal (GLIA), amongst 
others. The choice of appraisal instrument ultimately depends on the type of assessment 
that needs to be carried out. Many instruments provide an intricate assessment of quality, 
specifically targeted towards CG developers and decision makers in health policy. These 
instruments often contain multiple assessment criteria, which can be too burdensome to 
use within clinical practice and as a result more rapid assessment instruments with 
primarily busy clinicians in mind have also been developed (Siebenhofer et al., 2016). 
Most of the appraisal instruments identified in the SR by Siering et al (2013), were 
concerned with assessing the technical aspects of CG development, principally pertaining 
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to the evaluation and synthesis of evidence and the formation of recommendations (88% 
of appraisal systems looked at the evidence evaluation process). Only 50% of the appraisal 
tools covered dissemination, and 45% covered implementation and final evaluation, 
highlighting an issue around the exclusion of many pertinent aspects affecting CG 
development (Qaseem et al., 2012).  
An appraisal instrument that adopts a mixed methods approach provides the most 
effective assessment. This includes a scoring system that enables a formal quantification of 
the assessors’ opinions thus allowing systematic cross-comparison, as well as a qualitative 
assessment as a means to contextualise the scoring decision (Qaseem et al., 2012). The SR 
by Siering et al (2013) found that only 20 (50%) of the instruments identified incorporated 
a scoring system, which severely limits their ability to provide a trustworthy appraisal.  
The most renowned appraisal instruments for comprehensive assessment are the DELBI 
and AGREE II, with the latter being the internationally preferred instrument for developing 
and assessing CGs (Grimmer et al., 2014). The AGREE II instrument replaces the original 
AGREE instrument that was created in 2003 and contains modifications to items in several 
domains such as ‘scope and purpose’ and ‘applicability’. The DELBI instrument contains 34 
items, organised into eight domains (Beyer, 2006). The developers state that the 
instrument represents what high quality CGs should look like within the German healthcare 
system, and accordingly have a domain named “Applicability to the German Healthcare 
System”. Omitting this domain allows the DELBI to have international relevance.  
The AGREE II and DELBI both cover pertinent aspects of CG development, contain 
quantitative and qualitative assessment, and can be applied across a broad-range of 
settings. The AGREE II has been evaluated for reliability, whereas the DELBI tool has not 
(Siering et al., 2013). Validation is essential to verify the instrument is measuring what it is 
supposed to measure (Lai, 2013).  
If more emphasis should be given to clinical content, then the ADAPTE (assessment module 
from the ADAPTE Manual and Toolkit) is a trustworthy choice. The instrument is unique, as 
it was developed for the adaption of local CGs from one cultural setting to another. 
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Although this instrument has been validated, its use is limited to appraisers who are highly 
skilled in EBM (Siering et al., 2013). If the main purpose is to assess the implementability of 
CGs in clinical practice then the GLIA instrument, developed by the Yale Centre for Medical 
informatics should be utilised. Some ‘global questions’ relate to the wider quality of the 
CGs but there is no scoring system attached to these items (Shiffman et al., 2005).  
Based on this mini-review of the literature, it was concluded that whilst there are clear 
merits in all appraisal instruments, the AGREE II is the only previously validated instrument 
that covers all pertinent aspects of CG development. The instrument uses a scoring system 
and incorporates a qualitative assessment, allowing the most accurate and interpretable 
scoring of results. In addition, the aim of this review was to provide a comprehensive 
evaluation of NGB CGs therefore rapid assessment tools were not suitable.  
A newer systematic review of appraisal instruments was also available (Buccheri & Sharifi, 
2017). This was only discovered after conduction of the present study; therefore, it was not 
considered during selection of an instrument. This could be considered a limitation. 
Furthermore, not conducting a novel review for the purposes of instrument selection may 
also be considered a limitation. 
3.5.3.2 The AGREE II Instrument  
The present author (AJ) and a second reviewer (ES), independently assessed the quality of 
the NGB CGs using the AGREE II instrument. One of the appraisers (AJ) is experienced in 
the field of EBM, urology and health economics. The second appraiser (ES) is a urologist by 
training with advanced knowledge in EBM. The appraisers underwent the official AGREE II 
training available online (AGREE, N.D).  
The AGREE II instrument has proven to have acceptable reliability and construct validity, 
with statistically significant (p <0.05) differences found between high and low quality CGs 
in 20 of the 23 items it is composed of (Brouwers et al., 2010). The items are grouped into 
six domains: (1) scope and purpose (items 1-3), (2) stakeholder involvement (items 4-6), (3) 
rigor of development (items 7-14), (4) clarity and presentation (items 15-17), (5) 
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applicability (items 18-21), and (6) editorial independence (items 22-23). Table 3.1 displays 
the instrument domains including the questions (items) that comprise them.  
 
Table 3.1 The Appraisal of Clinical Guidelines for Research and Evaluation (AGREE) II 
instrument  
Domain Questions 
One – scope and purpose 
 
1. The overall objective(s) of the guideline is (are) specifically 
described. 
2. The health question(s) covered by the guideline is (are) 
specifically described. 
3. The population (patients, public, etc.) to whom the 
guideline is meant to apply is specifically described. 
Two – stakeholder involvement 4. The guideline development group includes individuals from 
all relevant professional groups. 
5. The views and preferences of the target population 
(patients, public, etc.) have been sought. 
6. The target users of the guideline are clearly defined. 
Three – rigour of development 
 
 
 
 
 
 
 
 
 
 
7. Systematic methods were used to search for evidence. 
8. The criteria for selecting the evidence are clearly described. 
9. The strengths and limitations of the body of evidence are 
clearly described. 
10. The methods for formulating the recommendations are 
clearly described. 
11. The health benefits, side effects, and risks have been 
considered in formulating the recommendations. 
12. There is an explicit link between the recommendations 
and the supporting evidence. 
13. The guideline has been externally reviewed by experts 
prior to its publication. 
14. A procedure for updating the guideline is provided. 
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Four – clarity of presentation 15. The recommendations are specific and unambiguous. 
16. The different options for management of the condition or 
health issue are clearly presented. 
17. Key recommendations are easily identifiable. 
Five – applicability 18. The guideline describes facilitators and barriers to its 
application. 
19. The guideline provides advice and/or tools on how the 
recommendations can be put into practice. 
20. The potential resource implications of applying the 
recommendations have been considered. 
21. The guideline presents monitoring and/or auditing 
criteria. 
Six – editorial independence 22. The views of the funding body have not influenced the 
content of the guideline. 
23. Competing interests of guideline development group 
members have been recorded and addressed. 
 
Each item is rated on a seven-point Likert scale, where the score increases as more criteria 
are fulfilled (seven correlates to strongly agree) (Figure 3.2). It is important to note that a 
score of 1 does not necessarily mean that the item criteria was not fulfilled, instead this 
could represent a lack of relevant information available to the appraiser to assign an 
appropriate score. However, this in itself could be considered a limitation as it indicates the 
development methodology is not transparent enough. The information used to appraise 
the instrument can be derived from the CG itself or supplementary information such as a 
technical development document. There is the chance for the appraiser to input qualitative 
reasoning for the score of any item.  
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Strongly 
Disagree 
1 2 3 4 5 6 7 Strongly 
Agree 
No information/poorly reported                                                                                  Full criteria has been met                                                                          
Figure 3.2 Likert scale AGREE II rating system 
 
The domain scores were calculated by the following equation, formulated by the AGREE II 
developers: 
(Obtained score – Minimum possible score) 
(Maximum possible score – Minimum possible score) 
Where the: 
 Obtained score is the sum of the individual all possible item scores by all appraisers 
 Minimum possible score is the minimum possible score by any appraiser x n items 
x n appraisers 
 Maximum possible score is the maximum possible score by any appraiser x n items 
x n appraisers (AGREE, 2013) 
The instrument also asks appraisers to make two additional assessments; on the overall CG 
quality, using the Likert scoring system, and on whether they would recommend the CGs 
for use in clinical practice, whilst taking into account their appraisals from the main six-
domain review. The options for the latter question are ‘Yes’, ‘Yes with modifications’ or 
‘No’. The overall assessments are calculated independent of the main six-domain review.  
3.5.3.3 Interrater Reliability  
Given that the AGREE II appraisal is ultimately a subjective exercise, it is highly likely that 
the appraisers assigning scores interpret the evidence relating to each domain differently. 
In order to demonstrate the degree of confidence in the study results the interrater 
reliability was calculated in two ways; the intraclass correlation (ICC) and the Cohen’s Kappa 
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statistic (McHugh, 2012). The IBM SPSS Statistics v. 24 (IBM Corporation) package was used 
to calculate these statistics.  
3.5.3.3.1 Intraclass Correlation 
The ICC reflects the degree of correlation and agreement between measurements and is 
deemed an appropriate choice of statistic in evaluating the interrater reliability of 
reviewers (Burton, 2000). The range of ICC is between 0 and 1, where the closer to 1 a score 
is, the smaller the variation between scores of raters on each item (Koo and Li, 2016). The 
ICC score is interpreted as per Table 3.2 below.  
 
Table 3.2 Interpretation of intraclass correlation scores  
Reliability Values 
Poor >0.49 
Moderate 0.5-0.74 
Good 0.75-0.89 
Excellent 0.9-1 
Values derived from: Koo and Li, 2016 
 
The same two independent appraisers rated each domain, and the sample of raters were 
selected from a larger population, therefore a two-way random effects model, based on a 
single rater was chosen. The level of absolute agreement between raters was measured. 
Based on the overall form of the chosen model, the following calculation was used to 
calculate the ICC (McGraw and Wong, 1996): 
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𝑀𝑆𝑅 −𝑀𝑆𝐸
𝑀𝑆𝑅 + (𝑘 − 1)𝑀𝑆𝐸 +
𝑘
𝑛 (𝑀𝑆𝐶 −𝑀𝑆𝐸)
 
MSR= mean square for rows; MSE = mean square for error; MSC= mean square for columns, k= 
observations per object of measurement 
3.5.3.3.2 Cohen’s Kappa Statistic  
There are some inherent limitations in using the ICC in the context of this study. The ICC 
relies on the underlying assumption of normality, however the AGREE II items are scored 
using a Likert scale, which does not produce normally distributed data, making its use 
questionable. This statistic was incorporated into this analysis as an overwhelming number 
of publications using the AGREE II instrument have made use of the ICC, thus comparability 
is made easier by using the same statistic (Zhang et al., 2013; Smith et al., 2015; Lucendo 
et al., 2017). 
The Cohen’s kappa statistic was calculated in addition to the ICC, to improve the statistical 
integrity of the interrater reliability analysis. This statistic is often used to calculate the 
interrater reliability when using categorical data and was developed to account for the 
possibility that raters guess on some variables due to uncertainty (McHugh, 2012). Similar 
to the ICC, the range is between 0-1, although occasionally negative scores are observed 
(Kvalseth, 2015). The interpretation of Cohen’s Kappa can be found in Table 3.3. 
 
Table 3.3 Interpretation of Cohen’s Kappa Statistic  
Reliability Values 
No agreement <0 
Slight 0.01-0.2 
Fair 0.21–0.40 
Moderate 0.41– 0.60 
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Substantial  0.61–0.80 
Almost perfect 0.81–1.00 
Values derived from: McHugh, 2012 
 
The Cohen’s Kappa is based on the chi-square table, and is derived through the following 
formula:  
k =
𝑃𝑟(𝑎) − Pr⁡(𝑒)
1 − Pr⁡(𝑒)
 
Pr(a), actual observed agreement; Pr(e), chance agreement 
 
The expected chance agreement, or Pr(e) is calculated via the following calculation: 
 
(
(𝑐𝑚1) × (𝑟𝑚1)
𝑛 ) + (
(𝑐𝑚2) × (𝑟𝑚2)
𝑛 )
𝑛
 
m1 =column 1 marginal; cm2 =column 2 marginal; rm1 =row 1 marginal; rm2 =row 2 marginal; n=the 
number of observations (not the number of raters) (McHugh, 2012) 
3.5.3.3.3 Confidence Intervals 
95% confidence intervals (CIs) were used to measure the level of uncertainty around the 
results. If the CI crossed zero, the result was considered non-significant, and the CI was not 
reported in such an instance.  
3.5.3.4 Data Management 
All appraisals were conducted using the online AGREE II appraisal platform, named ‘My 
AGREE PLUS’. The system automatically calculates the scaled domain percentage scores 
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using the calculation displayed in Section 3.5.3.2. These scores were then copied into an 
SPSS document to calculate the ICC and Cohen’s statistic. 
3.5.3.5 Ethical Considerations 
Ethical considerations were not applicable as this study utilised CGs that have already been 
published and there was no handling of and patient sensitive data. 
3.5.4 Results 
The NICE CGs were deemed highly compliant to the AGREE II domains and received an 
overall score of 92%. They scored highest in stakeholder involvement domain (94%), and 
the lowest scoring domains were clarity of presentation and scope and purpose (86% in 
both domains). The EAU CGs received an overall score of 83%, the highest scoring domain 
was clarity of presentation (89%) and the lowest scoring domain was the applicability 
domain (63%). The ICI CGs achieved the lowest overall score (75%) amongst the CGs. The 
highest scoring domain in this CG was clarity of presentation (94%) and the lowest scoring 
domain was applicability (54%) (Table 3.4 and Figure 3.3). The individual appraisal results 
for each CG can be found in Appendix 6. 
 
Table 3.4 Scaled domain percentages for AGREE II domains in the appraisal of neurogenic 
bladder clinical guidelines  
 
Scope 
and 
purpo
se  
Stakehol
der 
involvem
ent  
Rigour of 
developm
ent 
Clarity of 
presenta
tion 
Applicabi
lity 
Editorial 
independ
ence 
Over
all 
score 
Recommen
ded for 
use? 
ICI 89% 67% 77% 94% 54% 79% 75% Yes, with 
modificatio
ns - 2 
EAU 83% 78% 79% 89% 63% 88% 83% Yes, with 
modificatio
ns - 2 
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NICE 86% 94% 89% 86% 90% 88% 92% Yes - 1, 
Yes, with 
modificatio
ns - 1 
Avera
ge 
(95% 
CI) 
86% 
(82.6
%-
89.5%
) 
79.7% 
(64.3%-
95.1%) 
81.7% 
(74.4%-
89%) 
89.7% 
(85.1%-
94.3%) 
69% 
(47.8%-
83.2%) 
85% 
(79.1%-
90.9%) 
83.3
% 
(73.7
%-
92.9
%) 
 
NICE, National Institute for Health and Care Excellence; EAU, European Association of Urology; ICI, 
International Consultation on Incontinence; CI, confidence interval 
 
 
NICE, National Institute for Health and Care Excellence; EAU, European Association of Urology; ICI, 
International Consultation on Incontinence  
Figure 3.3 AGREE II appraisal of neurogenic bladder clinical guidelines (domains 1-6) 
89
67
77
94
54
79
83
78 79
89
63
8886
94
89 86
90 88
0
10
20
30
40
50
60
70
80
90
100
ICI EAU NICE
  
 
 
 
92 
 
The ICC varied from low to excellent reliability; however, CIs were not significant in some 
domains, and very wide in the stakeholder involvement and applicability domains (Table 
3.5). The Cohens Kappa statistic varied from no agreement to substantial agreement, 
however most results were not significant (Table 3.6). 
 
Table 3.5 Intraclass correlation between two appraisers of neurogenic bladder clinical 
guidelines 
Domain ICC (95% CI) Degree of agreement 
Scope and purpose 0.4 Poor 
Stakeholder involvement  0.8 (0.4-1) Good 
Rigour of development 0.5 Moderate 
Clarity of presentation 0.7 (0.1-0.9) Moderate 
Applicability 1 (0.9-1) Excellent 
Editorial independence 0.3 Poor 
Where the 95% confidence interval (CI) is not presented this indicates that the CI crossed 0, therefore 
the result is not significant.  
Degree of agreement from Koo and Li, 2016 
 
Table 3.6 Level of agreement between two appraisers of neurogenic bladder clinical 
guidelines - Cohen’s kappa statistic 
Domain Cohen’s Kappa (95% CI) Degree of agreement 
Scope and purpose 0.3 Fair 
Stakeholder involvement  0.6 (0.2-0.9) Moderate 
Rigour of development 0.2 Slight  
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Clarity of presentation 0.5 Moderate 
Applicability 0.9 Almost perfect 
Editorial independence  -0.2 No agreement 
Where the 95% confidence interval (CI) is not presented this indicates that the CI crossed 0, therefore 
the result is not significant. 
Degree of agreement from Landis and Koch, 1977 
 
3.5.5 Discussion  
The study demonstrated that quality varied moderately across the AGREE II domains as 
well as between the NGB CGs. Amongst all CGs, the highest scoring domain was clarity of 
presentation and the lowest scoring was applicability. NICE achieved the highest overall 
score and the ICI achieved the lowest overall score, however all CGs were deemed to be of 
high quality and were recommended for use in clinical practice (mostly with some 
modifications, apart from one appraiser that deemed the NICE CGs did not require 
modifications).  
To the best of the researcher’s knowledge, this is the first study that assesses the quality 
of currently available NGB CGs. The aim of the following discussion is to provide an in-depth 
analysis, considering how well the NICE, EAU and ICI CGs fulfilled the requirements of the 
AGREE II domains. 
3.5.5.1 Level of Agreement Between Appraisers 
The level of agreement between reviewers varied substantially between poor to excellent 
in the ICC and no agreement to substantial in the Cohen’s kappa statistic. The two statistics 
were similar in terms of degree of agreement.  
The lowest level of agreement was observed in the editorial independence domain, where 
an ICC level of 0.3 (poor) and Kappa score of -0.2 (no agreement) was reached. The Kappa 
score demonstrated slight agreement (0.2) in the rigour of development domain compared 
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to moderate agreement (0.5) in the ICC. The applicability domain demonstrated full 
agreement between the appraisers (ICC=1), and almost perfect agreement (0.9) in the 
Kappa statistic. This was also the most significant result in the ICC, with a narrow confidence 
interval of 0.9-1. 
3.5.5.2 Scope and Purpose (Domain One)  
This domain reviews whether the overall aim of the CG, specific health questions and target 
population are described in a sufficient level of detail (Section 3.4.1) (Brouwers et al., 2010). 
All CGs scored highly in this domain. The ICI scored the highest (89%) due to the 
comprehensive way in which the patient population was described and the detailed aims 
of development. This was followed by NICE (86%) and the EAU (83%). 
Before the NICE CGs were created, the UK lacked national CGs for NGB, thus they filled an 
important gap in clinical practice. The objective of the EAU and ICI is to standardise 
urological practice across European and International spheres respectively, thus given that 
many CGs for NGB are limited to a national scope and often confined to management in 
one neurological condition, these CGs also fill a very important gap. 
According to EAU CGs, there are four aims that are of paramount importance when treating 
NGB, regardless of aetiology. Clinicians must choose the best course of management to 
ensure these aims are met. The aims, in order of priority are: 
1) Protection of the upper urinary tract 
2) Improvement of UI 
3) Restoration of some lower urinary tract function  
4) Improvement of the patient’s Quality of Life (QoL) 
These recommendations delineate the specific health benefits the EAU hope to achieve 
with implementation of their recommendations. The aims of NICE and the ICI are not as 
detailed. NICE’s objectives for their NGB CGs are ‘to improve care by recommending 
specific treatments based on what symptoms and neurological conditions people have’. 
They do not make reference to any specific improvements in patients’ health. The ICI’s 
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objectives also do not specifically relate to NGB, instead they provide overarching aims for 
all of their CGs relating to LUTD. The aims of the ICUD are: 
1)  To update present knowledge and modern management of the thematic disease 
and assess the cost-effectiveness of various diagnostic and therapeutic options. 
2)  To prepare recommendations, based on the most convincing information available, 
for a number of selected topics. 
3) To prepare, whenever possible, consensus or a widely accepted strategy concerning 
diagnosis and treatment according to evidence based medicine.  
Information on patients’ demographics, signs and symptoms, clinical results and typical 
comorbidities should be included to ensure precision in describing the target population 
(Rosenfeld and Shiffman, 2009). The ICI CGs in particular did an excellent job of accurately 
describing the NGB population. They provided context around how complex and 
heterogeneous this population is and how this introduces obstacles in proficient 
management. None of the CGs considered the common comorbidities patients may have. 
This is an important omission because comorbidities can influence the neurological 
condition, urological dysfunction, as well as modifying treatment effects. 
Both NICE and the ICI CGs present the specific health questions covered. NICE have unique 
healthcare questions for every sub-topic, relating to efficacy, safety and costs. For every 
sub-section the ICI provide a comprehensive overview of the safety and efficacy of 
treatment options. The EAU have only provided health questions sporadically, thus it is 
unclear in which manner the information in sub-sections without health questions has been 
sought.  
3.5.5.3 Stakeholder Involvement (Domain Two) 
The stakeholder representation domain evaluates the extent to which CGs have accurate 
representation from all relevant intended users (Section 3.4.3). The appraisal revealed that 
the individuals responsible for developing and providing input into the NGB CGs are notably 
dissimilar between the three organisations. Due to the exceptional consideration given to 
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stakeholder involvement, NICE scored the highest in this domain (94%). The EAU and ICI 
achieved lower scores in this domain (78% and 67% respectively). 
NICE’s principles of openness and transparency are symbiotic with their role as a public 
body (Chidgey et al., 2007). This means that their guidance is developed, not only with 
experts in the field but through a rigorous process of cross-collaboration with specialist 
and/or general physicians, as well as lay representatives. These representatives make up 
the Guideline Development Group (GDG). NICE also engages with stakeholders who may 
be affected by the CG recommendations, this includes, but is not limited to; patients, 
practitioners, local Healthwatch organisations and commercial industries related to public 
health. Registered stakeholders such as these have a considerable part to play in the 
providing feedback on the draft CGs through their highly personalised and relevant 
experiences.  
In contrast to NICE, the development groups for both the EAU and ICI NGB CGs are made 
up almost exclusively of neuro-urological experts. To their credit, the two CGs made 
considerable effort to ensure global representation of experts, which increased their 
applicability. The EAU scored slightly higher than the ICI, as where possible, they sought 
input from patients during the development of the SR questions and drafting of 
recommendations. Further information pertaining to the exact process by which the 
patient input is incorporated is not provided, which could be an indication that it is not 
done in a structured manner. In the ICI CGs some consideration given to QoL in the 
discussion of treatments; however, at present, very little input is directly sought from 
patients. The developers acknowledge that increased efforts to incorporate the patient 
voice into their CGs is necessary. 
NICE and the EAU need to improve the transparency with which the stakeholder’s 
comments are incorporated into recommendations. In other words, more information 
could have been made available on the issues patients/GPs raised and how these shaped 
the resulting recommendations.   
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It is widely accepted that broad stakeholder representation, in particular, that of patients 
is necessary in the development of CGs (Section 3.4.3.2). However, some alternative 
judgement suggests that there is in fact no empirical evidence supporting the idea that 
patient participation enhances the quality of CGs, particularly owing to the unstructured 
way in which their opinions are incorporated, and the lack of support offered to them (van 
de Bovenkamp and Trappenburg, 2009). NICE have taken measures to ensure that all 
members of the GDG have equal chance to contribute, and that lay members are offered 
training to improve their capabilities in critical evidence appraisal. This suggests that 
patient involvement has a well-integrated and accommodated for role, ensuring that their 
participation has the ability to enhance CG quality. However, despite measures to improve 
patient input, there remains some risk that the individuals involved are not accurately 
representative of that patient population as a whole. One of the requirements NICE 
advertises to participate in a GDG is the ability to understand scientific articles, which would 
suggest this opportunity is only available to highly educated individuals who represent a 
small segment of a wider lay group (van de Bovenkamp and Trappenburg, 2009).  
Neurologists are also an important, yet uninvited addition to the development group of all 
the NGB CGs. Neurologists can provide valuable insight into the issues patient’s face 
because of their primary condition, and how these interplay with their LUTD. The inclusion 
of UK neurologists into NGB CG development may however be a difficult task to achieve. 
Firstly, despite having one of the highest prevalence rates of conditions such as MS, the UK 
scores third worst in Europe for numbers of neurologists per person (MS society, 2011). 
This indicates there may be potential difficulty in recruiting UK neurologists, as their time 
is limited in a resource-deprived environment. Consequently, organisations may need to 
focus their recruitment efforts in other parts of the world. Another issue may be the 
unwillingness of neurologists to offer their time and expertise on this topic, due to a 
presumed lack of understanding on the importance of urological issues (Drake and de 
Ridder, 2017). 
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Benefits in terms of enhancing neurologists understanding of NGB are likely if they are 
actively involved in CG development. This could encourage increased uptake of the CGs by 
neurologists working in clinical practice, owing to an increased sense of ownership over the 
CGs. The development process also encourages active dialogue between neurologists and 
urologists. Communication and consensus are especially important when constructing 
recommendations for contentious issues that affect both these stakeholders. One such 
example of this is the use of central acethylcholinesterase (ACE) inhibitors that are often 
prescribed by neurologists for amelioration of cognitive functioning in patients with 
Alzheimer’s disease (AD) (Gao et al., 2013). There remains controversy over whether these 
drugs can exacerbate UI and/or cognitive impairment (Demaagd and Davenport, 2012). By 
considering the evidence and constructing these recommendations together, both expert 
opinions can be integrated and given due credence.  
3.5.5.4 Rigour of Development (Domain Three)  
This domain relates to the thoroughness with which the SR was conducted, and how results 
were synthesised. It also evaluates the link between recommendations and the supporting 
evidence, whilst asking appraisers to determine whether key concerns such as health 
benefits and risk profile were considered. The NICE SR process was deemed the most 
superior, thus achieved the highest score in this domain (score 89%). This was followed by 
the EAU (79%), the ICI (77%). 
The NICE process involves a specific team for evidence review, made up of an information 
specialist, systematic reviewer and (in most cases) an economist, who independently and 
systematically review all available evidence from RCTs and observational studies. Searches 
are conducted using a wide range of sources, including grey literature. Although the 
broadest possible search is employed, effort is also made to strike a balance between 
specificity and sensitivity of the search strategy. 
The EAU previously employed a condensed process of evidence review due to the sheer 
scale of reviewing all available literature for the 20 separate CGs that the organisation 
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develops (Aus et al., 2009). Young clinicians known as Guideline Associates (supported by 
methodologists and statisticians) appraised SRs, meta-analysis and some RCTs (as opposed 
to original research papers included by NICE). The institution recently announced a gradual 
implementation of the Cochrane methodology across their CG panels. The 2017 version of 
the NGB CGs contained three new SRs using the Cochrane methodology, thus elevating 
their score for this domain. There are plans for further SRs to be conducted where the 
appointed CGs panel will select the clinical questions. Although a step in the right direction, 
there will continue to be inconsistencies in the level of rigour for each health question until 
complete implementation of the Cochrane methodology is achieved.  
The recommendations of the ICI CGs are based mainly on the subjective knowledge of the 
experts, using evidence from a comprehensive literature search from multiple sources 
(Syan and Brucker, 2016). The topic of interest is studied collaboratively by ten 
international committee members over email and face-to-face meetings, for a period of 
two years. Members submit their conclusions and recommendations at the end of the two 
years for discussion with thousands of other colleagues at a plenary session. The committee 
members then edit a consensual summary of the recommendations, which are submitted 
to WHO and subsequently published. The consultation takes place again every 2-3 years 
(Khoury et al., 2000). Although still deemed to be of high quality, this method of 
development was considered to be less rigorous than the NICE and the EAU, and 
consequently the ICI scored the least in this domain.  
Recommendations in all three NGB CGs occasionally relied on expert opinion, which is 
evidenced by the often-conflicting guidance between them (Chapter 4). Unfortunately, as 
the evidence base underlying NGB is sparse and mostly composed of trials with perceived 
weak methodological design, such inconsistency cannot be avoided. 
All three CGs used a validated grading system to assess the strengths and limitations of the 
underlying body of evidence. In the NICE review, the GDG make the ultimate decision on 
the content of recommendations through considering both the evidence and their own 
experiences and knowledge of the disease area. Quality assurance is integrated throughout 
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the duration of the development process, ensuring there are few deviations from the pre-
determined development process and that the evidence incorporated is ‘up-to-date, 
credible, robust and relevant’, with a clear link to the resulting recommendations. 
Recommendations are based on the highest-level of evidence available. 
NICE use the GRADE appraisal system for rating the overall quality of evidence and grading 
of recommendations, however the terminology used differs slightly to the use of levels and 
grades. If there is a strong body of empirical evidence to support a recommendation, 
clinicians should ‘offer’ the treatment. If evidence is weak, then the clinician should 
‘consider’ the treatment. EAU and ICI use distinct modified versions of OCEBM 2011. In the 
EAU CGs, recommendations are given a level of evidence ranging from 1-4, as well as a 
grade from A-C to represent the strength of the recommendation. Contrastingly, the ICI 
assign a level of evidence to conclusions drawn from the literature, and then further award 
a grade to recommendations. All grading systems are viable; however, the GRADE 
methodology is generally considered superior to other grading systems (Section 3.4.2).  
External review from experts (and in some cases patients), that were not involved in the 
development of the CGs and having an explicit procedure for updating the CGs also garners 
high scores within this domain. The NICE CGs invite feedback on their draft CGs from 
stakeholders via their website for a 6-week period of public consultation. Changes may be 
made to the CGs in light of comments received. Although there is a process for external 
review, NICE do not routinely commission peer review by external experts such as 
practitioners or academics. In contrast, the ICI and EAU CGs are not crosschecked and 
validated via external means, leaving room for unimpeded error, and thus causing them to 
lose points in this domain.   
3.5.5.5 Clarity of Presentation (Domain Four)  
The clarity of presentation domain pertains to the quality of presentation of the CG and 
whether all relevant interventions have been considered. The extensive list of treatments 
analysed and compared, as well as good aesthetic considerations helped the ICI CGs 
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achieve the highest score in this domain (94%). This was followed by the EAU (89%) and 
then NICE (86%).  
All CGs developers gave apposite attention to the proper placement of visual elements, 
including diagrams and visuals where necessary. The NICE CGs are structured with the 
following headings: treatments to improve bladder storage, stress incontinence, bladder 
emptying, catheter valves, ileal conduit diversion, and treatments to prevent UTI. The 
recommendations are based on symptoms, whereas the EAU and ICI base their 
recommendations on urodynamics. The EAU and ICI CGs are structured more simply, with 
the management of NGB split between ‘Non-invasive treatment’ and ‘Surgical treatment’. 
The EAU feature further subheadings and provide additional recommendations for urinary 
tract dysfunction and sexual dysfunction. All CGs presented their final graded 
recommendations in an easily identifiable table below a comprehensive discussion of the 
evidence, which was deemed to be an informative and intuitive choice of display.  
In addition to aesthetic considerations, it is important that all possible management 
options are presented, so that end users can make fully informed clinical decisions. The ICI 
do not promote their CGs to be directly applied in clinical practice, instead they are 
endorsed as the reference document for the condition of interest (in reality however they 
may still be interpreted as CGs and be applied in clinical practice). Because of their broad 
objective, the ICI consider an exhaustive number of management strategies, many of which 
were not mentioned in the other CGs such as oestrogens, certain types of electrical 
neuromodulation, and several surgical techniques (ICUD, 2015).  
NICE did not consider an exhaustive list of treatment options which could be due to their 
narrow remit, focusing specifically on UI, consequently, they scored the lowest in this 
domain. The EAU lost points, as despite providing a thorough discussion on behavioural 
techniques, no graded recommendations were made for this type of management. the 
developers of the CG do not disclose the definite reason however the limited evidence base 
may have precluded the formation of solid recommendations. 
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3.5.5.6 Applicability (Domain Five)  
The applicability domain assesses the measures taken to improve uptake, how well uptake 
is monitored, and the consideration given to the resource implications. Implementation 
into clinical practice is considered throughout the duration of the NICE CG development 
process, thus they scored exceptionally high in this domain (90%). Scores were much lower 
for the EAU and ICI, awarded 63% and 54% respectively. Discussion of this domain is 
subdivided into implementation and dissemination, health economics, and auditing and 
monitoring.  
3.5.5.6.1 Implementation and Dissemination 
NICE consider the most important populations and the feasibility of implementation for the 
most challenging institutions during the initial scoping. This ensures their 
recommendations could be applicable to across all possible institutions, including the most 
resource deprived. 
Both NICE and the EAU have dedicated teams to promote implementation of the CGs. 
NICE’s implementation team work with local organisations to develop strategies for 
adapting recommendations locally, using two important tools, the ‘baseline assessment 
tool’ and the ‘costing statement’, which help health authorities estimate the likely financial 
impact of adopting the recommendations. The EAU strives for harmonisation in urological 
care across all EU Member States, thus they have a much larger task than NICE in achieving 
optimal implementation of their CGs. The EAU’s ‘IMpact Assessment of CGs 
Implementation and Education (IMAGINE)’ team is tasked with overcoming barriers to 
implementation and education of key stakeholders. Unfortunately, there is little 
information freely available online that explains the exact activities of the IMAGINE group. 
Perhaps due to their worldwide relevance, the ICI CGs do not have a dedicated 
implementation team. In the early years of development, a sub-committee named ‘Faecal 
Incontinence and Incontinence in the Developing World’, created tailor-made 
recommendations for countries with underdeveloped or resource-deprived healthcare 
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systems; however, this committee has not featured in the CGs, nor made 
recommendations since the second edition of publication.  
A multi-faceted approach to dissemination is necessary in order to reach the widest 
possible audience, and achieve the greatest impact (Suman et al., 2016). The EAU and NICE 
publish abridged versions of their CGs to reach a diverse range of stakeholders. The EAU’s 
abridged CGs, named ‘pocket CGs’, are aimed at busy urologists. NICE’s version is published 
on their website, which makes them easier for various stakeholders to access. 
Recommendations also appear in the ‘NICE pathways’, which are interactive flowcharts 
that provide an intuitive way to read recommendations, reaching a population that may 
otherwise have little time to read the full edition (NICE, 2018e). In contrast, the ICI do not 
actively promote dissemination of their recommendations, as they are foremost targeted 
towards ICI members and urologists. Their guidance is published as a book which is 
available for a fee from their website. A publication is also made in the journal 
‘Neurourology and Urodynamics’. The publication allows users to view the 
recommendations in a shorter, easier-to-read format; however, it is still not as accessible 
as the EAU’s pocket-guideline, or NICE’s online versions. Furthermore, passive methods of 
publication in professional journals are unlikely to change practice (Hoecke and 
Cauwenberge, 2007). Furthermore, the level of complexity of CGs has proven to be 
inversely proportional to its adoption and compliance (Scott, 2008; Gurses, 2010). 
Therefore, although the ICI CGs could be directly applied to clinical practice, their 
comprehensiveness may in fact impede the possibility of this.  
The EAU is unique from the other CGs in that it also has a designated team named the 
‘Social Media (SoMe) working group’, who are responsible for promoting the CGs on 
Facebook and Twitter by creating polls and updates highlighting key recommendations 
(Loeb et al., 2017). This is a particularly impactful means of dissemination, in an age where 
SoMe has become a frequent vehicle to disseminate medical information. The EAU is also 
endorsed by 41 National Urological Societies worldwide, who promote the CGs. 
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It is not clear whether any of the CGs are disseminated via means of CDSS, but this would 
most likely depend on individual institutions or national policies.  
3.5.5.6.2 Health Economics  
NICE are the only CG to incorporate economic evaluations into their recommendations. 
Importantly, costs are integrated during the recommendation development process (Eccles 
et al., 2000). This approach ensures that costs are not calculated in isolation of clinical 
efficacy, which would derive erroneous results (Mason, 1998).  
De-novo economic analysis is conducted where necessary, but in most cases previously 
published economic literature and relevant technology appraisals are utilised (Drummond, 
2016). One could argue that the economic evidence that was not formulated de-novo lacks 
applicability to the specific health questions asked because previously published 
evaluations are conducted from a wide range of perspectives, analytic techniques, using 
disparate baseline data (Woolf et al., 2012). 
In the UK, only certain medicines and medical devices are invited by NICE to submit health 
economic data for reimbursement, which means many new technologies are not reviewed 
(Parvizi and Parvizi, 2017). In addition, interventions introduced pre-NICE’s technology 
appraisal system have not been evaluated for their cost-effectiveness. This could introduce 
a distortion in health care policy, where newer technologies are evaluated with greater 
scrutiny than those existing in the pre-NICE technological appraisal era (Mason, 1998). In 
theory, the integrated cost-effectiveness in CGs can remedy this by providing an oversight 
of the whole disease area; reviewing all current treatments available. However, in order for 
this to happen, NICE would need to consider wider studies of multiple competing 
interventions (Drummond, 2016). Ranking interventions in order of cost-effectiveness and 
working down until the budget is completely spent has been proposed as the superior way 
to create a truly cost-effective CG (Brockis, 2016). However, this method is not feasible 
because the number and variety of interventions, patients, settings and other variables is 
too large and the resources necessary to conduct such a monumental task would be 
difficult to procure (Drummond, 2016; Birch and Gafni, 2004) 
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The CG economic evaluation is conducted in complete isolation from the NICE Health 
Technology Assessment (HTA) program via a distinct methodology, in fact the GDG is not 
permitted to access health economic data from the programme (Wilsdon, 2013; Brockis, 
2016). This lack of coordination can result in potential discrepancies in the 
recommendations made in the NICE NGs CGs and reimbursement decisions, consequently 
leading to inefficiencies for the NHS, and confusion amongst prescribers (Wilsdon, 2013). 
Due to their broad country remits, no cost assessment or consideration to resource 
constraints are given in the EAU or ICI CGs. It would be difficult to generalise costs, access 
conditions and resources across multiple countries as they have notably different 
healthcare systems and face unique challenges when it comes to resource allocation and 
cost containment. This reality casts uncertainty on EAU’s mission to harmonise urological 
care across Europe. There are however some technical solutions to transferring cost data 
that were not considered by these CGs. A study focusing on three chronic diseases; type 2 
diabetes mellitus, epilepsy and schizophrenia across multiple countries concluded that 
calculating the raw cost data into percentage of gross domestic product (GDP)/capita of 
individual country was a feasible approach to transfer the direct medical cost across 
countries (Gao et al., 2016).  
Another possible reason that the EAU and ICI did not include economic analyses is the 
paucity of high-level economic analyses in the literature. This is particularly true for NGB, 
where there is also a scarcity in basic cost data preventing de-novo analyses. Whilst charge 
data may be available, the analytical steps and assumptions required to transform it to cost 
data can be complex (Eccles et al., 2000). Large scale epidemiological studies such as the 
one presented in Chapter 6, 7 and 8 of this thesis are necessary to fill this gap.  
Alternatively, the EAU and ICI CGs may have not included economic analyses because 
interventions that demonstrate benefits in the future (for example, smoking cessation), 
rather than having immediate impact such as NGB, are more likely to include economic 
analysis, as there may be greater rationale to justify program benefits economically 
(Wallace et al., 2002).  
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Unlike the ICI CGs, the EAU CGs are intended to be directly applied to clinical practice, which 
may in fact not be possible due to the lack of attention given to costs. In particular, when 
considering a country with a weak economy, adopting costly technologies would be near 
impossible. Countries that are looking to adapt these CGs to their local healthcare systems 
should conduct their own economic assessment, taking account the issues specific to their 
country (Wise and Billi, 1995). This could nonetheless be challenging to execute, as the skills 
required for economic analysis are unlikely to be available in every local setting, and can 
also prove expensive (Drummond et al., 2003; Silagy et al., 2002). 
3.5.5.6.3 Auditing and Monitoring 
Auditing and monitoring uptake are essential to highlight whether additional 
implementation and dissemination efforts are necessary. NICE have a dedicated 
programme for monitoring CG uptake; however, this is limited to some selected CGs. Upon 
checking the ‘NICE uptake data’ page in 2018, data on the uptake of the NGB CGs was not 
available (NICE, 2018b).  
The EAU Twitter platform has been used to estimate adherence to recommendations, but 
this is not an accurate measure. The ICI CGs are used as the basis for other national CGs; 
however, they do not provide monitoring data around which institutions have utilised their 
CGs in this way.  
3.5.5.7 Editorial Independence (Domain Six) 
This domain seeks to assess how well the CGs have achieved editorial independence. In the 
first iteration of the AGREE instrument, appraisers were only asked to assess whether 
potential conflict of interest had been recorded. The AGREE II instrument goes one step 
further and asks whether provisions have been made to address the potential conflict. The 
NICE and EAU CGs have specific and detailed policies on how to manage conflict of interest; 
hence, they scored highly in this domain (88% in both CGs). The ICI scored much lower 
(79%). 
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When analysing funding sources, there seems to be little risk of bias. NICE is funded by the 
NHS, whose main goal is to provide good healthcare to all individuals in the UK, irrespective 
of wealth (NHS, 2015b). The EAU and ICI both are independent, self-funded bodies with the 
ultimate goal of improving urological care. 
None of the CGs included into this study were pharmaceutical industry funded; however, 
some of the developers did declare financial relationships with the industry, which could 
have skewed their perspectives about certain interventions. The NICE and EAU CGs place 
high emphasis on the importance of managing conflict of interest effectively. Cautionary 
measures are employed such as routinely collecting conflict of interest information (rather 
than the standard single collection at the beginning of development) and excluding 
development members from developing recommendations related to their area of conflict 
(NICE, 2014b; EAU, 2017). As with all stages of the CG development process, transparency 
in the conflict of interest process is of paramount importance. Although the ICI CG 
developers are under obligation to disclose all likely conflicts, procedures for managing 
them could not be identified, which implies their process is less rigorous than NICE and the 
EAU. For this reason, the CGs achieved a lower score in this domain. 
Despite the adoption of cautionary measures, there remain disadvantages to the current 
conflict of interest management processes. Relying upon a process of self-reporting runs 
the risk of making important omissions, and there is no other choice but to rely upon the 
honesty of all parties involved (Graham et al., 2015). Some have argued that a public 
database listing payment made to experts by the industry would increase transparency, 
however even with such a measure, it would remain difficult to list all potential conflicts 
(Norris et al., 2011).  
3.5.6 Comparison to Previous AGREE II Appraisals of Similar Clinical Guidelines  
Two studies that measured the quality of the NICE, EAU and ICI CGs in the disease area of 
urology using the AGREE II instrument were identified. Whereas one study assessing the 
quality of the CGs on urinary incontinence was more liberal in their judgement (Syan and 
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Brucker, 2016), the other study focusing on CGs for non-neurogenic male LUTD reported 
fairly similar results to the present study (Chua et al., 2015).  
In the present study and the study by Chua et al (2015), none of the CGs scored 100% in 
any domain. Conversely, all three CGs in the study by Syan et al (2016) received 100% in 
the scope and purpose, stakeholder involvement, and clarity of presentation domains. 
Furthermore, Syan et al (2016) deemed all three CGs to have excellent (100%) quality 
overall. Given there were intrinsic differences in development, and obvious issues such as 
a clear lack of stakeholder representation in the EAU and ICI CGs, the perfect scores 
awarded by Syan et al (2016) do not seem apt. 
Both our study and the study by Chua et al (2015) deemed the applicability of the ICI CGs 
to be very low, scoring them 54% and 45% respectively. In contrast, Syan et al (2016) judged 
the applicability of these CGs in clinical practice to be feasible with little to no modification 
to current development procedures, scoring them 83%. This is surprising considering the 
ICI gave very little attention to implementation and dissemination techniques.  
In some domains, such as clarity of presentation the study by Syan et al (2016) mirrored 
the results of this study more so than Chua et al (2015). In the present study, the ICI CGs 
were deemed very high quality for clarity of presentation (94%), similarly Syan et al (2016) 
gave them a perfect score (100%). Conversely Chua et al (2015) only scored the ICI CGs 64% 
in this domain.  
This comparison to other studies in this area highlights the immense subjectivity that 
comes with assessment of quality. The appraiser’s perceptions could have been 
conditioned by a number of factors such as their experience in the EBM field, the weight 
they give to each domain in the AGREE II instrument, and even the day on which they 
conducted the appraisal. These findings suggest that although inter-rater reliability may 
prove to be high within any given a study (although, both of these studies did not report 
statistics of interrater reliability), when looking across studies this may not be the case. 
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3.5.7 Limitations 
A major limitation when conducting quality appraisals pertains to the ambiguous definition 
of quality. The AGREE II developers do not provide thresholds for what should be 
considered ‘low quality’ and ‘high quality’, thus interpretation of the resulting scores was 
ultimately based on capricious human judgement. A third of AGREE II users have specified 
their own threshold level to indicate ‘high quality’ (Hoffmann-Esser et al., 2017), however 
the level is largely inconsistent across studies. Some have used the threshold of 50% to 
indicate acceptable quality, with any domain that scores <50% considered to be of limited 
use (Lo Vecchio et al., 2011). Other studies have chosen a threshold of 60% in at least three 
domains to indicate high quality (Fehlings and Nater, 2015). A valid basis for thresholds 
would require a detailed and transparent approach, whereas many studies utilising them 
did not report their rationale for choosing a particular cut-off. The inconsistency and lack 
of evidence surrounding threshold values is the reason they were not incorporated into 
this study. 
The overall assessments are scored completely independently of the main six-domain 
scores; however, the results from the main-domain assessment are still expected to be 
considered. Alonso-Coello et al (2010) noted that:  
… the validity of the overall assessment may be limited, as there were no clear rules on how 
to weigh the different domain scores in making a decision about whether or not to 
recommend the CGs (Alonso-Coello et al., 2010: e58) 
Due to the of the lack of clarity, many authors using the AGREE II instrument have 
erroneously calculated a weighted average of the six domains to comprise their overall 
assessment (Hoffmann-Esser et al., 2018). In other cases, domains three (rigour of 
development) and five (applicability) had a greater influence than the other domains in 
determining the overall score.  
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Although the number of appraisers in this study was in line with the recommendations from 
the AGREE collaboration (they recommend at least two, but preferably four appraisers), 
increasing this number could have improved the interrater reliability. The number of 
appraisers necessary to reach an ICC of 0.7 ranges from two to five across domains 
(Zeraatkar et al., 2016). Furthermore, the external validity of quality appraisal studies may 
be low due to the subjectivity of the appraisal exercise. Repetition of the assessment 
several times by multiple appraisers, and pooling together the results could remedy this 
issue.  
More information was publicly available on the NICE method; therefore, it may have been 
useful to request additional information from the EAU and ICI on their development 
process. However, given that the published CG remains the only practical source of 
information for most stakeholders, the results are most relevant without grey sources of 
information. 
One of the authors of this study (MJD) was involved in the development of the ICI CGs, 
which could have introduced an element of bias. However, they were not involved in the 
appraisal of any of the CGs, thus their involvement did not risk the study results immensely. 
In addition, three authors work in Urology Research and Development (R&D) based roles 
for a pharmaceutical company (AJ, ES & JN), which raises an important conflict of interest, 
although the fact that they are in non-promotional roles mitigated some of this bias. All 
authors are based in the UK, which could also have affected the reliability of conclusions. 
Steps that were taken to reduce bias include the same two appraisers assessed all domains 
using the AGREE II tool, and the anonymisation of results, meaning there was no 
communication during the appraisal process. 
3.5.8 Further Considerations 
Mainstream opinion suggests that attention to the quality of CGs is undoubtedly an 
important facet of development because this is what usability is ultimately dependent 
upon; however, there is some opinion to suggest otherwise. 
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A modified Delphi panel was conducted in 2008 to determine whether good technical 
quality translated into CGs that providers will find acceptable (Nuckols et al., 2008). Of the 
five CGs deemed to have excellent technical quality as determined by the AGREE II 
instrument, according to the providers, four CGs were considered moderately 
comprehensive and valid, and one CG was deemed invalid overall.  
This study highlights the current misconception that high quality CGs will automatically be 
applicable to experts working in the field. Even if feasibility issues have been addressed, 
there still remains questions around how well the CGs relate to clinical practice. This also 
challenges the significance of the EBM hierarchy, and how applicable RCTs are in real world 
decision making. The perception that observational research and expert opinion is always 
inherently of lower value should be challenged. 
3.5.9 Conclusions and Recommendations 
This study demonstrated that quality varied moderately across the AGREE II domains as 
well as between the NGB CGs. Amongst all CGs, the highest scoring domain was clarity of 
presentation and the lowest scoring was applicability. NICE achieved the highest overall 
score and the ICI achieved the lowest overall score, however all CGs were deemed to be of 
high quality and were recommended for use (mostly with some modifications). 
The lower score overall for the ICI CGs could partly be attributed to their contrasting 
purpose of development and intention of use as an international guidance document. NICE 
CGs were deemed to be of the highest quality due to characteristics such as the 
involvement of multiple stakeholders and economic evaluation of treatment options. It is 
important to note that NICE has steady funding from the UK government, which makes 
fulfilment of many of the AGREE II domains a lot easier. The EAU has some promising 
initiatives such as increased involvement of patient groups and gradual implementation of 
Cochrane methodology that will elevate the quality in coming years.  
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The findings support the importance of enhanced cross-speciality interactions, which will 
result in increased harmonisation of development methodologies, and ultimately improve 
and standardise outcomes for NGB internationally. One of the most challenging barriers 
will be ensuring the clinical and economic applicability of recommendations to a diverse 
range of healthcare systems across the globe. This will require considerable resources in 
order to conduct the distinct SRs and economic analyses for each country. Alternatively, 
aiding countries, and in some instances, states or hospitals to carry out adaptions to their 
local settings present a viable option. Considering there will be three sources of funding in 
this tripartite, resourcing will likely be manageable. NICE’s remit is to only provide guidance 
for the UK, therefore it may seem as if their resolve to be involved in an international 
venture may be missing. However, it could align with their initiative ‘NICE international’, 
which offers advice to governments around improving health policy through enhancing 
their evidence synthesis and review capabilities (NICE, 2009). 
Increased collaboration between not only experts, but also a wider range of stakeholders 
is necessary to ensure external validity of the CGs to target healthcare systems. 
Nevertheless, it is important to consider that with additional collaboration, there is a risk 
that reaching consensus may become more difficult, especially amongst institutions with 
contrasting objectives.  
3.6 Chapter Summary 
This chapter involved a novel and thorough assessment of the prominent CGs currently 
available for use in NGB, using the AGREE II instrument. The study gives assurance to users 
of the CG that they are evidence-based and follow high-quality methodological process of 
development. It also highlights several shortcomings which should be addressed to 
enhance the quality of care for NGB patients.  
The next chapter tackles a separate but indubitably connected topic of recommendations 
made in the CGs. A CG with high methodological quality production is more likely to have 
relevant and appropriate recommendations. Given that the CGs utilised distinct methods 
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of development and often relied on expert opinion, this may translate in differing 
recommendations, which can cause varying drug utilisation patterns and therefore 
variations in clinical practice.  
4) Chapter Four - Differences and Similarities in the NICE, EAU and ICI 
Neurogenic Bladder Guidelines Treatment Recommendations 
4.1 Introduction  
The previous chapter presented the Appraisal of Guidelines for Research & Evaluation 
(AGREE) II critical appraisal of the most prominent clinical guidelines (CGs) for neurogenic 
bladder (NGB). The appraisal demonstrated variations in the development processes of the 
different institutions. Given that there is only one evidence base for NGB, it is of interest to 
determine whether as a consequence of the differing development processes, the 
institutions have interpreted the data differently and whether this translated in contrasting 
recommendations.  
In this chapter, the recommendations for the management of NGB were compared 
between the CGs, to determine the level of concordance. This research provides further 
insight into how sufficient the current management of NGB patients is in clinical practice. 
Additionally, the evidence gap that persists in this disease area is investigated and possible 
solutions to closing it are put forward.  
4.2 Contrasting Recommendations in Clinical Guidelines and the 
Implications  
There are myriad treatment options for the management of NGB, supported by a 
substantial corpus of evidence (Dorsher and McIntosh, 2012). The evidence base is 
however composed mainly of trials with perceived weak methodological design, leaving 
room for subjective expert opinion and personal judgements to influence the resulting 
recommendations. This could lead to conflicting recommendations between institutions. 
Notably, the AGREE II appraisal uncovered the use of different evidence appraisal systems 
  
 
 
 
114 
(GRADE and OCEBM), which can often result in contradictory interpretations of the 
underlying evidence base. Furthermore, the incorporation of health economics in some 
CGs (NICE) and omission in others (EAU and ICI) is bound to result in divergent conclusions. 
Research in other disease areas has demonstrated that CG developers will arrive at 
different conclusions, even within national borders and despite a common evidence base 
(Burgers et al., 2002). 
Contrasting recommendations between CGs create uncertainty for healthcare 
professionals (HCPs) and patients when devising management strategies, ultimately 
leading to sub-optimal standards of care (SOC). Where one CG may advocate for the use of 
a certain technique, another may prohibit it, consequently the dilemma arises of which 
recommendation should be followed. For clinicians fearing the risk of medical negligence 
litigation, this situation can prove onerous (Samanta et al., 2006). For patients, this 
confusion can imperil their right to make informed decisions regarding treatment options. 
Contrasting recommendations can also affect the standardisation of care, which can cause 
the overuse of certain medical procedures and techniques in some geographical areas and 
underuse in others (Brownlee et al., 2017) This threatens patient health and hinders the 
ability to appropriately allocate budgets (Wallace et al., 2002).  
4.3 Aims 
The aim of this study was to assess the concordance of prominent NGB CGs. The similarities 
and differences of treatment recommendations made in the NICE, EAU and ICI CGs were 
assessed.  
4.4 Ethical Considerations 
The CGs considered in this study have already been published, additionally, there was no 
handling of and patient sensitive data. Therefore, given the descriptive nature of this study, 
ethical considerations were not applicable.  
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4.5 Methods 
The recommendations made in the three most prominent CGs for NGB were assessed 
through rigorous content analysis, incorporating a process of constant comparison of each 
recommendation appearing in the CGs. The recommendations were tabulated to aid in 
cross-comparisons and identifying similarities and discrepancies.  
4.6 Results 
4.6.1 Behavioural Management  
Behavioural techniques are summarised in Table 4.1 below. They are often used as a first 
line technique by virtue of their conservative nature (Ginsberg, 2013). Whilst no graded 
recommendations are made in the EAU CGs, they are advocated in both the NICE and ICI 
CGs, though recommendations are based on a lack of clinical evidence. The EAU may lack 
recommendations for behavioural management either due to the dearth in evidence or 
because it is often deemed unsuitable to manage patients with NGB solely through this 
method (Manack et al., 2011). Similarly, level 2 evidence in the ICI states behavioural 
management techniques should be used in conjunction with other therapies, as 
administered alone, they are not sufficient for symptom control. 
NICE advises the consideration of timed voiding (toilet breaks at timed intervals), bladder 
retraining (developing a personalised toileting schedule) and habit retraining (patient is 
encouraged to initiate own voiding through positive reinforcement). The committee makes 
this recommendation using evidence from the general elderly idiopathic population, on the 
basis that no relevant evidence exists for patients with neurological disorders. As both habit 
retraining and prompted voiding involve encouragement and reinforcement by the 
caregiver, they are especially useful techniques for patients with cognitive difficulties, 
which is a predominant symptom in neurological conditions (NICE, 2012). The ICI and NICE 
both advocate prompted voiding and NICE recommends habit retraining as an additional 
option. These techniques can be supported with behavioural modification such as purging 
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of diuretics from the diet and controlled fluid intake, but this is not specifically mentioned 
in either of the CGs (Hashim and Abrams, 2008).  
NICE recommends pelvic floor muscle training (PFMT) in potential combination with 
electrical stimulation or biofeedback in SCI or MS, or other conditions in which the ability 
to voluntarily contract the pelvic floor is present. The procedure involves repeated 
contractions and relaxations of the pelvic floor musculature, stimulating urethral closure 
(Zhu et al., 2016). In patients who have difficulty in identifying and contracting the correct 
pelvic floor muscle, electrical stimulation can be used (Yamanishi et al., 2008). Although 
not providing an explicit recommendation, the EAU mention that peripheral temporary 
electrostimulation, which involves the use of surface electrodes, combined with PFMT and 
biofeedback to control the correct contraction of the PFMT, can reduce symptoms in MS. 
The ICI make a grade C/D recommendation for electrical stimulation of the pelvic floor 
muscle in all NGB patients. 
ICI and EAU endorse expression techniques such as the Crede manoeuvre (manual 
compression of the lower abdomen) and Valsalva manoeuvre (abdominal straining), only if 
it is urodynamically safe to do so. Both CGs stress the manoeuvres are potentially 
hazardous due to potential creation of high intra-vesical pressures, and therefore where 
possible the use of these procedures should be avoided. NICE CGs do not mention 
expression techniques.  
Both the ICI and EAU provide cautionary statements on autonomic dysreflexia, a serious 
condition that can arise in patients with SCI with lesions above T6 region. Autonomic 
dysreflexia is characterised by a dramatic increase in blood pressure, and if patients do not 
receive immediate attention it can cause hypertensive encephalopathy, stroke, cardiac 
arrest, seizure and even death (Eldahan and Rabchevsky, 2018). Iatrogenic causes include 
invasive urodynamic testing and triggered voiding. The ICI specifically recommend that SCI 
units should have the capability to manage potential cases of autonomic dysreflexia.  
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Table 4.1 Behavioural management recommendations in the neurogenic bladder clinical 
guidelines by the European Association of Urology, National Institute for Health and Care 
Excellence and the International Consultation on Incontinence 
NICE EAU ICI 
Recommendations which are similar for the three guidelines 
Consider a behavioural 
management programme 
(for example, timed voiding, 
bladder retraining or habit 
retraining) for people with 
NLUTD  
 
Consider PFMT in SCI and MS 
and in neurological 
conditions where voluntarily 
contraction of pelvic floor is 
preserved. Consider 
combining with biofeedback 
and/or electrical stimulation 
No graded recommendations Behavioural techniques are a 
suitable component of the 
rehabilitation program for 
each individual (C) 
 
In patients with incomplete 
denervation and some 
voluntary contraction of the 
pelvic floor muscle and the 
striated sphincter, electrical 
stimulation may be an option 
to improve pelvic floor 
function, thus improve 
incontinence (C/D) 
Recommendations differing between the three guidelines 
 No graded recommendations Before recommending 
bladder expression by 
Valsalva or Credé, it must be 
proven that the LUT is 
urodynamically safe (B) 
 
Triggered voiding could be 
recommended only for 
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patients whose situation has 
proven to be urodynamically 
safe and stable, and who can 
manage reflex incontinence 
 
Reflex voiding can be 
recommended only if an 
adequate follow-up is 
guaranteed (C) 
PFMT, pelvic floor muscle training; SCI, spinal cord injuries; MS, multiple sclerosis; NULTD, neurogenic 
urinary lower tract dysfunction 
Grade of recommendations displayed in brackets  
 
4.6.2 Oral Pharmacotherapy  
Oral pharmacotherapy is summarised in Table 4.2 below. All CGs agree that bladder 
muscarinics are the preferred pharmacological treatment for neurogenic detrusor 
overactivity (NDO). NICE make the distinction between offering bladder muscarinics for SCI 
and MS and considering their use in brain conditions. On the other hand, the EAU and ICI 
recommend bladder muscarinics indiscriminate of underlying neurological condition. NICE 
also suggest that these strategies should only be employed if more conservative treatments 
such as bladder training have proved unsuccessful, which is in direct contrast to the ICI, 
who only advocate behavioural training in conjunction with other treatments. 
All CGs advise cautionary use of bladder muscarinics due to the increased possibility of 
adverse effects such as urinary tract infections (UTIs) and constipation (Macdiarmid, 2008). 
These drugs also have the potential to cause cognitive dysfunction by binding to the M1 
and M2 receptors in the brain (Svoboda et al., 2017) (Section 2.5.1). Therefore, the ICI and 
NICE CGs express concern of use in patients with pre-existing cognitive impairment with 
the ICI accordingly advocating the use of bladder muscarinics that are less likely to have 
further impact on cognition. Level 1 evidence states tolterodine, propiverine, trospium and 
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extended release (ER) oxybutynin have significantly less side effects compared to 
immediate release (IR) oxybutynin. Contrastingly, due to the lack of evidence 
differentiating bladder muscarinics, NICE recommend balancing the side effect profile with 
cost, rather than advocating the use of one drug over another. The EAU do not necessarily 
advocate the use of one drug over the other but present a brief evidence profile of the 
bladder muscarinics currently available on the market.   
Due to the additional increased severity of symptoms in the NGB population in comparison 
to the idiopathic overactive bladder (OAB) population the EAU suggests employing bladder 
muscarinics in combinations, and in higher doses in order to achieve optimal treatment 
effectiveness. Based on level 2 evidence, the ICI states that dual therapy (with 
combinations of oxybutynin, tolterodine and trospium) have shown positive results in some 
patients, but a graded recommendation is not given.  
At present, most bladder muscarinics do not have marketing authorisation (MA) for use in 
NGB, thus there is not a manufacturer’s recommended dose to follow, instead, it is carefully 
selected through a ‘trial and error’ approach (Kennelly and Devoe, 2008). A warning is 
featured in the EAU CGs implicating higher doses to increased rates of adverse events and 
consequently potential low adherence to medication due to lack of tolerance, however 
there was no underlying evidence to support this, suggesting this recommendation is based 
on expert opinion.  
None of the CGs describe the manner in which bladder muscarinics should be administered, 
which leaves some room for clinical discretion. In an interview with an expert, they 
described a method of administering one bladder muscarinic that acts as the principal 
method of management, and a second bladder muscarinic prescribed to consume on a pro 
re nata (PRN) basis (as and when is needed) (Drake and de Ridder, 2017). One example of 
when an individual may consume their second bladder muscarinic is when additional 
support is required in social situations where a toilet may not be easy to locate. This 
technique is not outlined in any, CGs nonetheless; it may still be widely applied by 
physicians to suit patients’ individual lifestyle requirements.  
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Although graded recommendations are not made (presumably due to the lack of evidence), 
if bladder muscarinics are not tolerated or prove ineffective, the ICI suggest the β3-
adrenoceptor agonist mirabegron as a viable alternative, as it has demonstrated 
a favourable efficacy-tolerability profile in randomised controlled trials (RCTs), particularly 
involving idiopathic OAB patients. The drug works via a different pharmacological 
mechanism to bladder muscarinics, although the exact means by which beneficial effects 
are exerted are yet to be elucidated. What is known is that the distinct mechanism of 
mirabegron avoids the systemic side effects associated with bladder muscarinics such as 
dry mouth and cognitive impairment (Chen et al., 2018). The EAU suggest combination 
therapy with mirabegron and bladder muscarinics may be an option in the future, as trials 
have demonstrated efficacy in idiopathic OAB patients (in particular with solifenacin) (Xu 
et al., 2017).  
The ICI and EAU recommend α-adrenergic antagonists for bladder outlet obstruction (BOO) 
resistance. Although previously confined for use in benign prostatic hyperplasia (BPH), a 
selective α-1 adrenoreceptor antagonist such as terazosin is effective in treatment other 
lower urinary tract dysfunction (LUTD) (Nitti, 2005). The EAU give this form of treatment a 
grade A, whereas it is a grade B/C in the ICI CGs. Conversely, α-adrenergic antagonists are 
recommended against in the NICE CGs for bladder emptying problems, as they are deemed 
not cost-effective. The GDG group also noted that patients were unlikely to experience 
better Quality of Life (QoL) from improved flow rate.  
For stress incontinence, EAU and NICE CGs both recommend against the administration of 
drugs. Conversely, the ICI state that α-adrenergic antagonists could increase stress 
incontinence.  
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Table 4.2 Oral pharmacotherapy recommendations in the neurogenic bladder clinical 
guidelines by the European Association of Urology, National Institute for Health and Care 
Excellence and the International Consultation on Incontinence 
NICE EAU ICI 
Recommendations which are similar for the three guidelines 
 Use bladder muscarinic therapy as 
the first-line medical treatment 
for NDO (A) 
 
Prescribe α-adrenergic 
antagonists to decrease BOO 
resistance (A) 
Bladder muscarinic drugs 
should be recommended for 
the treatment of NDO (A) 
 
For decreasing BOO in NGB 
a-adrenergic antagonists may 
be used (B/C) 
Recommendations differing between the three guidelines 
Offer bladder muscarinics to 
people with spinal cord 
disease (e.g. MS or SCI) and 
symptoms of OAB 
 
Consider bladder muscarinic 
drug treatment in people with 
conditions affecting the brain 
(for example, cerebral palsy, 
head injury or stroke) and 
symptoms of OAB 
 
Consider bladder muscarinic 
drug treatment in people with 
urodynamic investigations 
showing impaired bladder 
Maximise outcomes for NDO by 
considering a combination of 
bladder muscarinic agents (B) 
 
 
Do not prescribe drug treatment 
in neurogenic SUI (A) 
 
Do not prescribe 
parasympathomimetics for 
underactive detrusor (A) 
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storage 
 
Do not offer α-adrenergic 
antagonists for bladder 
emptying problems caused by 
neurological disease 
OAB, overactive bladder; NDO, neurogenic detrusor overactivity; BOO, bladder outlet obstruction; SCI, 
spinal cord injuries; MS, multiple sclerosis; NGB, neurogenic bladder 
Grade of recommendations displayed in brackets 
 
4.6.3 Minimally Invasive Techniques  
Minimally invasive techniques are summarised in Table 4.3 below. Despite the fact that 
several trials have proven its efficacy, intradetrusor injections of Onabotulinum-A do not 
have an indication for NGB (except in Switzerland), meaning that use is off label (Weckx et 
al., 2016). The treatment represents a minimally invasive strategy to control symptoms in 
patients who do not tolerate or do not experience efficacy from bladder muscarinics 
(Orasanu and Mahajan, 2013). On account of high-level evidence, the EAU and NICE 
advocate Onabotulinum-A in NDO as a consequence of SCI and MS. In contrast, the ICI 
recommends Onabotulinum-A for NDO in any underlying neurological condition. The ICI 
again diverges from EAU and NICE when it recommends Onabotulinum-A for detrusor 
sphincter dyssynergia (DSD) in SCI. 
Based on level 2 evidence, the EAU recommend alternative (non-oral) routes of 
administration of bladder muscarinic drugs including intravesical injections or intradermal 
patches. In contrast, the evidence underpinning intravesical instillation of oxybutynin is 
classified as low (level 4) by the ICI. Intravesical implant or rectal suppository are not 
mentioned in any CGs (Lai et al., 2002). Both the ICI and NICE do not provide graded 
recommendations for alternative forms of bladder muscarinic administration. 
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The ICI CGs provide a grade C/D recommendation for electrical neuromodulation 
techniques including sacral neuromodulation (SNM), anogenital stimulation, pudendal 
nerve stimulation, dorsal genital nerve stimulation, percutaneous tibial nerve stimulation, 
magnetic stimulation and deep brain stimulation. Both the EAU and ICI agree there are 
limited reports proving efficacy. 
 
Table 4.3 Minimally invasive treatment recommendations in the neurogenic bladder 
clinical guidelines by the European Association of Urology, National Institute for Health 
and Care Excellence and the International Consultation on Incontinence 
NICE EAU ICI 
Recommendations which are similar for the three guidelines 
Offer bladder wall injection with 
BTX-A with spinal cord disease 
(e.g. MS or SCI) and with 
symptoms of OAB and in whom 
bladder muscarinic drugs have 
proved to be ineffective or poorly 
tolerated. 
 
Offer bladder wall injection with 
BTX-A to adults with spinal cord 
disease and with urodynamic 
investigations showing impaired 
bladder storage and in whom 
bladder muscarinic drugs have 
proved to be ineffective or poorly 
tolerated. 
Use BTX-A injection in the 
detrusor to reduce NDO in MS 
or SCI if bladder muscarinic 
therapy is ineffective (A) 
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Recommendations differing between the three guidelines 
 Alternative routes of 
administration (i.e., transdermal 
or intravesical) of bladder 
muscarinic agents may be used 
(A) 
BTX-A should be offered as 
a treatment option for 
incontinence associated 
with NDO (A). 
 
BTX-A may be considered 
for DSD in SCI patients (B) 
 
If pharmacotherapy fails to 
relax the overactive 
detrusor, electrical 
neuromodulation (sacral 
neuromodulation (SNM), 
anogenital stimulation, 
pudendal nerve 
stimulation, dorsal genital 
nerve stimulation, 
percutaneous tibial nerve 
stimulation, magnetic 
stimulation and deep brain 
stimulation) may be 
optional in patients with 
neurogenic DO (C/D) 
BTX-A, botulinum toxin A; SCI, spinal cord injuries; MS, multiple sclerosis; NDO, neurogenic detrusor 
overactivity 
Grade of recommendations displayed in brackets 
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4.6.4 Catheters and Appliances 
Catheters and appliances are summarised in Table 4.4 below. Retention symptoms in most 
cases co-exist with storage symptoms, thus catheterisation is often necessary in 
conjunction with bladder muscarinics or Onabotulinum-A injections (Phé et al., 2016). The 
practice involves the insertion of a catheter through the urethra into the bladder to allow 
the dispel of urine. All CGs recommend intermittent catheters (IC) over indwelling catheter 
(IndUC) due to decreased risk of attributable infections, calculi and in severe cases, bladder 
carcinoma (Moussa et al., 2009).  
The use of IC is impeded by the fact that use requires a high level of manual dexterity to 
frequently insert and remove the catheter (Seth et al., 2014). This can be an issue for 
patients with certain neurological conditions, for example, those with PD often have 
symptoms of bradykinesia, severely affecting regular movement (Mazzoni et al., 2012). In 
such cases, unless assisted IC is an option, use of indwelling catheters is unavoidable. The 
ICI do not completely preclude use of IndUC, stating that short-term use is safe during the 
acute phase of neurological injury. NICE also recognise that in some instances the choice of 
management technique is limited by what the patient can manage. Patient education in 
catheterisation is encouraged by NICE and EAU CGs.  
When considering appliances to expel the urine from the catheter, NICE recommend the 
use of catheter valves over drainage bags. The ICI and EAU CGs advocate the use of condom 
catheters with a collection device in men. The ICI advises awareness on skin breakdown, 
and the EAU ask clinicians to closely monitor infection risk.  
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Table 4.4 Catheters and appliances recommendations in the neurogenic bladder clinical 
guidelines by the European Association of Urology, National Institute for Health and Care 
Excellence and the International Consultation on Incontinence. 
NICE EAU ICI 
Recommendations which are similar for the three guidelines 
When discussing treatment 
options, tell the person that 
IndUC may be associated 
with higher risks of renal 
complications (such as 
kidney stones and scarring) 
than other forms of bladder 
management (such as 
intermittent self-
catheterisation) 
Use IC, whenever possible aseptic 
technique, as a standard 
treatment for patients who are 
unable to empty their bladder (A) 
 
Avoid IndUC and SPC whenever 
possible (A) 
IC is first choice treatment for 
inability to empty the bladder 
adequately and safely in 
neurogenic voiding 
dysfunction (A) 
 
Long-term IndUC should be 
the last resort and may be safe 
only if a careful check-up of 
urodynamic, renal function, 
and upper and lower tract 
imaging are performed (B) 
Recommendations differing between the three guidelines 
In people for whom it is 
appropriate a catheter valve 
may be used as an 
alternative to a drainage bag 
 Short-term IndUC during the 
acute phase of neurological 
injury is a safe management 
for neurologic patients (B) 
 
Regular bladder emptying with 
low bladder pressures 
and low post void residual 
should be confirmed with 
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condom catheters and 
external appliances (B) 
IndUC, indwelling catheterisation; SPC, suprapubic catheterisation; IC, intermittent catheterisation  
Grade of recommendations displayed in brackets 
 
4.6.5 Surgical Management  
Surgical management is summarised in Table 4.5 below. If conservative measures have 
failed, then surgery is a viable option. All CGs recommend augmentation, a surgical 
technique designed to enlarge the bladder, using intestinal segment in refractory NDO. 
NICE consider augmentation to be more cost-effective than Onabotulinum-A in patients 
likely to benefit from treatment for more than 10 years. Therefore, although a step-wise 
approach to treatment is generally recommended, in such an instance, they recommend 
that augmentation be carried out earlier on in the treatment pathway. 
All CGs recommend use of autologous urethral slings for neurogenic SUI, which aim to 
restore the urethral support during sudden movement thus avoiding the involuntary 
leakage of urine. A lack of evidence prevents endorsement of synthetic tapes. In addition, 
there are concerns about the need for placement under tension for neurogenic SUI, due to 
sphincter deficiency. In contrast to the other CGs, the EAU recommend autologous sling 
use in female patients only due to anatomical differences to males. The ICI make further 
surgical recommendations for SUI which are not covered by the other CGs, including 
bulking agents and bladder neck reconstruction. They also present bladder neck closure as 
a last resort if all possible alternatives are unsuitable or have failed to relieve symptoms. 
Artificial urinary sphincter (AUS) works by simulating the biological urinary sphincter. It is 
the gold standard procedure for men with neurogenic sphincter deficiency, Both the ICI 
and NICE recognise the paucity of research in using this procedure in women, but do not 
exclude use in this group, conversely, the EAU only recommend use in men. NICE only 
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recommend AUS use after autologous sling procedures have failed, due to the high rate of 
re-operation within 10 years. 
According to the EAU, continent cystostomy is the preferable urinary diversion technique 
(redirect the stream of urine) in refractory NGB. Conversely, NICE do not consider evidence 
for continent cystostomy, and only provide recommendations for ileal conduit diversion. 
The ICI do not advocate one type of urinary diversion technique over the other. 
The ICI recommend urethral stenting (insertion of permeant thin tube in urthera) or 
surgical sphincterotomy (incision of sphincter) to lower bladder pressure for patients with 
DSD, in whom IC is not an option. Graded recommendations for these techniques are not 
provided by the EAU, however they state that sphincterotomy is safe and does not cause 
severe adverse events. On the other hand, although stenting has comparable efficacy, 
possible complications and re-interventions limit its use. 
Sacral rhizotomy in conjunction with sacral anterior root stimulation (SARS), which aims to 
producing detrusor contractions is given a graded recommendation by the ICI, and 
advocated in the EAU CGs, in highly selected individuals. 
Table 4.5 Surgical procedure recommendations in the neurogenic bladder clinical 
guidelines by the European Association of Urology, National Institute for Health and Care 
Excellence and the International Consultation on Incontinence 
NICE EAU ICI 
Recommendations which are similar for the three guidelines 
Consider autologous fascial sling 
surgery for people with SUI 
 
Do not routinely use synthetic 
tapes and slings in people with 
 Autologous slings can be used 
to treat SUI (B) 
 
Artificial urinary sphincter can 
be used to treat SUI (A) 
  
 
 
 
129 
SUI because of the risk of 
urethral erosion 
 
Consider surgery to insert an 
AUS for people with SUI only if 
an alternative procedure, such 
as insertion of an autologous 
fascial sling, is less likely to 
control incontinence 
 
Due to the limited evidence 
base, possible sphincter 
deficiency, perceived risk of 
complications 
and potential consequences 
on future management 
options, the Committee is 
unable to recommend routine 
use of synthetic slings and 
tapes to treat SUI in 
neurogenic patients (D) 
Recommendations differing between the three guidelines 
Consider augmentation 
cystoplasty using an intestinal 
segment for people with non-
progressive neurological 
disorders and complications of 
impaired bladder storage (for 
example, hydronephrosis or 
incontinence) 
 
For people with neurogenic 
lower urinary tract dysfunction 
who have intractable, major 
problems with urinary tract 
management, such as 
incontinence or renal 
Perform bladder augmentation 
to treat refractory NDO (A)  
 
Place an autologous urethral 
sling in female patients with 
SUI who are able to self-
catheterise. (B) 
 
Insert an AUS in male patients 
with SUI (A) 
Any segment of the 
gastrointestinal tract may be 
used for bladder 
augmentation, but the ileum 
seems to give the best results 
in terms of ease of use, risk of 
complications and efficacy (B) 
 
Synthetic tapes could be 
recommended in older women 
with stable neurological 
conditions and SUI due to 
urethral hypermobility 
(C) 
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deterioration consider ileal 
conduit diversion 
 
Bulking agents can be used to 
treat SUI when there is a 
demand for a minimally 
invasive treatment (D) 
 
Bladder neck reconstruction 
can be used to treat SUI (D) 
 
Bladder neck closure should be 
offered to patients who have 
persistent neurogenic stress 
incontinence where 
alternative treatments have 
either failed or are likely to fail 
(B)  
 
Non-continent urinary 
diversion is the last resort 
for patients with NGB (A) 
 
Ileal conduit urinary diversion 
has the best long-term results 
for non-continent diversion, if 
the following pre- and peri-
operative precautions are 
taken (B) 
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Where clean IC is not possible, 
the use of a urethral stent is 
possible (in DSD (B) 
 
Although surgical 
sphincterotomy is the 
accepted reference treatment 
for neurogenic DSD, analysis of 
the literature highlights the 
lack of reliable 
efficacy and reproducibility 
criteria for the technique (B)  
In certain situations, dorsal 
rhizotomies can be undertaken 
in association with ventral root 
stimulators 
(Brindley’s technique) or even 
with continent 
cystostomy (B) 
SUI, stress urinary incontinence; AUS, artificial urinary sphincter; NDO, neurogenic detrusor 
overactivity; NGB, neurogenic bladder; DSD, detrusor sphincter dysynergia 
Grade of recommendations displayed in brackets 
 
4.6.6 Stem Cell Treatment and Tissue Engineering  
The NICE, EAU and ICI CGs do not mention the potential of stem cell or tissue engineering 
techniques to manage bladder dysfunction subsequent to neurological disease. In contrast 
to the treatment options currently available that are only able to provide symptomatic 
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relief and are often associated with severe side effects and high rates of non-response, 
stem cell therapy and tissue engineering have the ability to halt disease progression and 
reverse the underlying pathology (Tran and Damaser, 2015; Kim et al., 2014). One example 
of regenerative medicine in the bladder is during the augmentation process. 
Gastrointestinal segment used for bladder augmentation can increase the chances of 
metabolic disturbances, urolithiasis, infection, perforation and increased mucus 
production because of differing composition and permeability compared to the bladder 
tissue (Soler et al., 2009). Utilising autologous bladder tissue provides a promising solution 
to this issue.  
Although regenerative medicine in bladder dysfunction has been conceptualised for some 
time, research into it is scarce, which could be the reason it is not mentioned in any of the 
NGB CGs. It likely to be a number of years before the clinical and funding challenges relating 
to the implementation of stem cell therapies are addressed and it is routinely used for the 
resolution of bladder dysfunction (Adamowicz et al., 2017).  
4.7 Discussion  
CGs are crucial in establishing up-to-date evidence-based medicine (EBM) in clinical 
practice. Adequate management in NGB offers benefits to the patient in terms of 
protection of the upper urinary tract, reduction in the rate of adverse sequelae and 
promotion of good QoL (Bloc et al., 2017). Additionally, widespread adoption of best 
effective practice avoids unnecessary costs to the healthcare system linked to treatment 
related adverse events. Due to varying development processes (Chapter 3), the NGB CGs 
contain discordant treatment recommendations, which can cause variation in care 
amongst patients, and across practices. Dissimilarities arose as a result of the differing 
interpretation of the underlying evidence base, varying considerations given to cost, and 
the weight given to expert opinion. Since the ICI CGs attempt worldwide relevance, they 
were most comprehensive. For example, the CGs provide extensive recommendations for 
patients with SUI, considering treatments that were not assessed in the NICE or EAU CGs.  
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The CGs generally agree on their approach to conservative management, including for 
behavioural therapies and catheterisation techniques. However, the EAU CGs lacked 
graded recommendations for behavioural management, the reason for which is unclear. 
When considering oral pharmacotherapy, all three CGs place bladder muscarinics as first 
line for NDO. Despite highlighting the potential adverse effects of these drugs, none of the 
CGs clearly acknowledges the particular concern of use in progressive neurological 
conditions (although NICE asks clinicians to ‘consider’ their use in brain conditions). Even if 
notable impairment does not already exist, the blood brain barrier (BBB) can become 
compromised, increasing the susceptibility of experiencing cognitive side effects (Section 
2.5.1). The ICI and NICE recommend further research into the use of newer bladder 
muscarinics in NGB. It is interesting to note that although the ICI CGs were published five 
years after the NICE CGs; the same recommendation is made, indicating that little progress 
has been made in the way of this particular research. This further fuels the belief that major 
institutions are not aware of the differences between bladder muscarinics that influence 
their ability to cause cognitive deficits. This has a direct influence on the knowledge and 
behaviour of prescribers and payers. 
When it comes to using a combination of bladder muscarinics, only the EAU provided 
graded recommendations. Expert consensus may have had a large influence in formulating 
this recommendation, as only evidence generated from a few small-scale RCTs currently 
exists. 
The CGs contain contrasting recommendations on α-adrenergic antagonists and 
Onabotulinum-A. Although some evidence exists demonstrating efficacy of α-adrenergic 
antagonists in NGB patients with BOO, the need for large-scale RCTs remains (Nitti, 2005). 
Despite this, they are advocated for use in the EAU and ICI CGs. Onabotulinum-A is only 
licensed for NDO in SCI and MS due to the paucity of adequate research in other 
neurological conditions. The ICI CGs still recommend Onabotulinum-A in all patients with 
NDO, regardless of underlying aetiology, thus it is evident that the EAU and NICE CGs more 
accurately reflect the evaluated patient population in this instance. In the absence of high-
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quality clinical evidence, recommendations for α-adrenergic antagonists and 
Onabotulinum-A were primarily reliant upon expert opinion. 
Disparities were most apparent in surgical treatments. One major difference between the 
EAU CGs and the other CGs were the presence of some sex-specific recommendations. 
Male autologous slings are relatively new interventions, with consequently less data 
supporting their use than female autologous slings (Groen et al., 2012). For this reason, use 
in males is not advocated the EAU CGs. On the other hand, AUS is not recommended in 
females, as physiological barriers introduce technical difficulties in implantation (Phé et al., 
2014). All CGs also differed in recommendations for urinary diversion. Whereas continent 
cystostomy is advocated in the EAU CGs, NICE recommend ileal conduit diversion. The ICI 
do not advocate any one kind of urinary diversion, which is perhaps most suitable, as 
superiority of one type of technique in terms of functionality and health related quality of 
life (HRQoL) has not yet been proven (Evans et al., 2010). The discrepancy between the 
NICE and EAU CGs is again most likely because of differing expert opinion. 
An advantage of the NICE CGs was the well-integrated economic evaluation, which aims to 
improve national healthcare efficiency in the UK. As a result, certain recommendations 
diverged from what is recommended by the EAU and ICI, for example, the option to 
introduce bladder augmentation earlier than Onabotulinum-A in the treatment pathway in 
patients likely to benefit for more than 10 years. Traditionally, invasive techniques to 
control bladder dysfunction are only carried out if non-invasive measures have failed to 
provide adequate relief. However, in such instances health economic analyses may 
conclude that breaching the traditional sequence is in fact more cost-effective in certain 
patient groups. Another analysis conducted in the UK healthcare system derived a similar 
conclusion to NICE. This study compared the 10-year costs of Onabotulinum-A to 10-year 
costs of clam cystoplasty and deemed that if symptoms were severe enough to require 4 
or more catheterisations per day, cystoplasty was the less costly choice (Lamb et al., 2010).  
It would be of interest to determine whether this recommendation is actually adopted in 
real world practice given that the health translation process is exceedingly slow, with 
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multiple sources estimating a 17-year time lag between research evidence generation and 
its enactment in clinical practice (Morris et al., 2011). This means it could take a long time 
before this recommendation is fully embedded in clinical practice. Taking an even more 
pessimistic stance, this recommendation may in fact never be adopted by clinicians. There 
may be significant resistance to abandoning a step-wise approach in favour of conducting 
invasive bladder augmentation before administering Onabotulinum-A injections; a 
considerably more conservative technique. In essence, clinicians are expected to ‘un-learn’ 
the most basic tenets of patient management practices, which is to leave surgery until 
absolutely necessary (Gupta et al., 2017). This resistance is further exacerbated by 
clinicians’ distrust of health economics (Section 3.3.7) (Wailoo et al., 2004; Gupta et al., 
2017). Due to their broad country remit, cost assessment and/or consideration of resource 
utilisation is not conducted in the EAU and ICI CGs (Section 3.6.5.6.2).  
4.7.1  Filling the Neurogenic Bladder Evidence Gap  
The underlying evidence base of a disease dictates the trustworthiness of the 
recommendations featuring in CGs (McAlister et al., 2007). In the absence of high-quality 
clinical evidence, many of the recommendations made across all three NGB CGs were 
unavoidably based on expert opinion and/or knowledge. One of the main ways in which 
the dearth in research is remedied is through the extrapolation of evidence pertaining to 
the use of treatments in idiopathic OAB to justify management practices in NGB. This was 
evident in the recommendations for behavioural techniques in the NICE CGs. Such 
extrapolation is often inappropriate, as NGB patients are distinct from the idiopathic OAB 
population; they tend to have a lower health related quality of life (HRQoL), substantial 
disability, and high rates of complications including recurrent infection, autonomic 
dysreflexia, chronic disease of the urinary tract, and sexual dysfunction (Tapia et al., 2013; 
Bodner, 2006).  
A recent systematic review (SR) showed that despite an increase in the number of RCTs in 
NGB conducted from 1976 to 2014, most of the trials contained a small number of subjects, 
thus were not adequately powered; extended over short periods, therefore were 
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insufficient to assess long-term outcomes and included heterogeneous populations, 
preventing the ability to aggregate results (Persu, 2014). The authors of the SR also noted 
that the numbers of RCTs were still low, especially when considering the review’s 30-year 
long search window, and when compared to research in other disease areas. In addition, 
the majority of research was concentrated in SCI (Figure 4.1), which creates a gap in our 
understanding of NGB related to other neurological conditions (applying evidence across 
different conditions is typically insufficient due to the vast patient heterogeneity) 
(Apostolidis et al., 2017). Ultimately, the trials were considered inadequate to reach solid 
conclusions on the optimal management and care of patients. Other reviews since 2014 
focusing on specific treatments also derived similar conclusions. One SLR on the use of 
alpha-blockers and another on the use of bladder augmentation in NGB determined that 
further RCTs are necessary in this area to determine efficacy of interventions (Schneider et 
al., 2019 and Hoen, 2017). Thus, it is evident that research efforts in NGB need to be 
enhanced.  
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Figure 4.1 Trials conducted in neurogenic bladder from the years 1976-2014 (Persu, 
2014). 
 
In beginning to construct an understanding of the evidence gap that exists in NGB, it is first 
important to consider the inherent limitations associated with RCTs. Most NGB trials are 
industry sponsored (as is the case with all RCTs), which means they are meticulously 
designed to demonstrate benefit in an ideal environment (i.e. they possess high internal 
validity) (Persu, 2014). They are carried out by highly specialised researchers, and every 
effort is made to adhere to strict protocols (Perez-Gomez et al., 2016). Moreover, the 
inclusion and exclusion criteria are very specific; selecting a narrow section of the 
population that are most likely to derive benefit from the treatment (van Spall et al., 2007). 
An SR found that industry sponsored trials were likely to exclude women, patients with high 
rates of comorbidities, high polypharmacy and low socioeconomic status, thus are not 
representative of the real-world patient population (van Spall et al., 2007). These stringent 
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controls are in place to meet the requirements of the regulatory agencies, namely the 
European Medicines Agency (EMA) and the Food and Drugs Approval Body (FDA) in the 
USA, which necessitate high quality trials demonstrating efficacy and safety, in order to 
approve a drug to market. This does however mean that outcomes are often not relevant, 
appropriate or of importance to patients in real world clinical settings (i.e. the trials have 
low external validity) (Booth and Tannock, 2014). Austin Bradford Hill in 1984 proclaimed: 
At its best such a trial shows what can be accomplished with a medicine under careful 
observation and certain restricted conditions. The same results will not invariably or 
necessarily be observed when the medicine passes into general use (Hoffman, 2015: 673). 
Due to these shortcomings of RCTs and evolving attitudes towards observational research, 
decision makers are increasingly demanding Real-World Evidence (RWE) in order to 
manage uncertainty when making reimbursement and policy decisions. The International 
Society of Pharmacoeconomics (ISPOR) defined RWE as ‘everything that goes beyond what 
is normally collected in the Phase III clinical trials program in terms of efficacy’ (Annemans, 
2012: online). RWE is created from the analysis of real-world data (RWD), which is derived 
from a number of sources including electronic healthcare records (EHRs), claims databases, 
disease registries, and health monitoring devices (Wilk et al., 2017; Ha et al., 2018). In 
contrast to RCTs, RWE represents the actuality of healthcare delivery in clinical practice, 
where patients are notably heterogeneous in terms of characteristics such as age, sex, 
ethnicity, comorbidity and polypharmacy than the patients recruited in the trials where 
interventions were tested (Cohen et al., 2015).   
Similar to the dearth in adequate clinical research in NGB, the generation of RWE also falls 
short in comparison to the plethora of research conducted for many other chronic 
conditions. With the recent progression in technology, EHRs in particular provide an 
excellent, yet untapped opportunity to uncover longer term safety and tolerability 
outcomes of NGB patients, something that is not possible through RCTs (Poon et al., 2006). 
Furthermore, observational studies are easier to access, cheaper and can often include 
much larger patient populations (Poon et al., 2006). Disease registries also contain 
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observational data; however, they are especially set up for patients with shared 
characteristics and clinicians collect data as per a pre-defined protocol to support specific 
health questions (Yörük, 2015).  
Analysing RWD from EHRs and registries does come with its intrinsic limitations, with the 
potential to undermine the validity of results. Selection bias is one of the most difficult 
issues that occur in the analysis of RWD, arising when there are systematic differences in 
patient groups that can influence the outcomes of interest. Due to the lack of 
randomisation in observational studies, all confounding factors cannot be accounted for. 
Techniques for controlling missing data such as last observation carried forward, mixed 
models and multiple imputation techniques may help mitigate some of the risk related to 
selection bias, however it is largely unavoidable, thus the impact this form of bias can have 
on the resulting outcomes should always be acknowledged. Another form of bias common 
in observational studies is when the association between the exposure and the outcome is 
confounded by indication. Techniques including multivariable regression modelling and 
propensity score matching help to reduce this form of bias however unknown confounders 
of course cannot be controlled for (Hammer et al., 2009).  
Pragmatic trials arose from the realisation that traditional RCTs fail to inform real life 
practice, and accordingly, there are several dimensions which position these trials as better 
tools to demonstrate effectiveness. Firstly, participants are similar to patients who would 
receive the intervention in real world practice, as opposed to the highly selected patients 
recruited into RCTs (Ford and Norrie, 2016). Furthermore, rather than highly specialised 
experts, a variety of investigators with varying experience administer the interventions, 
which is also true of the real-life clinical situation. Other differences include the lack of 
blinding, no artificial expectation of follow up and the selection of outcomes that are 
important to patients (Zuidgeest et al., 2017). Pragmatic studies normally fall on a 
continuum between purely explanatory (traditional RCTs) and purely pragmatic (RWE), 
although few tend to meet all of the criteria of the latter, thus they are said to represent 
close to real-life practice conditions (Patsopoulos, 2011). 
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A certain level of pragmatism needs to be adopted when determining the optimal type of 
evidence required to bridge an evidence gap such as the one that exists in NGB, because as 
established above, ‘better evidence’, according to the EBM hierarchy (i.e. RCTs) is not the 
most generalisable (Rosner, 2012). Further than this, management practices in NGB have 
become well established over the years, often without the backing of formalised trials. 
Some international experts suspect that many aspects of patient care in NGB will in fact 
never be tested in RCTs due to their apparent self-evident nature (Apostolidis et al., 2017). 
Moreover, there is a high cost attached to trials and lack of incentive for developers to seek 
marketing authorisation (MA) given that many of the interventions are already being 
applied in clinical practice. They can also be challenging to conduct due to the difficult 
patient populations (children, the elderly, patients with comorbidities and cognitive 
dysfunction). Thus, it is clear that in order to promote evidence-based practice in NGB, 
increased research effort should be focused on generating knowledge beyond the 
traditional sphere of clinical research. RWE has been paramount in providing much needed 
empirical evidence and strengthening recommendations in a number of CGs outside of NGB 
(Gores, 2018). In NGB, EHRs, pragmatic trials, and prospective registries conducted at 
centres managing a diverse range of neurological conditions represent excellent solutions 
to bridge the lacuna between efficiency and real-world effectiveness and provide rich and 
comprehensive evidence on which to base future CG recommendations (Patsopoulos, 
2011).  
It is in some sense vital that recommendations, at least in part, are formulated using RWE 
because they will be applied to patients in the real world who do not fit into the contrived 
categories of RCTs. Although evidence appraisal systems such as the GRADE promote a 
multidisciplinary approach and do a good job ensuring clinical discretion and assimilation 
of the patient perspective, grading the strength of the underlying evidence is still skewed 
towards RCTs as the optimum. In order for RWE studies to be readily accepted, and 
consequently for the NGB CGs to become more inclusive of patient diversity, the EBM 
hierarchy requires transformation. In its current state it is inflexible, failing to take into 
account the inter-connected non-linear nature of health that is best analysed using a 
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variety of study designs and techniques. Therefore, the notion that external validity is 
equally as important as internally validity in the formation of recommendations needs to 
be promoted, whilst taking into account the compromise that sometimes needs to be made 
between randomisation which mitigates several forms of bias, and the applicability of 
evidence which is only possible through observational studies (Fernandez et al., 2015).  
4.8 Conclusions 
There is relative unanimity between the NICE, EAU and ICI CGs despite the fact that they 
are developed independently of each other via distinct methodological processes (Chapter 
3). However, they do provide differing emphasis on costs and expert opinion, which 
translated in some notably different recommendations. This is not surprising in the absence 
of high-quality clinical evidence for NGB. Varying recommendations can cause unwarranted 
variations in care, leading to inequity in urological care for NGB patients. 
Increased efforts in enriching the underlying evidence for NGB are necessary to ensure 
recommendations are grounded in tested theory and promote evidence-based practice. 
Given that conducting RCTs is difficult in this patient population and recommendations are 
to be applied in the real-world, research efforts should focus on generating RWE. 
Generation of such data poses fewer ethical challenges and represents an expedited path 
to evidence collection.  
Coordinated collaboration between organisations will also aid in great concordance 
between the resulting recommendations (Chapter 3). If differences do exist, it is 
recommended that CGs acknowledge other CGs in the same area and explain these 
differences, so to be as transparent as possible for users.  
4.9 Chapter Summary 
This study demonstrated that divergent development methodologies, as well as differing 
emphasis on costs and expert opinion results in notably different recommendations within 
the three most prominent guidelines for NGB. The research in this chapter falls short of 
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understanding how patients are actually managed in the real-world. Accordingly, the next 
chapter outlines an SR that to identify the real-world treatment patterns in NGB, which will 
elucidate whether CGs are applied in clinical practice, as well as dispel further gaps that 
remain in our understanding of the management pathway in NGB.    
  
 
 
 
143 
5) Chapter Five - Real world Treatment Patterns in the Neurogenic Bladder 
Population - A Systematic Literature Review  
5.1 Introduction and Rationale  
The results of the study detailed in Chapter Three and Four of this thesis demonstrated that 
on account of the varying developmental processes, the treatment recommendations 
made in the National Institute for Health and Care Excellence (NICE), European Association 
of Urology (EAU) and International Consultation on Incontinence (ICI) clinical guidelines 
(CGs) for neurogenic bladder (NGB), can often be contradictory. This inconsistency spans 
across conservative methods, such as behavioural techniques as well as more invasive 
forms of management, such as surgery. This can have implications for the standardisation 
of care for NGB patients across different care settings.  
This systematic review (SR) aims to collate evidence on the management strategies that 
are employed in the real world and determine which CGs, if any, practices are aligned with. 
This gives indication as to how well recommendations are followed. In theory, because CGs 
represent the optimum, if real world practices are broadly consistent with the suggestions 
in CGs, then it can be assumed that management is of high quality. This exercise of 
comparison is useful because it indicates where CGs could potentially be modified to better 
reflect real life conditions. Furthermore, dangerous or disadvantageous practices can be 
identified in the real world, and the accompanying information in the CGs evaluated to 
determine whether it is comprehensive enough to adequately inform care providers and 
patients.  
As the EAU and ICI CGs have a broad geographic scope, studies conducted in all corners of 
the globe were included. By casting a wide geographical net, potential variation in practices 
across the world can be distinguished and the possible reasons discussed. Through 
employing a wide time-frame, this research also aims to demonstrate the evolution of 
management strategies over time, and the changes that occur with the introduction of CGs. 
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To the author’s knowledge, this is the first attempt to collate information on the real-world 
treatment practices in NGB.  
5.2 Aim 
The aim of this SR was to describe the treatment patterns and management strategies of 
NGB in real world clinical practice.  
5.3 Protocol Registration  
Prospective registration of SRs is important to increase transparency, reduce bias, and 
avoid duplication of efforts for researchers seeking to address the same question (Stewart 
et al., 2012). To address this, the University of York centre for reviews and dissemination 
manage the international Prospective Register of Systematic Reviews (PROSPERO) 
database. The Unique IQ number for this SR is: 42017055499 and is available in full at:  
https://www.crd.york.ac.uk/prospero/display_record.asp?ID=CRD42017055499 
5.4 Methods 
5.4.1 Eligibility Criteria  
The following studies were eligible for inclusion to this study:  
● Studies that included patients with any neurological condition. The National NGB CGs 
(UK) aided in selecting qualifying conditions. These included; Parkinson’s disease (PD), 
multiple sclerosis (MS), stroke, spinal cord injuries (SCI), spina bifida, diabetes mellitus, 
cerebral palsy, head injury, dementia’s, spinal dysraphism, cervical spondylosis with 
myelopathy, ano-rectal anomalies, sacral agenesis, cauda equine syndrome, peripheral 
nerve injury from radical pelvic surgery and peripheral neuropathy (NICE, 2012).  
● Studies that measure treatments and management strategies, specifically related to 
managing urological symptoms (i.e. not for other end-organ effects or treatment 
related adverse events (AEs) such as antibiotics to treat urinary tract infection (UTI) as 
a result of catheterisation). Qualifying studies could present and calculate treatment in 
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a number of ways, for example percentage use, duration of use, treatment switching 
or combination use.  
● Real world studies, with any period follow-up, which could be either retrospective or 
prospective and be designed as cohort, case-control, cross-sectional or chart reviews.  
5.4.2 Inclusion/Exclusion Criteria  
The full inclusion and exclusion criteria for studies in this review are listed in Table 5.1.  
 
Table 5.1 Inclusion and exclusion criteria 
Inclusion Exclusion  
 Published in English 
 Includes human subjects  
 Reporting the treatment patterns/use in NGB 
 Conducted in a real-world setting 
 Non-English publications 
 In vitro, pre-clinical or animal studies 
 RCTs, SRs, case-report/series, editorials, 
questionnaires, letters, commentaries, legal 
cases, newspaper articles or patient education 
materials 
NGB, neurogenic bladder; RCTs, Randomised Controlled Trials; SRs, systematic reviews 
 
5.4.2.1 Modification to Inclusion/Criteria  
This SR had originally aimed to explicate the treatment patterns in adult NGB patients only. 
However, upon conducting a pilot search of the literature, no articles that focused solely 
on adults were retrieved. For this reason, the researchers of this SR decided to broaden the 
remit of the search to include patients of all ages. Upon reflection, it was decided that this 
was a positive move, as the scope of all NGB CGs also do not discriminate by age. This 
modification to inclusion criteria is reflected in the PROSPERO protocol dated, January 18th, 
2017.  
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5.4.3 Eligibility Assessment  
Eligibility assessment of articles was conducted in two stages. In the first stage, an 
independent reviewer (AJ) screened titles and abstracts for alignment with pre-defined 
inclusion and exclusion criteria, defined in Table 5.1. Ten percent of included articles were 
cross-examined by a second independent reviewer (FF). In the second stage, full versions 
of the included texts, compliant with the inclusion criteria, were screened by both 
reviewers. Any disagreements were mediated by discussion.  
5.4.4 Databases 
The MEDLINE® and EMBASE® databases were used to retrieve papers for this study. The 
USA National Library of Medicine (NLM) biomedical journal articles database, MEDLINE®, 
contains surplus of 22 million articles, spanning from the year 1946 to present. One of the 
special features of this database is the use of Medical Subject Headings (MeSH) controlled 
terms, used to index the articles (NLM, 2016). 
EMBASE® is a biomedical journal articles database produced by Elsevier. EMBASE® gathers 
its papers from over 8,500 journals from over 90 countries, with 29 million records overall, 
including all citations included in MEDLINE®. It is important to note that journals from 
EMBASE® have less coverage of American journals (33.8%) in comparison to MEDLINE®, 
(40.5%). The indexing in EMBASE® is recorded by controlled Emtree terms (NLM, 2016). 
5.4.5 Data Management  
Data management was fulfilled by using EndNote reference management system (X7 
version, Thomson Reuters). This software is ideal for storing, sorting and grouping large 
numbers of references and removing duplicates. 
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5.4.6 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines 
This SR was conducted according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines. The PRISMA guidelines evolved from the 
QUOROM (quality of reporting of meta-analysis) statement, which was first published in 
1999. The original QUOROM was conceptualised in response to abundant SRs that were of 
poor quality and were being poorly presented. The developers hoped these CGs would help 
standardise and improve the quality and reporting. Since the first iteration of the 
QUOROM, many conceptual, methodological, and practical advances have been made. This 
expansion in knowledge incentivised the development of an updated set of guidelines, and 
in 2009 a multidisciplinary team of 29 consumers, clinicians, review authors, 
methodologists, and medical editors developed the PRISMA statement.  
The PRISMA statement is a 27-item checklist used widely in the scientific research sphere 
to enhance the transparency of reporting in SRs and meta-analyses (Moher et al., 2009). 
The checklist includes seven major headings: title; abstract; introduction; methods; results; 
discussion; and funding. Certain expectations of review quality are set out within each 
heading. 
As well as the checklist, the authors provide researchers with a four-phase flow diagram, 
which guides the researchers through the paper inclusion process, from initial search to 
the appropriateness and eligibility of full inclusion of papers. PRISMA encourages 
researchers to add an explanation as to why papers were not included into the study, in 
order to promote full transparency in the decision-making process.  
5.4.7 Search Strategy  
Firstly, a list of related words to each of the eligibility criteria were compiled in order to 
capture the maximum pool of articles, this formed the ‘free form’ text words. In addition, 
‘controlled terms’, that indexers could have used when recording citations were also 
included. Search terms were developed in collaboration with a medical librarian. 
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 A search was run on 15th February 2017 using a combination of free form text words and 
controlled terms in MEDLINE®, and EMBASE®. Limits were applied for studies published 
between the years of 1996-2017; this period was chosen to allow a sufficient detection of 
changes in management techniques over the years. Further papers were sought by hand 
searching the references of studies meeting the inclusion criteria.  
Search terms for NGB & observational studies were first nested before combining search 
terms for treatment patterns. Without the parentheses, all search terms would have been 
combined at the same time. While there may be overlap from the different techniques, 
each method would generate a different set of results. The search strategy employed was 
found to be more robust than combining all sets at the same time. The complete search 
strategy can be found in Appendix 7.  
5.4.7.1 Use of Limits in EMBASE and MEDLINE 
Limits (filters) are often used in SRs to narrow search results to articles that are most 
relevant to the research question. However, indexing correspondence with the nature and 
topics of the citation has often proven to be low. Indexers may not have the relevant 
subject matter expertise, or the objectives and topics of the study may not be clear and 
therefore cannot be indexed appropriately (Higgins, 2011). Thus, due to inappropriate 
indexing or missing indexes, using limits such as ‘human’ or ‘English language’ may retrieve 
irrelevant citations as well as running the risk of potential applicable citations being missed 
out.  
There is also the issue of delayed indexing of newer publications. Newer records which 
have not yet received MeSH term allocation of ‘human’ will not be retrieved through a 
search utilising this limit (Sladek et al., 2010). Indexing for MeSH terms can take months for 
certain journals, meaning many pertinent articles could be missed (Mao and Lu, 2017). In 
EMBASE®, provisions have been made to automatically allocate Emtree terms using a pre-
defined computer algorithm (Embase, 2018). This in theory should by-pass the risk of 
missing relevant papers; however, candidate terms and subheadings are not indexed 
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(Embase, 2018). Another important point to note is that the algorithm is a temporary 
measure until the citations can be manually indexed, suggesting that the precision of 
indexing by the algorithms may be lower than manual indexing.  
In light of this, only one limit for year of publication (1996-2017) was employed in this 
study. Although only studies published in English and including human subjects were 
selected, unlike years of publication, limits were not applied for these conditions. Instead, 
the two researchers (AJ and FF) manually inspected the papers for evidence of non-human 
or non-English papers, which were subsequently removed.  
5.4.8 Data Extraction  
To ensure that no significant information was unavailable from the studies, information on 
the study design, patient characteristics, and treatments in NGB was independently 
extracted by two researchers (AJ & FF), using a piloted data extraction form. This form was 
designed in relation to the SR’s aims and objectives and summarised the relevant 
information necessary for the analysis (Appendix 8).   
5.4.9 Summary Measures 
Treatment patterns were descriptively summarised using narrative review (the descriptive 
objective meant that meta-analysis was not appropriate). Thematic content webbing was 
used to categorise and organise the results. This process involves reading the articles 
several times over, as well as the extracted data in order to conceptualise and explore 
overarching themes between the results and map them using a spider diagram (Popay et 
al., 2006). Where possible, percentage of treatment use was summarised using ranges.  
5.4.10  Quality Appraisal  
Quality appraisal is relevant when the topic of research is concerned with the efficacy or 
safety of interventions. This SR seeks to determine treatment patterns, which is purely 
descriptive in nature. For this reason, quality appraisal was not applicable. 
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5.5 Results 
The search yielded a total of 116 publications. In the first stage of review, only titles and 
abstracts were screened for eligibility in fulfilling the objective of this SR, and further for 
pre-defined inclusion and exclusion criteria. Any remaining duplicates were also manually 
removed during this stage (ProQuest Dialog® removed most duplicates during the running 
of the search). After the first stage of review, ten articles were retrieved, and the full texts 
were reviewed. Based on full text review, five papers were excluded for reasons according 
to the study protocol (detailed in Figure 5.1). In total, five papers were retrieved from the 
search. Upon searching the references of the five included articles, a further three articles 
were retrieved and included in the final articles for review. Altogether, eight articles were 
included in this SR. 
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Figure 5.1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) flow diagram 
Databases: MEDLINE and EMBASE 
Limits applied: publication year 
1996-2017 
Search results from treatment 
patterns AND neurogenic bladder 
AND observational study (n= 116) 
Inclusion of articles screen on the 
basis of title and abstract (n= 10) 
Inclusion of articles screened on the 
basis of full text (n= 5) 
Inclusion of articles retrieved through 
handsearching (n= 3) 
Total inclusion (n= 8) 
Excluded (n= 106) 
Duplicated (n= 4) 
Literature review (n= 8) 
Article/opinion (n= 10) 
Efficacy/safety of intervention (n= 
43) 
Clinical guidelines (n= 1) 
Diagnostics (n= 9) 
Different conditions (n= 27) 
Survey (n= 4) 
 
Excluded (n= 5) 
Does not mention treatment 
patterns (n= 2) 
Does not focus on neurogenic 
bladder (n= 2) 
Not Real World Evidence (n= 1) 
  
 
 
 
152 
5.5.1 Study and Patient Characteristics  
From the eight studies included (summarised in Table 5.2), study designs, country, and 
patient groups were notably heterogeneous. Overall, there were 47,706 patients with NGB 
and of these, 43.8% were male and the mean age was 42.8. The majority of included 
patients (46,271) came from two studies. Despite being published at separate times (2009 
and 2011), these studies included the same cohort of patients (using the same inclusion 
criteria and database). Patients included in these studies had mixed underlying neurological 
conditions including MS, SCI, PD, paralytic syndrome, cerebral palsy and spina bifida. What 
differentiates the two studies is the 2011 study identified separate sub-cohorts for SCI and 
MS, including 4,168 and 9,315 patients respectively; thus, due to this additional 
information, the decision was made to include both studies into the analysis. 
Most of the included studies (62.5%) focused on patients with SCI (or included a subgroup), 
at various levels of neurological injury and varied time since injury. Across the studies, there 
were a total of 5,182 patients with SCI. One study focused on spina bifida patients, including 
421 individuals. The earliest period of data collection began in 1984 and the most recent 
ended in 2007.  
Six studies reviewed retrospective data to gain insight into treatment patterns. Two studies 
incorporated a longitudinal retrospective study design using a large US medical and a 
pharmacy claims database (El-Masri et al., 2012; Lemelle et al., 2006). These were the 
largest studies; all other studies were notably smaller. Three studies used retrospective 
longitudinal study designs in the UK, France and USA (El-Masri et al., 2012; Lemelle et al., 
2006; Manack et al., 2011; Manack et al., 2009). One study was conducted using a large 
healthcare database based in Taiwan, however in contrast to the other five retrospective 
studies; a cross-sectional study design was adopted (Chia-Cheng et al., 2012). The 
remaining two studies prospectively collected data from patients in the UK and US 
respectively (Anson and Shepherd, 1996; Drake et al., 2005).   
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The way severity of NGB was described differed between the studies. Of those that focused 
on SCI, Anson et al, described the severity according to the location of injury (cervical 
nerves or thoracic nerves) and time since injury. El-Masri et al and Drake et al described 
severity using the Frankel grade system, which is the most widely used medical 
classification system, based on the patient evaluation of the location of injury. Weld et al 
classified SCI according to the level of injury completeness. Lemelle et al classified spina 
bifida according to mobility. The two remaining studies did not stratify individuals based 
on level of injury. The different classification systems and heterogeneity of the patient 
populations made comparisons more tenuous.  
 
Table 5.2 Summary of study and patient characteristics of included studies. 
Study Data 
collectio-
n period 
Study design Country Patient sample 
characteristics 
Neurogenic condition 
and severity 
Anson and 
Shepard 
(1996) 
Not 
reported 
Prospective 
(longitudinal) 
USA 348 individuals, 
33% aged over 18, 
mean age 36.6, 
82% male and 18% 
female, 80.2% 
Caucasian 
SCI 
● C0-C4: 19.7% 
● C5-C8: 36.2% 
● T1-T11: 29.4% 
● T12-S5: 14.7% 
Years since injury: 
● 1-2 years: 26% 
● 3-5 years: 25.2% 
● 6-10 years: 29.3% 
● 11-15 years: 12% 
● 15+ years: 8% 
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Chia-Cheng 
et al., (2012) 
2006- 
2008 
Retrospective 
(cross-
sectional) 
Taiwan 165 patients, 
mean age 54, 64% 
male and 46% 
female 
Patients with 
emergency department 
visits or 
hospitalisations for SCI 
Drake et al., 
(2005) 
 1990-
1996  
Prospective 
(longitudinal) 
UK 196 individuals, 
aged 15-55, mean 
age 57.4, 86% 
male and 24% 
female.   
SCI for at least 20 years 
Level of injury: 
● Paraplegics with 
complete SCI (Frankel 
grade A, B, or C): 49% 
● Tetraplegics with 
complete SCI (Frankel 
grade A, B, or C): 31.1% 
● Incomplete SCI 
(Frankel grade E): 
18.9% 
● Mean years since 
injury: 33.26 
El-Masri et 
al., (2012) 
From 
1984, 
with 
follow up 
ranging 
between 
8 and 21 
years 
Retrospective 
(longitudinal) 
UK 119 individuals, 
aged 16-63, mean 
age 29, 83.2% 
males, 16.8% 
females 
SCI 
● Paraplegic (two had 
S3 sacral lesion): 37.3% 
● Tetraplegic: 27% 
● Frankel grade A: 34% 
● Frankel grade B: 4.3% 
● Frankel grade C: 7.7% 
● Frankel grade D: 
18.4% 
● Mean years since 
injury: 29 
Lemelle et 
al., (2006) 
2003-
2004 
Retrospective 
(longitudinal) 
France 421 individuals, 
aged 10-47.5, 
mean age 22.1, 
140 aged 10-18 
Spina bifida 
(myelomeningocele at 
the neonatal period, 
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and 281 aged over 
18. 55% male and 
45% female. 
which was treated 
surgically)  
Ability to move: 
● Walk with minor aid: 
63% 
● Walk with walking 
appliance: 3% 
● Wheelchair outside + 
walk at home: 8% 
● Wheelchair most of 
time: 26% 
Manack et 
al., (2011) & 
Manack et 
al., (2009) 
(NGB cohort 
only) 
April 1, 
2002- 
March 
31, 2007 
Retrospective 
(longitudinal) 
USA 46,271 individuals 
in NGB cohort, 
9,315 individuals 
in MS, 4,168 
individuals in SCI, 
aged 0-60+, mean 
age of NGB cohort 
was 62.5 years, 
mean ages in the 
MS and SCI 
subcohorts, 53.2 
and 61.9 years 
respectively. 
43.6% males and 
57.4% females in 
NGB cohort, 31.3% 
male and 79.7% 
female, 41.9% 
male and 59.1% 
female in MS and 
SCI subcohorts 
respectively.  
MS, (SCI (including 
paraplegia, 
quadripledia, 
tetraplegia), spina 
bifida, Parkinson’s 
disease, cerebral palsy, 
hemipledia/hemiparesi, 
late effects of stroke, 
other paralytic 
syndromes, and 
neoplasm of the spinal 
cord) 
Weld and 
Dmochowski 
(2000) 
Years not 
reported. 
Follow 
up:18.3 
years 
Retrospective 
(longitudinal) 
USA 316 individuals, 
mean age- 38 
years, 99% male 
and 1% females 
SCI 
Injury completeness: 
● Complete:14.2% 
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since 
injury. 
● Incomplete:85.8% 
Injury level: 
● Suprasacral:85.1% 
● Sacral:14.9% 
● Mean years since 
injury:18.3 years 
C, cervical nerves; T, thoracic nerves; SCI, spinal cord injuries; MS, multiple sclerosis; UK, United 
Kingdom, NGB, neurogenic bladder 
 
5.5.2 Treatment Patterns  
Figure 5.2 below shows the result of the thematic content webbing (Popay et al., 2006). 
After reading the papers and extracting the data, the various management methods were 
identified. In line with the objective of this study, these management techniques 
constituted the main topics of discussion (shown in yellow and then further expanded in 
blue in Figure 5.2). As well as the management methods, additional topics of ‘combination 
use’ and ‘switching’ were also identified as key themes; these describe the ways in which 
treatments may be administered (shown in green in Figure 5.2). These key themes were all 
described in the papers by percentage use of technique (or percentage switch), drug 
patterns and names. This drug taking information was then used to guide and structure the 
results and following discussion. 
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Sacral 
Neuromodulation
Cholinergic 
Agents
Bladder Neck 
Procedures 
Antimuscarinic 
Drugs
Straining and/or 
Expression
Bladder 
Augmentation
Mitranoff 
Procedure
Alpha-
Blockers
Antimuscarinic 
Drugs
Indwelling 
Intermittent
Suprapubic
+ Bladder 
Injections
+ Surgery
+ 
Catheterisation
Spontaneous 
Voiding
Not defined
Surgery
Oral Drugs
Catheterisation
Combination 
Reflex
Switching
Management 
for NGB
% Use
% Use
% Use
% Use
% Use
% 
Switch
Patterns
Drug 
Names
 
 
 
 
 
 
 
 
 
Key 
Orange – Theme of spider web (management of NGB) 
Yellow – Conservative and interventional management types 
Blue – Specific management types (expansion of yellow) 
Green – Treatment administration types 
Grey – Description of use 
Figure 5.2 Thematic content analysis results 
5.5.2.1 Oral Pharmacotherapy  
Five out of the eight included studies included data on the use of oral pharmacotherapy. 
Three studies included information on bladder muscarinic drug use, which spanned 
between 12.6%-86.7%. Results from two studies demonstrated a range of 12.6%-39% 
patients using oxybutynin.  
Lemelle et al reported the lowest recorded bladder muscarinic drug use, where 12.6% of 
spina bifida patients used oxybutynin regularly. The percentage of patients receiving 
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bladder muscarinics was almost double in the study by Chia-Cheng et al, where it was used 
by 26% of SCI patients with neurogenic detrusor overactivity (NDO). Manack et al (2011) 
reported much higher percentages, with 71.5% of patients in the NGB cohort, 80.9% in the 
SCI cohort and 86.7% in the MS cohort using this treatment. A prescription of a bladder 
muscarinic drug, (rather than any form of bladder management method) was one way in 
which a patient could be included into this study which could explain why percentage use 
was higher than other studies included into this SR. There is no indication of whether the 
remaining patients were not on therapy or using some other form of management. The 
highest use of oxybutynin of all publications was also recorded in this study (39%), followed 
by tolerodine (36.9%). El-Masri et al, mention that bladder muscarinics were administered 
to those with NDO, but percentage use is not delineated. Other studies did not report 
bladder muscarinic use; however, this should not be interpreted as lack of prescription of 
these medications. 
El-Masri et al and Chia-Cheng et al reported the use of α-adrenergic antagonists; however, 
neither of the authors communicated the names of drugs. In the study by Chia-Cheng et al, 
the most prevalent drugs amongst SCI patients with NDO were α-adrenergic antagonists, 
used by 33% of individuals. α-adrenergic antagonists were administered to SCI patients 
with marked bladder outlet obstruction (BOO) in the study by El-Masri, but as with bladder 
muscarinic use, percentage use is not described.  
The study by Chia-Cheng et al was the only one to mention use of cholinergics, where it 
was used by 15% of SCI patients with NDO.  
5.5.2.1.1 Patterns of Oral Pharmacotherapy Use 
Manack et al (2011) provides information on patterns of oral drug use, which is not 
available from the other studies. 7,782 individuals continued on an OAB drug, 10,110 
discontinued and did not start, and a further 9,030 stopped and restarted. The average 
length of time on drug was 209.1 days for the MS sub-cohort and 195.5 days for the SCI 
cohort. 
  
 
 
 
159 
5.5.2.2 Catheterisation 
Urinary catheter use varied substantially across the studies. Intermittent catheterisation 
(IC) use was reported in six studies, with a range between 0%-84%. Indwelling 
catheterisation (IndUC) (in this study, described as both indwelling urethral catheterisation 
(IDUC) and indwelling suprapubic catheterisation (SPC)) was reported in four studies, with 
a range of 0% to 100%.  
Chia-Cheng et al reported that catheterisation was used by 67% of patients with NDO as a 
consequence of SCI, however it is unclear whether catheterisation refers to IC or IDC.   
5.5.2.2.1 Intermittent Catheterisation 
Lemelle et al reported that 71.3% patients with spina bifida were using IC. Anson et al and 
Weld et al reported much smaller percentages in post-acute phase SCI, with 30.5% and 
29.1% respectively.  
When considering studies with observations at multiple time points, El-Masri et al reported 
27% of SCI patients using assisted IC immediately before admission to the hospital; 
however, no patients utilised this method upon admission. During hospitalisation, four-
hourly IC was the most utilised method, with 84% of patients using it at least once. This is 
the highest report of IC use from all publications. This markedly declined to 15.1% patients 
at discharge from hospital. In contrast, the use of IC increased by 10.2% in the study by 
Drake et al; from 3.6% SCI patients in 1990 to 13.8% in 1996.  
The difference in IC use between these two studies could be attributable to the varied 
follow-up. In the study by Drake et al, changes take place over six years whereas follow up 
in the study by El-Masri ranged between 8 and 21 years (mean 17.7).  
5.5.2.2.2 Indwelling Catheterisation 
Weld et al reported 36.1% post-acute SCI patients that utilised IDUC and 11.4% patients 
had a SPC fitted. In the study by Anson et al, much lower percentages were reported, with 
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9.8% that used IDUC and 3.2% that used SPC. The lowest recorded use of SPC use amongst 
the publications was one spina bifida patient in the study by Lemelle et al.   
Studies with multiple observations seemed to paint a heterogeneous picture of IDUC use. 
Overall, IDUC use substantially decreased (by 60.6%) in SCI patients, throughout the 
duration of the study by El-Masri et al, but the general trend was not a linear decline. SPC 
use decreased at a much lower rate (0.8%) from hospitalisation to discharge. In contrast to 
this, the number of SCI patients utilising IDUC increased by 1.6% during the study by Drake 
et al, and SPC use increased by 7.2%.  
In the study by El-Masri et al, 69% were managed with IDUC before admission to hospital 
and this increased to all patients upon admission. 21% of patients utilised this method at 
least once during hospitalisation. After discharge, 8.4% patients remained with IDUC. In the 
study by Drake et al, 12.2% had IDUC in 1990 and this increased to 13.8% in 1996. 
The first recorded use of SPC was in the study by El-Masri was during hospitalisation, where 
5% of patients utilised this method. After discharge, it was used by 4.2% of patients. Only 
2% utilised SPC at study entry in the study by Drake et al, but this increased at a much 
higher rate than IDUC use, with 9.2% of patients utilising this method at study end.  
5.5.2.3 Reflex Voiding  
Multiple definitions exist for reflex voiding (RV), including bladder expression (Credé 
manoeuvre), straining (Valsalva manoeuvre) and triggered RV (Apostolidis et al., 2017). In 
this SR, RV use was reported in four studies, varying from 2.5% to 53.1%. 
RV methods are used by 25% of SCI patients in the study by Anson et al and 23% of SCI 
patients in the study by Weld et al. Although these percentages are close in range, they 
cannot be directly compared as Anson et al fail to provide a definition of RV. Weld et al 
defines spontaneous voiding as ‘reflexive voiding with a post-void residual urine of less 
than 100 cc and a voiding pressure of less than 40 cm’ (Weld and Dmochowski: 768). 
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In the study by Drake et al, RV was defined as ‘leaving a post void residual <10% and with 
no upper tract dilation, with or without prior sphincterotomy or urethral stent’ (Drake et 
al.., 2005: 112). Use decreased by 11.8% during the study period, from 53.1% to 41.3%, but 
it remained the most used method within the study.  
El-Masri et al did not specifically define RV, thus it is difficult to compare results to other 
studies. In this study, a small number of patients (2.5%) were managed with RV prior to 
admission, and during hospitalisation it was used by 16.8% individuals. It was the most 
common form of bladder management after patients were discharged from the hospital, 
where it was utilised by 49.8% of patients.  
In the study by Drake et al, straining methods (in this case, defined as either Credé or 
Valsalva manoeuvres) decreased by 8.2%, from 19.4% to 11.2%. A much lower percentage 
(2.6%) of patients used expression techniques (defined as the Credé manoeuvre) at the end 
of the study by El-Masri et al. 
5.5.2.4 Surgery  
Two authors report the use of surgery to manage bladder symptoms. Manack et al (2009) 
reports particularly low numbers of bladder augmentation and interstim therapy (0.2% and 
0.4% respectively) in NGB patients. This is in contrast to Lemelle et al, where the majority 
of spina bifida patients (55%) were surgically treated. Of these patients, 21.3% underwent 
bladder neck surgery, without bladder augmentation (with or without continent diversion), 
36% patients underwent intestinal bladder augmentation (with or without bladder neck 
procedure) and 28.3% patients underwent intestinal bladder augmentation in addition to 
Mitrofanoff (with or without bladder neck procedure).  
5.5.2.5 Other Management Options  
Other methods of bladder management related to the collection of urine were also 
mentioned in one study. In the study by Lemelle et al, some patients used external 
collection devices, namely 8.3% of people used pads and 1% of patients used a uriseath. 
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5.5.2.6 Combination Use 
Combinations of various procedures are often employed to manage the complex interplay 
of different symptomology or to control more severe bladder dysfunction. The different 
combinations of management techniques identified in the included studies are described 
below.  
5.5.2.6.1  Combinations of Oral Pharmacotherapy 
Manack et al (2011) reported 8.7% of patients on a combination of two or more bladder 
muscarinic drugs. 8.3% of patients were on two drugs, 0.4% were on three drugs and a 
negligible amount were on four or more drugs. A similar pattern was seen in the MS and 
SCI subcohorts. 9.5% patients in the MS subcohort were on a combination of two or more 
bladder muscarinics, a further 9% were on two drugs, 0.5% were on three drugs and only 
two patients were on four or more drugs. When considering the SCI cohort, 9.2% patients 
were on a combination of two or more bladder muscarinics, 8.9% were on two drugs, 0.3% 
were on three drugs and no patients were on four of more drugs.  
A combination of α-adrenergic antagonists and bladder muscarinics were given to those 
with detrusor sphincter dyssynergia (DSD) and autonomic dyssynergia in the study by El-
Masri et al. Percentages of combination use were not reported in this study.  
5.5.2.6.2 Combination of a Therapy with Catheterisation  
Lemelle et al states that 12.6% of spina bifida patients regularly utilised IC in combination 
with oxybutynin. Also, in this study, 90% of patients used IC in addition to undergoing 
surgery, including 61% through a continent neoconduit and 39% on the abdominal wall.  
In the study by Anson et al, 11.5% patients were on a combination of IC and reflex. There 
is also a report of 3.7% of patients on some combination of treatments between IC, reflex, 
IDUC, SPC and self-voiding, but actual combinations are not provided.  
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5.5.2.6.3 Combination of Surgical Procedures and Bladder Neck Injections  
Lemelle et al reports 39% of patients undergoing a combination of surgical procedures to 
achieve adequate reservoir and neck management in spina bifida patients. The most 
popular combination of procedures is intestinal bladder augmentation + Mitronaff 
principle + neck closure (Table 5.3).  
 
Table 5.3 Combination of reservoir and neck management in study by Lemelle et al., 
(2006) 
Management Type Number of Patients 
Sling + Mitrofanoff 2 
Sling + neck injection  1 
Kropp + sling 1 
Neck injection + Mitrofanoff 3 
Neck closure + Mitrofanoff 3 
Neck injection + PippiSalle + Mitrofanoff 1 
Intestinal bladder augmentation + urinary 
artificial sphincter  
11 
Intestinal bladder augmentation + sling 14 
Intestinal bladder augmentation + Kropp 4 
Intestinal bladder augmentation + Young-Dees + 
neck injection 
5 
Intestinal bladder augmentation + neck injection 10 
Intestinal bladder augmentation + sling + neck 
injection 
3 
Intestinal bladder augmentation + Kropp + sling 1 
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Intestinal bladder augmentation + urethral 
transposition 
1 
Intestinal bladder augmentation + Young-Dees 1 
Intestinal bladder augmentation +  Young-Dees + 
sling + neck injection 
1 
Intestinal bladder augmentation +  Young-Dees + 
artificial urinary sphincter 
1 
Intestinal bladder augmentation + PippiSalle 2 
Intestinal bladder augmentation + PippiSalle + 
neck injections 
2 
Intestinal bladder augmentation + PippiSalle + 
sling 
1 
Intestinal bladder augmentation + Mitronaff 
principle + neck closure 
21 
Intestinal bladder augmentation + Mitronaff 
principle + sling 
8 
Intestinal bladder augmentation + Mitronaff 
principle + neck injection 
7 
Intestinal bladder augmentation + Mitronaff 
principle + sling + neck injection 
1 
Intestinal bladder augmentation + Mitronaff 
principle + suprapubic urethral transportation 
2 
Intestinal bladder augmentation + Mitronaff 
principle + V-Y neck plasty 
1 
Intestinal bladder augmentation + Mitronaff 
principle + artificial sphincter urinary cuff only 
1 
Intestinal bladder augmentation + Mitronaff 
principle + pippisale 
2 
Intestinal bladder augmentation + Mitronaff 
principle + pippisale + neck injection 
1 
Intestinal bladder augmentation + Mitronaff 
principle + Kropp 
2 
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Intestinal bladder augmentation + Mitronaff 
principle + Young-Dees + sling + neck injection 
3 
Intestinal bladder augmentation + Mitronaff 
principle + artificial urinary schincter 
2 
Adapted from: Lemelle et al., 2006 
 
5.5.2.7 Switching  
Weld et al mentions that most post-acute SCI patients switched bladder management 
methods over the course of the study period; with the most prevalent change being from 
IC to IDUC, although the percentage is not provided. 14.3% of patients in the study by Drake 
et al, and one patient in the study by El-Masri also made this particular switch of treatments.  
Drake et al provides a table of change in management methods from 1990 to 1996 (Table 
5.4). As in the study by Weld et al, most patients switched from their original mode of 
management (62.8%), however the most prevalent change was straining to IC (28.9%). The 
most used method in 1990 was RV, and this remained the case in 1996, despite 24% 
switching to an alternative form of treatment. The second most used method was the 
straining method in 1990 but changed to IDUC and IC in 1996. SPC remained the least used 
form of management, along with ‘other’.  
El-Masri et al also showed a large proportion of patients (39.5%) that switched treatments 
during hospitalisation (Table 5.5). In contrast to both Weld et al and Drake et al, the most 
prevalent switch was IC to sphincterotomy and IDUC to IC.  
 
Table 5.4 Change in bladder management methods (BMM) between 1990 and 1996 in 
study by Drake et al., 2005 
 Bladder management method (BMM) in 1996 
BMM IN 1990 RV Strain IDUC SPC IC Normal Other 
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RV 104 
(53.1%) 
79 (76%) 5 (4.8%) 5 (4.8%) 4 (3.8%) 10 (9.6%) 1 (0.9%) - 
Strain 38 
(19.4%) 
1 (2.6%) 17 
(44.7%) 
2 (5.3%) 7 
(18.4%) 
11 
(28.9%) 
- - 
IDUC 24 
(12.2%) 
1 (4.2%) - 19 
(79.2%) 
3 
(12.5%) 
1 (4.2%) - - 
SPC 4 (2%) - - - 4 (100%) - - - 
IC 7 (3.6%) - - 1 (14.3%) - 4 (57.1%) - 2 
(28.6%) 
Normal 19 
(9.7%) 
- - - - 1 (5.3%) 18 
(94.7%) 
- 
Total 196  81 
(41.3%) 
22 
(11.2%) 
27 
(13.8%) 
18 
(9.2%) 
27 
(13.8%) 
19 (9.7%) 2 (1%) 
BMM, bladder management method; RV, reflex voiding; IC, intermittent catheterisation; IDUC, 
indwelling urethral catheterisation; SPC, suprapubic catheterisation 
Reproduced with permission from Drake et al (2005)  
 
Table 5.5 Bladder management switching during hospitalisation. Adapted from El-Masri 
et al., 2012 
Bladder management switch No. of patients 
IC → SPC 4 
IC → sphincterotomy  RV 3 
IC → RV 7 
IndUC → IC 11 
IndUC → IC→ RV 3 
IC → sphincterotomy 11 
IC → SPC → sphincterotomy → RV 1 
IC → IndUC 1 
  
 
 
 
167 
IC → IndUC → sphincterotomy → RV 1 
IndUC → IC → sphincterotomy 2 
IndUC → SPC 1 
RV → sphincterotomy 2 
Total 47 
IC, intermittent catheterisation; IndUC, indwelling catheterisation; RV, reflex voiding; SPC, suprapubic 
catheterisation 
 
5.6 Discussion  
Selecting optimal treatments and employing appropriate management strategies for NGB 
patients is integral to improving patients’ bladder symptoms and Quality of Life (QoL). With 
passing time, clinicians have moved away from techniques associated with higher rates of 
complications and mortality, and consequently in recent years, the survival chances of NGB 
patients have improved considerably (Harrison, 2010). This SR revealed that numerous 
treatments and management strategies have been used to control the symptoms of NGB 
throughout the years, mostly consistent with the signs and symptoms of NGB and there 
has also been a large variance in their use.  
The most popular oral pharmacotherapy in this SR were bladder muscarinics, which are 
correspondingly cited as first line therapy for NDO in the NICE, EAU and ICI CGs (NICE, 2012; 
Bloc et al., 2017; Drake et al., 2005). This conclusion should however be interpreted with 
some caution, as many studies in this review did not measure the use of oral 
pharmacotherapy, instead focusing their attention on other methods of bladder 
management. It is unclear why oral pharmacotherapy was not as thoroughly documented 
in the included studies, however it is well known that NDO is frequently observed in SCI 
(which 62.5% of included studies focused on), and bladder muscarinics have acted as the 
primary mode of treatment for this condition for a number of years (Madhuvrata et al., 
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2012). Speculation therefore suggests that a greater number of patients included into this 
SR were on some form of bladder muscarinic, but utilisation rates were not recorded.  
Most studies did not mention the type of bladder muscarinic drug used. Two studies 
mentioned a wide range of oxybutynin use. Oxybutynin is one of the oldest and most 
prescribed bladder muscarinics available on the market for NDO, thus the findings in this 
SR are as expected (Suguino, 2012). It is also one of the most toxic bladder muscarinics, 
with the ability to cause various forms of cognitive impairment, including dementia (Gray 
et al., 2015).  
In the study by Manack et al (2011), some patients used a combination of two or more 
bladder muscarinics. Based on evidence from a few small clinical trials, the EAU provide a 
grade B recommendation, asking physicians to consider a combination of bladder 
muscarinic agents. None of the prominent NGB CGs however recommend more than two 
bladder muscarinics to be prescribed at one time, which was observed in this study, thus 
demonstrating an example of how real-world practices can deviate from guidance featured 
in CGs.  
In NGB, invasive forms of management such as bladder augmentation are typically only 
employed once more conservative measures have been exhausted. In spina bifida, two-
thirds of patients can become continent through IC and oral pharmacotherapy alone 
(Frimberger et al., 2012). The minority of spina bifida patients that do not respond to 
conservative treatments must undergo surgery to improve bladder functionality (Mingin 
and Baskin, 2003). The one study included in this SR, focusing on spina bifida, reported that 
the majority of patients underwent surgery. This result is unexpected given that most spina 
bifida patients should be managed with conservative measures. Possible reasons for this 
could be the high severity of incontinence in the sample, higher incidence of refractory NGB 
or a less conservative attitude of physicians towards surgery in France between 2003-2004 
(the study period). This result may also imply surgery was the more cost-effective solution 
in this situation. Although of course these rationalisations are purely speculative.  
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Many of the studies in this SR have early periods of data collection therefore it is perhaps 
comprehensible that some practices deviated from what is currently considered safe and 
effective. One example of such variance is the use of the Credé and Valsalva manoeuvres 
in studies that collected data in the 1980’s and 1990’s (El-Masri et al., 2012; Drake et al., 
2005). In current CGs, these techniques are contraindicated due to complications including 
epidydymoorchitis and haemorrhoids (Bloc et al., 2017; Apostolidis et al., 2017). It is 
thought that these manoeuvres have been progressively phased out in real world practice 
in the West, and this is supported in the study by Drake et al, where use of these 
manoeuvres decreased by 8.3% throughout the study duration. In many developing 
countries these techniques are still endorsed as viable forms of bladder management 
because they require little to no resources to implement (Przydacz et al., 2017). The ICI CGs 
aim to modify and improve clinical practice globally however as mentioned in Section 
3.6.5.6 the dedicated sub-committee named ‘Faecal Incontinence and Incontinence in the 
Developing World’ no long exists, which could make the reduction of detrimental practices 
such as the Crede and Valsalva manouevers in developing countries less likely. 
IndUC was also widely used (up to 100%) despite the fact that this type of catheterisation 
is associated with an increased risk of UTI, as well as serious sequalae such as bladder 
cancer (NICE, 2012; Bloc et al., 2017) (Section 2.4). The high frequency of this procedure 
may again be because of the earlier years of data collection; however, it is also important 
to consider that SCI can result in limited manual dexterity (for example, in the case of 
tetraplegia), impeding the ability of intermittent self-catheterisation (ISC) (Taweel and 
Seyam, 2015). Similarly, the current NICE CGs recognise that in some instances the choice 
of management technique is limited by what the patient can manage (NICE, 2012).  
The latest ICI CGs suggest that assigning causation of urinary tract damage to IndUC may 
not always be accurate, as the technique is often utilised in patients in whom urinary tract 
damage has already occurred. Drake et al actually suggest that IndUC might in fact be 
protective for the upper urinary tract.  
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There is little evidence-based research supporting SPC use. Some opinion suggests that SPC 
is generally preferred over IDUC due to a number of advantages including comfort and ease 
of access for cleaning. In addition, the risk of urethral trauma, necrosis or catheter-induced 
urethritis and urethral strictures is eliminated (Reitz et al., 2006). Despite these advantages, 
SPC was used at a much lower rate than IDUC in this SR. This could possibly be because 
placement of SPC is a more invasive procedure than IDUC or because there are no clear 
CGs around the choice between SPC and IDUC (Apostolidis et al., 2017). Accordingly, 
increased research efforts may be necessary in this area to help illuminate optimal 
catheterisation choice. 
This review had a global geographical scope; thus, one may assume that the management 
methods employed reflect the healthcare system and national CGs in which the study was 
conducted. At present, the American Urology Association (AUA) lacks any specific CGs for 
the management of NGB. High bladder muscarinic use in the two US studies by Manack et 
al are in line with other internationally available CGs, where bladder muscarinics are first 
line therapy for patients with NDO (Bloc et al., 2017; NICE, 2012; Apostolidis et al., 2017). 
In the study by Chia-Cheng et al, conducted in Taiwan, α-adrenergic antagonists were the 
main method of management for NDO, despite Taiwanese NGB CGs stating there is strong 
evidence to support the use of bladder muscarinics in NDO (Kuo et al., 2014). The greater 
use of α-adrenergic antagonists use may indicate patients had retention symptoms, in 
conjunction to NDO. Alternatively, several small clinical trials have demonstrated efficacy 
of α-adrenergic antagonists in NDO, which could indicate that clinicians in the real world 
are making choices in divergence from CG recommendations (Yasuda et al., 1996; 
Swierzewski et al., 1994). This notion correlates with results from a survey which showed 
that urologists did not follow CG recommendations meticulously. Nevertheless, this survey 
also found that despite non-adherence, urologists still tended to make choices in 
accordance with recommendations (Rikken and Blok, 2008). 
Three studies demonstrated notable treatment switching, which could be indicative of the 
dynamic progression of NGB. Treatment switching has showed to increase costs to the 
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healthcare system (Ivanova, 2014). Duration of time since injury in SCI can have an impact 
on bladder compliance that can consequently influence changes in the choice of 
management strategy (Harrison, 2010). Alternatively, treatment switching may 
demonstrate that a trial and error approach is necessary to establish an optimal treatment 
regime (Martinez et al., 2016). A number of factors influence the initial choice of 
management method, including type of NGB, sex, age, hand dexterity and healthcare 
access (Taweel and Seyam, 2015). In the study by Drake et al, reasons for switching 
treatments pertained to complications such as functional decline and UTIs. Some patients 
included in this review made their own treatment choices, for example, El-Masri et al 
mention there is the risk of danger ‘if the patient chooses RV when bladder overactivity 
with DSD is not properly dealt with’ (El-Masri et al., 2012: 19). This indicates that individual 
preference plays a large role in the management pathway (Drake et al., 2005; El-Masri et 
al., 2012; Weld, 2000). Current CGs promote active dialogue between the physician and 
patient/their carer. In particular, NICE CGs make specific recommendations for education 
of patients and their carers on the advantages and disadvantages of all available options so 
they are able to make informed management decisions (NICE, 2012; Engkasan et al., 2013).  
The wide variety of methods employed demonstrate that NGB is a notably heterogenous 
condition. The research presented in this SR can act as an important preliminary step in 
influencing future CG recommendations to reflect what is working for clinicians in the real 
world. For example, administration of more than one bladder muscarinic or the use of 
IndUC over IC. Essentially, CG quality could be improved if they are based on what is already 
being used to manage patients in the real world and has some clinical evidence to support 
its use. This is especially important in NGB, due to the infeasibility of conducting RCTs and 
the supposed self-evident nature of treatment efficacy.  
5.6.1 Methodological Limitations  
Both the sensitivity (comprehensiveness) and specificity (focus) is important to balance 
when devising a search strategy (Bramer et al., 2018). In order to decrease the chances of 
missing relevant citations, a sensitive search strategy is generally preferred (Sutherland, 
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2001). However, adopting this type of search this will often retrieve thousands of citations, 
of which a high percentage will be irrelevant. Due to time and resource constraints, 
specificity was given greater importance in this search over sensitivity. The highly specific 
search used in this SR may have translated in greater accuracy; however, it could also have 
meant that relevant publications were potentially missed.  
The sensitivity of the search strategy could have been increased in a number of ways. 
Utmost effort was made to incorporate as many potential terms related to NGB. However, 
potentially relevant articles may not have mentioned, or indexed terms directly associated 
with NGB. To account for this, including search terms for underlying neurological conditions 
in combination with search terms for urinary incontinence (UI) or bladder dysfunction may 
have retrieved additional relevant citations.   
In order to improve the accuracy, this search strategy also included terms to retrieve only 
real-world studies. The indexing quality of observational studies has proven to be 
inconsistent in the past (Fraser et al., 2006). Furthermore, the terminology used to describe 
certain study designs can vary and be used in different ways by different researchers, which 
can make identifying particular types of studies even more difficult. For these reasons, 
manually identifying real world studies, rather than including specific search terms may 
have been a superior search strategy. Search filters also could have been employed, but as 
mentioned in Section 5.4.7.1, they can often lead to important omissions.  
As the purpose of this SR was purely descriptive in nature, the study design (apart from 
being conducted in a real-world setting) was not of great importance. Inclusion of mixed 
study designs (retrospective, prospective, cross-sectional etc.) could however, have 
affected the reliability of results.   
Several forms of bias could have affected the results. Publication bias is a well-known 
phenomenon in scientific research, where studies that do not disprove the pre-specified 
null-hypothesis are less likely to be published than those with ‘positive’ results (Dirnagl and 
Lauritzen, 2010). Although this form of bias is not a pressing issue in the modern day since 
the introduction of mandatory clinical trial reporting in 2007, it is relevant since this SR 
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included papers published as far back as 1996. Moreover, most NGB studies are industry-
sponsored and publication bias is an even heightened issue in these trials compared to 
those which are government-funded (Mayo-Wilson et al., 2018). This SR did not make a 
special attempt to search the ‘grey’ literature, i.e. literature with limited distribution, where 
results from ‘negative’ studies are more likely to be retrieved. Although publication bias is 
not a real disadvantage in this SR, as it is purely descriptive, omission of grey literature 
could have meant relevant studies were missed. Furthermore, this SR included English 
language publications only. This can introduce language bias, as articles are more likely to 
be published in English if they report significant results (Egger et al., 1997).  
In order to minimise bias, eligibility assessment should involve two independent reviewers 
screening all titles, abstracts, and full-text articles (Moher et al., 2009). Due to time and 
resource constraints, a restricted method of eligibility assessment was employed in this 
review, which involved only one reviewer (AJ) conducting the initial abstract screening and 
the second reviewer (FF) screening a small proportion of those (10%). This could be 
considered a major source of bias.  
This review was completed manually, except during the first stage of de-duplication, which 
was automatically conducted by ProQuest Dialog®. Although meticulously following the 
protocol leads to robust analysis, automation could help improve efficiencies. Automation 
tools are currently available for searching, snowballing, screening, extraction of data, meta-
analysis and write-ups (Tsafnat et al., 2014). They allow for more of the reviewer’s time to 
be devoted to producing a high-quality protocol and continual monitoring of the overall 
quality of the results. Improving efficiency is essential in an age where medicine is 
progressing at an unprecedented rate, and clinical research questions need to be answered 
quickly (Tsafnat et al., 2014). 
5.7 Conclusions 
Many treatments reported in this review are in line with current CG recommendations; 
however, possibly due to the early years of data collection, some divergence was also 
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evident. Due to the small number of studies, varied patient baseline characteristics, and 
selectiveness in the type of treatments and bladder management methods reported, a 
representative picture of real-world treatment patterns in NGB could not be fully 
elucidated. Furthermore, only one study was retrieved that included a UK population. 
Increasing the sensitivity by employing a broader range of search terms, and searching the 
grey literature could have increased reliability in conclusions drawn from this SR.  
It is clear from this review that large epidemiological studies using electronic healthcare 
records (EHRs) are necessary to advance our understanding of how patients are managed 
in current practice and determine how well patterns relate to CGs. This information can 
then be used to enhance current management practices through modifications to CGs and 
ultimately improve patient outcomes and the allocation of resources.  
5.8 Chapter Summary 
This chapter sought to identify and describe the real-world treatment patterns in the 
worldwide NGB population. Some strategies were supported by current NGB CG 
recommendations but particularly owing to the earlier years of data collection, some 
practices also diverged.  
The next chapter aims to build on the gaps identified in this SR, by generating an 
understanding of the patient characteristics and treatment patterns in UK NGB patients 
using the Clinical Practice Research Datalink (CPRD) database. The study will also determine 
the healthcare resource utilisation (HRU) which is intrinsically linked to the effectiveness of 
the management pathway. 
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6) Chapter Six – Clinical Practice Research Datalink (CPRD) Study: Methods 
6.1 Introduction  
The previous chapters in this thesis have provided an in-depth overview of neurogenic 
bladder (NGB) by collating and presenting the demographics and healthcare resource 
utilisation (HRU) (Chapter 2), clinical guideline (CG) quality (Chapters 3 and 4) and drug 
utilisation patterns (Chapter 5). One of the main findings from the previous chapters was 
the multiple evidence gaps in NGB, which impedes the optimal quality of CGs. One of the 
first steps to encouraging research in any disease area is to conduct epidemiological 
research to characterise the patient population. There are very few studies that effectively 
describe NGB, and furthermore, none in a UK population. In fact, the only epidemiological 
study that investigates drug utilisation patterns and HRU was conducted in the USA using 
data from over ten years ago (Manack et al., 2011). It would be infeasible to transfer this 
information to a UK population, not only because of the outdated period of data collection, 
but because patient characteristics, healthcare systems and available treatments differ 
between countries. With this in mind, there is a pressing need to better distinguish NGB in 
a UK population; understand how overactive bladder (OAB) drugs (specifically, bladder 
muscarinics and mirabegron) are used in the real-world setting and discuss the associated 
economic and health outcomes.  
Accordingly, a novel epidemiological study using the Clinical Practice Research Datalink 
(CPRD) database is presented in the following chapters, providing estimates on important 
parameters and thus insight into the manifestation of NGB in a UK population. Through 
answering the objectives set forth in this study, the unmet medical need of this patient 
population can be elucidated, which can provide direction for future research through the 
prompting of new hypotheses. These hypotheses can be tested and verified to determine 
association and ultimately promote the safe and effective use of interventions in clinical 
practice. Furthermore, the aspects of patient care that are resource intensive and 
expensive to the National Healthcare System (NHS) demonstrate possible areas where cost 
savings can be made and the salience of the disease against competing public health 
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priorities can be determined. This research also aids in elucidating where initial 
improvements in CGs can be introduced. The methodology to the CPRD study is presented 
in this chapter, followed by the results (Chapter 7) and discussion (Chapter 8). 
6.2 Funding Statement  
This study was carried out as part of a Knowledge Transfer Partnership (KTP) program 
between Astellas Pharma EU and Manchester Metropolitan University. Funding for this 
research was provided by Astellas Pharma EU and Innovate UK. 
6.3 Aims of the Study 
Section 1.6 outlined the overall aims of this research, which are to ultimately build a better 
understanding of the NGB population. The CPRD study was presented as one of the 
objectives by which to achieve this. The aims of this study are listed below. 
Primary Aim: To describe the patient demographics, comorbidities, complications and 
current patterns of drug use over 12 months in NGB patients, stratified by underlying 
neurological condition (Parkinson’s disease (PD), multiple sclerosis (MS), spinal cord 
injuries (SCI), spina bifida (SB) and stroke (STK)). Drug use includes: 
 Calculation of Anticholinergic Cognitive Burden (ACB) score  
 Rates of OAB drug (bladder muscarinic or mirabegron) use including: daily dose, 
cumulative numbers of days’ supply and level of combination use 
Secondary Aim: To describe the HRU and NGB related costs in the 12 months post 
OAB/NGB diagnosis or OAB drug prescription, stratified by underlying neurological 
condition (PD, MS, SCI, SB and STK). 
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6.4 Methods 
6.4.1 Databases 
6.4.1.1 The Clinical Practice Research Database GOLD 
The main data source employed in this study was the UK CPRD GP Online Data (GOLD). The 
database is generally accepted as a reliable resource and is used extensively throughout 
the world to conduct epidemiological research (Herrett, 2015).  
In 2007, the Department of Health’s (DoH) National Institute for Health Research (NIHR) 
launched its pilot ‘Research Capability Programme’ (RCP), with the aim of reaching a 
consensus on the use of electronic health record (EHR) data and increasing the availability 
of such data to researchers in the UK. At the time, the Medicines and Healthcare Products 
Regulatory Agency (MHRA) had ownership of the General Practice Research Datalink 
(GPRD), a large longitudinal database collecting primary care data since 1987. An 
opportunity was recognised for collaboration between these institutions, and resultantly, 
the CPRD was launched in 2012 with the aim of improving the standard of research within 
the UK and reducing development time for new interventions (Knight; MHRA, 2012).  
The CPRD database is currently the largest longitudinal primary care EHR available in the 
world. It contains anonymised data from 1987, on over 13.6 million patients from 674 
practices which equates to around 20% of the UK population. It is broadly representative 
of the UK population in terms of age, sex and geographical distribution (Williams, 2012; 
Herrett, 2015). Data is collected as part of routine primary care practice by healthcare 
professionals (HCPs) and is recorded into the database. This includes information on 
demographics (age, sex and registration information), diagnoses (from both primary and 
secondary care), symptoms, prescriptions (date, formulation, strength, and quantity), 
specialist referrals, immunisations, behavioural factors and laboratory tests. Overall 
estimates of diagnostic validity in the CPRD have proven to be high (Herret, 2010). 
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The standard clinical terminology in UK General Practitioner (GP) practices is the Read code 
classification; a comprehensive system developed by Dr James Read in 1987, that goes well 
beyond simply classifying diseases (Spencer et al., 2011). The classification consists of 
alphanumeric codes encompassing all aspects of patient care such as clinical signs, 
symptoms and observations; laboratory tests and results; diagnoses; diagnostic, 
therapeutic or surgical procedures performed; as well as a variety of administrative items. 
It even covers additional information such as social circumstances and occupation (Strom, 
2013). Drug prescriptions are recorded via the product code system, which can be 
identified by drug substance name or the British National Formulary (BNF) code 
representing the chapter and section from the BNF (Section 6.3.12.1.7). The CPRD Code 
Browser (Medical Dictionary and Product Dictionary) is used to identify Read and product 
codes. 
The CPRD is organised into distinct datasets which are combined via each patient’s unique 
identifier to provide information about the patient that is both understandable and 
analysable (Table 6.1). 
 
Table 6.1 Datasets in the Clinical Practice Research Datalink 
Dataset Description 
Patient File Identification, demographic and registration details 
Clinical File All medical events including symptoms, signs and diagnoses 
Additional Clinical Details File Data linked to events in the Clinical File 
Test File All tests requested for the patient 
Referral File All referrals made to secondary care 
Therapy File All prescriptions issued to patients 
Consultation File  The type of consultation entered by the GP 
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Practice File Details of the practice (region and collection information) 
Staff File Information on practice staff 
Available from: Padmanabhan (2017). 
 
6.4.1.2 Hospital Episode Statistics Admitted Patient Care and Outpatient  
A subset of the cohort included into this study were linked to the UK HES Admitted Patient 
Care (APC) and outpatient databases and utilised for the secondary objective of the 
research. The original purpose of the HES, which is managed and curated by NHS Digital, 
was for administration and hospital performance assessment, but it has since evolved into 
a vital resource for epidemiological research (Herbert, 2017). 
The CPRD linkage scheme allows the longitudinal analysis of both primary and secondary 
care data (Herrett, 2015). Around 75% of patient records in CPRD is linked to the HES APC 
and outpatient databases which provides data on all inpatient admissions since 1989 and 
outpatient appointments since 2004 in English NHS Trusts. Linked data is available from 
April 1997 (Herbert, 2017). Since linkage become available, the use of HES to determine 
HRU has expanded extensively owing to its comprehensive data capture on diagnoses, 
surgical procedures and outpatient attendance.  
Diagnosis in HES is coded by the International Classification of Disease, 10th revision (ICD-
10), a modified medical classification system by the World Health Organisation (WHO). 
Procedures are coded by the Office of Population Censuses and Surveys Classification of 
Surgical Operations and Procedures, 4th edition (OPCS-4.8) (NHS, 2017). Finished consultant 
episodes (FCEs) are the basic counting units and represent a period of care for a patient 
under one consultant. FCEs can then be aggregated into ‘spells’ which represent the 
complete time a patient spends in one hospital (Aylin, 2004). The strengths and limitations 
of the two main databases used in this study can be found in Appendix 9. 
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6.4.2 Ethical Approval, Governance and Patient Confidentiality  
Ethics approval for this study was granted from Manchester Metropolitan University 
(MMU) and can be found in Appendix 10.  
Governance approvals were granted by three multi-disciplinary review bodies within 
Astellas Medical Affairs Europe. The bodies are called the Protocol Review Committee 
(PRC), the Core Medical Team (CMT) and the Medical Affairs Protocol Advisory Committee 
(MA-PAC). These bodies included representation from medical, pharmacovigilance and 
statistics, and they scrutinise the scientific integrity, study design and statistical soundness 
of the protocol.   
Protocol submission to the MHRA’s, Independent Scientific Approval Committee (ISAC) 
prior to the commencement of any analyses is mandatory. The protocol was approved on 
29th September 2017 and assigned the ISAC number 17_207R (Appendix 11).  
Only anonymised data is used in this research, therefore patient consent was not required 
for this study. All analysis was conducted in accordance with the Guidelines for Good 
Pharmacoepidemiological Practice (GPP), which sets out best practice for ensuring data 
integrity and patient confidentiality (International Society for Pharmacoepidemiology 
[ISPE], 2008). In order to ensure security, the data for this study was only available to 
individuals with personalised log in credentials, who have undergone CPRD and Astellas’ 
specific real-world informatics (RWI) training. Furthermore, the data was held and analysed 
in the secure Amazon Web Services (AWS) platform.  
6.4.2.1 Practical Set Back – Governance  
As a result of the rigorous governance procedures, there were some setbacks in 
commencing analysis on the intended start date. Gaining access to the analysis platform 
was also met with significant delays owing to the long administration process and issues 
pertaining to the new General Data Protection Regulation (GDPR) guidelines.  
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6.4.3 Study Design and Aim  
This was a descriptive, exploratory study, performed using the CPRD GOLD database, 
amongst adult patients (>19) who have NGB, with the aim of characterising the population, 
describing current treatment patterns, and HRU. The study sample data was drawn from 
January 1st, 2004 to December 31st, 2016 (12 years). 
6.4.4 Quality Control  
Before analysis can begin, data must be converted to research-ready status. Analysis was 
conducted on patients flagged by CPRD as being of ‘research acceptable’ status, for whom 
their study observation period occurs during an uninterrupted period of practice 
registration, where the practice is deemed UTS by CPRD. All data management was done 
in accordance with Astellas standard operating procedures (SOPs). After reception of the 
data from CPRD, data management (selection, variable derivation), summarisation, and 
analyses was conducted using the SAS software, Version 9.4. All data transformations were 
logged in the SAS coding files.  
To determine patients’ age, it was necessary to convert the ‘year of birth’ variable by adding 
1800 to the integer value of the number of years since 01/01/1800. Gender (referring to 
patient sex) is pre-defined with category in the patient table with values of 0, 1, or 2, which 
map to the labels; “Not entered”, “Male”, “Female”, respectively. 
In order to generate the code lists for this study, search terms were first conceptualised by 
AJ and then reviewed by an in-house (Astellas) urologist. Once search terms had been 
agreed, the relevant CPRD code dictionary was searched for appropriate codes. The 
resulting codes were again confirmed by the urologist to ensure applicability and decide 
whether any changes were required to the original search terms. This was repeated until 
the final code list was derived. An effort was made throughout the duration of this process 
to enhance inclusivity but also be as specific as possible. 
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6.4.5 Missing Data 
Routinely collected data such as that from the CPRD, are normally used for administrative 
purposes, without a-priori research goals. This can introduce inconsistencies and increase 
the chances of missing data (Farmer et al., 2018). In this study, only data from patients 
flagged as being of ‘research-acceptable’ quality was used therefore there was no missing 
data for age, sex or practice. Due to the descriptive nature of this study, no imputation 
methods were employed for any data other than prescription data described in the sections 
below. 
6.4.5.1 Missing Values for Prescription Data 
In the CPRD data, prescription duration is not a mandatory field, and overall, only 7% of 
drug prescriptions are recorded with a duration value. Drug quantity (i.e. the number of 
pills in a pack) is recorded more consistently, with around 99% of all drug prescriptions 
possessing a valid quantity value.  
A CPRD-derived daily quantity field (number of pills per day or numerical daily dose) is 
provided. Some prescriptions do not clearly specify the numerical daily dose, and instead 
the physician has provided instructions for the patient to take ‘as needed’ or ‘as directed, 
making 26% of values invalid (Matcho et al., 2014).  
Patients for which duration or information to calculate the duration of treatment was 
missing were still included in the study population and imputation of the numerical daily 
dose and duration were performed when missing or invalid. 
To estimate the duration, a numeric daily dose (daily quantity) was imputed for all 
prescriptions with missing or invalid values. This imputation was performed stepwise, using 
the following set of assumptions, as described by Matcho et al (2014): 
1) If the numeric daily dose was missing or invalid, the most common valid numerical 
daily dose in the data for the same combination of product, quantity and strength 
was used.  
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2) If the first step failed to produce a valid daily quantity, then the most common valid 
numeric daily dose in the data for the product only was used. 
3) Otherwise, the daily quantity was set at one per day. 
This method utilises the most common quantities, i.e. the mode, to replace missing data 
via a hot decking approach. This consists of using replacing missing data with observed data 
from a similar unit, in this case, from the same combination or single product. This is a fast 
and simple way to make up the missing daily quantity values however utilising the mode 
does lack accuracy and can potentially underestimate daily quantity. This method can 
nevertheless be used for drugs with large sample sizes. When considering the hot decking 
method, the issue of too many missing values being imputed from the same donor can arise 
(Joenssen & Bankhofer, 2012). 
6.4.6 Identification of the Neurogenic Bladder Study Population 
Defining the patient cohort was an important first step before beginning analysis. In order 
to determine appropriate diagnostic codes to identify NGB patients, the search terms 
shown in in Table 6.2 were inputted into the CPRD code browser, searching the clinical, test 
and referral files.  
 
Table 6.2 Search terms used to identify Read codes for neurogenic bladder 
Condition Inclusion terms 
Neurogenic bladder *neurogenic*, *neuropathic*bladder*, 
*neuromuscular*bladder* 
 
 
Upon conducting the search, read codes were retrieved for neurogenic bladder, 
neuropathic bladder and neuromuscular bladder, but no Read codes were retrieved for 
neurogenic detrusor overactivity (NDO) or underactivity (Table 6.3). Neuropathic bladder 
* - represents a wild card indicating that any character can take this place.  
Words could appear on either side of the ‘AND’ search term.  
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and neuromuscular bladder were confirmed to be interchangeable terms with neurogenic 
bladder (Game, 2010; Drake and de Ridder, 2017). The term ‘NGB’, is used throughout this 
study to refer all three of these Read codes. 
 
Table 6.3 Read codes for neurogenic bladder 
Search term Read code label Read code 
*neurogenic* Neurogenic bladder K16V011 
 Neurogenic bladder F246112 
*neuropathic bladder* Neuropathic bladder K16V00 
 Neuropathic bladder F246113 
 Reflex neuropathic bladder, not elsewhere 
classified 
K16W.00 
 Uninhibited neuropathic bladder, NEC K16X.00 
*neuromuscular*bladder* Other neuromuscular dysfunction of bladder Kyu5200 
 Neuromuscular dysfunction of bladder, 
unspecified  
Kyu5E00 
 Neuromuscular dysfunction of bladder, 
unspecified  
K16V.00 
 
A feasibility count was conducted using the Read codes listed in Table 6.4, with no 
application of any inclusion/exclusion criteria. It came to light that a small number of 
patients with NGB were recorded in the CPRD database (Table 6.4). Over the period of 
2004-2015, 327 patients were diagnosed neurogenic bladder and 660 patients were 
diagnosed neuropathic bladder. Taking into consideration the prevalence estimates in 
Section 2.2 it seemed unlikely that this was representative of the UK NGB population 
(discussed further in Section 8.2).  
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Table 6.4 Number of neurogenic bladder patients retrieved per calendar year from the 
CPRD database  
Year of 
diagnosis 
200
4 
200
5 
200
6 
200
7 
200
8 
200
9 
201
0 
201
1 
201
2 
201
3 
201
4 
201
5 
Tot
al 
Patients with a diagnosis of: 
Neurogenic 
bladder 
35 32 28 29 29 28 34 41 27 28 14 10 327 
Neuropathic 
bladder 
82 95 78 68 82 71 62 56 42 42 37 8 660 
Neuromuscu
lar bladder 
0 0 0 0 0 0 0 0 0 0 0 0 0 
Neurogenic 
or 
Neuropathic 
bladder 
117 127 114 96 110 98 95 97 68 70 51 18 697 
 
Resultantly, a proxy means of identification; combining Read codes for neurological 
conditions and a diagnosis of OAB or a prescription of an OAB drug (bladder muscarinic or 
mirabegron from Therapy file) was employed to uncover further patients that most likely 
have NGB (Table 6.5 and 6.6). Accordingly, in this study, two separate definitions of NGB 
were employed. ‘Definitive NGB’ refers to those patients with a Read coded diagnosis of 
NGB, and ‘probable’ were those identified via the proxy means of identification. Another 
feasibility assessment was conducted on 29th July 2016 using both definitions of NGB 
(Table 6.7). 
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Table 6.5 Search terms used to identify Read codes for probable neurogenic bladder 
patients  
Condition Inclusion terms 
Overactive bladder *overactive* *detrusor* 
Stroke *stroke*, *haemorrhage*, *cereb* AND 
(*infarct* OR *thrombos* OR *embol* OR 
*occlusion*), *brain* AND *infarct*, 
*wallenberg*, *lateral medullary*,  
Spinal cord injury *spinal cord injur* 
Multiple sclerosis  *multiple sclerosis*, *disseminated sclerosis*  
Parkinson’s disease *parkinson*, * paralysis agitans* 
Spina bifida *spina bifida* 
* - represents a wild card indicating that any character can take this place.  
Words could appear on either side of the ‘AND’ search term.  
 
Table 6.6 Overactive bladder drugs used to identify probable NGB patients (in 
combination with search terms for neurological conditions of interest) 
Active ingredient Formulation 
Fesoterodine Oral tablet 
Mirabegron Oral tablet 
Oxybutynin ER Oral extended release tablet 
Oxybutynin IR Oral immediate release tablet 
Solifenacin Oral tablet 
Tolterodine ER Oral extended release capsule 
Tolterodine IR Oral immediate release tablet 
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Trospium Oral tablet 
Darifenacin Oral tablet 
Propiverine Oral tablet, capsules 
Flavoxate Oral Tablet 
IR, immediate release; ER, extended release 
 
Table 6.7 Feasibility assessment conducted on 29th July 2016 using the CPRD database to 
determine number of patients with neurogenic bladder between 2004-2015. 
Diagnosis No. of pts with a 
diagnosis (coded) 
No. of pts with ≥ 1 
prescription of an 
OAB drug 
No. of pts with ≥ 1 
prescription of an 
OAB drug and/or 
diagnosis of OAB  
Neurogenic bladder 967 Not searched 654 
Stroke 159,628 48,612 54,135 
Multiple sclerosis 12,859 5,593 5,846 
Spinal cord injuries 1,556 519 547 
Parkinson’s disease 24,678 9,469 10,433 
pts, patients; OAB, overactive bladder 
 
The full list of Read codes and prodcodes used to identify both definitive and probable NGB 
patients can be found in Appendix 12 and 13. 
6.4.7 Inclusion and Exclusion Criteria  
Inclusion Criteria  
To be included in this study, a patient must have been: 
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1) Diagnosed with NGB (1.a) or probable NGB (1.b or 1.c), in order to capture the broad 
NGB population: 
a. At least one diagnosis by Read code/medcode of either Neurogenic bladder 
OR Neuropathic bladder within the study period (January 1st, 2004 to 
December 31st, 2016).  
OR 
b. Have a diagnosis by Read code/medcode of least one of the following 
conditions: PD, MS, SCI or STK within the selection period (2004-2016) AND 
at least one prescription of an OAB drug AND/OR one diagnosis of OAB 
within the study period (January 1st, 2004 to December 31st, 2016). 
OR 
c. Have a diagnosis by Read code/medcode of SB within the whole follow-up 
period (from start to end of enrolment in CPRD) AND at least one 
prescription of an OAB drug AND/OR one diagnosis of OAB within the study 
period (January 1st, 2004 to December 31st, 2016). A longer enrolment 
period was employed in this neurological condition because SB is a 
congenital disorder, therefore patients are likely to have been diagnosed 
earlier on in their enrolment to the CPRD. 
2) Be >19 years at index date to ensure all data in the analysis (including within the 
look-back period) was collected when the patient was aged 18 or over. 
3) Have >12 months of continuous enrolment in the CPRD GOLD database prior to the 
index date, without prescription of an OAB drug or diagnosis of NGB or OAB to 
ensure new patient status. The pre-index period is also used to determine co-
morbidity score. As SB is a congenital condition, it is not possible to discern the date 
of first diagnosis within the study period. Therefore, the purpose of the 12 months 
pre-index period in SB patients serves only to determine the co-morbidity score. 
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4) Have >12 months of continuous enrolment in the CPRD GOLD database post 
OAB/NGB diagnosis or OAB drug prescription to determine drug utilisation patterns 
and HRU estimates.   
5) Have patient acceptable data at UTS practice (CPRD quality criteria)  
Exclusion criteria 
Patients are excluded from the study if they: 
1) Have a diagnosis of dementia (due to company restrictions in analysing this patient 
group) (Appendix 14) 
2) Have idiopathic OAB (i.e. they do not have an accompanying neurological condition 
diagnosis or a diagnosis of NGB)  
After application of inclusion and exclusion criteria to the source cohort, a patient file was 
produced which listed the patient identification number (patid) for all suitable patients. 
This file was used to extract the relevant data for this study. 
6.4.8 Patient Selection Flow Diagram 
Visual aids are often useful when there are multiple ways by which patients could be 
included into a study.  
Patients could have been included into the present study in the following ways:  
 
 
 
 
 
 
 
Index date - diagnosis of 
NGB 
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Figure 6.1 Patients with definitive neurogenic bladder  
 
 
Figure 6.2 Patients with probable neurogenic bladder (PD, MS, SCI or Stroke) 
 
 
 
Figure 6.3 Patients with probable neurogenic bladder (spina bifida) 
 
6.4.9 Index Date 
For patients with an NGB diagnosis, the index date is defined as the first date of NGB 
diagnosis within the selection period (January 1st, 2004 to December 31st, 2016). For 
patients with PD, MS, STK or SCI the first diagnosis date of the underlying neurological 
Index date- 
diagnosis of PD, 
MS, SCI or STK 
Diagnosis of OAB 
or OAB drug 
prescription 
Diagnosis of 
spina bifida 
Index date - 
diagnosis of OAB/NGB or 
OAB drug prescription  
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condition within the selection period will be considered as the index date. For patients with 
SB, the index date will be the first OAB drug prescription or first OAB/NGB diagnosis date, 
(whichever comes first) within the selection period. 
6.4.10   Study Sub-Cohorts 
NGB patients face unique challenges according to their underlying neurological condition 
and thus should be managed accordingly (Apostolidis et al., 2017). Moreover, by identifying 
which groups are more resource intensive, those more likely to be in need of services and 
treatments can be identified. Taking this into account, six sub-groups of patients were 
identified, and outcomes were described separately according to NGB diagnosis or 
underlying neurological condition.  
 
Table 6.8 Study sub-cohorts 
Subgroup Description  
Definitive NGB sub-cohort Patients who meet the study inclusion/exclusion 
criteria with at least one diagnosis of NGB (within the 
selection period) and no NGB/OAB diagnosis or OAB 
drug prescription before the index date. 
PD sub-cohort (probable NGB) Patients who meet the study inclusion/exclusion 
criteria, with at least one diagnosis of PD (within the 
selection period) and no NGB/OAB diagnosis or OAB 
drug prescription before index date to ensure the 
underlying condition precedes NGB/OAB diagnosis or 
treatment. 
MS sub-cohort (probable NGB) Patients who meet the study inclusion/exclusion 
criteria with at least one diagnosis of MS (within the 
selection period) and no NGB/OAB diagnosis or OAB 
drug prescription before index date to ensure the 
underlying condition precedes NGB/OAB diagnosis or 
treatment. 
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STK Sub-cohort (probable NGB) Patients who meet the study inclusion/exclusion 
criteria with at least one diagnosis of STK (within the 
selection period) and no NGB/OAB diagnosis or OAB 
drug prescription before index date to ensure the 
underlying condition precedes NGB/OAB diagnosis or 
treatment. 
SCI Sub-cohort (probable NGB) Patients who meet the study inclusion/exclusion 
criteria with at least one diagnosis of SCI (within the 
selection period) and no NGB/OAB diagnosis or OAB 
drug prescription before index date to ensure the 
underlying condition precedes NGB/OAB diagnosis or 
treatment. 
SB Sub-cohort (probable NGB) Patients who meet the study inclusion/exclusion 
criteria with at least one diagnosis of SB. 
NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson’s disease; MS, multiple sclerosis; 
STK, stroke; SCI, spinal cord injuries; SB, spina bifida.  
Definitive NGB refers to those patients with a Read coded diagnosis of NGB. ‘Probable’ indicates that 
the cohort of patients were identified via proxy means. 
 
There are prominent health differences between the young and old, and between sexes, 
which can augment treatment patterns and the level of HRU (Keene and Li, 2005; Regitz-
Zagrosek, 2012). Further subgroup analysis was employed to stratify the results by age 
groups (19 years – 65 years and over 65 years) and by sex.  
6.4.11   Hospital Episode Statistics Linkage Process  
A full HES record was requested for all candidate patients, where available, to enable 
accurate characterisation of secondary care resource use. The broadest possible patient 
definition was used to compile a list of NGB patient IDs (patids) (i.e. the definition used in 
the sensitivity analysis (Section 6.3.15.1)). The unique patid was used to link these records 
with text files available in the CPRD customer website that specify individuals with HES 
eligibility (binary flag for patient eligibility). This filtered the CPRD patids that met the 
inclusion/exclusion criteria for this study. This resulting list of patids was sent to CPRD, who 
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then provided the linkage data (HES APC & Outpatient), which was loaded onto the analysis 
platform.  
6.4.12   Analysis of Outcomes 
Table 6.9 lists the various endpoints that were sought in this study and the definitions, 
where applicable. All of the variables are described in more detail in the sections below. 
 
Table 6.9 Primary and secondary endpoints of the epidemiological study using the CPRD 
database 
Endpoint Variable Definition 
Primary endpoints 
Patient 
demographics 
Age at index date 
Sex 
 
Comorbidities Number of distinct BNF headers 
within the 12-month pre-index 
period 
Defined by the number of distinct BNF 
headers within 12-months before the 
index date 
Number of QoF comorbidities 
within the 12-month pre-index 
period 
Defined by the number of QoF 
comorbidities as defined by the NHS 
business rules within 12-months before 
the index date 
Diagnosis of NGB 
or underlying 
neurological 
condition 
Diagnosis of NGB or OAB preceded 
by diagnosis of underlying 
neurological condition (PD, MS, SCI, 
STK or SB) 
 
Duration between diagnosis of 
NGB/underlying condition and OAB 
diagnosis/OAB drug prescription 
Calculated as the difference between 
the date of OAB diagnosis/OAB drug 
prescription (whichever comes first), 
and the date of NGB/underlying 
condition (whichever comes first) 
Complications Complications over 12-month 
follow-up period, i.e., UTI, 
incontinence, sepsis/septicaemia, 
urinary retention, obstructive 
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uropathy, renal failure (acute and 
other), hydronephrosis 
Drug utilisation at 
index date  
ACB score Sum of ACB scores for all 
anticholinergic medicines prescribed at 
time of the first OAB/NGB diagnosis or 
OAB drug prescription 
Polypharmacy Defined by the number of distinct BNF 
headers within 30 days before and 
after index date, and the number of 
distinct substance names within 30 
days before and after index date 
Drug utilisation 
during the 
12-month follow-
up period 
OAB drug prescribed at index date Defined by the bladder muscarinic or 
mirabegron that was prescribed at 
index date 
Number of OAB prescriptions   
Cumulative number of days’ supply 
of OAB drugs 
Sum of days’ supply of all prescriptions 
occurring over the 12-month post-
index period 
Total quantity of OAB drug (mg) Sum of all doses prescribed over the 
12-month post-index period 
Number of patients with 
concomitant use of two or more 
OAB drugs (combination use) 
Patients were considered to having a 
combination of OAB drugs if at least 
two drugs overlapped for more than 30 
days 
Number of patients with 
intermittent catheter and 
indwelling catheter accompanying 
OAB drug use 
 
Number of patients with 
prescriptions for α-adrenergic 
antagonist or 5-ARIs  
 
Number of patients with 
prescriptions for antibiotics for UTI 
 
Secondary endpoints 
Healthcare 
resource use 
Occurrence (yes/no) and number of 
outpatient referrals (CPRD) 
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during the 12-
month follow up 
period 
Occurrence (yes/no) and number of 
outpatient referrals (urologists, and 
gynaecologists) (CPRD) 
Number of all-cause GP 
consultations (CPRD) 
 
Number of pads used (CPRD)   
Urological investigations/tests  Included: urinalysis; culture and 
assessment of post-void residual urine; 
cystoscopy; urodynamics; imaging 
(upper tract, spine) 
Radiology (CPRD) Radiology procedures used in NGB, ie, 
mercaptuacetyltriglycine (MAG, renal 
scan), ultrasound, computed 
tomography scan 
Number of hospital admissions 
(urology) (HES) 
All admissions associated with: a 
primary ICD-10 code related to a 
urological disease; a primary ICD-10 
code related to PD, MS, SCI, STK, SB 
and a secondary ICD-10 code related to 
a urological disease 
Number of procedures and 
operations performed (HES) 
All events from the HES procedure 
dataset associated with an OPCS-4 
code related to the following surgical 
interventions: intermittent 
catheterisation; indwelling 
catheterisation; injections of botulinum 
toxin A; sacral nerve stimulation; 
bladder augmentation; sling 
procedures; artificial urinary sphincter 
Healthcare 
resource use costs 
during the 12-
month follow-up 
period 
Costs of primary care visits 
Costs of secondary care referrals 
Costs of incontinence pad use 
Costs of diagnostic tests 
Costs of laboratory tests, i.e., costs 
of radiology 
Costs of hospitalisations 
Costs of procedures and operations 
performed 
Healthcare resource use costs 
potentially related to NGB were 
estimated at the patient level by 
applying to each resource utilisation 
unit observed during the 12-month 
follow-up period the associated unit 
cost from the NHS perspective, and 
then summing costs by healthcare 
resource category 
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5-ARI, 5α-reductase inhibitor; ACB, anticholinergic cognitive burden; BNF, British National Formulary; 
QoF, Quality Outcomes Framework; CPRD, Clinical Practice Research Datalink; GP, general practitioner; 
HES, Hospital Episode Statistics; ICD-10, International Classification of Diseases, 10th Revision; MS, 
Multiple Sclerosis; NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson’s disease; SB, spina 
bifida; SCI, Spinal Cord injuries; SD, standard deviation; STK, stroke; UTI, urinary tract infection. 
 
 
6.4.12.1 Patient Demographics 
6.4.12.1.1 Duration Between Diagnosis of Underlying Conditions and OAB/NGB 
Diagnosis/OAB Drug Prescription   
The duration between diagnosis of underlying neurological condition and diagnosis of OAB, 
NGB or prescription of an OAB drug was determined. This was calculated as the difference 
between the date of OAB diagnosis/OAB drug prescription (whichever comes first), and the 
date of NGB/underlying condition (whichever comes first). 
6.4.12.1.2 Number of Distinct British National Formulary Headers and Substances 
at Index Date (Polypharmacy) 
The concurrent use of multiple medications is defined as polypharmacy. High 
polypharmacy has been implicated in drug–drug interactions, low adherence to 
medications and increased rates of adverse events (Rohrer, 2013). In this study, 
polypharmacy was defined by the number of distinct BNF headers within 30 days before 
and after index date, and the number of distinct substance names within 30 days before 
and after index date. Repeat prescriptions of the same drug or different drugs in the same 
class were only counted once 
The BNF is a reference book that lists the medications that are generally prescribed in the 
UK (including over 70,000 medicines). It is organised in a hierarchical fashion, beginning 
with the BNF chapter (i.e. the BNF header) which correlates to specific aspects of medical 
care (French, 2017). The variable –bnfcode- in the therapy file of CPRD represents a chapter 
in the BNF, including all drugs within the same class. Substances may be included in multiple 
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BNF headers. An example of how BNF headers and substances appear in the CPRD is shown 
in Table 6.10.  
 
Table 6.10 Example of BNF headers and substances in the clinical practice research 
datalink (CPRD) database 
BNF Header Substance 
Alpha-adrenoceptor Blocking Drugs/Alpha-blockers (in Urinary 
Retention) 
Indoramin hydrochloride 
Alpha-adrenoceptor Blocking Drugs/Alpha-blockers (in Urinary 
Retention) 
Prazosin hydrochloride 
Drugs for Urinary Frequency, Enuresis, and Incontinence Flaxovate Hydrochloride 
Urinary Incontinence Mirabegron 
Urinary Incontinence Darifenacin 
hydrobromide 
Urinary Incontinence Flaxovate Hydrochloride 
Urinary Incontinence Fesoterodine fumarate 
BNF, British National Formulary 
 
6.4.12.1.3 Measurements of Comorbidity Score 
Comorbidity refers to the total burden of illness (Gijsen et al., 2001). Chronic conditions 
can be summarised into a single numerical variable to indicate the level of comorbidity. 
There is no gold standard for calculation of comorbidity. Two measures were employed to 
calculate the comorbidity score: 
1) The number of unique BNF headers (variable –bnfcode-) in an individual’s 
prescription data was counted from the therapy table to determine their level of 
comorbidity. The nature of the BNF is described in Section 6.4.12.1.2; although 
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primarily used as a means to determine polypharmacy, it has proved a useful proxy 
measure of comorbidity.  
2) A count of the 17 chronic diseases included in the Quality Outcomes Framework 
(QoF) were counted. The QoF is a pay-for-performance (P4P) scheme that 
incorporates 17 common chronic diseases in the UK including chronic heart disease, 
diabetes and certain mental health conditions (Gillam et al., 2012; Forbes, 2016). 
Recording for data points in these diseases are considerably complete (Section 
8.2.1.3). Read codes of the QoF business rules, sought in the therapy table of CPRD 
can be found in Appendix 15.  
In a study measuring the explanatory power of various morbidity measures both the BNF 
and QoF counts were deemed to have moderate predictive validity for consultation in 
primary care, with the BNF score being the most powerful of six different measures tested 
(Brilleman and Salisbury, 2013; Bessou, 2015). 
6.4.12.1.4 Complications Over 12-Month Follow up Period 
The number of complications specific to NGB were calculated over the 12 months post 
OAB/NGB diagnosis or OAB drug prescription. The search terms in Table 6.11 were used to 
identify relevant read codes. The full list of Read codes can be found in Appendix 16.  
 
Table 6.11 Inclusion terms to identify Read codes for complications related to neurogenic 
bladder 
Condition Inclusion terms 
UTI *urinary*infec*, *UTI*, *cystitis*, 
*pyelonephritis*, *urethritis* 
Incontinence *urin*incont*, *enuresis* 
Sepsis  *sepsis*, *septicaemia*, *bacteremia*, *septic 
syndrome* 
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Urinary retention  *urinary reten* 
Obstructive uropathy  *obstructive urop* 
Renal failure (acute and other) *renal fail*, *kidn*fail*,  
Hydronephrosis  *hydroneph*, *hydroureter*, *hydronephrotic 
solitary kidney* 
*-represents a wild card indicating that any character can take this place. 
Words could appear in any order.  
 
6.4.12.2 Drug Utilisation 
6.4.12.2.1 Overactive Bladder Drug Prescriptions  
This outcome was measured by conducting a simple count of individuals prescribed OAB 
drugs. OAB drugs are defined as a prescription of any of the drugs listed in Table 6.5 (Full 
prodcode list can be found in Appendix 13). According to medical experts, these 
medications are most likely utilised to manage NGB in UK clinical practice (Drake and de 
Ridder, 2017).  
6.4.12.2.2 Total Quantity of Bladder Muscarinic Drug (in mg) (Sum of Daily Dose) 
An automated algorithm in the CPRD database derives a numerical daily dose from 
unstructured text dosage instructions. The derived numerical daily dose values of OAB 
drugs calculated by this algorithm were utilised in this study along with the dose per tablet. 
The daily dose is calculated as follows:  
dose per tablet x numeric daily dose 
The overall consumption of OAB drugs was calculated as the sum of the daily dose over the 
12-month post OAB/NGB diagnosis or OAB drug prescription period. 
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6.4.12.2.3 Cumulative Number of Days’ Supply of OAB drugs 
This was defined as the sum of days’ supply of all prescriptions occurring over the 12-month 
post-index period. If a prescription date fell within the 12-month post-index period but 
ended outside it, only days’ supply within the follow-up period were considered. 
6.4.12.2.4 Number of Combinations of Overactive Bladder Drugs  
In this study, combination use is defined as overlapping use of two or more OAB drugs for 
more than 30 days (i.e. concurrent use for 30 days) (Figure 6.4). The number of patients on 
any combinations of OAB drugs (Table 6.5) were reported. 
 
 
 
 
 
 
 
 
 
6.4.12.2.5 Number of Patients Prescribed α-Adrenergic Antagonist or 5-Alpha-
Reductase Inhibitors at Any Dosage 
A simple count of individuals that were prescribed α-adrenergic antagonists and 5-Alpha-
Reductase Inhibitors (5-ARIs) was conducted (Full prodcode list Appendix 17).  
Prescription of 
Drug B 
Day 1 Prescription of 
Drug C 
Day 1 
Prescription of 
Drug C 
Day 30 
Prescription of 
Drug B 
Day 60 
Combination use of Drug B and 
Drug C 
Patient A’s 
medical record 
Figure 6.4 Combination use of overactive bladder drugs 
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α-adrenergic antagonists are recommended for management of bladder outlet obstruction 
(BOO) by the EAU and ICI CGs. Identifying patients on these drugs could act as a proxy 
means to identify individuals that were also suffering from bladder emptying problems. 
Several small clinical trials have also demonstrated efficacy of α-adrenergic antagonists in 
NDO. 5-ARIs are primarily used for BOO in benign prostatic hyperplasia (BPH).  
6.4.12.2.6 Number of Patients Prescribed Antibiotics for Urinary Tract Infection 
There is a high incidence of UTI in NGB. The causes are multifactorial, including urodynamic 
testing, catheterisation or surgery (Vigil, 2016). Common antibiotics used to manage UTI’s 
are trimethoprim, ciprofloxacin, nitrofurantoin, amoxyicllin, co-amoxiclav, trimethoprim, 
ampicillin, nitrofurantoin, pivmecillinam hydrochloride, quinolone, cephalexin, fosfomycin, 
gentamicin, or ofloxacin. The number of patients using any of these antibiotics, at any 
dosage, were recorded (Full prodcode list, Appendix 18) 
6.4.12.2.7 Anticholinergic Burden Score at Date of First Bladder Muscarinic Drug 
Prescription  
Anticholinergic burden is defined as the cumulative effect of one or more drugs with the 
potential to cause anticholinergic adverse effects (Nishtala et al., 2016). Individuals with 
certain neurological conditions are at an increased risk of experiencing cognitive 
dysfunction due to anticholinergic load (Kay, 2008) (Section 2.5.3). Around ten scales exist 
to calculate the anticholinergic burden and are used varyingly both in clinical practice and 
in research. There is currently no gold standard for measurement. The scales are 
constructed via distinct methodologies, ranging from in vitro measures to utilising evidence 
from literature reviews. In all scales, expert opinion has a large influence in the resulting 
classifications, which affects their reliability (Villalba-Moreno et al., 2015; Salahudeen et 
al., 2015). 
The ACB scale was used in this analysis, as it is one of the most widely used and validated 
scales in the literature. It was developed by an interdisciplinary expert team, through a 
systematic review (SR) of studies measuring anticholinergic activity of medications and the 
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association with cognitive function in the elderly (Campbell et al., 2013). It uses a three-
point rating scale, where 0 means little/no anticholinergic activity and 3 equates to high 
anticholinergic activity (Table 6.12). To determine an individual’s ACB score, the associated 
potency scores of each bladder muscarinic medication prescribed is added together 
(Kersten, 2014). The definition used in this study was: the sum of ACB scores for all 
anticholinergic medicines prescribed at time of the first OAB/NGB diagnosis or OAB drug 
prescription. The drugs used to calculate the ACB score can be found in Appendix 19. 
 
Table 6.12 Grading criteria of anticholinergic cognitive burden (ACB) scale 
Category Criteria ACB score 
No anticholinergic effects  0 
Possible anticholinergic 
effects 
Evidence of in vitro anticholinergic activity or 
affinity for muscarinic receptors but with no 
clinically relevant negative cognitive effects 
1 
Definite anticholinergic 
effects 
Evidence from literature, prescriber’s information, 
or expert opinion of clinical anticholinergic effect 
2 
Definite anticholinergic 
effects 
Evidence from literature, expert opinion, or 
prescriber’s information that medication may cause 
delirium 
3 
 
6.4.13   Healthcare Resource Utilisation  
The concept of Cost-of-Illness (COI) was introduced in Section 2.8. This following section 
will outline the methods used to conduct this type of study, with particular emphasis on 
the HRU aspect. 
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6.4.13.1 Methods of Healthcare Resource Utilisation Studies 
6.4.13.1.1 Perspectives and Costs Considered  
The perspective adopted in COI analysis dictates the costs considered in the analysis. 
Perspectives can include the society, healthcare system, government or payers (Costa et 
al., 2012). Costs can be categorised into two discrete categories: direct and indirect, and 
within these categories, medical and non-medical costs can be calculated (Tarricone, 2006).  
Direct costs relating to medical services and goods include GP visits, diagnostic tests and 
secondary care services, amongst others. These costs are most commonly sought when 
taking a healthcare or payer perspective. Direct costs can also be non-medical related, for 
example the out-of-pocket expense borne by the patient for transportation to the hospital, 
or community care services, and are usually considered when taking a societal perspective. 
(Walter, 2006). Indirect costs may also be considered in the analysis. These costs arise as a 
result of illness but are not related to the direct purchasing of medical services (Yousefi et 
al., 2014). The commonly counted costs of this nature are labour and productivity losses, 
which result in a deficit in economic output due to disease related work absenteeism and 
other caregiver costs (NCCID, 2016). There are a number of different approaches that are 
used to calculate indirect costs such as the Human Capital Approach (HCA); its variation, 
the Friction Cost Method (FCM); and the Health State Valuation (HSV), however they are 
beyond the scope of this research (Garattini et al., 2001). The present study takes on the 
perspective of the UK NHS and calculates direct medical costs. 
6.4.13.1.2 Approach Taken to Healthcare Resource Utilisation Studies 
Based on the epidemiological design of the study, there are two different approaches to 
estimating resource use and subsequent calculation of costs. The incidence-based 
approach measures averted costs if new cases of the disease are prevented. This study 
design involves following the patient from date of diagnosis to cure (or death) in order to 
determine lifetime costs, hence requires a considerable amount of data, which can often 
prove difficult to obtain (Jo, 2014). The variations in cost that arise at different stages of 
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disease can be determined from this method, proving a useful advantage when observing 
changes in disease costs over time and demonstrating the impact of early interventions 
(Larg and Moss, 2011). Alternatively, the prevalence approach may be adopted, which 
measures the impact of all patients (including new and recurrent cases), usually over a 
period of one year, making this study design considerably more practical to conduct in 
terms of data collection. In contrast to the incidence-based approach, this design presides 
on the notion that costs should be assigned to the years in which they are borne. It has 
been posited as the superior choice for the construction of cost-containment policies and 
to draw an attention from health policy makers to the burden of disease (Tarricone, 2006). 
For these reasons and because of the availability of data, the prevalence approach was 
utilised in the present study.  
6.4.13.1.3 Costing Methods 
As well as the selection of an epidemiological design which governs the time-frame in which 
resources and costs are collected, a costing method should also be chosen. There are two 
common methods to examine costs; the top-down approach (gross-costing) or the bottom-
up approach (micro-costing) (Songer, 1998).  
The top-down approach (otherwise known as population based), measures costs on an 
aggregate level. Costs related to the use of healthcare services is typically calculated by 
averaging total health expenditures by the number of individuals with the disease (Songer, 
1998). In contrast, the bottom-up approach estimates the frequency of separate health 
resources used by the individual. The resources are then multiplied by the unit costs to 
derive a final cost calculation of resources consumed (Tarricone, 2006). Using unit costs 
ascertains the value, reflecting the opportunity cost of the resources consumed. In some 
instances, there may be uncertainty around which unit costs should be employed because 
of variation between hospitals or payers. In this study, the perspective of the UK NHS was 
employed, where the unit costs are averaged on a national scale, and the official data is 
made freely accessible to researchers. 
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In comparison to the top-down approach, the bottom-up approach to costing can be time-
consuming to apply, as granular data is necessary to create a comprehensive picture of the 
resources consumed (Jo, 2014). In addition, the bottom-up approach relies on 
extrapolation of results from a sample to the population, therefore, it is imperative that 
the sample is unbiased and truly representative of the population at large. The present 
study uses the CPRD database and unit costs from the PSSRU and NHS schedule reference 
costs which are representative of the UK population. One disadvantage of extrapolation is 
the potential for double counting of costs, whereas the top-down approach avoids this risk 
through the use of aggregated data (Hodgson, 1994). There are also a number of inherent 
disadvantages to the top-down approach, in particular the inability to calculate costs on a 
longitudinal scale, which limits applicability in the present study. Furthermore, because 
costs are calculated at an aggregate level, the ability to provide cost estimates stratified by 
disease subgroups or patient characteristics is limited (Larg and Moss, 2011). 
The bottom-up approach is generally considered the superior method of costing, by virtue 
of its reliable and flexible nature, and thus was employed in the present study. Determining 
the level of resources consumed consists of a simple counting method of variables outlined 
in the sections below, which was then multiplied by unit costs to derive total per patient 
costs. 
6.4.13.2 Healthcare Resource Utilisation Variables  
6.4.13.2.1 Number of Outpatient General Practitioner Consultations 
Face-to-face and telephone GP consultations were identified from the consultation table 
using the -constype- variable. The consultations counted are shown in Table 6.13. More 
than one consulting record per day was counted as separate consultations. For example, if 
a patient visited their GP in the surgery and then later on in the day received a telephone 
consultation, this counted as two separated consultations.  
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Table 6.13 General Practitioner consultation types 
Code (constype) Role Consultation categories 
9 Surgery consultation Surgery consultation 
22 Third party consultation Surgery consultation 
1 Clinic Clinic 
10 Telephone call from a patient Telephone consultation 
21 Telephone call to a patient Telephone consultation 
11 Acute visit Home visit/surgery consultation 
8 Out of hours, non-practice Out of hours 
27 Home visit Home visit 
3 Follow-up/routine visit Home visit/surgery consultation 
7 Out of hours, practice Out of hours 
2 Night visit, Deputising service Out of hours 
30 Nursing home visit Home visit 
55 Telephone consultation Telephone consultation 
6 Night visit, practice Out of hours 
31 Residential home visit Home visit 
4 Night visit, local rota Out of hours 
34 Walk-in centre Surgery consultation 
36 Co-op surgery consultation Surgery consultation 
37 Co-op home visit Home visit 
32 Twilight visit Out of hours 
40 Community clinic Clinic 
28 Hotel visit Home visit 
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6.4.13.2.2 Urodynamic and Radiological Tests 
The NICE and ICI CGs recommend that urodynamic tests are carried out in individuals that 
are at high risk of renal damage. In contrast, the EAU CGs recommend that urodynamic 
tests are carried out for all NGB patients. In order to determine how many individuals 
undergo urodynamic testing, medcodes for a number of different tests were sought and 
the number of patients with any of these codes over the 12-month follow up period were 
counted. Urological investigations/tests include: urinalysis, culture and assessment of post-
void residual urine, cystoscopy, urodynamics, imaging (upper tract, spine). All events from 
the test tables associated with a medcode related to urological investigations/tests were 
selected. The codes were identified by means of the CPRD medical dictionary as test events 
with a medcode including specific key words related to urological tests (Table 6.14). Full 
code list can be found in Appendix 20. 
 
Table 6.14 Inclusion terms for urodynamic and radiological tests to retrieve relevant 
medcodes 
Variable Inclusion terms 
Urodynamic and Radiological Tests *urinalys*, *cystoscop*, *urodynam*, 
*urin*tract*, *spine*, *uroflowmetr*, 
*cystometr*, *electromyogr *, *ultrason*, 
*comput*tomograph*. 
 
6.4.13.2.3 Number of Visits to a Specialist  
The number of visits a patient made to the urologist or gynaecologist can give an indication 
of severity of urological symptoms and an understanding of the common practices in 
referrals amongst physicians. The frequency of visits over the 12-month follow-up period 
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was counted from the CPRD GOLD and determined by using the NHS speciality (–nhsspec- 
variable) in the referral table (Full code list, Appendix 21). 
6.4.13.2.4 Number of Incontinence Pads 
Pads are often used as a precaution against urinary incontinence, in conjunction with other 
management strategies (Dorsher and McIntosh, 2012). All events from the Therapy file 
associated with a product code (-prodcode- variable) related to pad prescriptions were 
chosen. The codes were selected by means of the CPRD product dictionary as prescriptions 
events with a BNF header including the following specific key word: ‘*pad*’. Each code (and 
related product name) was reviewed to avoid misclassification. The average number of 
pads used per person over the 12-month follow up period was calculated (Full code list, 
Appendix 22). 
6.4.13.2.5 Number of Procedures and Operations Performed 
The number of pre-specified procedures and operations performed over the 12-month 
follow up period were counted. These included all events from the HES procedure dataset 
associated with an OPCS-4 code related to the following interventions: intermittent 
catheterisation; indwelling catheterisation; injections of Onabotulinum-A; sacral nerve 
stimulation; bladder augmentation; sling procedures; artificial urinary sphincter (AUS) (Full 
code list, Appendix 23). 
6.4.13.2.6 Number of Hospitalisations and Duration of Hospitalisation 
The number of times an individual was hospitalised due to NGB related events over the 12-
month follow up period was counted using data from the HES. A hospitalisation counted as 
a primary ICD-10 code related to a urological disease or a primary ICD-10 code related to 
PD, MS, SCI, STK, SB and a secondary ICD-10 code related to a urological disease (Full code 
list, Appendix 24).  
The duration of hospital stays was defined as the difference between the admission and 
discharge dates (“admidate”, “discharged”) for admissions taking place within 12 months 
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following the NGB/OAB date. If a hospital admission was overlapping with the 12-month 
follow-up period (e.g. a patient admitted within the 12-month period and discharged after), 
only the days of overlap between the admission and the 12-month period were considered. 
The sum of all admissions durations was calculated. 
6.4.14   Statistical Methods 
6.4.14.1 Sample Size Justification 
Although sample size calculations are not necessary for a descriptive study, determination 
of the minimum sample size can provide information on the level of precision required to 
provide estimates of summary statistics such as the mean (Berkowitz, 2007). Chochran’s 
formula was used to calculate the minimum sample size in this study (Cochran, 1977):  
 
n0 =
𝑧2𝑝𝑞
𝑒2
 
Where:  
e = desired level of precision  
p = (estimated) proportion of the population which has NGB 
q = 1 – p. 
A recent meta-analysis found the prevalence of urinary incontinence (UI) was 50.9% in 
patients with MS, 52.3% with SCI, 33.1% with PD and 23.6% with STK (Ruffion et al., 2013). 
Assuming a 95% confidence level, a precision of +/- 5% and an infinite population 
(conservative assumption), the minimum sample size for patients with neurogenic bladder 
would be 384 patients with MS or SCI, 341 patients with PD, 278 patients with STK (Table 
6.15). Based on these minimum sample size calculations, expected numbers from the 
feasibility analysis (Table 6.6) were deemed sufficiently large enough to provide a 
representative sample.  
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Table 6.15 Minimum sample size calculations 
  Prevalence among the 
underlying condition (Ruffion 
et al., 2013) 
Confidence 
level 
Precision Sample size (assuming 
an infinite population) 
MS 50.90% 0.95  +/- 5% 384 
SCI 52.30% 0.95  +/- 5% 384 
PD  33.10% 0.95  +/- 5% 341 
Stroke 23.60% 0.95  +/- 5% 278 
MS, multiple sclerosis; SCI, spinal cord injuries; PD, Parkinson’s disease. 
 
6.4.14.2 Data Analyses 
The aim of this study was to describe the uncharacterised UK NGB patient population 
therefore only descriptive statistics were used. 
Aggregate summary statistics were reported. N, mean, median, standard deviation, 
minimum, maximum, 25th percentile and 75th percentile was calculated for continuous 
variables and frequency tables were presented for categorical variables. The calculation of 
proportions did not include the missing/invalid category.  
6.4.14.3 Calculation of Healthcare Costs 
A bottom-up approach to costing was employed (Section 6.3.13.3). Healthcare costs were 
evaluated at the patient level, by multiplying resource utilisation units observed within 12 
months, with associated unit costs, from the perspective of the NHS (Table 6.16). 
Healthcare costs were calculated by summing costs for all healthcare resources consumed, 
overall and by type of resource. This study included data over a 12-year period; however, 
in order to account for inflation and variations in pricing over time, costs were used from 
one base year only (2016-17), reflecting the most recent period. 
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Primary care costs in the UK are derived from the Unit Costs of Health and Social Care 2015 
from the Personal Social Services Research Unit (PSSRU). The GP visit costs were calculated 
by multiplying the average minutes of GP time spent during a particular type of 
consultation (Table 6.16), by the cost per minute (£4). The average number of minutes was 
derived from the GP workload survey, carried out in 2006/07, which asked GPs from a 
representative sample of 329 practices across the UK to complete diary sheets for one week 
in September or December of 2006 (The Information Centre, 2007). The time for home 
visits included the time spent at the patient’s home only (i.e. excluding travel costs). 
The cost of secondary care is calculated according to national tariff prices, based on the 
national average unit costs available in the National Schedule of Reference Costs. Patient 
activity is described according to groupings referred to as Healthcare Resource Groups 
(HRG), containing diagnostic codes, treatments and procedures with similar levels of 
resource utilisation, which are used to attract a tariff (Weir et al., 2017). An algorithm is 
used to generate an appropriate HRG code by grouping secondary care events such as 
procedures and operations performed and duration of care into spells (Weir et al., 2017). 
A file was created containing HRG codes and the corresponding tariff, which was then 
merged with the HES to assign a cost to each hospitalisation or procedure carried out. 
 
Table 6.16 Unit costs of outpatient primary and specialist consultations 
Variable Unit costs Source 
Primary care (general practitioner) 
Surgery consultation (lasting 9.22 
minutes) 
£37.00 Curtis et al. 2017 
Clinic £68.80a Curtis et al. 2017; Curtis 2014 
Home visit £45.60b Curtis et al. 2017; Curtis 2014 
Telephone consultation £28.40c Curtis et al. 2017; Curtis 2014 
Specialists (outpatient attendance) 
Urologist £109.40 NHS 2016–17 
Gynaecologist £140.93 NHS 2016–17 
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Urological tests   
Urodynamic test £126.00 NHS 2016–17 
Cystoscopy £146.00 NHS 2016–17 
Incontinence pads 
One pad £0.20d Age UK 
Radiology  
Ultrasound  £144.00 NHS 2016–17 
Computed tomography £83.00 NHS 2016–17 
Procedures and surgical interventions  –e Adapted from NHS 2016–17 
Hospital visits –e Adapted from NHS 2016–17 
a17.2 minutes @ £4 per minute. 
b11.4 minutes @ £4 per minute. 
c7.1 minutes @ £4 per minute. 
dLille Healthcare Classic Pad PE Backed Maxi 1250 ml pack of 30 (£5.99 for 30 pads). 
eFor each episode, costs were derived from HRG tariffs published by the NHS (2016/17) as follows:  
short episodes (length of stay (LOS) ≤ trimpoint) 
cost=T; long episodes (LOS > trimpoint) 
cost =T + (LOS - D) * E.  
Where:  
T= combined day case/ordinary elective spell tariff 
D= ordinary elective long-stay trimpoint (days) 
 E= per day long-stay payment (for days exceeding trimpoint) (£) 
Trimpoint= excess bed days beyond the standard number of days anticipated for a given HRG 
Missing Healthcare Resource Group (HRG) tariffs were collected from the national schedule of reference 
costs OR if not available, determined from previous years if available and an inflation rate was applied 
OR, if not available, imputed as £0.1 (Gaughan, 2012). 
 
6.4.15   Sensitivity Analyses 
Neurological conditions may be mistaken for milder prodromal symptoms such as sleep 
disorders or depression. This could mean that the diagnosis of these conditions are made 
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later than actual occurrence of disease (Butler and Zeman, 2005). In these instances, it is 
plausible to assume that diagnosis of OAB/NGB or prescription of an OAB drug could occur 
before the diagnosis of the neurological condition. Therefore, the sensitivity analysis 
employed in this study consisted of altering the patient definition where the diagnosis of 
underlying neurological condition or OAB/NGB or OAB drug prescription could appear in 
any order within the selection period (Butler and Zeman, 2005). 
It was hypothesised that this method of case ascertainment could improve the sensitivity 
of the search. Although, of course a tradeoff with increasing sensitivity is that that 
specificity decreases, and some patients included into the analysis may not be genuine NGB 
patients, however expert opinion suggests that the margin of error will not be large (Drake 
and de Ridder, 2017) 
6.5 Chapter Summary 
This chapter outlined the methodology for a novel descriptive epidemiological study using 
the CPRD database, with the aim of characterising many pertinent aspects of the NGB 
patient journey. The CPRD and HES databases, including the strengths and weaknesses 
were described. Furthermore, the methods of HRU and costing were presented. Finally, the 
variables sought in this study which provide a detailed picture of the NGB population from 
the perspective of the NHS were outlined. The next chapter will present the results from 
this study. 
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7) Chapter Seven - Clinical Practice Research Datalink (CPRD) Study – 
Results 
7.1 Introduction 
The following section presents the results from the Clinical Practice Research Datalink 
(CPRD) study into the patient characteristics, drug utilisation patterns and healthcare 
resource utilisation (HRU) of patients with neurogenic bladder (NGB) in the UK.  
7.2 Inclusion into the Study 
Patients’ inclusion in the study is described in Figure 7.1. Between January 1st, 2004 and 
December 31st, 2016, 19,499 patients with NGB or probable NGB were identified and 
included into the study. For patients with Parkinson’s disease (PD), multiple sclerosis (MS), 
spinal cord injuries (SCI) or stroke (STK) the first diagnosis date of the underlying condition 
was considered as the index date. For patients with spina bifida (SB), it was the first 
overactive bladder (OAB) drug prescription or first OAB/NGB diagnosis, whichever comes 
first, within the selection period. 
Among the patients included in the source cohort, 29.0% (n=5658) had already received 
OAB drugs or a diagnosis of NGB or OAB in the year prior to the index date or had less than 
12 months history before the index date. These patients were excluded to ensure patients 
included in the study were newly diagnosed. In addition, 13.8% (n=2695) patients had less 
than 12 months follow-up after the NGB/OAB diagnosis or OAB prescription date, 3.1% 
(n=598) were  aged less than 19 years, 61.3% (n=11946) were without referral to a 
urologist, 0.3% (n=54) had idiopathic OAB and 12.5% (n=2439) had dementia, and thus 
were excluded from the study. In total, 79.9% of the source cohort patients were excluded 
(n=15,586). The final study cohort was comprised of 3913 patients. Amongst these, 59.5% 
(n=2330 patients) had available data from the hospital episode statistics (HES) database. 
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NGB, neurogenic bladder; OAB, overactive bladder; HES, hospital episode statistics  
Figure 7.1 Flow chart of neurogenic bladder patient selection and linkage to Hospital 
Episode Statistics Data 
Exclusions 
Total excluded - 15586 (79.9%) 
 
By exclusion/inclusion criteria 
(independently one from each 
other): 
 Patients aged < 19 years 
at index date - 598 
(3.1%) 
 Patients with less than 
12-month history prior 
index date, with 
NGB/OAB diagnosis or 
OAB-related 
prescriptions - 5658 
(29.0%) 
 Patients with less than 
12-month follow-up - 
2695 (13.8%) 
 No referral to urologist 
within the 12-month pre-
index and follow-up 
periods- 11946 (61.3%) 
 Diagnosis of idiopathic 
OAB- 54 (0.3%) 
 Diagnosis of dementia 
within the selection 
period- 2439 (12.5%) 
 
Source cohort 
Patients with NGB or probable NGB between 
January 1st, 2004 and December 31st, 2016   
N= 19499 
 
Study cohort 
Eligible patients aged ≥19 years old 
with NGB during selection period  
N= 3913 (20.1%) 
Linked study cohort (HES data) 
Eligible patients aged ≥19 years old 
with NGB during selection period and 
having linkage with HES 
N= 2330 (59.5% of the study cohort) 
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7.3 Study Sub-Cohorts 
The distribution of patients by sub-cohort is presented in Table 7.1. The definitive NGB 
group consisted of 363 patients (9.3% of study cohort) which was smaller than the STK sub-
cohort (n=1720, 44.0%), MS sub-cohort (n=1029, 26.3%) and PD sub-cohort (n=713, 18.2%). 
The SCI sub-cohort and SB sub-cohort accounted for the rest (5.6%) of the population.  
 
Table 7.1 Distribution of patients by sub-cohort of interest  
Subgroup*  (n=3913) 
Definitive NGB 363 (9.3%) 
PD cohort 713 (18.2%) 
MS cohort 1029 (26.3%) 
STK cohort 1720 (43.9%) 
SCI cohort 41 (1.0%) 
SB cohort 180 (4.6%) 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injury; SB, spina bifida 
*The groups are defined inclusively, i.e. patients may be included in more than one group (NGB group 
and/or underlying neurological condition group). 
 
7.4 Demographics and Clinical Characteristics 
7.4.1 Age of Patients at Index Date 
Age of the population at index date ranged from 19 and 104 years old with a mean of 61.7 
years (SD=16.3) (Table 7.2). The mean age was 65.0 years (SD=15.1) in the male group and 
56.8 years (SD=16.8) in the female group (Table 7.3). The PD sub-cohort showed the highest 
mean age at 70.7 years (SD=9.2), closely followed by the STK sub-cohort (mean=70.3 
[SD=11.6]). Patients in the SB sub-cohort were the youngest with a mean age of 36.1 years 
(SD=11.9) (Table 7.2). 
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Table 7.2 Age at index date by underlying neurological condition 
Characteristics 
 
Definitiv
e 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=102
9 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=391
3 
Age at index-
date 
 
No. of valid 
values 
363 713 1029 1720 41 180 3913 
Mean (SD) 48.30 
(15.91) 
70.67 
(9.16) 
48.71 
(11.84) 
70.32 
(11.56) 
46.63 
(14.76) 
36.11 
(11.93) 
61.72 
(16.29
) 
Median 48 72 49 72 49 34.5 64 
Min-Max [19.0; 
87.0] 
[31.0; 
92.0] 
[19.0; 
83.0] 
[21.0; 
98.0] 
[20.0; 
68.0] 
[19.0; 
76.0] 
[19.0; 
98.0] 
Q1-Q3 [36.0; 
60.0] 
[65.0; 
77.0] 
[40.0; 
57.0] 
[63.5; 
79.0] 
[34.0; 
58.0] 
[26.0; 
44.0] 
[50.0; 
75.0] 
SD, standard deviation; NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson’s disease; MS, 
multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina bifida 
 
Table 7.3 Age at index date by age and sex subgroups 
Characteristics 
 
[19 years – 
65 years[ 
 n=2038 
Over 65 
years 
n=1875 
Male 
n=2334 
Female 
n=1579 
Age at index-
date 
 
No. of valid values 2038 1875 2334 1579 
Mean (SD) 49.03 
(11.69) 
75.51 (6.33) 65.03 
(15.09) 
56.82 
(16.76) 
Median 51 75 68 56 
Min-Max [19.0; 65.0] [66.0; 98.0] [19.0; 98.0] [19.0; 97.0] 
Q1-Q3 [41.0; 59.0] [70.0; 80.0] [57.0; 76.0] [45.0; 70.0] 
SD, standard deviation 
 
7.4.2 Number of Quality Outcomes Framework Chronic Diseases within the 
Pre-Index Period (Comorbidity) 
The Quality Outcomes Framework (QoF) was employed to determine comorbidity. The STK 
sub-cohort showed the highest level of comorbidity over the 12-month pre-index period 
with a mean number of QoF chronic diseases of 1.4 (SD=1). Amongst the other sub-cohorts, 
the level varied from 0.2 (SD=0.5) in the SCI sub-cohort to 0.3 (SD=0.6) in the definitive NGB 
sub-cohort (Table 7.4). Elderly patients (>65 years old) showed a higher level of morbidity 
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than patients aged <65 years old with a mean of 1 (SD=0.9) QoF chronic diseases vs 0.5 
(SD=0.7). The level of morbidity was also higher in male patients than in female patients: 
0.8 (SD=0.9) vs 0.6 (SD=0.8) (Table 7.5). 
 
Table 7.4 Count of chronic diseases from the QOF within the 12-month pre-index period 
by underlying neurological condition 
Characteristics 
 
Definitive 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
QoF count No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
0.29 
(0.59) 
0.27 
(0.60) 
0.17 
(0.45) 
1.37 
(0.69) 
0.17 
(0.50) 
0.21 
(0.47) 
0.73 
(0.83) 
Median [0.0; 3.0] [0.0; 
4.0] 
[0.0; 
3.0] 
[0.0; 
5.0] 
[0.0; 
2.0] 
[0.0; 
2.0] 
[0.0; 
5.0] 
Min-
Max 
0 0 0 1 0 0 1 
Q1-Q3 [0.0; 0.0] [0.0; 
0.0] 
[0.0; 
0.0] 
[1.0; 
2.0] 
[0.0; 
0.0] 
[0.0; 
0.0] 
[0.0; 
1.0] 
QoF, Quality Outcomes Framework; SD, standard deviation; NGB, neurogenic bladder; OAB, overactive 
bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina 
bifida 
 
Table 7.5 Count of chronic diseases from the QOF within the 12-month pre-index period 
by age and sex subgroups 
Characteristics 
 
[19 years 
– 65 
years[ 
 n =2038 
Over 65 
years 
n =1875 
Male 
n =2334 
Female 
n =1579 
QoF count No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 0.49 
(0.74) 
0.99 
(0.85) 
0.81 
(0.85) 
0.61 
(0.80) 
Median [0.0; 5.0] [0.0; 5.0] [0.0; 5.0] [0.0; 5.0] 
Min-Max 0 1 1 0 
Q1-Q3 [0.0; 1.0] [0.0; 1.0] [0.0; 1.0] [0.0; 1.0] 
QoF, Quality Outcomes Framework; SD, standard deviation 
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7.4.3 Number of Distinct British National Formulary Headers within the Pre-
Index Period (Comorbidity) 
The number of distinct British National Formulary (BNF) headers was the second method 
employed to determine comorbidity. Overall, the mean level of comorbidity was 8.6 
(SD=7.6) and ranged from 6.5 (SD=7.1) in the MS subgroup and 11 (SD=8.9) in the SB 
subgroup. Most patients (n=1511, 39.6%) received drug from 8-19 BNF headers. The SB 
subgroup showed the largest portion of patients prescribed drugs from 20+ BNF headers 
(n=28, 15.6%) (Table 7.6). 
Comorbidity over the pre-index period was higher in elderly patients (10 [SD=7.3]) than in 
patients aged less than 65 years old (7.4 [SD=7.7]). Most elderly patients were prescribed 
drugs from 8-19 BNF headers (n=891 [SD=47.5%]), as were most patients aged between 
19-64 (n=620, 30.4%). Comorbidities were slightly higher in females (9.1 [SD=8.3]) than 
males (8.3 [SD=7.2]) (Table 7.7). 
 
Table 7.6 Comorbidity using the British National Formulary headers by underlying 
neurological condition 
Characteristics 
 
Definitive 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
Number 
of 
distinct 
BNF 
headers 
within 
the 12-
month 
pre-
index 
period 
  
  
  
Valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
9.55 
(9.06) 
9.12 
(6.93) 
6.50 
(7.11) 
9.26 
(7.58) 
7.07 
(8.55) 
10.97 
(8.91) 
8.62 (7.64) 
Min-
Max 
[0.0; 
45.0] 
[0.0; 
44.0] 
[0.0; 
42.0] 
[0.0; 
56.0] 
[0.0; 
35.0] 
[0.0; 
42.0] 
[0.0; 56.0] 
Median 8 8 4 8 3 9 7 
Q1-Q3 [2.0; 
15.0] 
[4.0; 
13.0] 
[1.0; 
9.0] 
[4.0; 
13.0] 
[0.0; 
14.0] 
[4.0; 
16.0] 
[3.0; 13.0] 
0 78 
(21.5%) 
77 
(10.8%) 
211 
(20.5%) 
263 
(15.3%) 
11 
(26.8%) 
16 
(8.9%) 
620 (15.8%) 
1-3 43 
(11.8%) 
81 
(11.4%) 
243 
(23.6%) 
150 
(8.7%) 
11 
(26.8%) 
27 
(15.0%) 
533 (13.6%) 
4-7 53 
(14.6%) 
187 
(26.2%) 
236 
(22.9%) 
382 
(22.2%) 
4 (9.8%) 35 
(19.4%) 
881 (22.5%) 
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8-19 143 
(39.4%) 
302 
(42.4%) 
273 
(26.5%) 
751 
(43.7%) 
12 
(29.3%) 
74 
(41.1%) 
1511 
(38.6%) 
20+ 46 
(12.7%) 
66 
(9.3%) 
66 
(6.4%) 
174 
(10.1%) 
3 (7.3%) 28 
(15.6%) 
368 (9.4%) 
BNF, British National Formulary; SD, standard deviation; NGB, neurogenic bladder; OAB, overactive 
bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina 
bifida 
 
Table 7.7 Comorbidity using the British National Formulary headers and substances by 
age and sex subgroups 
Characteristics 
 
[19 years 
– 65 
years[ 
 n =2038 
Over 65 
years 
n=1875 
Male 
n=2334  
 
Female 
n=1579 
Number of distinct BNF 
headers 
Within the 12-month 
pre-index period 
  
  
  
Valid values 2038 1875 2334 1579 
Mean (SD) 7.39 (7.71) 9.96 (7.34) 8.33 (7.16) 9.05 (8.29) 
Min-Max [0.0 ; 51.0] [0.0 ; 56.0] [0.0 ; 46.0] [0.0 ; 56.0] 
Median 5 9 7 7 
Q1-Q3 [1.0 ; 11.0] [5.0; 14.0] [3.0 ; 12.0] [3.0 ; 13.0] 
0 411 
(20.2%) 
209 
(11.1%) 
357 
(15.3%) 
263 
(16.7%) 
1-3 398 
(19.5%) 
135 
(7.2%) 
321 
(13.8%) 
212 
(13.4%) 
4-7 444 
(21.8%) 
437 
(23.3%) 
555 
(23.8%) 
326 
(20.6%) 
8-19 620 
(30.4%) 
891 
(47.5%) 
917 
(39.3%) 
594 
(37.6%) 
20+ 165 
(8.1%) 
203 
(10.8%) 
184 
(7.9%) 
184 
(11.7%) 
SD, standard deviation; BNF, British National Formulary 
 
7.4.4  Number of Distinct British National Formulary Headers at Index Date 
(Polypharmacy) 
The mean number of distinct BNF headers at index date was 5.2 (SD=4.8) with the majority 
of patients taking drugs from 4 to 7 different BNF categories (n=1175, 30%) or from 8 to 19 
(n=997, 26%) (Table 7.8). The level of polypharmacy varied between sub-cohorts: it was the 
highest in the SB sub-cohort (mean=6.3 [SD=5.9]) and the lowest in the MS sub-cohort 
(mean=3.7 [SD=4.2]) (Table 7.8). Polypharmacy was lower in patients aged between 19 and 
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65 years (mean=4.4 [SD=4.8]] than in elderly patients [mean=6.1 (SD=4.6)] and relatively 
similar in male patients (mean=5.3, [SD=4.7]) and female patients (mean=5.1 [SD=4.9]); the 
level of polypharmacy was slightly higher in elderly patients than in patients aged less than 
65 years old: in the former (elderly), 35% received drugs from 4 to 7 BNF headers at index 
date, 33% from 8 to 19 BNF headers and 17% from 1 to 3 different BNF headers, and in the 
second age group (less than 65 years old) it was respectively 26%, 19% and 30%. 
Distributions were similar in female patients and male patients (Table 7.9).  
Results on the mean number of substances prescribed at index date were similar to the 
results on the mean number of BNF headers in the general cohort and when stratifying by 
age and sex. When looking at underlying condition sub-cohorts, results were slightly 
different, the STK sub-cohort showed the highest level of polypharmacy (mean=5.7 
[SD=4.6]), closely followed by the PD sub-cohort and the SB sub-cohort (mean=5.6 
[SD=4.2]). 
 
Table 7.8 Polypharmacy using the British National Formulary headers and substances by 
underlying neurological condition 
Characteristics 
 
Definitive 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
Polypharmacy1 
at index-date 
(using BNF 
headers) 
  
  
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
5.48 
(5.68) 
5.61 
(4.41) 
3.71 
(4.21) 
5.79 
(4.75) 
4.44 
(5.74) 
6.35 
(5.88) 
5.24 
(4.78) 
Median 4 5 2 5 1 5 4 
Min-
Max 
[0.0 ; 
30.0] 
[0.0 ; 
24.0] 
[0.0 ; 
30.0] 
[0.0 ; 
25.0] 
[0.0 ; 
19.0] 
[0.0 ; 
31.0] 
[0.0 ; 
31.0] 
Q1-Q3 [1.0 ; 9.0] [2.0 ; 
8.0] 
[1.0 ; 
5.0] 
[2.0 ; 
9.0] 
[0.0 ; 
8.0] 
[2.0 ; 
9.0] 
[1.0 ; 
8.0] 
0 89 
(24.5%) 
84 
(11.8%) 
251 
(24.4%) 
335 
(19.5%) 
18 
(43.9%) 
19 
(10.6%) 
754 
(19.3%) 
1-3 80 
(22.0%) 
182 
(25.5%) 
386 
(37.5%) 
262 
(15.2%) 
6 
(14.6%) 
51 
(28.3%) 
934 
(23.9%) 
4-7 84 
(23.1%) 
252 
(35.3%) 
227 
(22.1%) 
577 
(33.5%) 
6 
(14.6%) 
55 
(30.6%) 
1175 
(30.0%) 
8-19 101 
(27.8%) 
189 
(26.5%) 
156 
(15.2%) 
520 
(30.2%) 
11 
(26.8%) 
49 
(27.2%) 
997 
(25.5%) 
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>20 9 (2.5%) 6 
(0.8%) 
9 
(0.9%) 
26 
(1.5%) 
0 
(0.0%) 
6 
(3.3%) 
53 
(1.4%) 
Polypharmacy1 
at index-date 
(using BNF 
substances) 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
4.62 
(4.95) 
5.63 
(4.22) 
3.32 
(3.65) 
5.71 
(4.56) 
3.59 
(4.82) 
5.38 
(4.79) 
4.99 
(4.44) 
Median 3 5 2 5 1 4 4 
Min-
Max 
[0.0 ; 
26.0] 
[0.0 ; 
22.0] 
[0.0 ; 
25.0] 
[0.0 ; 
25.0] 
[0.0 ; 
18.0] 
[0.0 ; 
24.0] 
[0.0 ; 
26.0] 
Q1-Q3 [0.0 ; 7.0] [3.0 ; 
8.0] 
[0.0 ; 
5.0] 
[2.0 ; 
9.0] 
[0.0 ; 
6.0] 
[2.0 ; 
8.0] 
[1.0 ; 
8.0] 
0 98 
(27.0%) 
85 
(11.9%) 
258 
(25.1%) 
337 
(19.6%) 
19 
(46.3%) 
21 
(11.7%) 
773 
(19.8%) 
1-3 94 
(25.9%) 
167 
(23.4%) 
392 
(38.1%) 
256 
(14.9%) 
7 
(17.1%) 
57 
(31.7%) 
935 
(23.9%) 
4-7 84 
(23.1%) 
257 
(36.0%) 
251 
(24.4%) 
582 
(33.8%) 
8 
(19.5%) 
55 
(30.6%) 
1212 
(31.0%) 
8-19 83 
(22.9%) 
202 
(28.3%) 
123 
(12.0%) 
532 
(30.9%) 
7 
(17.1%) 
44 
(24.4%) 
968 
(24.7%) 
>20 4 (1.1%) 2 
(0.3%) 
5 
(0.5%) 
13 
(0.8%) 
0 
(0.0%) 
3 
(1.7%) 
25 
(0.6%) 
SD, standard deviation; NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson’s disease; MS, 
multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina bifida 
1Polypharmacy was defined as the number of distinct BNF headers/ drug substances (including non-
NGB/OAB drugs) in the therapy dataset 
 
 
Table 7.9 Polypharmacy using the British National Formulary headers and substances by 
age and sex subgroups 
Characteristics 
 
[19 years 
– 65 
years[ 
 n =2038 
Over 65 
years 
n =1875 
Male 
n=2334 
Female 
n=1579 
Polypharmacy1 at index-
date (using BNF headers) 
  
  
No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 4.42 
(4.82) 
6.13 
(4.59) 
5.32 
(4.69) 
5.11 
(4.92) 
Median 3 6 5 4 
Min-Max [0.0 ; 
31.0] 
[0.0 ; 
25.0] 
[0.0 ; 
31.0] 
[0.0 ; 
30.0] 
Q1-Q3 [1.0 ; 6.0] [3.0 ; 9.0] [1.0 ; 8.0] [1.0 ; 8.0] 
0 492 
(24.1%) 
262 
(14.0%) 
437 
(18.7%) 
317 
(20.1%) 
1-3 615 
(30.2%) 
319 
(17.0%) 
525 
(22.5%) 
409 
(25.9%) 
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4-7 519 
(25.5%) 
656 
(35.0%) 
734 
(31.4%) 
441 
(27.9%) 
8-19 381 
(18.7%) 
616 
(32.9%) 
611 
(26.2%) 
386 
(24.4%) 
>20 31 (1.5%) 22 (1.2%) 27 (1.2%) 26 (1.6%) 
Polypharmacy1 at index-
date (using BNF substances) 
No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 4.08 
(4.35) 
5.98 
(4.33) 
5.10 
(4.34) 
4.84 
(4.58) 
Median 3 6 4 4 
Min-Max [0.0 ; 
26.0] 
[0.0 ; 
22.0] 
[0.0 ; 
24.0] 
[0.0 ; 
26.0] 
Q1-Q3 [0.0 ; 6.0] [3.0 ; 9.0] [1.0 ; 8.0] [1.0 ; 7.0] 
0 510 
(25.0%) 
263 
(14.0%) 
448 
(19.2%) 
325 
(20.6%) 
1-3 620 
(30.4%) 
315 
(16.8%) 
518 
(22.2%) 
417 
(26.4%) 
4-7 537 
(26.3%) 
675 
(36.0%) 
763 
(32.7%) 
449 
(28.4%) 
8-19 354 
(17.4%) 
614 
(32.7%) 
595 
(25.5%) 
373 
(23.6%) 
>20 17 (0.8) 8 (0.4) 10 (0.4) 15 (0.9) 
SD, standard deviation; BNF, British National Formulary 
1Polypharmacy was defined as the number of distinct BNF headers/ drug substances (including non-
NGB/OAB drugs) in the therapy dataset 
 
 
7.4.5 Duration between Diagnosis of Neurogenic Bladder/Underlying 
Conditions and Overactive Bladder Diagnosis/Overactive Bladder Drug 
Prescription 
Mean duration between diagnosis of NGB/underlying conditions and OAB diagnosis/OAB 
drug prescription was 1140.1 days (SD =1352.6).  The longest duration was in the SB cohort 
(mean=4149.4 [SD=4161.2]), and the shortest duration was in the SCI cohort (mean=457.8 
[SD=519.9]) (Table 7.10). Duration was longer in younger patients (mean=1347.8 
[SD=1678.8]) than the elderly (mean=928.9 [SD=858.6]). Males (mean=1134.8 
[SD=1312.6]) had a slightly longer duration than females (mean=1147.9 [SD=1410) (Table 
7.11).  
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Table 7.10 Duration between diagnosis of NGB/underlying conditions and OAB 
diagnosis/OAB drug prescription by underlying neurological condition 
Characteristics 
 
Definitiv
e 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
Duration 
between 
diagnoses 
No. of 
valid 
value
s 
135 711 1017 1715 37 135 3678 
Mean 
(SD) 
846.27 
(1063.57
) 
1034.01 
(1008.44
) 
1095.89 
(1010.47
) 
1028.50 
(986.38) 
457.84 
(519.94
) 
4149.35 
(4161.17
) 
1140.06 
(1352.63
) 
Min-
Max 
[1.0 ; 
5890.0] 
[4.0 ; 
12935.0] 
[1.0 ; 
4364.0] 
[1.0 ; 
15911.0
] 
[3.0 ; 
2454.0] 
[2.0 ; 
16025.0] 
[1.0 ; 
16025.0] 
Medi
an 
487 778 787 721 218 2625 748.5 
Q1-
Q3 
[136.0 ; 
1158.0] 
[302.0 ; 
1506.0] 
[250.0 ; 
1715.0] 
[259.0 ; 
1567.0] 
[115.0 ; 
828.0] 
[624.0 ; 
6514.0] 
[258.0 ; 
1647.0] 
SD, standard deviation; NGB, neurogenic bladder; OAB, overactive bladder; PD, Parkinson’s disease; MS, 
multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina bifida 
 
 
Table 7.11 Duration between diagnosis of NGB/underlying conditions and OAB 
diagnosis/OAB drug prescription by age and sex subgroups 
SD, standard deviation; NGB, neurogenic bladder; OAB, overactive bladder 
 
Characteristics 
 
[19 years 
– 65 
years[ 
 n =2038 
Over 65 
years 
n =1875 
Male 
n=2334 
Female 
n=1579 
Duration between 
diagnosis of 
NGB/underlying conditions 
and OAB diagnosis/OAB 
drug prescription (days) 
No. of valid 
values 
1854 1824 2192 1486 
Mean (SD) 1347.83 
(1678.79) 
928.87 
(858.55) 
1134.77 
(1312.62) 
1147.87 
(1410.00) 
Min-Max [1.0 ; 
16025.0] 
[2.0 ; 
4122.0] 
[1.0 ; 
15911.0] 
[1.0 ; 
16025.0] 
Median 875.5 662 748.5 749 
Q1-Q3 [293.0 ; 
1876.0] 
[235.0 ; 
1389.0] 
[266.5 ; 
1660.5] 
[251.0 ; 
1597.0] 
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7.4.6 Complications Attributable to the Source Condition  
In the general cohort, 558 patients (14.3%) experienced urinary tract infection (UTI), 557 
patients (14.2%) experienced incontinence, and 96 patients (2.5%) experienced urinary 
retention. Other complications of interest were detected in less than 1% of patients.  
Incontinence was the most frequent complication in the PD sub-cohort (16.7%) and STK 
sub-cohort (15.1%), followed by UTI (10.1%, and 13.8%, respectively). In other underlying 
condition sub-cohorts, the most frequent complication was UTI (definitive NGB sub-cohort: 
19.6%, MS sub-cohort: 14.9%, SCI sub-cohort: 34.1%, SB sub-cohort: 19.4%) followed by 
incontinence (8.5%, 13.7%, 4.9% and 11.7%, respectively) (Table 7.12). Proportions of 
complications were very similar between the two age groups. Proportions of patients with 
incontinence or with UTI were almost twice as high in female patients (incontinence: 
n=315, 19.9%, UTI: n=301, 19.1%) than male patients (incontinence: n=242, 10.4%, UTI: 
n=257, 11.0%) (Table 7.13).  
 
Table 7.12 Complications within 12 months after the first OAB/NGB diagnosis or OAB 
prescription date, overall and by underlying conditions sub-cohorts) 
Characteristics Definitive 
NGB (n 
=363) 
PD 
cohort 
(n =713) 
MS 
cohort 
(n 
=1029) 
STK 
cohort 
(n 
=1720) 
SCI 
cohort 
(n =41) 
SB 
cohort 
(n =180) 
All (n 
=3913) 
Urinary tract 
infection 
71 (19.6%) 72 
(10.1%) 
153 
(14.9%) 
237 
(13.8%) 
14 
(34.1%) 
35 
(19.4%) 
558 
(14.3%) 
Incontinence 31 (8.5%) 119 
(16.7%) 
141 
(13.7%) 
260 
(15.1%) 
2 (4.9%) 21 
(11.7%) 
557 
(14.2%) 
Sepsis/septicaemia 4 (1.1%) 5 (0.7%) 7 (0.7%) 18 
(1.0%) 
1 (2.4%) 2 (1.1%) 34 
(0.9%) 
Urinary retention 13 (3.6%) 21 
(2.9%) 
19 
(1.8%) 
45 
(2.6%) 
0 (0.0%) 1 (0.6%) 96 
(2.5%) 
Obstructive 
uropathy 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.6%) 1 (0.0%) 
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Renal failure (acute 
and other) 
13 (3.6%) 5 (0.7%) 2 (0.2%) 7 (0.4%) 0 (0.0%) 5 (2.8%) 27 
(0.7%) 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, Multiple Sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida 
 
 
Table 7.13 Complications within 12 months after the first OAB/NGB diagnosis or OAB 
prescription date, by age and sex subgroups 
Characteristics [19 years – 65 years[ 
(n=2038) 
Over 65 years 
(n=1875) 
Male  
(n=1579) 
Female 
(n=2334) 
Urinary tract infection 312 (15.3%) 246 (13.1%) 257 
(11.0%) 
301 (19.1%) 
Incontinence 278 (13.6%) 279 (14.9%) 242 
(10.4%) 
315 (19.9%) 
Sepsis/septicaemia 13 (0.6%) 21 (1.1%) 25 (1.1%) 9 (0.6%) 
Urinary retention 36 (1.8%) 60 (3.2%) 83 (3.6%) 13 (0.8%) 
Obstructive uropathy 1 (0.0%) 0 (0.0%) 1 (0.0%) 0 (0.0%) 
Renal failure (acute and 
other) 
15 (0.7%) 12 (0.6%) 19 (0.8%) 8 (0.5%) 
 
7.5 Drug Utilisation  
7.5.1 Prescriptions of Anticholinergics and Anticholinergic Burden Score  
Overall, nearly half of the population (1776, 45.4%) were not prescribed any anticholinergic 
drugs within the 12-month pre-index period and 893 (22.8%) were prescribed only 1 
anticholinergic drug. A sizable proportion 366 (9.4%) of patients were prescribed 4 or more 
anticholinergics (Table 7.14). Distributions were similar across age subgroups and sex 
subgroups (Table 7.15).  
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The mean Anticholinergic Cognitive Burden (ACB) score in the general study cohort was 6.6 
(SD=5.9). The lowest mean ACB score was observed in the definitive NGB sub-cohort (2.9 
[SD=4.5]) and the highest mean ACB score was observed in the STK sub-cohort (7.6 
[SD=6.3]) (Table 7.14). The general trend showed that ACB score increased in the post-
index period within all subgroups, with the same also being true within the age and sex 
subgroups. Patients between 19 and 65 years old had a slightly lower mean ACB score (6.3 
[SD=5.9]), compared to elderly patients (6.9 [SD=5.7])) and male patients had a slightly 
lower mean ACB score (6.5 [SD=5.7]), compared to female patients (6.7 [SD=6.1]) (Table 
7.15). 
 
Table 7.14 Anticholinergic burden and number of anticholinergics prescribed by 
underlying neurological condition 
Characteristics 
 
Definitive 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
n=3913 
ACB score1 
  
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
2.85 
(4.47) 
6.80 
(5.94) 
6.04 
(4.89) 
7.62 
(6.26) 
6.93 
(7.06) 
4.58 
(4.67) 
6.59 
(5.85) 
Median [0.0 ; 
37.0] 
[0.0 ; 
57.0] 
[0.0 ; 
69.0] 
[0.0 ; 
66.0] 
[0.0 ; 
37.0] 
[0.0 ; 
33.0] 
[0.0 ; 
69.0] 
Min-
Max 
0 6 5 6 6 3 6 
Q1-Q3 [0.0 ; 5.0] [3.0 ; 
8.0] 
[3.0 ; 
7.0] 
[4.0 ; 
9.0] 
[3.0 ; 
9.0] 
[3.0 ; 
6.0] 
[3.0 ; 
8.0] 
ACB Score at 
date d 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
0.65 
(1.42) 
3.09 
(1.12) 
3.19 
(1.43) 
3.22 
(1.13) 
3.02 
(1.56) 
2.38 
(1.60) 
2.98 
(1.42) 
Median [0.0 ; 7.0] [0.0 ; 
11.0] 
[0.0 ; 
23.0] 
[0.0 ; 
12.0] 
[0.0 ; 
6.0] 
[0.0 ; 
9.0] 
[0.0 ; 
23.0] 
Min-
Max 
0 3 3 3 3 3 3 
Q1-Q3 [0.0 ; 0.0] [3.0 ; 
3.0] 
[3.0 ; 
3.0] 
[3.0 ; 
3.0] 
[3.0 ; 
4.0] 
[0.0 ; 
3.0] 
[3.0 ; 
3.0] 
ACB Score 12 
months before 
d 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
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Mean 
(SD) 
11.17 
(20.35) 
15.70 
(23.28) 
12.59 
(18.22) 
18.54 
(26.50) 
15.24 
(23.86) 
12.59 
(19.95) 
15.67 
(23.48) 
Median 2 6 5 10 4 3 7 
Min-
Max 
[0.0 ; 
133.0] 
[0.0 ; 
265.0] 
[0.0 ; 
202.0] 
[0.0 ; 
348.0] 
[0.0 ; 
100.0] 
[0.0 ; 
155.0] 
[0.0 ; 
348.0] 
Q1-Q3 [0.0 ; 
14.0] 
[3.0 ; 
19.0] 
[3.0 ; 
15.0] 
[4.0 ; 
22.0] 
[3.0 ; 
14.0] 
[3.0 ; 
17.0] 
[3.0 ; 
19.0] 
ACB Score 12 
months after d 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
18.22 
(27.58) 
37.35 
(42.88) 
34.20 
(39.82) 
41.70 
(46.53) 
46.10 
(36.26) 
24.80 
(32.41) 
36.68 
(43.03) 
Median 6 30 27 31 45 15 27 
Min-
Max 
[0.0 ; 
204.0] 
[0.0 ; 
471.0] 
[0.0 ; 
450.0] 
[0.0 ; 
622.0] 
[0.0 ; 
180.0] 
[0.0 ; 
298.0] 
[0.0 ; 
622.0] 
Q1-Q3 [0.0 ; 
26.0] 
[14.0 ; 
46.0] 
[10.0 ; 
42.0] 
[15.0 ; 
53.0] 
[18.0 ; 
63.0] 
[3.5 ; 
36.0] 
[12.0 ; 
46.0] 
Number of 
prescribed 
anticholinergic 
drugs within 
the pre-index 
period  
Valid 
values 
363 713 1029 1720 41 180 3913 
0 178 
(49.0%) 
305 
(42.8%) 
564 
(54.8%) 
738 
(42.9%) 
24 
(58.5%) 
36 
(20.0%) 
1776 
(45.4%) 
1 68 
(18.7%) 
172 
(24.1%) 
223 
(21.7%) 
384 
(22.3%) 
6 
(14.6%) 
63 
(35.0%) 
893 
(22.8%) 
2 49 
(13.5%) 
116 
(16.3%) 
133 
(12.9%) 
263 
(15.3%) 
4 
(9.8%) 
34 
(18.9%) 
580 
(14.8%) 
3 22 (6.1%) 47 
(6.6%) 
59 
(5.7%) 
154 
(9.0%) 
3 
(7.3%) 
22 
(12.2%) 
298 
(7.6%) 
4+ 46 
(12.7%) 
73 
(10.2%) 
50 
(4.9%) 
181 
(10.5%) 
4 
(9.8%) 
25 
(13.9%) 
366 
(9.4%) 
SD, standard deviation; BNF, British National Formulary; NGB, neurogenic bladder; PD, Parkinson’s 
disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina bifida; ACB, Anticholinergic 
Cognitive Burden 
1 The ACB score was calculated within 1 month before and after the first OAB/NGB diagnosis or OAB  
prescription date (date 'd') 
For patients with no anticholinergic prescriptions between 1 month before/after date 'd': ACB score =0 
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Table 7.15 Anticholinergic burden and number of anticholinergics prescribed by age and 
sex subgroups 
Characteristics 
 
[19 years 
– 65 
years[ 
 n=2038 
Over 65 
years 
n=1875 
Male 
n=2334 
Female 
n=1579 
ACB score1 
  
No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 6.31 
(5.94) 
6.90 
(5.73) 
6.51 
(5.65) 
6.72 
(6.14) 
Min-Max [0.0 ; 
69.0] 
[0.0 ; 
66.0] 
[0.0 ; 
64.0] 
[0.0 ; 
69.0] 
Median 5 6 6 6 
Q1-Q3 [3.0 ; 8.0] [3.0 ; 8.0] [3.0 ; 8.0] [3.0 ; 9.0] 
ACB Score at date d No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 2.85 
(1.60) 
3.11 
(1.17) 
2.95 
(1.36) 
3.02 
(1.51) 
Min-Max [0.0 ; 
23.0] 
[0.0 ; 
12.0] 
[0.0 ; 
12.0] 
[0.0 ; 
23.0] 
Median 3 3 3 3 
Q1-Q3 [3.0 ; 3.0] [3.0 ; 3.0] [3.0 ; 3.0] [3.0 ; 3.0] 
ACB Score 12 months 
before d 
No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 15.06 
(24.22) 
16.32 
(22.62) 
14.91 
(22.67) 
16.79 
(24.58) 
Min-Max [0.0 ; 
309.0] 
[0.0 ; 
348.0] 
[0.0 ; 
348.0] 
[0.0 ; 
309.0] 
Median 5 9 7 6 
Q1-Q3 [3.0 ; 
18.0] 
[3.0 ; 
21.0] 
[3.0 ; 
18.0] 
[3.0 ; 
21.0] 
ACB Score 12 months after 
d 
No. of valid 
values 
2038 1875 2334 1579 
Mean (SD) 36.47 
(44.03) 
36.90 
(41.92) 
35.70 
(41.97) 
38.12 
(44.53) 
Min-Max [0.0 ; 
471.0] 
[0.0 ; 
622.0] 
[0.0 ; 
471.0] 
[0.0 ; 
622.0] 
Median 27 27 27 28 
Q1-Q3 [9.0 ; 
45.0] 
[14.0 ; 
46.0] 
[11.0 ; 
45.0] 
[12.0 ; 
48.0] 
Number of patients on 
anticholinergic drugs 
within the pre-index period 
  
Valid values 2038 1875 2334 1579 
0 1016 
(49.9%) 
760 
(40.5%) 
1100 
(47.1%) 
676 
(42.8%) 
1 463 
(22.7%) 
430 
(22.9%) 
554 
(23.7%) 
339 
(21.5%) 
2 250 
(12.3%) 
330 
(17.6%) 
329 
(14.1%) 
251 
(15.9%) 
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3 135 
(6.6%) 
163 
(8.7%) 
164 
(7.0%) 
134 
(8.5%) 
4+ 174 (8.5) 192 (10.2) 187 (8.0) 179 (11.3) 
SD, standard deviation; ACB, Anticholinergic Cognitive Burden  
1 The ACB score was calculated within 1 month before and after the first OAB/NGB diagnosis or OAB 
prescription date (date 'd') 
For patients with no anticholinergic prescriptions between 1 month before/after date 'd': ACB score=0 
 
 
7.5.2 Overactive Bladder Drug Use 
Overall, the mean number of bladder muscarinic prescriptions over 12 months after the 
first OAB/NGB diagnosis or OAB prescription date was 6.9 (SD=8.2). It was relatively 
heterogeneous from one underlying condition sub-cohort to another, varying from 1.6 
(SD=3.5) in the definitive NGB sub-cohort to 9 (SD=5.6) in the SCI sub-cohort. Most patients 
were prescribed 1 to 4 bladder muscarinic prescriptions over the 12-month period, except 
in the SCI sub-cohort (63.4% of patients reported 5 to 14 OAB prescriptions) and in the 
definitive NGB sub-cohort (70% of patients did not report any OAB prescriptions) (Table 
7.16). The mean numbers of OAB prescriptions were very similar between age subgroups; 
19 and 65 years old (mean=6.9 [SD=8.1]) and elderly patients (mean=7 [SD=8.3]). The mean 
numbers of OAB prescriptions were also similar between male patients (mean=6.9 
[SD=8.2]) and female patients (mean=7 [SD=8.1]) (Table 7.17). 
The average cumulative numbers of days’ supply of OAB drugs over 12 months following 
the first OAB/NGB diagnosis or OAB prescription date was 202.9 days (SD=210.9). It was 
relatively heterogeneous between the different underlying condition sub-cohorts, varying 
from 50.5 days in the definitive NGB sub-cohort (SD=112.5) to 273.2 (SD=158.5, 
median=336 days) in the SCI sub-cohort. In the definitive NGB sub-cohort, majority of 
individuals received >30 cumulative days’ supply of OAB drugs (74.9%) (Table 7.16). The 
average cumulative numbers of days’ supply of OAB drugs was relatively similar in both age 
groups and both sex groups: 207.95 days (SD=246.6) in patients between 19 and 65 years 
old, 197.3 days (SD=163.4) in elderly patients, 200.7 (SD=179.12) in female patients and 
206.1 (SD=250.6) in male patients (Table 7.17).  
  
 
 
 
231 
Overall, 312 patients (8.0%) were prescribed at least two OAB drugs concomitantly over 
the 12 months following the first OAB/NGB diagnosis or OAB prescription date. It varied 
from 2.8% in the definitive NGB sub-cohort to 10.2% in the MS sub-cohort (Table 7.16). 
There was a small difference between age subgroups (for patients aged between 19 and 
65 years old: 8.1%, for the elderly: 7.8%). Combination use was higher in female patients 
(10.4%) than in male patients (6.3%) (Table 7.17). Overall, the most frequently prescribed 
drugs concomitantly were solifenacin, tolterodine and oxybutynin immediate release (IR) 
(Table 7.18).  
 
Table 7.16 Overactive bladder drug use by underlying neurological condition 
Characteristics Definitiv
e 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
Number of 
OAB 
prescription
s 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
1.56 
(3.47) 
7.62 
(8.07) 
7.10 
(7.33) 
7.51 
(9.07) 
9.00 
(5.62) 
4.99 
(6.30) 
6.92 
(8.20) 
Min-
Max 
[0.0 ; 
21.0] 
[0.0 ; 
55.0] 
[0.0 ; 
64.0] 
[0.0 ; 
104.0] 
[0.0 ; 
24.0] 
[0.0 ; 
52.0] 
[0.0 ; 
104.0] 
Media
n 
0 6 6 5 9 3 5 
Q1-Q3 [0.0 ; 1.0] [2.0 ; 
12.0] 
[2.0 ; 
11.0] 
[1.0 ; 
11.0] 
[6.0 ; 
13.0] 
[1.0 ; 
8.5] 
[1.0 ; 
11.0] 
0 255 
(70.2%) 
11 
(1.5%) 
35 
(3.4%) 
29 
(1.7%) 
4 (9.8%) 44 
(24.4%) 
307 
(7.8%) 
1-4 58 
(16.0%) 
304 
(42.6%) 
412 
(40.0%) 
759 
(44.1%) 
5 
(12.2%) 
63 
(35.0%) 
1571 
(40.1%) 
5-9 31 (8.5%) 160 
(22.4%) 
275 
(26.7%) 
416 
(24.2%) 
13 
(31.7%) 
32 
(17.8%) 
911 
(23.3%) 
10-14 14 (3.9%) 177 
(24.8%) 
243 
(23.6%) 
370 
(21.5%) 
13 
(31.7%) 
37 
(20.6%) 
841 
(21.5%) 
15-44 5 (1.4%) 51 
(7.2%) 
52 
(5.1%) 
117 
(6.8%) 
6 
(14.6%) 
3 (1.7%) 231 
(5.9%) 
45+ 0 (0.0%) 10 
(1.4%) 
12 
(1.2%) 
29 
(1.7%) 
0 (0.0%) 1 (0.6%) 52 
(1.3%) 
Cumulative 
numbers of 
days’ supply 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
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of OAB 
drugs 
Mean 
(SD) 
50.50 
(112.48) 
221.53 
(202.27
) 
222.21 
(188.47
) 
210.42 
(232.57
) 
273.20 
(158.49
) 
155.04 
(155.61
) 
202.86 
(210.90
) 
Min-
Max 
[0.0 ; 
637.7] 
[0.0 ; 
3392.0] 
[0.0 ; 
3177.0] 
[0.0 ; 
6956.0] 
[0.0 ; 
532.0] 
[0.0 ; 
447.6] 
[0.0 ; 
6956.0] 
Media
n 
0 206 210 174.5 336 88 168 
Q1-Q3 [0.0 ; 
30.0] 
[56.0 ; 
364.0] 
[56.0 ; 
364.0] 
[56.0 ; 
364.0] 
[128.0 ; 
392.0] 
[21.0 ; 
333.0] 
[30.0 ; 
360.0] 
0-29 272 
(74.9%) 
101 
(14.2%) 
155 
(15.1%) 
283 
(16.5%) 
7 
(17.1%) 
66 
(36.7%) 
804 
(20.5%) 
30-119 40 
(11.0%) 
190 
(26.6%) 
250 
(24.3%) 
455 
(26.5%) 
2 (4.9%) 34 
(18.9%) 
952 
(24.3%) 
120-
349 
32 (8.8%) 201 
(28.2%) 
318 
(30.9%) 
515 
(29.9%) 
15 
(36.6%) 
44 
(24.4%) 
1107 
(28.3%) 
350-
549 
18 (5.0%) 211 
(29.6%) 
292 
(28.4%) 
445 
(25.9%) 
17 
(41.5%) 
36 
(20.0%) 
1003 
(25.6%) 
>550 1 (0.3%) 10 
(1.4%) 
14 
(1.4%) 
22 
(1.3%) 
0 (0.0%) 0 (0.0%) 47 
(1.2%) 
OAB 
combination 
use (yes/no) 
Yes: n 
(%) 
10 (2.8%) 58 
(8.1%) 
105 
(10.2%) 
130 
(7.6%) 
2 (4.9%) 11 
(6.1%) 
312 
(8.0%) 
SD, standard deviation; NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, 
stroke; SCI, spinal cord injuries; SB, spina bifida; OAB, overactive bladder 
 
Table 7.17 Overactive bladder drug use by age and sex subgroups 
Characteristics [19 years – 
65 years[ 
 n =2038 
Over 65 
years 
n =1875 
Male 
n=2334 
 
Female 
n=1579 
Number of OAB prescriptions No. of 
valid 
values 
2038 1875 2334 1579 
Mean (SD) 6.87 (8.10) 6.99 
(8.31) 
6.90 
(8.24) 
6.96 
(8.14) 
Min-Max [0.0 ; 104.0] [0.0 ; 
102.0] 
[0.0 ; 
104.0] 
[0.0 ; 
102.0] 
Median 5 5 5 5 
Q1-Q3 [1.0 ; 11.0] [1.0 ; 
11.0] 
[1.0 ; 
11.0] 
[1.0 ; 
11.0] 
0 243 (11.9%) 64 (3.4%) 181 
(7.8%) 
126 
(8.0%) 
1-4 724 (35.5%) 847 
(45.2%) 
944 
(40.4%) 
627 
(39.7%) 
5-9 483 (23.7%) 428 
(22.8%) 
540 
(23.1%) 
371 
(23.5%) 
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10-14 441 (21.6%) 400 
(21.3%) 
508 
(21.8%) 
333 
(21.1%) 
15-44 118 (5.8%) 113 
(6.0%) 
128 
(5.5%) 
103 
(6.5%) 
45+ 29 (1.4%) 23 (1.2%) 33 (1.4%) 19 (1.2%) 
Cumulative numbers of days’ 
supply of OAB drugs 
No. of 
valid 
values 
2038 1875 2334 1579 
Mean (SD) 207.95 
(246.60) 
197.34 
(163.37) 
200.69 
(179.12) 
206.08 
(250.63) 
Min-Max [0.0 ; 6956.0] [0.0 ; 
1440.0] 
[0.0 ; 
3392.0] 
[0.0 ; 
6956.0] 
Median 170 150 168 168 
Q1-Q3 [30.0 ; 360.0] [30.0 ; 
360.0] 
[30.0 ; 
364.0] 
[30.0 ; 
360.0] 
0-29 463 (22.7%) 341 
(18.2%) 
476 
(20.4%) 
328 
(20.8%) 
30-119 439 (21.5%) 513 
(27.4%) 
579 
(24.8%) 
373 
(23.6%) 
120-349 568 (27.9%) 539 
(28.7%) 
641 
(27.5%) 
466 
(29.5%) 
350-549 538 (26.4%) 465 
(24.8%) 
615 
(26.3%) 
388 
(24.6%) 
>550 30 (1.5%) 17 (0.9%) 23 (1.0%) 24 (1.5%) 
OAB combination use (yes/no) Yes: n (%) 166 (8.1%) 146 
(7.8%) 
147 
(6.3%) 
165 
(10.4%) 
 
 
Table 7.18 Combination use overall in neurogenic bladder patients 
Substance 1 Substance 2 n (%) * 
Solifenacin Tolterodine 58 (14.7 %) 
Oxybutynin IR Tolterodine 56 (14.2 %) 
Oxybutynin IR Solifenacin 47 (11.9 %) 
Oxybutynin ER Oxybutynin IR 33 (8.4 %) 
Tolterodine Trospium 25 (6.3 %) 
Solifenacin Trospium 20 (5.1 %) 
Oxybutynin ER Tolterodine 19 (4.8 %) 
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Oxybutynin IR Trospium 18 (4.6 %) 
Oxybutynin ER Solifenacin 18 (4.6 %) 
Fesoterodine Solifenacin 12 (3.0 %) 
Mirabegron Solifenacin 11 (2.8 %) 
Flavoxate Oxybutynin IR 10 (2.5 %) 
Propiverine Tolterodine 9 (2.3 %) 
Fesoterodine Tolterodine 7 (1.8 %) 
Flavoxate Solifenacin 6 (1.5 %) 
Fesoterodine Trospium 5 (1.3 %) 
Fesoterodine Oxybutynin IR 5 (1.3 %) 
Mirabegron Oxybutynin IR 5 (1.3 %) 
Propiverine Trospium 4 (1.0 %) 
Mirabegron Trospium 3 (0.8 %) 
Flavoxate Tolterodine 3 (0.8 %) 
Oxybutynin IR Propiverine 2 (0.5 %) 
Oxybutynin ER Trospium 2 (0.5 %) 
Mirabegron Tolterodine 2 (0.5 %) 
Mirabegron Oxybutynin ER 2 (0.5 %) 
Propiverine Solifenacin 2 (0.5 %) 
Darifenacin Oxybutynin IR 2 (0.5 %) 
Darifenacin Mirabegron 2 (0.5 %) 
Fesoterodine Oxybutynin ER 1 (0.3 %) 
Fesoterodine Mirabegron 1 (0.3 %) 
Flavoxate Trospium 1 (0.3 %) 
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Flavoxate Oxybutynin ER 1 (0.3 %) 
Darifenacin Solifenacin 1 (0.3 %) 
Darifenacin Trospium 1 (0.3 %) 
IR, immediate release; ER, extended release  
* Total ≥ 312 as some patients have multiple combinations 
 
7.5.3 Other Drug Use 
More than 50% of the study population had antibiotics prescriptions for UTI (53.9%), the 
average number of prescriptions over 12 months follow-up period was 2.91 (SD=7.95). This 
was similar between the neurological conditions (ranged between 2 and 3 prescriptions on 
average, over 12 months) (Table 7.19). When comparing male and female patients, the 
former had less prescriptions 1.7 (3.5) compared to the latter 2.9 (4.6). The numbers were 
relatively similar between the age subgroups with 2.3 (4.2) prescriptions in the 19-65 years 
subgroup and 2.1 (3.9) in the over 65 years subgroup (Table 7.20). 
α‐adrenergic antagonists or 5-Alpha-Reductase Inhibitors (5-ARIs) prescriptions were 
identified in 25.5% of the overall population. Prescriptions were higher in PD and STK 
populations compared to the other sub-cohorts (>4 prescriptions vs. less than 1 
prescription on average respectively) (Table 7.19). Prescriptions were higher in the elderly 
compared to younger patients (4.5 prescriptions vs. 1.5 prescriptions on average over 12 
months respectively). Between sexes, the male subgroup had a significantly higher number 
of prescriptions 4.7 (9.7) compared to females 0.3 (2.4). 
 
 
 
  
 
 
 
236 
Table 7.19 Number of α-adrenergic antagonists, 5-Alpha-Reductase Inhibitors (5-ARIs) 
and antibiotics prescriptions by underlying neurological condition 
Characteristics Definitive 
 NGB 
n=363 
PD 
Cohort 
n=713 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1720 
SCI 
Cohort  
n=41 
SB 
Cohort  
n=180 
All 
 
n=3913 
Number of 
antibiotics 
prescriptions 
for UTI 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
2.72 
(4.25) 
1.70 
(3.31) 
2.37 
(4.24) 
2.14 
(3.80) 
3.46 
(4.86) 
3.13 
(6.22) 
2.22 
(4.03) 
Min-
Max 
[0.0 ; 
24.0] 
[0.0 ; 
44.0] 
[0.0 ; 
36.0] 
[0.0 ; 
46.0] 
[0.0 ; 
18.0] 
[0.0 ; 
59.0] 
[0.0 ; 
59.0] 
Median 1 0 1 1 1 1 1 
Q1-Q3 [0.0 ; 4.0] [0.0 ; 
2.0] 
[0.0 ; 
3.0] 
[0.0 ; 
2.0] 
[0.0 ; 
7.0] 
[0.0 ; 
4.0] 
[0.0 ; 
3.0] 
0 159 
(43.8%) 
371 
(52.0%) 
473 
(46.0%) 
768 
(44.7%) 
20 
(48.8%) 
71 
(39.4%) 
1803 
(46.1%) 
1–4 130 
(35.8%) 
261 
(36.6%) 
384 
(37.3%) 
713 
(41.5%) 
8 
(19.5%) 
70 
(38.9%) 
1520 
(38.8%) 
5–9 42 
(11.6%) 
55 
(7.7%) 
97 
(9.4%) 
144 
(8.4%) 
9 
(22.0%) 
25 
(13.9%) 
352 
(9.0%) 
10–14 23 (6.3%) 22 
(3.1%) 
49 
(4.8%) 
54 
(3.1%) 
2 
(4.9%) 
9 
(5.0%) 
155 
(4.0%) 
15–19 9 (2.5%) 4 
(0.6%) 
26 
(2.5%) 
40 
(2.3%) 
2 
(4.9%) 
4 
(2.2%) 
81 
(2.1%) 
≥20 0 (0.0%) 0 
(0.0%) 
0 
(0.0%) 
1 
(0.1%) 
0 
(0.0%) 
1 
(0.6%) 
2 
(0.1%) 
Number of α-
blockers or 5-
ARI’s 
prescriptions 
No. of 
valid 
values 
363 713 1029 1720 41 180 3913 
Mean 
(SD) 
0.84 
(2.87) 
4.34 
(9.81) 
0.55 
(2.44) 
4.27 
(9.53) 
0.63 
(3.75) 
0.63 
(2.70) 
2.91 
(7.95) 
Min-
Max 
[0.0 ; 
25.0] 
[0.0 ; 
106.0] 
[0.0 ; 
29.0] 
[0.0 ; 
108.0] 
[0.0 ; 
24.0] 
[0.0 ; 
23.0] 
[0.0 ; 
108.0] 
Median 0 0 0 0 0 0 0 
Q1-Q3 [0.0 ; 0.0] [0.0 ; 
6.0] 
[0.0 ; 
0.0] 
[0.0 ; 
6.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
1.0] 
0 321 
(88.4%) 
448 
(62.8%) 
958 
(93.1%) 
1107 
(64.4%) 
39 
(95.1%) 
165 
(91.7%) 
2916 
(74.5%) 
1–4 14 (3.9%) 63 
(8.8%) 
18 
(1.7%) 
126 
(7.3%) 
1 
(2.4%) 
6 
(3.3%) 
223 
(5.7%) 
5–9 16 (4.4%) 76 
(10.7%) 
26 
(2.5%) 
177 
(10.3%) 
0 
(0.0%) 
4 
(2.2%) 
296 
(7.6%) 
10–14 10 (2.8%) 76 
(10.7%) 
23 
(2.2%) 
190 
(11.0%) 
0 
(0.0%) 
4 
(2.2%) 
300 
(7.7%) 
15–19 2 (0.6%) 41 
(5.8%) 
4 
(0.4%) 
102 
(5.9%) 
1 
(2.4%) 
1 
(0.6%) 
151 
(3.9%) 
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≥20 0 (0.0%) 9 
(1.3%) 
0 
(0.0%) 
18 
(1.0%) 
0 
(0.0%) 
0 
(0.0%) 
27 
(0.7%) 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation; UTI, urinary tract infection; 5-ARIs, 5-Alpha-Reductase 
Inhibitors 
 
Table 7.20 Number of α-adrenergic antagonists, 5-Alpha-Reductase Inhibitors (5-ARIs) 
and antibiotics prescriptions by age and sex subgroups 
Characteristics [19 years – 
65 years[ 
 n =2038 
Over 65 
years 
n =1875 
Male 
n =2334 
Female 
n =1579 
Number of antibiotics 
prescriptions for UTI 
No. of 
valid 
values 
2038 1875 2334 1579 
Mean (SD) 2.29 (4.17) 2.14 
(3.88) 
1.74 
(3.51) 
2.93 
(4.62) 
Min-Max [0.0 ; 59.0] [0.0 ; 
46.0] 
[0.0 ; 
46.0] 
[0.0 ; 
59.0] 
Median 1 1 0 1 
Q1-Q3 [0.0 ; 3.0] [0.0 ; 2.0] [0.0 ; 2.0] [0.0 ; 4.0] 
0 954 (46.8%) 849 
(45.3%) 
1221 
(52.3%) 
582 
(36.9%) 
1–4 753 (36.9%) 767 
(40.9%) 
855 
(36.6%) 
665 
(42.1%) 
5–9 199 (9.8%) 153 
(8.2%) 
158 
(6.8%) 
194 
(12.3%) 
10–14 87 (4.3%) 68 (3.6%) 62 (2.7%) 93 (5.9%) 
15–19 44 (2.2%) 37 (2.0%) 37 (1.6%) 44 (2.8%) 
≥20 1 (0.0%) 1 (0.1%) 1 (0.0%) 1 (0.1%) 
Number of α-blockers or 5-ARI’s 
prescriptions 
No. of 
valid 
values 
2038 1875 2334 1579 
Mean (SD) 1.45 (5.51) 4.50 
(9.69) 
4.66 
(9.71) 
0.32 
(2.43) 
Min-Max [0.0 ; 108.0] [0.0 ; 
107.0] 
[0.0 ; 
108.0] 
[0.0 ; 
54.0] 
Median 0 0 0 0 
Q1-Q3 [0.0 ; 0.0] [0.0 ; 6.0] [0.0 ; 7.0] [0.0 ; 0.0] 
0 1743 (85.5%) 1173 
(62.6%) 
1384 
(59.3%) 
1532 
(97.0%) 
1–4 75 (3.7%) 148 
(7.9%) 
216 
(9.3%) 
7 (0.4%) 
5–9 97 (4.8%) 199 
(10.6%) 
277 
(11.9%) 
19 (1.2%) 
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10–14 87 (4.3%) 213 
(11.4%) 
283 
(12.1%) 
17 (1.1%) 
15–19 29 (1.4%) 122 
(6.5%) 
149 
(6.4%) 
2 (0.1%) 
≥20 7 (0.3%) 20 (1.1%) 25 (1.1%) 2 (0.1%) 
SD, standard deviation; UTI, urinary tract infection; 5-ARIs, 5-Alpha-Reductase Inhibitors 
 
7.5.4 Distribution of Patients by Overactive Bladder drug at the Date of the 
First Neurogenic Bladder/Overactive Bladder Diagnosis or Overactive 
Bladder Prescription 
Overall, 738 of patients included into the study cohort (18.9%) did not receive any OAB 
treatment at the date of the first NGB/OAB diagnosis or OAB prescription. 992 individuals 
(25.4%) were prescribed with solifenacin, 803 individuals (20.5%) with oxybutynin IR and 
723 individuals (18.5%) with tolterodine. In all subgroups solifenacin, tolderodine and 
oxybutynin were the most prescribed OAB drugs (Table 7.21). 
Among the 363 patients that were diagnosed with definitive NGB, the majority of them 
(n=326, 89.8%) did not receive any OAB treatment at the date of the first NGB/OAB 
diagnosis or OAB prescription (due to the way patients are included into the study), 12 
patients (3.3%) were prescribed with oxybutynin IR, followed by 10 patients that were 
prescribed with solifenacin (2.8%).  
The PD sub-cohort consisted of 713 patients; 99 of them (13.9%) did not receive any OAB 
treatment at the date of the first NGB/OAB diagnosis or OAB prescription. Most patients 
received solifenacin (n=208, 29.2%), followed by tolterodine (n=143, 20.1%) and 
oxybutynin IR (n=119, 16.7%) respectively. 
Amongst the 1029 patients who were diagnosed with MS, 144 (14.0%) did not receive any 
OAB treatment at the date of the first NGB/OAB diagnosis or OAB prescription. The rest 
were mainly prescribed with oxybutynin IR (n=265, 25.8%), solifenacin23.6%) or 
tolterodine (n=194, 18.9%).  
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Amongst the 1720 patients in the STK group, 205 (11.9%) did not receive any OAB 
treatment at the date of the first NGB/OAB diagnosis or OAB prescription. Patients were 
prescribed with solifenacin (n=495, 28.8%), oxybutynin IR (n=380, 22.1%) and tolterodine 
(n=349, 20.3%), respectively.  
In the SCI sub-cohort (n=41), 7 (17.1%) did not receive any OAB treatment at the date of 
the first NGB/OAB diagnosis or OAB prescription. 12 patients (29.3%) used oxybutynin ER 
and 8 patients used solifenacin (19.5%).  
Amongst the 180 patients under SB condition, 49 (27.2%) did not receive any OAB 
treatment at the date of the first NGB/OAB diagnosis or OAB prescription. 41 patients 
(22.8%) were prescribed with solifenacin, 36 were prescribed with tolterodine (20.0%) and 
31 with Oxybutynin IR (17.2%). 
 
Table 7.21 Distribution of patients by overactive bladder (OAB) drug at the date of the 
first neurogenic bladder/OAB diagnosis or OAB prescription by underlying neurological 
condition 
Drug Definitive 
 NGB 
(n=363) 
PD 
Cohort 
(n=713) 
MS 
Cohort  
(n=1029) 
STK 
Cohort  
(n=1720) 
SCI 
Cohort  
(n=41) 
SB 
Cohort  
(n=180) 
All 
 
(n=3913) 
No OAB 
treatment 
326 
(89.8%) 
99 
(13.9%) 
144 
(14.0%) 
205 
(11.9%) 
7 
(17.1%) 
49 
(27.2%) 
738 
(18.9%) 
Darifenacin 0 (0.0%) 8 (1.1%) 2 (0.2%) 4 (0.2%) 0 (0.0%) 0 (0.0%) 14 (0.4%) 
Emepronium 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Fesoterodine 0 (0.0%) 20 
(2.8%) 
31 
(3.0%) 
49 (2.8%) 2 (4.9%) 2 (1.1%) 104 
(2.7%) 
Flavoxate 0 (0.0%) 12 
(1.7%) 
11 
(1.1%) 
17 (1.0%) 0 (0.0%) 3 (1.7%) 43 (1.1%) 
Mirabegron 0 (0.0%) 19 
(2.7%) 
9 (0.9%) 19 (1.1%) 0 (0.0%) 1 (0.6%) 48 (1.2%) 
Meladrazine 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
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Oxybutynin ER 3 (0.8%) 33 
(4.6%) 
78 
(7.6%) 
96 (5.6%) 12 
(29.3%) 
14 
(7.8%) 
233 
(6.0%) 
Oxybutynin IR 12 (3.3%) 119 
(16.7%) 
265 
(25.8%) 
380 
(22.1%) 
6 
(14.6%) 
31 
(17.2%) 
803 
(20.5%) 
Propiverine 1 (0.3%) 5 (0.7%) 11 
(1.1%) 
10 (0.6%) 1 (2.4%) 1 (0.6%) 28 (0.7%) 
Solifenacin 10 (2.8%) 208 
(29.2%) 
243 
(23.6%) 
495 
(28.8%) 
8 
(19.5%) 
41 
(22.8%) 
992 
(25.4%) 
Terodiline 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Tolterodine 7 (1.9%) 143 
(20.1%) 
194 
(18.9%) 
349 
(20.3%) 
4 (9.8%) 36 
(20.0%) 
723 
(18.5%) 
Trospium 4 (1.1%) 47 
(6.6%) 
41 
(4.0%) 
96 (5.6%) 1 (2.4%) 2 (1.1%) 187 
(4.8%) 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injury; SB, spina bifida; IR, immediate release; ER, extended release 
 
7.5.5 Cumulative prescribed quantity of OAB drugs within 12 months after the 
first NGB/OAB diagnosis or OAB prescription 
For most OAB drugs (solifenacin, oxybutynin IR, tolterodine, trospium, fesoterodine, 
mirabegron and propiverine), the highest mean cumulative OAB drug quantity was 
observed in the SCI sub-cohort; the lowest mean cumulative OAB drug quantities for 
solifenacin, mirabegron and propiverine were observed in SB sub-cohort; the lowest mean 
cumulative OAB drug quantities of oxybutynin IR and fesoterodine were observed in 
definitive NGB sub-cohort (Table 7.22). Patients aged less than 65 years old showed higher 
mean cumulative quantities compared to elderly patients when treated with solifenacin, 
oxybutynin IR, tolterodine, trospium, oxybutynin ER and propiverine. Male patients 
showed higher mean cumulative quantities than female patients when treated with 
oxybutynin IR, oxybutynin ER, fesoterodine, mirabegron and darifenacin (Table 7.23). 
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Table 7.22 Cumulative prescribed quantity (in grams) within 12 months after the first 
NGB/OAB diagnosis or OAB prescription, overall and by underlying neurological 
condition 
Substances Definitive 
 NGB 
N=363 
PD 
Cohort 
N=713 
MS 
Cohort  
N=1029 
STK 
Cohort  
N=1720 
SCI 
Cohort  
N=41 
SB 
Cohort  
N=180 
All 
 
N=3913 
Solifenacin 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
40 272 341 681 11 55 1377 
Mean 
(SD) 
1.05 
(1.21) 
1.23 
(1.04) 
1.40 
(1.39) 
1.18 
(1.15) 
2.07 
(1.56) 
1.00 
(0.81) 
1.24 
(1.19) 
Min-
Max 
[0.1 ; 4.4] [0.1 ; 
4.5] 
[0.1 ; 
15.9] 
[0.0 ; 
7.9] 
[0.1 ; 
4.3] 
[0.1 ; 
3.6] 
[0.0 ; 
15.9] 
Median 0.4 1 1.2 0.8 2 0.8 0.9 
Q1-Q3 [0.2 ; 1.7] [0.3 ; 
2.0] 
[0.3 ; 
2.0] 
[0.3 ; 
1.9] 
[0.8 ; 
4.2] 
[0.3 ; 
1.7] 
[0.3 ; 
2.0] 
Oxybutynin IR 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
31 205 298 491 4 42 1052 
Mean 
(SD) 
0.42 
(0.38) 
0.73 
(0.72) 
0.65 
(0.58) 
0.63 
(0.59) 
1.19 
(0.83) 
0.60 
(0.57) 
0.65 
(0.61) 
Min-
Max 
[0.1 ; 1.7] [0.0 ; 
6.8] 
[0.0 ; 
2.9] 
[0.0 ; 
3.1] 
[0.1 ; 
2.1] 
[0.1 ; 
1.7] 
[0.0 ; 
6.8] 
Median 0.3 0.5 0.4 0.3 1.3 0.3 0.4 
Q1-Q3 [0.1 ; 0.6] [0.1 ; 
1.3] 
[0.1 ; 
1.1] 
[0.1 ; 
1.1] 
[0.6 ; 
1.7] 
[0.1 ; 
1.3] 
[0.1 ; 
1.2] 
Tolterodine 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
30 159 332 471 9 39 1024 
Mean 
(SD) 
1.04 
(1.13) 
0.69 
(0.76) 
1.03 
(1.15) 
0.98 
(1.28) 
1.86 
(0.92) 
0.95 
(1.24) 
0.95 
(1.16) 
Min-
Max 
[0.0 ; 3.6] [0.0 ; 
3.6] 
[0.0 ; 
6.7] 
[0.0 ; 
10.0] 
[0.4 ; 
3.1] 
[0.0 ; 
5.9] 
[0.0 ; 
10.0] 
Median 0.4 0.3 0.6 0.4 2 0.5 0.4 
Q1-Q3 [0.1 ; 2.0] [0.1 ; 
1.1] 
[0.2 ; 
1.7] 
[0.1 ; 
1.3] 
[1.4 ; 
2.6] 
[0.2 ; 
1.4] 
[0.1 ; 
1.4] 
Trospium 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
8 59 111 134 14 18 340 
Mean 
(SD) 
1.94 
(3.05) 
1.27 
(1.26) 
1.11 
(1.18) 
1.94 
(6.18) 
2.27 
(1.48) 
2.24 
(2.52) 
1.57 
(4.04) 
Min-
Max 
[0.2 ; 9.2] [0.1 ; 
4.2] 
[0.1 ; 
7.2] 
[0.1 ; 
69.6] 
[0.3 ; 
5.1] 
[0.2 ; 
9.2] 
[0.1 ; 
69.6] 
Median 0.8 0.8 0.8 0.7 1.7 1.3 0.8 
Q1-Q3 [0.4 ; 1.8] [0.3 ; 
1.9] 
[0.2 ; 
1.8] 
[0.2 ; 
2.0] 
[1.1 ; 
3.3] 
[0.6 ; 
3.1] 
[0.2 ; 
2.0] 
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Oxybutynin 
ER 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
12 82 83 149 5 4 326 
Mean 
(SD) 
7.21 
(6.15) 
7.03 
(7.93) 
7.44 
(6.96) 
7.39 
(7.46) 
4.77 
(5.99) 
12.74 
(7.39) 
7.30 
(7.41) 
Min-
Max 
[0.3 ; 
15.7] 
[0.0 ; 
31.2] 
[0.6 ; 
24.8] 
[0.0 ; 
38.4] 
[1.1 ; 
15.1] 
[1.7 ; 
16.8] 
[0.0 ; 
38.4] 
Median 6.3 3.4 4.6 3.6 1.7 16.2 3.6 
Q1-Q3 [1.2 ; 
13.5] 
[1.2 ; 
9.4] 
[1.2 ; 
13.4] 
[1.7 ; 
11.2] 
[1.1 ; 
4.8] 
[8.7 ; 
16.8] 
[1.2 ; 
12.0] 
Fesoterodine 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
5 36 48 81 2 5 177 
Mean 
(SD) 
0.65 
(0.62) 
0.99 
(0.87) 
0.75 
(0.83) 
0.79 
(0.77) 
2.18 
(0.71) 
0.68 
(0.94) 
0.83 
(0.81) 
Min-
Max 
[0.1 ; 1.7] [0.1 ; 
3.7] 
[0.1 ; 
3.1] 
[0.1 ; 
3.2] 
[1.7 ; 
2.7] 
[0.2 ; 
2.4] 
[0.1 ; 
3.7] 
Median 0.6 0.7 0.4 0.4 2.2 0.2 0.6 
Q1-Q3 [0.2 ; 0.7] [0.3 ; 
1.5] 
[0.1 ; 
1.1] 
[0.2 ; 
1.2] 
[1.7 ; 
2.7] 
[0.2 ; 
0.4] 
[0.2 ; 
1.3] 
Mirabegron 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
3 33 24 51 1 3 114 
Mean 
(SD) 
3.25 
(1.89) 
10.71 
(8.47) 
7.02 
(6.49) 
7.32 
(6.81) 
14.85 
(--) 
1.97 
(0.90) 
8.11 
(7.32) 
Min-
Max 
[1.5 ; 5.3] [0.8 ; 
25.5] 
[1.5 ; 
22.5] 
[0.8 ; 
25.2] 
[14.9 ; 
14.9] 
[1.4 ; 
3.0] 
[0.8 ; 
25.5] 
Median 3 9 4.5 5.1 14.9 1.5 4.5 
Q1-Q3 [1.5 ; 5.3] [3.0 ; 
19.5] 
[2.6 ; 
10.5] 
[1.5 ; 
12.0] 
[14.9 ; 
14.9] 
[1.4 ; 
3.0] 
[1.5 ; 
15.0] 
Flavoxate 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
1 17 16 30 0 
(0.0%) 
3 67 
Mean 
(SD) 
216.00 
(0) 
65.88 
(77.10) 
101.25 
(107.25) 
72.35 
(85.39) 
- 72.00 
(112.24) 
79.74 
(90.06) 
Min-
Max 
[216.0 ; 
216.0] 
[11.2 ; 
252.0] 
[16.8 ; 
352.8] 
[5.6 ; 
270.0] 
- [6.0 ; 
201.6] 
[5.6 ; 
352.8] 
Median 216 33.6 45 23.6 - 8.4 33.6 
Q1-Q3 [216.0 ; 
216.0] 
[18.0 ; 
90.0] 
[17.4 ; 
180.0] 
[18.0 ; 
117.6] 
- [6.0 ; 
201.6] 
[18.0 ; 
117.6] 
Propiverine 
Cumulative 
dose in grams 
  
  
  
No. of 
valid 
values 
2 8 26 17 2 1 54 
Mean 
(SD) 
4.64 
(5.37) 
2.02 
(1.61) 
5.71 
(5.89) 
3.22 
(3.53) 
10.50 
(10.10) 
0.84 (--) 4.47 
(5.12) 
Min-
Max 
[0.8 ; 8.4] [0.8 ; 
5.9] 
[0.4 ; 
16.8] 
[0.4 ; 
11.2] 
[3.4 ; 
17.6] 
[0.8 ; 
0.8] 
[0.4 ; 
17.6] 
Median 4.6 1.7 2.9 1.7 10.5 0.8 1.7 
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Q1-Q3 [0.8 ; 8.4] [1.3 ; 
1.8] 
[0.8 ; 
10.9] 
[0.8 ; 
4.4] 
[3.4 ; 
17.6] 
[0.8 ; 
0.8] 
[0.8 ; 
6.7] 
Darifenacin 
Cumulative 
dose in grams 
No. of 
valid 
values 
1 8 3 10 0 
(0.0%) 
0 (0.0%) 22 
Mean 
(SD) 
0.42 (0) 2.09 
(2.30) 
0.28 
(0.12) 
0.85 
(1.07) 
- - 1.20 
(1.67) 
Min-
Max 
[0.4 ; 0.4] [0.2 ; 
5.9] 
[0.2 ; 
0.4] 
[0.1 ; 
2.9] 
- - [0.1 ; 
5.9] 
Median 0.4 0.8 0.2 0.4 - - 0.5 
Q1-Q3 [0.4 ; 0.4] [0.4 ; 
4.1] 
[0.2 ; 
0.4] 
[0.2 ; 
0.6] 
- - [0.2 ; 
1.1] 
SD, standard deviation; NGB, neurogenic bladder; PD, Parkinson’s disease; MS, Multiple Sclerosis, STK, 
stroke; SCI, spinal cord injuries; SB, spina bifida; IR, immediate release; ER, extended release, SD, 
standard deviation  
 
Table 7.23 Cumulative prescribed quantity (in grams) within 12 months after the first 
NGB/OAB diagnosis or OAB prescription, by age and sex subgroups 
Substances  [19 years 
– 65 
years[ 
 n=2038 
Over 65 
years 
n=1875 
Male 
n=2334 
Female 
n=1579 
Solifenacin 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
698 679 830 547 
Mean (SD) 1.35 (1.28) 1.12 (1.08) 1.23 (1.13) 1.26 (1.27) 
Min-Max [0.0 ; 15.9] [0.0 ; 7.9] [0.0 ; 7.9] [0.1 ; 15.9] 
Median 1.1 0.8 0.8 0.9 
Q1-Q3 [0.3 ; 2.0] [0.3 ; 1.8] [0.3 ; 2.0] [0.3 ; 2.0] 
Oxybutynin IR 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
503 549 590 462 
Mean (SD) 0.68 (0.65) 0.63 (0.57) 0.70 (0.64) 0.60 (0.57) 
Min-Max [0.0 ; 6.8] [0.0 ; 3.1] [0.0 ; 6.8] [0.0 ; 3.1] 
Median 0.4 0.4 0.4 0.3 
Q1-Q3 [0.1 ; 1.2] [0.1 ; 1.1] [0.1 ; 1.3] [0.1 ; 1.0] 
Tolterodine 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
538 486 575 449 
Mean (SD) 1.10 (1.27) 0.79 (1.01) 0.94 (1.10) 0.97 (1.24) 
Min-Max [0.0 ; 10.0] [0.0 ; 6.7] [0.0 ; 6.9] [0.0 ; 10.0] 
Median 0.6 0.3 0.4 0.4 
Q1-Q3 [0.2 ; 1.7] [0.1 ; 1.1] [0.2 ; 1.4] [0.1 ; 1.4] 
Trospium 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
190 150 191 149 
Mean (SD) 1.77 (5.18) 1.31 (1.70) 1.48 (1.72) 1.68 (5.79) 
Min-Max [0.1 ; 69.6] [0.1 ; 14.4] [0.1 ; 14.4] [0.1 ; 69.6] 
Median 0.9 0.7 1 0.7 
  
 
 
 
244 
Q1-Q3 [0.3 ; 2.0] [0.2 ; 1.8] [0.3 ; 2.1] [0.2 ; 1.8] 
Oxybutynin ER 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
145 181 200 126 
Mean (SD) 7.71 (7.41) 6.97 (7.42) 7.48 (7.53) 7.00 (7.24) 
Min-Max [0.3 ; 31.2] [0.0 ; 38.4] [0.0 ; 38.4] [0.0 ; 31.2] 
Median 4.8 3.6 3.6 3.6 
Q1-Q3 [1.2 ; 14.4] [1.7 ; 10.1] [1.2 ; 13.4] [1.2 ; 11.5] 
Fesoterodine 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
101 76 108 69 
Mean (SD) 0.83 (0.87) 0.83 (0.74) 0.86 (0.79) 0.78 (0.86) 
Min-Max [0.1 ; 3.7] [0.1 ; 3.2] [0.1 ; 3.7] [0.1 ; 3.2] 
Median 0.4 0.6 0.7 0.4 
Q1-Q3 [0.2 ; 1.2] [0.2 ; 1.3] [0.2 ; 1.4] [0.2 ; 1.0] 
Mirabegron 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
62 52 73 41 
Mean (SD) 6.76 (6.32) 9.72 (8.13) 8.57 (7.32) 7.29 (7.35) 
Min-Max [1.4 ; 25.2] [0.8 ; 25.5] [0.8 ; 25.5] [0.8 ; 25.2] 
Median 3.4 6 6 3 
Q1-Q3 [1.5 ; 10.5] [1.7 ; 18.2] [1.5 ; 15.0] [1.5 ; 13.5] 
Flavoxate 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
27 40 48 19 
Mean (SD) 79.70 
(97.46) 
79.76 
(85.99) 
71.73 
(90.95) 
99.96 
(86.85) 
Min-Max [5.6 ; 
352.8] 
[6.0 ; 
270.0] 
[5.6 ; 
352.8] 
[6.0 ; 
260.4] 
Median 18 34.8 18 108 
Q1-Q3 [16.8 ; 
117.6] 
[18.0 ; 
125.4] 
[18.0 ; 
89.4] 
[18.0 ; 
162.0] 
Propiverine 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
33 21 22 32 
Mean (SD) 5.37 (5.93) 3.04 (3.10) 4.45 (5.49) 4.48 (4.93) 
Min-Max [0.4 ; 17.6] [0.4 ; 11.2] [0.4 ; 17.6] [0.4 ; 16.8] 
Median 1.9 1.7 1.4 1.7 
Q1-Q3 [0.8 ; 10.2] [0.8 ; 4.4] [0.8 ; 5.9] [0.8 ; 7.6] 
Darifenacin 
Cumulative dose in grams 
  
  
  
No. of valid 
values 
12 10 13 9 
Mean (SD) 1.19 (2.04) 1.22 (1.17) 1.58 (1.99) 0.65 (0.88) 
Min-Max [0.1 ; 5.9] [0.2 ; 2.9] [0.1 ; 5.9] [0.2 ; 2.9] 
Median 0.3 0.6 0.6 0.2 
Q1-Q3 [0.2 ; 0.6] [0.2 ; 2.7] [0.2 ; 2.7] [0.2 ; 0.6] 
IR, immediate release; ER, extended release, SD, standard deviation  
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7.6 Resource Utilisation and Costs 
7.6.1 Specialist Visits 
Almost 50% of the patients had a urologist and/or gynaecologist visit over 12 months after 
the first OAB/NGB diagnosis or OAB prescription date (46.7%) (Table 7.24). When stratified 
by age groups, the proportion of visits was almost the same (47.4% in the elderly vs 46.1% 
for those under 65 years old) (Table 7.25). More men visited the specialist (49.1%) 
compared to women (43.2%). The overall average number of visits was 2.6 (SD=1.65, 
median=2) visits during the 12-month period (similar in all the neurological condition 
subgroups) and ranged from 1 visit to 15 visits (STK population) (Table 7.24). The average 
total cost associated with specialist visits was £252.53 (SD=£186.42, median=£218.8), and 
was comparable between, underlying conditions subgroups (Table 7.24). Costs were also 
comparable between age and sex subgroups (Table 7.25). 
 
Table 7.24 Number of specialist visits and costs by underlying neurological condition 
subgroups 
  Definit
ive 
NGB 
(n 
=363) 
PD 
cohort 
(n=713
) 
MS 
cohort 
(n=102
9) 
STK 
cohort 
(n=172
0) 
SCI 
cohort 
(n=41) 
SB 
cohort 
(n=180
) 
All 
(n=391
3) 
Specialist visits – all 
(Urologist/gynaecolo
gist)  
  
  
≥ 1 
visit n 
(%) 
184 
(50.7%
) 
342 
(48.0%
) 
396 
(38.5%
) 
859 
(49.9%
) 
23 
(56.1%
) 
92 
(51.1%
) 
1828 
(46.7%
) 
Mean 
(SD) 
2.42 
(1.64) 
2.11 
(1.42) 
2.09 
(1.41) 
2.38 
(1.83) 
2.09 
(1.24) 
1.98 
(1.41) 
2.26 
(1.65) 
Min-
Max 
[1.0 ; 
10.0] 
[1.0 ; 
12.0] 
[1.0 ; 
9.0] 
[1.0 ; 
15.0] 
[1.0 ; 
5.0] 
[1.0 ; 
7.0] 
[1.0 ; 
15.0] 
Medi
an 
2 2 2 2 2 1 2 
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Q1-
Q3 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
2.0] 
[1.0 ; 
3.0] 
Specialist visits 
(Urologist) 
>1 
visit n 
(%) 
174 
(47.9%
) 
328 
(46.0%
) 
367 
(35.7%
) 
820 
(47.7%
) 
20 
(48.8%
) 
85 
(47.2%
) 
1729 
(44.2%
) 
Mean 
(SD) 
2.28 
(1.69) 
2.01 
(1.45) 
1.88 
(1.40) 
2.19 
(1.79) 
1.87 
(1.42) 
1.72 
(1.30) 
2.07 
(1.63) 
Min-
Max 
[0.0 ; 
10.0] 
[0.0 ; 
12.0] 
[0.0 ; 
9.0] 
[0.0 ; 
15.0] 
[0.0 ; 
5.0] 
[0.0 ; 
6.0] 
[0.0 ; 
15.0] 
Medi
an 
2 2 1 2 2 1 2 
Q1-
Q3 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
2.0] 
[1.0 ; 
3.0] 
[1.0 ; 
3.0] 
[1.0 ; 
2.0] 
[1.0 ; 
3.0] 
Specialist visits 
(gynaecologist) 
  
  
≥ 1 
visit n 
(%) 
18 
(5.0%) 
20 
(2.8%) 
50 
(4.9%) 
79 
(4.6%) 
5 
(12.2%
) 
9 
(5.0%) 
175 
(4.5%) 
Mean 
(SD) 
0.15 
(0.51) 
0.11 
(0.53) 
0.21 
(0.65) 
0.19 
(0.75) 
0.22 
(0.42) 
0.26 
(1.03) 
0.18 
(0.70) 
Min-
Max 
[0.0 ; 
3.0] 
[0.0 ; 
6.0] 
[0.0 ; 
4.0] 
[0.0 ; 
8.0] 
[0.0 ; 
1.0] 
[0.0 ; 
6.0] 
[0.0 ; 
8.0] 
Medi
an 
0 0 0 0 0 0 0 
Q1-
Q3 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
 Costs (£) - all 
(Urologist/gynaecolo
gist)  
Mean 
(SD) 
269.80 
(181.6
2) 
234.69 
(158.6
0) 
235.63 
(160.2
4) 
266.85 
(206.9
7) 
235.17 
(132.2
9) 
224.65 
(171.4
0) 
252.53 
(186.4
2) 
Min-
Max 
[109.4 
; 
1094.0
] 
[109.4 
; 
1312.8
] 
[109.4 
; 
1079.2
] 
[109.4 
; 
1641.0
] 
[109.4 
; 
547.0] 
[109.4 
; 
955.0] 
[109.4 
; 
1641.0
] 
Medi
an 
218.8 218.8 218.8 218.8 218.8 140.9 218.8 
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Q1-
Q3 
[109.4 
; 
328.2] 
[109.4 
; 
328.2] 
[109.4 
; 
328.2] 
[109.4 
; 
328.2] 
[109.4 
; 
328.2] 
[109.4 
; 
234.6] 
[109.4 
; 
328.2] 
SD, standard deviation; NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis, STK, 
stroke; SCI, spinal cord injuries; SB, spina bifida 
 
Table 7.25 Number of specialist visits and costs by age and sex subgroups 
  [19 years – 65 
years[  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
(n=2334) 
 Female 
(n=1579) 
Specialist visits 
(Urologist/gynaecologist) 
  
  
  
≥ 1 visit 
n (%) 
940 (46.1%) 888 
(47.4%) 
1146 
(49.1%) 
682 
(43.2%) 
Mean 
(SD) 
2.23 (1.60) 2.28 (1.70) 2.31 (1.70) 2.17 (1.54) 
Min-Max [1.0 ; 15.0] [1.0 ; 12.0] [1.0 ; 15.0] [1.0 ; 11.0] 
Median 2 2 2 2 
Q1-Q3 [1.0 ; 3.0] [1.0 ; 3.0] [1.0 ; 3.0] [1.0 ; 3.0] 
Specialist visits (Urologist) 
  
  
  
≥ 1 visit 
n (%) 
866 (42.5%) 863 
(46.0%) 
1144 
(49.0%) 
585 
(37.0%) 
Mean 
(SD) 
2.17 (1.57) 2.21 (1.62) 2.30 (1.70) 1.97 (1.35) 
Min-Max [1.0 ; 15.0] [1.0 ; 12.0] [1.0 ; 15.0] [1.0 ; 11.0] 
Median 2 2 2 1 
Q1-Q3 [1.0 ; 3.0] [1.0 ; 3.0] [1.0 ; 3.0] [1.0 ; 3.0] 
Specialist visits 
(Gynaecologist)  
  
  
≥ 1 visit 
n (%) 
122 (6.0%) 53 (2.8%) 6 (0.3%) 169 
(10.7%) 
Mean 
(SD) 
1.74 (1.13) 2.26 (1.68) 1.17 (0.41) 1.92 (1.35) 
Min-Max [1.0 ; 6.0] [1.0 ; 8.0] [1.0 ; 2.0] [1.0 ; 8.0] 
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Median 1 2 1 1 
Q1-Q3 [1.0 ; 2.0] [1.0 ; 3.0] [1.0 ; 1.0] [1.0 ; 2.0] 
 Costs (£) - all 
(Urologist/gynaecologist)  
Mean 
(SD) 
250.93 
(180.23) 
254.23 
(192.86) 
252.69 
(186.63) 
252.27 
(186.22) 
Min-Max [109.4 ; 
1641.0] 
[109.4 ; 
1312.8] 
[109.4 ; 
1641.0] 
[109.4 ; 
1203.4] 
Median 218.8 218.8 218.8 218.8 
Q1-Q3 [109.4 ; 328.2] [109.4 ; 
328.2] 
[109.4 ; 
328.2] 
[109.4 ; 
328.2] 
SD, standard deviation 
 
7.6.2 Outpatient Physician Office Visits  
All study patients had at least one all-cause physician office visit over 12 months after the 
first OAB/NGB diagnosis or OAB prescription date. The overall average number of visits was 
67.7 (SD=42.6, median=59) and ranged from 1 to 402 visits (some patients had more than 
one visit a day). Patients with STK or SCI had higher average number of physician visits 
compared to the other underlying conditions cohorts; 76.3 (SD=44, median=67) and 75.49 
(SD=54.1, median=70) visits respectively vs. 55.20 (SD=43.8, median=48), 69.67 (SD=39.4, 
median=62), 57.4 (SD=39.4, median=50) and (49.9 SD=35.07, median=46) visits in NGB, PD, 
MS and SB cohorts respectively) (Table 7.26). 
Older patients (72.9 [SD=41.4], median=65) had higher cumulative number of physician 
office visits than those under 65 years old (mean=63.01 [SD=43.2], median=54) (Table 
7.27). The mean number of visits was similar between males 67.4 (SD=42.3, median=59) 
and females 68.3 (SD=43.1, median=60).  
The overall average total cost associated with outpatient physician office visits was 
£1448.39 (SD=£967.05, median= 1243.6) (Table 7.26). Costs were highest in the STK 
subgroup (£1627.33 [SD=£1004.93], median= £1398.1). Costs were lower in the younger 
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cohort with a cost of £1348.24 over 12 months, (SD=£969.96, median=£1144.9) in 
comparison to the older subgroup which had a total cost of £1557.20 (SD=£952.28, 
median= £1366.2). 
 
Table 7.26 Number of outpatient physician office visits by underlying neurological 
condition subgroups 
  Defini
tive 
NGB 
(n 
=363) 
PD 
cohor
t 
(n=71
3) 
MS 
cohor
t 
(n=10
29) 
STK 
cohort 
(n=172
0) 
SCI 
cohort 
(n=41) 
SB 
cohor
t 
(n=18
0) 
All 
(n=39
13) 
Outpatient physician 
office visits (all) 
  
  
  
≥ 1 
visit 
n (%) 
363 
(100.0
%) 
713 
(100.0
%) 
1029 
(100.0
%) 
1720 
(100.0
%) 
41 
(100.0
%) 
180 
(100.0
%) 
3913 
(100.0
%) 
Mea
n 
(SD) 
55.20 
(43.84
) 
69.67 
(39.35
) 
57.42 
(39.40
) 
76.29 
(43.97) 
75.49 
(54.07) 
49.93 
(35.07
) 
67.74 
(42.60
) 
Min-
Max 
[1.0 ; 
263.0] 
[3.0 ; 
295.0] 
[1.0 ; 
302.0] 
[4.0 ; 
402.0] 
[5.0 ; 
291.0] 
[1.0 ; 
185.0] 
[1.0 ; 
402.0] 
Med
ian 
48 62 50 67 70 46 59 
Q1-
Q3 
[22.0 ; 
76.0] 
[42.0 ; 
92.0] 
[30.0 ; 
74.0] 
[45.0 ; 
98.0] 
[38.0 ; 
92.0] 
[23.5 ; 
65.5] 
[38.0 ; 
89.0] 
Outpatient physician 
office visits (clinical) 
 
  
  
≥ 1 
visit 
n (%) 
283 
(78.0
%) 
662 
(92.8
%) 
869 
(84.5
%) 
1623 
(94.4%
) 
32 
(78.0%
) 
143 
(79.4
%) 
3510 
(89.7
%) 
Mea
n 
(SD) 
3.66 
(4.85) 
5.06 
(5.84) 
3.72 
(4.40) 
5.83 
(5.72) 
4.56 
(7.24) 
3.70 
(4.06) 
4.90 
(5.43) 
Min-
Max 
[0.0 ; 
49.0] 
[0.0 ; 
92.0] 
[0.0 ; 
54.0] 
[0.0 ; 
52.0] 
[0.0 ; 
44.0] 
[0.0 ; 
27.0] 
[0.0 ; 
92.0] 
Med
ian 
2 4 3 4 3 3 3 
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Q1-
Q3 
[1.0 ; 
5.0] 
[2.0 ; 
7.0] 
[1.0 ; 
5.0] 
[2.0 ; 
8.0] 
[1.0 ; 
5.0] 
[1.0 ; 
5.0] 
[2.0 ; 
7.0] 
Outpatient physician 
office visits (Surgery) 
  
  
  
≥ 1 
visit 
n (%) 
311 
(85.7
%) 
702 
(98.5
%) 
1001 
(97.3
%) 
1680 
(97.7%
) 
39 
(95.1%
) 
165 
(91.7
%) 
3787 
(96.8
%) 
Mea
n 
(SD) 
16.14 
(15.66
) 
21.54 
(14.30
) 
18.01 
(15.33
) 
22.45 
(16.02) 
23.07 
(17.54) 
15.51 
(13.24
) 
20.50 
(15.61
) 
Min-
Max 
[0.0 ; 
78.0] 
[0.0 ; 
92.0] 
[0.0 ; 
144.0] 
[0.0 ; 
128.0] 
[0.0 ; 
76.0] 
[0.0 ; 
80.0] 
[0.0 ; 
144.0] 
Med
ian 
12 19 15 19 20 13 17 
Q1-
Q3 
[4.0 ; 
23.0] 
[11.0 ; 
29.0] 
[8.0 ; 
24.0] 
[11.0 ; 
30.0] 
[10.0 ; 
33.0] 
[6.0 ; 
21.0] 
[10.0 ; 
27.0] 
Outpatient physician 
office visits (Home visit) 
 
  
  
  
≥ 1 
visit 
n (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Mea
n 
(SD) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
Min-
Max 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
Med
ian 
0 0 0 0 0 0 0 
Q1-
Q3 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
Outpatient physician 
office visits (Out of hours) 
  
  
  
≥ 1 
visit 
n (%) 
350 
(96.4
%) 
713 
(100.0
%) 
1024 
(99.5
%) 
1719 
(99.9%
) 
41 
(100.0
%) 
175 
(97.2
%) 
3896 
(99.6
%) 
Mea
n 
(SD) 
28.20 
(23.95
) 
35.28 
(21.49
) 
29.27 
(21.47
) 
39.33 
(23.78) 
40.05 
(31.50) 
24.67 
(18.32
) 
34.63 
(23.12
) 
Min-
Max 
[0.0 ; 
158.0] 
[1.0 ; 
147.0] 
[0.0 ; 
211.0] 
[0.0 ; 
198.0] 
[3.0 ; 
157.0] 
[0.0 ; 
111.0] 
[0.0 ; 
211.0] 
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Med
ian 
23 30 24 35 34 23 30 
Q1-
Q3 
[11.0 ; 
38.0] 
[19.0 ; 
46.0] 
[15.0 ; 
38.0] 
[22.0 ; 
51.0] 
[19.0 ; 
46.0] 
[11.5 ; 
33.5] 
[18.0 ; 
45.0] 
Outpatient physician 
office visits (Telephone 
consultation) 
  
  
  
≥ 1 
visit 
n (%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
0 
(0.0%) 
Mea
n 
(SD) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
Min-
Max 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
Med
ian 
0 0 0 0 0 0 0 
Q1-
Q3 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
Outpatient physician 
office visits (Home 
visit/surgery 
consultation)* 
  
  
  
≥ 1 
visit 
n (%) 
360 
(99.2
%) 
702 
(98.5
%) 
985 
(95.7
%) 
1697 
(98.7%
) 
40 
(97.6%
) 
173 
(96.1
%) 
3825 
(97.8
%) 
Mea
n 
(SD) 
7.20 
(6.35) 
7.80 
(6.42) 
6.42 
(6.52) 
8.68 
(7.24) 
7.80 
(7.16) 
6.05 
(5.16) 
7.71 
(6.83) 
Min-
Max 
[0.0 ; 
51.0] 
[0.0 ; 
67.0] 
[0.0 ; 
92.0] 
[0.0 ; 
62.0] 
[0.0 ; 
36.0] 
[0.0 ; 
39.0] 
[0.0 ; 
92.0] 
Med
ian 
6 6 5 7 5 5 6 
Q1-
Q3 
[3.0 ; 
10.0] 
[4.0 ; 
10.0] 
[2.0 ; 
8.0] 
[4.0 ; 
11.0] 
[3.0 ; 
10.0] 
[2.0 ; 
9.0] 
[3.0 ; 
10.0] 
Costs (£) outpatient 
physician office visits (all) 
 
Mea
n 
(SD) 
1180.
75 
(984.7
0) 
1500.
57 
(910.5
5) 
1217.
72 
(880.3
0) 
1627.3
3 
(1004.
93) 
1523.4
0 
(1157.
72) 
1104.
35 
(809.3
1) 
1448.
39 
(967.0
5) 
Min-
Max 
[45.6 ; 
6529.
8] 
[114.4 
; 
[37.0 ; 
9382.
2] 
[45.6 ; 
10776.
0] 
[45.6 ; 
6512.0
] 
[37.0 ; 
3924.
8] 
[37.0 ; 
10776
.0] 
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8099.
2] 
Med
ian 
937.4 1333.
4 
1024.
6 
1398.1 1423 963.2 1243.
6 
Q1-
Q3 
[456.8 
; 
1617.
2] 
[871.6 
; 
1936.
8] 
[617.8 
; 
1584.
6] 
[926.2 
; 
2099.9
] 
[763.2 
; 
1953.0
] 
[514.1 
; 
1493.
6] 
[776.0 
; 
1887.
4] 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation  
* Represents acute visits and follow-up/routine visit sub-categories from Table 6.5 
 
Table 7.27 Number of outpatient physician visits by age and sex subgroups 
  [19 years – 
65 years[  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
(n=2334) 
 Female 
(n=1579) 
Outpatient physician office visits 
  
  
  
≥ 1 
visit n 
(%) 
2038 
(100.0%) 
1875 
(100.0%) 
2334 
(100.0%) 
1579 
(100.0%) 
Mean 
(SD) 
63.01 
(43.18) 
72.89 
(41.38) 
67.38 
(42.28) 
68.28 
(43.09) 
Min-
Max 
[1.0 ; 
402.0] 
[2.0 ; 
348.0] 
[1.0 ; 
402.0] 
[1.0 ; 
302.0] 
Media
n 
54 65 59 60 
Q1-Q3 [33.0 ; 
83.0] 
[43.0 ; 
94.0] 
[37.0 ; 
89.0] 
[38.0 ; 
88.0] 
Outpatient physician office visits 
(Clinical) 
  
  
≥ 1 
visit n 
(%) 
1759 
(86.3%) 
1751 
(93.4%) 
2088 
(89.5%) 
1422 
(90.1%) 
Mean 
(SD) 
4.26 (4.85) 5.60 
(5.91) 
4.86 
(5.75) 
4.96 
(4.91) 
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  Min-
Max 
[0.0 ; 54.0] [0.0 ; 
92.0] 
[0.0 ; 
92.0] 
[0.0 ; 
49.0] 
Media
n 
3 4 3 4 
Q1-Q3 [1.0 ; 6.0] [2.0 ; 7.0] [2.0 ; 6.0] [2.0 ; 7.0] 
Outpatient physician office visits 
(Surgery) 
  
  
  
≥ 1 
visit n 
(%) 
1958 
(96.1%) 
1829 
(97.5%) 
2259 
(96.8%) 
1528 
(96.8%) 
Mean 
(SD) 
19.71 
(16.01) 
21.36 
(15.12) 
20.37 
(15.26) 
20.71 
(16.11) 
Min-
Max 
[0.0 ; 
144.0] 
[0.0 ; 
124.0] 
[0.0 ; 
128.0] 
[0.0 ; 
144.0] 
Media
n 
16 19 17 17 
Q1-Q3 [8.0 ; 26.0] [11.0 ; 
28.0] 
[10.0 ; 
27.0] 
[9.0 ; 
28.0] 
Outpatient physician office visits 
(Home visit) 
  
  
  
≥ 1 
visit n 
(%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mean 
(SD) 
0.00 (0.00) 0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
Min-
Max 
[0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] 
Media
n 
0 0 0 0 
Q1-Q3 [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] 
Outpatient physician office visits (out 
of hours) 
  
  
  
≥ 1 
visit n 
(%) 
2021 
(99.2%) 
1875 
(100.0%) 
2326 
(99.7%) 
1570 
(99.4%) 
Mean 
(SD) 
31.92 
(23.22) 
37.57 
(22.66) 
34.58 
(23.05) 
34.71 
(23.24) 
Min-
Max 
[0.0 ; 
211.0] 
[2.0 ; 
198.0] 
[0.0 ; 
198.0] 
[0.0 ; 
211.0] 
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Media
n 
27 33 29 30 
Q1-Q3 [16.0 ; 
42.0] 
[21.0 ; 
49.0] 
[18.0 ; 
45.0] 
[19.0 ; 
45.0] 
Outpatient physician office visits 
(Telephone consultation) 
  
  
  
≥ 1 
visit n 
(%) 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Mean 
(SD) 
0.00 (0.00) 0.00 
(0.00) 
0.00 
(0.00) 
0.00 
(0.00) 
Min-
Max 
[0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] 
Media
n 
0 0 0 0 
Q1-Q3 [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] [0.0 ; 0.0] 
Outpatient physician office visits 
(Home visit/surgery consultation)* 
  
  
  
≥ 1 
visit n 
(%) 
1980 
(97.2%) 
1845 
(98.4%) 
2279 
(97.6%) 
1546 
(97.9%) 
Mean 
(SD) 
7.12 (6.63) 8.35 
(6.97) 
7.58 
(6.58) 
7.91 
(7.17) 
Min-
Max 
[0.0 ; 92.0] [0.0 ; 
62.0] 
[0.0 ; 
67.0] 
[0.0 ; 
92.0] 
Media
n 
5 6 6 6 
Q1-Q3 [3.0 ; 10.0] [4.0 ; 
11.0] 
[3.0 ; 
10.0] 
[3.0 ; 
10.0] 
Costs (£) outpatient physician office 
visits (all) 
 
Mean 
(SD) 
1348.24 
(969.96) 
1557.20 
(952.28) 
1434.53 
(959.40) 
1468.89 
(978.20) 
Min-
Max 
[37.0 ; 
10776.0] 
[45.6 ; 
7423.6] 
[37.0 ; 
10776.0] 
[37.0 ; 
9382.2] 
Media
n 
1144.9 1366.2 1240.1 1255.1 
Q1-Q3 [683.6 ; 
1789.6] 
[900.8 ; 
1997.8] 
[767.8 ; 
1872.6] 
[791.6 ; 
1924.6] 
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SD, standard deviation 
* Represents acute visits and follow-up/routine visit sub-categories from Table 6.5 
 
7.6.3 Number of Incontinence Pad Prescriptions 
Few patients were prescribed with at least one incontinence pad over 12 months after the 
first OAB/NGB diagnosis or OAB prescription date (14 patients overall, 0.4%). The average 
number of pads prescribed during a 12-month period was 5.21 pads (SD=6, median=2), and 
ranged from 1 pad (SD=0, median=1) in the PD cohort to 10 pads in the MS cohort (SD=7, 
median=10) (Table 7.28). 
The overall average total cost associated with pads utilisation was £40.46 over 12 months 
(SD=£46.99, median=£14). Average total costs were higher in MS cohort compared to the 
other underlying conditions; £87.60 (SD=£49.24, median=£120), compared to £13.00 
(SD=£3.61, median=£13), £8.00 (SD=£2.83, median=£8.00), £10.48 (SD=£8.10, median=£6) 
and £50.00 (median=£50.00) respectively in the NGB, PD, STK and SCI cohorts (Table 7.26). 
Total costs were higher among younger patients compared to the elderly (mean=£57.11 
[SD=£51.78], median=£50) and (mean=£10.48 [SD=£8.10], median=£6) respectively), and 
also higher in females compared to males ((mean=£49.13 [SD=£49.83], median=£10), and 
(mean=£8.67 [SD=£2.31], median=£24) respectively) (Table 7.29). 
 
Table 7.28 Number of incontinence pads prescriptions and costs by underlying 
neurological condition subgroups  
  Definitive 
NGB 
(n=363) 
PD 
cohort 
(n=713) 
MS 
cohort 
(n=1029) 
STK 
cohort 
(n=1720
) 
SCI 
cohort 
(n=41) 
SB 
coho
rt 
(n=1
80) 
All 
(n=39
13) 
Incontinence 
Pads 
≥ 1 pad n 
(%) 
2 (0.6%) 2 
(0.3%) 
5 (0.5%) 5 (0.3%) 1 
(2.4%) 
0 
(0.0%
) 
14 
(0.4%) 
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Mean 
(SD) 
1.50 (0.71) 1.00 
(0.00) 
10.00 
(6.96) 
3.80 
(4.21) 
1.00 (-
-) 
- 5.21 
(5.95) 
Min-Max [1.0 ; 2.0] [1.0 ; 
1.0] 
[2.0 ; 
21.0] 
[1.0 ; 
11.0] 
[1.0 ; 
1.0] 
- [1.0 ; 
21.0] 
Median 1.5 1 10 2 1 - 2 
Q1-Q3 [1.0 ; 2.0] [1.0 ; 
1.0] 
[7.0 ; 
10.0] 
[1.0 ; 
4.0] 
[1.0 ; 
1.0] 
- [1.0 ; 
10.0] 
Costs (£) 
  
  
  
Mean 
(SD) 
13.00 
(4.24) 
8.00 
(2.83) 
87.60 
(49.24) 
10.48 
(8.10) 
50.00 
(--) 
- 40.56 
(46.99
) 
Min-Max [10.0 ; 
16.0] 
[6.0 ; 
10.0] 
[16.0 ; 
126.0] 
[4.4 ; 
24.0] 
[50.0 ; 
50.0] 
- [4.4 ; 
126.0] 
Median 13 8 120 6 50 - 14 
Q1-Q3 [10.0 ; 
16.0] 
[6.0 ; 
10.0] 
[56.0 ; 
120.0] 
[6.0 ; 
12.0] 
[50.0 ; 
50.0] 
- [6.0 ; 
56.0] 
 
 
Table 7.29 Number of incontinence pads prescriptions and costs by underlying age and 
sex subgroups 
  [19 years – 65 
years[  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
(n=2334) 
Female 
(n=1579) 
Incontinence 
Pads 
  
  
≥ 1 pad n 
(%) 
9 (0.4%) 5 (0.3%) 3 (0.1%) 11 (0.7%) 
Mean (SD) 6.00 (6.84) 3.80 (4.21) 1.00 (0.00) 6.36 (6.27) 
Min-Max [1.0 ; 21.0] [1.0 ; 11.0] [1.0 ; 1.0] [1.0 ; 21.0] 
Median 2 2 1 4 
Q1-Q3 [1.0 ; 10.0] [1.0 ; 4.0] [1.0 ; 1.0] [1.0 ; 10.0] 
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Costs (£) 
  
  
  
Mean (SD) 57.11 (51.78) 10.48 (8.10) 8.67 (2.31) 49.13 
(49.83) 
Min-Max [6.0 ; 126.0] [4.4 ; 24.0] [4.4 ; 
126.0] 
[6.0 ; 126.0] 
Median 50 6 10 24 
Q1-Q3 [10.0 ; 120.0] [6.0 ; 12.0] [6.0 ; 56.0] [10.0 ; 
120.0] 
SD, standard deviation 
 
7.6.4 Number of Urological Tests 
Three categories of urological tests were assessed: urodynamics, cystoscopy, and other 
diagnostic tests (mainly imaging). Overall, 2.5%, 8.8%, and 2.1% of the population had at 
least 1 test of urodynamics, cystoscopy, and imaging respectively, over a 12-month follow 
up period (Table 7.30). The average number of urological tests performed was similar 
between underlying condition cohorts as well as sex and age subgroups (Table 7.31).  
The cost associated with urological tests was comparable between the cohorts (generally 
there was no more than £100 difference). Total average costs were £178.71 (SD=93.88, 
median=£126), £171.11 (SD=£66.45, median=146), and £100.86 (SD=£82.89, 
median=£144) respectively for urodynamics, cystoscopy, and imaging tests (Table 7.30).  
 
Table 7.30 Number of urological tests and costs by underlying neurological condition 
subgroups 
  Definiti
ve NGB 
(n =363) 
PD 
cohort 
(n=713) 
MS 
cohort 
(n=1029
) 
STK 
cohort 
(n=172
0) 
SCI 
cohort 
(n=41) 
SB 
cohort 
(n=180) 
All 
(n=391
3) 
Urodynamics >1 test 
n (%) 
9 (2.5%) 11 
(1.5%) 
27 
(2.6%) 
51 
(3.0%) 
0 (0.0%) 3 (1.7%) 98 
(2.5%) 
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Mean 
(SD) 
1.11 
(0.33) 
1.82 
(0.60) 
1.70 
(1.07) 
1.25 
(0.52) 
- 1.00 
(0.00) 
1.42 
(0.75) 
Min-
Max 
[1.0 ; 
2.0] 
[1.0 ; 
3.0] 
[1.0 ; 
5.0] 
[1.0 ; 
3.0] 
- [1.0 ; 
1.0] 
[1.0 ; 
5.0] 
Media
n 
1 2 1 1 - 1 1 
Q1-Q3 [1.0 ; 
1.0] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.0] 
- [1.0 ; 
1.0] 
[1.0 ; 
2.0] 
Urodynamics 
costs (£) 
  
  
  
Mean 
(SD) 
140.00 
(42.00) 
229.09 
(75.98) 
214.67 
(134.51) 
158.12 
(65.92) 
- 126.00 
(0.00) 
178.71 
(93.88) 
Min-
Max 
[126.0 ; 
252.0] 
[126.0 ; 
378.0] 
[126.0 ; 
630.0] 
[126.0 ; 
378.0] 
- [126.0 ; 
126.0] 
[126.0 ; 
630.0] 
Media
n 
126 252 126 126 - 126 126 
Q1-Q3 [126.0 ; 
126.0] 
[126.0 ; 
252.0] 
[126.0 ; 
252.0] 
[126.0 ; 
126.0] 
- [126.0 ; 
126.0] 
[126.0 ; 
252.0] 
Cytoscopy 
  
  
>1  
test n 
(%) 
55 
(15.2%) 
74 
(10.4%) 
58 
(5.6%) 
147 
(8.5%) 
4 (9.8%) 22 
(12.2%) 
343 
(8.8%) 
Mean 
(SD) 
1.22 
(0.60) 
1.14 
(0.34) 
1.07 
(0.26) 
1.23 
(0.54) 
1.00 
(0.00) 
1.18 
(0.50) 
1.17 
(0.46) 
Min-
Max 
[1.0 ; 
4.0] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
4.0] 
[1.0 ; 
1.0] 
[1.0 ; 
3.0] 
[1.0 ; 
4.0] 
Media
n 
1 1 1 1 1 1 1 
Q1-Q3 [1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
Cytoscopy 
costs (£) 
  
  
  
Mean 
(SD) 
177.85 
(87.47) 
165.73 
(50.25) 
156.07 
(37.32) 
179.77 
(78.43) 
146.00 
(0.00) 
172.55 
(73.16) 
171.11 
(66.45) 
Min-
Max 
[146.0 ; 
584.0] 
[146.0 ; 
292.0] 
[146.0 ; 
292.0] 
[146.0 ; 
584.0] 
[146.0 ; 
146.0] 
[146.0 ; 
438.0] 
[146.0 ; 
584.0] 
Media
n 
146 146 146 146 146 146 146 
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Q1-Q3 [146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
Other tests 
(imaging) 
  
  
  
>1 test 
n (%) 
9 (2.5%) 9 (1.3%) 24 
(2.3%) 
37 
(2.2%) 
2 (4.9%) 5 (2.8%) 83 
(2.1%) 
Mean 
(SD) 
1.00 
(0.00) 
1.00 
(0.00) 
1.13 
(0.34) 
1.11 
(0.31) 
1.00 
(0.00) 
1.00 
(0.00) 
1.08 
(0.28) 
Min-
Max 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
2.0] 
Media
n 
1 1 1 1 1 1 1 
Q1-Q3 [1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
[1.0 ; 
1.0] 
Other tests 
(imaging) (£) 
  
  
  
Mean 
(SD) 
73.22 
(72.09) 
64.00 
(75.89) 
138.00 
(79.20) 
87.00 
(85.20) 
144.00 
(0.00) 
92.23 
(85.03) 
100.86 
(82.89) 
Min-
Max 
[0.0 ; 
144.0] 
[0.0 ; 
144.0] 
[0.0 ; 
288.0] 
[0.0 ; 
288.0] 
[144.0 ; 
144.0] 
[0.0 ; 
173.2] 
[0.0 ; 
288.0] 
Media
n 
83 0 144 144 144 144 144 
Q1-Q3 [0.0 ; 
144.0] 
[0.0 ; 
144.0] 
[144.0 ; 
144.0] 
[0.0 ; 
144.0] 
[144.0 ; 
144.0] 
[0.0 ; 
144.0] 
[0.0 ; 
144.0] 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida, SD, standard deviation 
 
Table 7.31 Number of urological tests and costs by age and sex subgroups  
 
[19 years – 65 
years [  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
 (n2334) 
Female 
 (n=1579) 
Urodynamics 
  
  
>1 test n 
(%) 
48 (2.4%) 50 (2.7%) 51 (2.2%) 47 (3.0%) 
Mean 
(SD) 
1.52 (0.90) 1.32 (0.55) 1.18 (0.39) 1.68 (0.93) 
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  Min-Max [1.0 ; 5.0] [1.0 ; 3.0] [1.0 ; 2.0] [1.0 ; 5.0] 
Median 1 1 1 1 
Q1-Q3 [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 1.0] [1.0 ; 2.0] 
Urodynamics costs (£) 
  
  
  
Mean 
(SD) 
191.63 (113.26) 166.32 
(69.43) 
148.24 
(48.51) 
211.79 
(117.81) 
Min-Max [126.0 ; 630.0] [126.0 ; 
378.0] 
[126.0 ; 
252.0] 
[126.0 ; 
630.0] 
Median 126 126 126 126 
Q1-Q3 [126.0 ; 252.0] [126.0 ; 
252.0] 
[126.0 ; 
126.0] 
[126.0 ; 
252.0] 
Cystoscopy  
  
  
  
>1 test n 
(%) 
154 (7.6%) 189 
(10.1%) 
210 (9.0%) 133 (8.4%) 
Mean 
(SD) 
1.14 (0.43) 1.20 (0.47) 1.21 (0.51) 1.11 (0.33) 
Min-Max [1.0 ; 3.0] [1.0 ; 4.0] [1.0 ; 4.0] [1.0 ; 3.0] 
Median 1 1 1 1 
Q1-Q3 [1.0 ; 1.0] [1.0 ; 1.0] [1.0 ; 1.0] [1.0 ; 1.0] 
Cytoscopy costs (£) 
  
  
  
Mean 
(SD) 
165.91 (62.61) 175.35 
(69.30) 
177.29 
(75.14) 
161.37 
(48.43) 
Min-Max [146.0 ; 438.0] [146.0 ; 
584.0] 
[146.0 ; 
584.0] 
[146.0 ; 
438.0] 
Median 146 146 146 146 
Q1-Q3 [146.0 ; 146.0] [146.0 ; 
146.0] 
[146.0 ; 
146.0] 
[146.0 ; 
146.0] 
Other tests (imaging) 
  
  
  
>1 test n 
(%) 
49 (2.4%) 34 (1.8%) 45 (1.9%) 38 (2.4%) 
Mean 
(SD) 
1.10 (0.31) 1.06 (0.24) 1.11 (0.32) 1.05 (0.23) 
Min-Max [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 2.0] 
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Median 1 1 1 1 
Q1-Q3 [1.0 ; 1.0] [1.0 ; 1.0] [1.0 ; 1.0] [1.0 ; 1.0] 
Other tests (imaging) 
costs (£) 
  
  
  
Mean 
(SD) 
109.78 (84.77) 88.00 
(79.58) 
86.83 
(93.44) 
117.47 
(65.74) 
Min-Max [0.0 ; 288.0] [0.0 ; 
288.0] 
[0.0 ; 
288.0] 
[0.0 ; 288.0] 
Median 144 144 83 144 
Q1-Q3 [0.0 ; 144.0] [0.0 ; 
144.0] 
[0.0 ; 
144.0] 
[144.0 ; 
144.0] 
SD, standard deviation. 
 
7.6.5 Procedures and Operations Performed  
Overall, 5.7% of the overall study patients had at least 1 procedure or operation performed 
during the 12-month follow up period. The proportion of patients having at least 1 
procedure or operation performed was higher in SCI and NGB cohorts compared to the 
other conditions (17.1% and 12.1% respectively) (Table 7.32) but was comparable between 
age (19-65 years old=5.9% and >65 years=5.4%) and sex (males=6.2% and females=4.9%) 
(Table 7.33). 
Average total costs associated with procedures or operations over 12 months was 
£2284.97 (SD=£3919.03, median=£1123) and was higher in the NGB cohort compared to 
the other conditions (£3407.87 (SD=£7294.86, median=£1513.4)) (Table 7.32). Average 
costs were higher in the elderly patients compared to those aged under 65 years old 
(£2678.66 (SD=£5091.57, median=£1417.7) vs. £1966.12 (SD=£2591.79, median=£1067.2)) 
(Table 7.33).  
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Table 7.32 Number of procedures and operations performed and costs by underlying 
neurological condition subgroup 
  Definiti
ve NGB 
(n 
=363) 
PD 
cohort 
(n=713) 
MS 
cohort 
(n=102
9) 
STK 
cohort 
(n=172
0) 
SCI 
cohort 
(n=41) 
SB 
cohort 
(n=180) 
All 
(n=391
3) 
Procedures and 
operations 
performed 
  
  
  
≥ 1 
procedu
re n (%) 
44 
(12.1%) 
30 
(4.2%) 
52 
(5.1%) 
104 
(6.0%) 
7 
(17.1
%) 
2 
(1.1%) 
223 
(5.7%) 
Mean 
(SD) 
1.39 
(0.78) 
1.57 
(0.86) 
1.38 
(0.57) 
1.28 
(0.63) 
1.29 
(0.49) 
1.00 
(0.00) 
1.36 
(0.67) 
Min-
Max 
[1.0 ; 
4.0] 
[1.0 ; 
4.0] 
[1.0 ; 
3.0] 
[1.0 ; 
4.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.0] 
[1.0 ; 
4.0] 
Median 1 1 1 1 1 1 1 
Q1-Q3 [1.0 ; 
1.5] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.0] 
[1.0 ; 
2.0] 
Costs (£) 
  
  
  
Mean 
(SD) 
3407.8
7 
(7294.8
6) 
2035.2
5 
(1773.8
6) 
1999.3
7 
(2563.9
0) 
2471.9
9 
(5141.9
5) 
788.6
3 
(504.6
7) 
2752.3
4 
(3143.4
1) 
2284.9
7 
(3919.0
3) 
Min-
Max 
[228.0 ; 
47418.
7] 
[228.0 ; 
6802.0] 
[168.0 ; 
14934.
1] 
[220.0 ; 
47418.
7] 
[168.0 
; 
1409.
9] 
[529.6 ; 
4975.1] 
[168.0 ; 
47418.
7] 
Median 1513.4 1528.7 1163.4 896.2 693.4 2752.3 1123 
Q1-Q3 [647.5 ; 
3404.4] 
[564.0 ; 
3095.8] 
[546.8 ; 
2205.5] 
[466.5 ; 
2990.0] 
[369.4 
; 
1360.
1] 
[529.6 ; 
4975.1] 
[502.4 ; 
2673.0] 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation 
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Table 7.33 Number of procedures and operations performed and costs by age and sex 
subgroups 
  [19 years – 
65 years[  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
(n=2334) 
Female 
 (n=1579) 
Procedures and 
operations performed 
  
  
  
≥1 
procedure n 
(%) 
121 (5.9%) 102 (5.4%) 145 (6.2%) 78 (4.9%) 
Mean (SD) 1.32 (0.62) 1.41 (0.72) 1.39 (0.72) 1.32 (0.57) 
Min-Max [1.0 ; 4.0] [1.0 ; 4.0] [1.0 ; 4.0] [1.0 ; 3.0] 
Median 1 1 1 1 
Q1-Q3 [1.0 ; 1.0] [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 2.0] 
Costs (£) Mean (SD) 1966.12 
(2591.79) 
2678.66 
(5091.57) 
2392.12 
(4509.63) 
2087.37 
(2502.87) 
Min-Max [168.0 ; 
14934.1] 
[220.0 ; 
47418.7] 
[168.0 ; 
47418.7] 
[168.0 ; 
14934.1] 
Median 1067.2 1417.7 1073.6 1129.3 
Q1-Q3 [466.5 ; 
2436.0] 
[565.3 ; 
3240.0] 
[466.5 ; 
2542.3] 
[529.6 ; 
2673.0] 
SD, standard deviation 
 
7.6.6 Urology Related Hospitalisations and Number of Days Admitted  
Overall, 11.0% of the study population had at least one urology related hospitalisation 
during the 12-month follow up period. The proportion of patients having at least one 
hospitalisation was higher in the NGB and SCI cohorts compared to the other conditions 
(20.1% and 19.5% respectively) (Table 7.34) but was comparable between age and sex 
subgroups (Table 7.35). 1.9% of the population was hospitalised following renal failure. 
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The average number of days spent in hospital was 12.5 days (SD=26.6, median=3 days). The 
highest number of days spent in hospital was the NGB cohort (15.5 [SD=32.8], median=2) 
(Table 7.34). The duration was slightly lower in older patients (12.1 [SD=20.5], median=4) 
compared to younger patients (12.89 [SD=32.02], median=2), and the results were higher 
in females (12.9 [SD=28.1], median=3) than in males (11.9 [SD=24.1], median=3) (Table 
7.35).  
Average total hospitalisation costs over 12 months was £6256.39 (SD=£13472.85, 
median=£2589.9) and was higher in the NGB cohort compared to the other conditions 
£8052.07 (SD=£20758.98, median=£1942.5) (Table 7.34). Costs were higher in younger 
patients (£6879.73 [SD=15604.59], median=£2191.2) compared to older patients 
(£5859.29 [SD=£11193.30], median=£2952.1) and in males (£6879.73 [SD=£15604.59], 
median=£2798.2) compared to females (£5283.82 [SD=£9172.44], median=£2257.3). 
 
Table 7.34 Urology related hospitalisations and costs by underlying neurological 
condition subgroups 
  Definiti
ve NGB 
(n 
=363) 
PD 
cohort 
(n=713
) 
MS 
cohort 
(n=102
9) 
STK 
cohort 
(n=172
0) 
SCI 
cohort 
(n=41) 
SB 
cohort 
(n=180
) 
All 
(n=391
3) 
Hospitalisations 
  
  
  
≥ 1 
hospitali
sation n 
(%) 
73 
(20.1%) 
78 
(10.9%
) 
84 
(8.2%) 
206 
(12.0%) 
8 
(19.5%
) 
12 
(6.7%) 
431 
(11.0%) 
Mean 
(SD) 
2.11 
(1.95) 
1.41 
(0.89) 
1.74 
(1.54) 
1.48 
(0.87) 
1.63 
(1.41) 
2.25 
(2.22) 
1.61 
(1.27) 
Min-Max [1.0 ; 
11.0] 
[1.0 ; 
6.0] 
[1.0 ; 
10.0] 
[1.0 ; 
5.0] 
[1.0 ; 
5.0] 
[1.0 ; 
9.0] 
[1.0 ; 
11.0] 
Median 1 1 1 1 1 2 1 
Q1-Q3 [1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
[1.0 ; 
1.5] 
[1.0 ; 
2.0] 
[1.0 ; 
2.0] 
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Hospitalised 
patients 
following renal 
failure 
n (%) 6 
(1.7%) 
14 
(2.0%) 
6 
(0.6%) 
49 
(2.8%) 
0 
(0.0%) 
1 
(0.6%) 
75 
(1.9%) 
Number of days 
admitted 
Mean 
(SD) 
13.68 
(38.39) 
9.53 
(14.53) 
15.49 
(32.79) 
12.71 
(23.51) 
7.13 
(9.55) 
3.33 
(6.07) 
12.49 
(26.61) 
Min-Max [0.0 ; 
223.0] 
[0.0 ; 
79.0] 
[0.0 ; 
140.0] 
[0.0 ; 
172.0] 
[0.0 ; 
28.0] 
[0.0 ; 
20.0] 
[0.0 ; 
223.0] 
Median 1 3 2 4 3.5 1 3 
Q1-Q3 [0.0 ; 
8.0] 
[0.0 ; 
14.0] 
[0.0 ; 
7.0] 
[0.0 ; 
15.0] 
[1.0 ; 
10.0] 
[0.0 ; 
2.5] 
[0.0 ; 
13.0] 
Hospitalisations 
costs (£) 
  
  
  
Mean 
(SD) 
8052.0
7 
(20758.
98) 
5884.7
1 
(8486.
26) 
6226.2
9 
(14321.
03) 
5913.7
5 
(11056.
11) 
2448.8
3 
(2630.
18) 
7216.5
5 
(15368.
58) 
6256.3
9 
(13472.
85) 
Min-Max [264.8 ; 
163720
.3] 
[220.0 
; 
50521.
2] 
[162.0 ; 
83316.
8] 
[162.0 ; 
134884
.6] 
[220.0 
; 
8335.2
] 
[264.8 ; 
55306.
3] 
[162.0 ; 
163720
.3] 
Median 1942.5 2604.3 1793.6 3146.4 1647.8 2134.4 2589.9 
Q1-Q3 [866.3 ; 
6663.7] 
[738.9 
; 
6791.1
] 
[564.0 ; 
4049.1] 
[1004.7 
; 
7396.3] 
[742.6 
; 
3127.3
] 
[734.8 ; 
6505.9] 
[738.9 ; 
6663.7] 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation 
 
Table 7.35 Urology related hospitalisations and costs by age and sex subgroups 
  [19 years – 
65 years[  
(n=2038) 
Over 65 
years  
(n=1875) 
Male 
 (n=2334) 
Female 
 (n=1579) 
Hospitalisations  
  
≥ 1 
hospitalisation 
n (%) 
207 (10.2%) 224 (11.9%) 262 (11.2%) 169 
(10.7%) 
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Mean (SD) 1.80 (1.56) 1.43 (0.88) 1.62 (1.30) 1.59 (1.22) 
Min-Max [1.0 ; 11.0] [1.0 ; 6.0] [1.0 ; 11.0] [1.0 ; 10.0] 
Median 1 1 1 1 
Q1-Q3 [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 2.0] [1.0 ; 2.0] 
Hospitalised 
following renal failure 
n (%) 30 (1.5%) 45 (2.4%) 54 (2.3%) 21 (1.3%) 
Number of admitted 
days 
Mean 12.89 (32.02) 12.13 
(20.45) 
12.91 
(28.14) 
11.85 
(24.13) 
Min-Max [0.0 ; 223.0] [0.0 ; 140.0] [0.0 ; 223.0] [0.0 ; 
140.0] 
Median 2 4 3 3 
Q1-Q3 [0.0 ; 8.0] [0.0 ; 15.5] [0.0 ; 13.0] [0.0 ; 11.0] 
Hospitalisations costs 
(£) 
  
  
  
Mean (SD) 6686.57 
(15588.16) 
5859.29 
(11193.30) 
6879.73 
(15604.59) 
5283.82 
(9172.44) 
Min-Max [162.0 ; 
163720.3] 
[162.0 ; 
134884.6] 
[162.0 ; 
163720.3] 
[162.0 ; 
80324.5] 
Median 2191.2 2952.1 2798.2 2257.3 
Q1-Q3 [647.5 ; 
6837.9] 
[933.0 ; 
6245.0] 
[724.4 ; 
6791.1] 
[794.4 ; 
6151.4] 
* Represents acute visits and follow-up/routine visit sub-categories from Table 6.5 
SD, standard deviation  
 
7.6.7 Overall costs  
The overall costs over 12 months was £2395.03 (SD=£5412.9, median=£1458.2). Costs were 
highest in the NGB cohort £3378.92 (SD=£10676.34, median=£1308), and lowest in the SB 
cohort £1756.61 (SD=£4346.80, median=£1182) (Table 7.36). Costs were higher in males 
£2488.28 (SD=6200.39, median=1458.2) than in females £2257.21 (SD=£3971.53, median= 
£1461.8) and comparable between the 19-65 years subgroup (£2268.61 [SD=£5804.00], 
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median=£1340) and the >65 years subgroup (£2532.48 [SD=£4950.70], median=£1578.1) 
(Table 7.37). 
 
Table 7.36 Total costs (£) within 12 months after the first OAB/NGB diagnosis or OAB 
prescription date by underlying conditions subgroups 
  Definitiv
e NGB 
(n=363) 
PD 
cohort 
(n=713) 
MS 
cohort 
(n=1029
) 
STK 
cohort 
(n=1720
) 
SCI 
cohort 
(n=41) 
SB 
cohort 
(n=180) 
All 
(n=3913
) 
Total 
costs 
Mean (SD) 3378.92 
(10676.
34) 
2355.86 
(3849.6
7) 
1923.18 
(5033.8
7) 
2624.23 
(4944.1
7) 
2290.2
8 
(2025.
19) 
1756.61 
(4346.8
0) 
2395.03 
(5412.9
8) 
Min-Max [45.6 ; 
166644.
4] 
[160.0 ; 
59695.7
] 
[37.0 ; 
94393.2
] 
[45.6 ; 
137793.
8] 
[119.6 
; 
10171.
4] 
[37.0 ; 
57354.3
] 
[37.0 ; 
166644.
4] 
Median 1308 1546.2 1180.1 1666.6 1858.2 1182 1458.2 
Q1-Q3 [651.4 ; 
2524.7] 
[986.0 ; 
2346.2] 
[697.9 ; 
1910.5] 
[1057.4 
; 
2645.8] 
[949.0 
; 
2703.3
] 
[684.5 ; 
1842.7] 
[896.1 ; 
2360.9] 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation 
 
Table 7.37 Total costs (£) within 12 months after the first OAB/NGB diagnosis or OAB 
prescription date by age and sex subgroups 
  [19 years – 65 
years[  
(N=2038) 
Over 65 years  
(N=1875) 
Male 
 (N=2334) 
 Female 
 (N=1579) 
Tota
l 
Mean 
(SD) 
2268.61 (5804.00) 2532.48 
(4950.70) 
2257.21 
(3971.53) 
2488.28 
(6200.39) 
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cost
s 
Min-Max [37.0 ; 166644.4] [45.6 ; 137793.8] [37.0 ; 90610.2] [37.0 ; 166644.4] 
Median 1340 1578.1 1461.8 1455.8 
Q1-Q3 [790.8 ; 2205.0] [1023.0 ; 2485.6] [889.6 ; 2376.1] [900.0 ; 2357.6] 
SD, standard deviation 
 
7.7 Sensitivity Analyses 
In this section, results of sensitivity analysis are presented, where patients were included 
into the study via a broader definition of NGB (Section 6.4.15). 
7.7.1 Patient Inclusion and Sub-Cohorts 
Comparisons between patient inclusion in the study as well as sub-cohorts between the 
base case (BC) and the sensitivity analysis (SA) are provided in Table 7.38 and Table 7.39. 
Overall, 4930 patients were included in the SA, patient inclusion proportions in the study 
was similar to the BC. 
 
Table 7.38 Patient inclusion into the study- base case vs sensitivity analysis 
Selection criteria Included  
(BC) 
Included  
(SA) 
1) Source cohort: NGB/probable NGB between 01/01/2004 
and 31/12/2016 
19499 24373 
2) Be >19 years at index date 18901 23776 
3) 12-month pre-index period, without NGB/OAB/Rx 13841 16963 
4) 12-month follow-up period, post NGB/OAB/Rx 16804 21315 
5) Referral to urologist within the 12-month pre-
index/follow-up period 
7553 9220 
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6) Idiopathic OAB 19445 24319 
7) Diagnosis of dementia within the selection period 17060 21153 
Final selection 3913 4930 
NGB, neurogenic bladder; OAB, overactive bladder; Rx, prescription; BC, base case; SA, sensitivity 
analysis 
 
The proportion of sub-cohorts was similar between the BC and SA, with a slightly higher 
proportion of definitive NGB and SB cohort in the BC analysis. 
 
Table 7.39 Sub-cohorts – base case vs sensitivity analysis 
Subgroup Study cohort – BC 
(n=3913) 
Study cohort –SA 
(n=4930) 
Definitive NGB 363 (9.3%) 365 (7.4%) 
PD cohort 713 (18.2%) 927 (18.8%) 
MS cohort 1029 (26.3%) 1175 (23.8%) 
STK cohort 1720 (44.0%) 2370 (48.1%) 
SCI cohort 41 (1.0%) 48 (1.0%) 
SB cohort 180 (4.6%) 181 (3.7%) 
BC, base case; SA, sensitivity analysis NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple 
sclerosis; STK, stroke; SCI, spinal cord injuries; SB, spina bifida 
 
7.7.2 Patient Characteristics  
Patient characteristics for the SA for study cohorts and subgroups are summarised in Table 
7.40 and Table 7.41.  
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Patient demographic and clinical characteristics in the SA were similar to the BC population 
characteristics: 
 Overall, the average age was 64.3 years (SD=16.4) which was similar to the BC (61.7 
years (SD=16.3) and the distribution amongst neurological disease sub-cohorts and 
age and sex subgroups also proved to be similar. 
 Count of chronic diseases from the QOF within the 12-month pre-index period was 
0.78 in SA compared to 0.73 in the BC. 
 Comorbidity described by BNF headers was also similar (9.6 in the SA vs 8.6 in the 
BC). 
 Mean polypharmacy was 5.8 in the SA compared to in the BC 5.4. 
 Average ACB score in the SA population was 6.41 (5.52), compared to 6.59 (5.85) 
for the BC, which is a comparable result. 
 As in the BC, the majority of patients did not have anticholinergic drugs prescription 
in the 12-month pre-index period (73.3% vs. 72.4 in the BC analysis). 
 
Table 7.40 Population demographic and clinical characteristics, overall and by study sub-
cohorts – sensitivity analyses 
Characteristics 
 
Definitive 
 NGB 
n=365 
PD 
Cohort 
n=927 
MS 
Cohort  
n=1029 
STK 
Cohort  
n=1175 
SCI 
Cohort  
n=48 
SB 
Cohort  
n=181 
All 
 
n=4930 
Age at index-
date 
 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
48.35 
(15.88) 
72.21 
(9.45) 
50.05 
(12.46) 
72.02 
(11.74) 
48.27 
(15.68) 
36.19 
(11.94) 
64.28 
(16.37) 
Median [19.0 ; 
87.0] 
[31.0 ; 
96.0] 
[19.0 ; 
90.0] 
[20.0 ; 
98.0] 
[20.0 ; 
91.0] 
[19.0 ; 
76.0] 
[19.0 ; 
98.0] 
Min-
Max 
48 73 50 74 49 35 67 
Q1-Q3 [37.0 ; 
60.0] 
[67.0 ; 
79.0] 
[41.0 ; 
58.0] 
[65.0 ; 
81.0] 
[34.5 ; 
58.5] 
[26.0 ; 
44.0] 
[53.0 ; 
77.0] 
Count of 
chronic 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
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diseases from 
the QOF 
within the 12-
month pre-
index period 
Mean 
(SD) 
0.29 
(0.59) 
0.27 
(0.59) 
0.17 
(0.46) 
1.38 
(0.73) 
0.25 
(0.56) 
0.21 
(0.47) 
0.78 
(0.86) 
Median [0.0 ; 3.0] [0.0 ; 
4.0] 
[0.0 ; 
3.0] 
[0.0 ; 
6.0] 
[0.0 ; 
2.0] 
[0.0 ; 
2.0] 
[0.0 ; 
6.0] 
Min-
Max 
0 0 0 1 0 0 1 
Q1-Q3 [0.0 ; 0.0] [0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[1.0 ; 
2.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
1.0] 
Number of 
distinct BNF 
headers 
Within the 12-
month pre-
index period 
(Comorbidity) 
  
  
  
Valid 
values 
365 927 1175 2370 48 181 4930 
0 78 
(21.4%) 
80 
(8.6%) 
220 
(18.7%) 
272 
(11.5%) 
11 
(22.9%) 
16 
(8.8%) 
641 
(13.0%) 
1-3 43 
(11.8%) 
91 
(9.8%) 
254 
(21.6%) 
177 
(7.5%) 
11 
(22.9%) 
27 
(14.9%) 
581 
(11.8%) 
4-7 53 
(14.5%) 
222 
(23.9%) 
255 
(21.7%) 
497 
(21.0%) 
6 
(12.5%) 
35 
(19.3%) 
1052 
(21.3%) 
8-19 144 
(39.5%) 
420 
(45.3%) 
334 
(28.4%) 
1096 
(46.2%) 
14 
(29.2%) 
75 
(41.4%) 
2037 
(41.3%) 
20 + 47 
(12.9%) 
114 
(12.3%) 
112 
(9.5%) 
328 
(13.8%) 
6 
(12.5%) 
28 
(15.5%) 
619 
(12.6%) 
Mean 
(Sd) 
9.57 
(9.06) 
10.36 
(7.78) 
7.63 
(8.28) 
10.64 
(8.13) 
8.83 
(10.12) 
10.97 
(8.89) 
9.85 
(8.30) 
Min-
Max 
[0.0 ; 
45.0] 
[0.0 ; 
54.0] 
[0.0 ; 
45.0] 
[0.0 ; 
73.0] 
[0.0 ; 
41.0] 
[0.0 ; 
42.0] 
[0.0 ; 
73.0] 
Median 8 9 5 10 5 9 8 
Q1-Q3 [2.0 ; 
14.0] 
[5.0 ; 
15.0] 
[2.0 ; 
11.0] 
[5.0 ; 
15.0] 
[1.0 ; 
15.5] 
[4.0 ; 
16.0] 
[4.0 ; 
14.0] 
Polypharmacy1 
at index-date 
(Using BNF 
headers) 
  
  
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
5.49 
(5.68) 
6.20 
(4.79) 
4.29 
(4.76) 
6.34 
(4.89) 
5.33 
(6.21) 
6.34 
(5.87) 
5.80 
(5.01) 
Median [0.0 ; 
30.0] 
[0.0 ; 
29.0] 
[0.0 ; 
30.0] 
[0.0 ; 
37.0] 
[0.0 ; 
21.0] 
[0.0 ; 
31.0] 
[0.0 ; 
37.0] 
Min-
Max 
4 5 3 6 2.5 5 5 
Q1-Q3 [1.0 ; 9.0] [3.0 ; 
9.0] 
[1.0 ; 
6.0] 
[3.0 ; 
9.0] 
[0.0 ; 
9.0] 
[2.0 ; 
9.0] 
[2.0 ; 
9.0] 
Polypharmacy1 
at index-date 
(Using BNF 
headers) 
  
  
Valid 
values 
365 927 1175 2370 48 181 4930 
0 89 
(24.4%) 
93 
(10.0%) 
267 
(22.7%) 
386 
(16.3%) 
18 
(37.5%) 
19 
(10.5%) 
830 
(16.8%) 
1-3 81 
(22.2%) 
213 
(23.0%) 
409 
(34.8%) 
344 
(14.5%) 
7 
(14.6%) 
51 
(28.2%) 
1071 
(21.7%) 
4-7 85 
(23.3%) 
329 
(35.5%) 
258 
(22.0%) 
775 
(32.7%) 
7 
(14.6%) 
56 
(30.9%) 
1482 
(30.1%) 
8-19 101 
(27.7%) 
278 
(30.0%) 
223 
(19.0%) 
834 
(35.2%) 
15 
(31.3%) 
49 
(27.1%) 
1471 
(29.8%) 
>20 9 (2.5%) 14 
(1.5%) 
18 
(1.5%) 
31 
(1.3%) 
1 
(2.1%) 
6 
(3.3%) 
76 
(1.5%) 
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Polypharmacy1 
at index-date 
(Using 
substances) 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
4.64 
(4.94) 
6.13 
(4.53) 
3.76 
(4.02) 
6.17 
(4.64) 
4.33 
(5.34) 
5.38 
(4.78) 
5.49 
(4.62) 
Median [0.0 ; 
26.0] 
[0.0 ; 
25.0] 
[0.0 ; 
25.0] 
[0.0 ; 
28.0] 
[0.0 ; 
18.0] 
[0.0 ; 
24.0] 
[0.0 ; 
28.0] 
Min-
Max 
3 5 3 6 2 4 5 
Q1-Q3 [0.0 ; 7.0] [3.0 ; 
9.0] 
[1.0 ; 
6.0] 
[3.0 ; 
9.0] 
[0.0 ; 
7.0] 
[2.0 ; 
8.0] 
[2.0 ; 
8.0] 
Polypharmacy1 
at index-date 
(Using 
substances) 
  
Valid 
values 
365 927 1175 2370 48 181 4930 
0 98 
(26.8%) 
94 
(10.1%) 
275 
(23.4%) 
390 
(16.5%) 
19 
(39.6%) 
21 
(11.6%) 
852 
(17.3%) 
1-3 94 
(25.8%) 
200 
(21.6%) 
418 
(35.6%) 
347 
(14.6%) 
9 
(18.8%) 
57 
(31.5%) 
1087 
(22.0%) 
4-7 85 
(23.3%) 
336 
(36.2%) 
294 
(25.0%) 
782 
(33.0%) 
10 
(20.8%) 
56 
(30.9%) 
1536 
(31.2%) 
8-19 84 
(23.0%) 
288 
(31.1%) 
183 
(15.6%) 
834 
(35.2%) 
10 
(20.8%) 
44 
(24.3%) 
1419 
(28.8%) 
>20 4 (1.1%) 9 
(1.0%) 
5 
(0.4%) 
17 
(0.7%) 
0 
(0.0%) 
3 
(1.7%) 
36 
(0.7%) 
ACB score2 
  
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
2.88 
(4.51) 
6.62 
(5.56) 
5.99 
(4.80) 
7.07 
(5.77) 
6.71 
(6.74) 
4.57 
(4.65) 
6.41 
(5.52) 
Median [0.0 ; 
37.0] 
[0.0 ; 
57.0] 
[0.0 ; 
69.0] 
[0.0 ; 
66.0] 
[0.0 ; 
37.0] 
[0.0 ; 
33.0] 
[0.0 ; 
69.0] 
Min-
Max 
0 6 5 6 5 3 6 
Q1-Q3 [0.0 ; 5.0] [3.0 ; 
8.0] 
[3.0 ; 
7.0] 
[3.0 ; 
9.0] 
[3.0 ; 
9.0] 
[3.0 ; 
6.0] 
[3.0 ; 
8.0] 
Number of 
patients on 
anticholinergic 
drugs within 
the 12-month 
pre-index 
period 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
0 272 
(74.5%) 
568 
(61.3%) 
775 
(66.0%) 
2014 
(85.0%) 
37 
(77.1%) 
45 
(24.9%) 
3616 
(73.3%) 
1 45 
(12.3%) 
163 
(17.6%) 
177 
(15.1%) 
139 
(5.9%) 
6 
(12.5%) 
62 
(34.3%) 
574 
(11.6%) 
2 17 (4.7%) 87 
(9.4%) 
100 
(8.5%) 
64 
(2.7%) 
3 
(6.3%) 
28 
(15.5%) 
290 
(5.9%) 
3 11 (3.0%) 42 
(4.5%) 
45 
(3.8%) 
30 
(1.3%) 
1 
(2.1%) 
19 
(10.5%) 
143 
(2.9%) 
4+ 20 (5.5%) 67 
(7.2%) 
78 
(6.6%) 
123 
(5.2%) 
1 
(2.1%) 
27 
(14.9%) 
307 
(6.2%) 
NGB, neurogenic bladder; PD, Parkinson’s disease; MS, Multiple Sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation; ACB, Anticholinergic Cognitive Burden; BNF, British 
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National Formulary; QoF, Quality Outcomes Framework 
1Polypharmacy was defined as the number of distinct BNF headers/ drug substances (including non-
NGB/OAB drugs) in the therapy dataset 
2The ACB score was calculated within 1 month before and after the first OAB/NGB diagnosis or OAB 
prescription date (date 'd'). For patients with no anticholinergic prescriptions between 1 month 
before/after date 'd': ACB score=0 
 
Table 7.41 Population demographic and clinical characteristics, age and sex subgroups – 
sensitivity analyses 
Characteristics 
 
[19 years 
– 65 
years[ 
 n=2038 
Over 65 
years 
n=1875 
Male 
n=2334 
Female 
n=1579 
Age at index-date 
 
No. of valid 
values 
2249 2681 2980 1950 
Mean (SD) 49.56 
(11.57) 
76.62 
(6.81) 
67.30 
(14.95) 
59.65 
(17.34) 
Median [19.0 ; 
65.0] 
[66.0 ; 
98.0] 
[19.0 ; 
98.0] 
[19.0 ; 
97.0] 
Min-Max 52 76 70 60 
Q1-Q3 [42.0 ; 
59.0] 
[71.0 ; 
82.0] 
[59.0 ; 
78.0] 
[47.0 ; 
74.0] 
Count of chronic diseases 
from the QOF 
Within the 12-month pre-
index period 
No. of valid 
values 
2249 2681 2980 1950 
Mean (SD) 0.50 
(0.75) 
1.01 
(0.88) 
0.85 
(0.87) 
0.68 
(0.83) 
Median [0.0 ; 5.0] [0.0 ; 6.0] [0.0 ; 6.0] [0.0 ; 5.0] 
Min-Max 0 1 1 0 
Q1-Q3 [0.0 ; 1.0] [0.0 ; 1.0] [0.0 ; 1.0] [0.0 ; 1.0] 
Number of distinct BNF 
headers 
Within the 12-month pre-
index period 
  
  
  
Valid values 2249 2681 2980 1950 
0 422 
(18.8%) 
219 (8.2%) 371 
(12.4%) 
270 
(13.8%) 
1-3 414 
(18.4%) 
167 (6.2%) 354 
(11.9%) 
227 
(11.6%) 
4-7 480 
(21.3%) 
572 
(21.3%) 
677 
(22.7%) 
375 
(19.2%) 
8-19 722 
(32.1%) 
1315 
(49.0%) 
1256 
(42.1%) 
781 
(40.1%) 
20 + 211 (9.4%) 408 
(15.2%) 
322 
(10.8%) 
297 
(15.2%) 
Mean (Sd) 7.39 (7.71) 9.96 (7.34) 8.33 (7.16) 9.05 (8.29) 
Min-Max [0.0 ; 51.0] [0.0 ; 56.0] [0.0 ; 46.0] [0.0 ; 56.0] 
Median 5 9 7 7 
Q1-Q3 [1.0 ; 11.0] [5.0 ; 14.0] [3.0 ; 12.0] [3.0 ; 13.0] 
Polypharmacy1 at index-
date 
No. of valid 
values 
2249 2681 2980 1950 
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(Using BNF headers) 
  
  
Mean (SD) 4.73 
(5.03) 
6.69 
(4.81) 
5.83 
(4.90) 
5.75 
(5.18) 
Median [0.0 ; 
37.0] 
[0.0 ; 
29.0] 
[0.0 ; 
37.0] 
[0.0 ; 
30.0] 
Min-Max 3 6 5 5 
Q1-Q3 [1.0 ; 7.0] [3.0 ; 
10.0] 
[2.0 ; 9.0] [1.0 ; 9.0] 
 Polypharmacy1 at index-
date (Using BNF headers) 
 
  
  
Valid values 2249 2681 2980 1950 
0 513 
(22.8%) 
317 
(11.8%) 
486 
(16.3%) 
344 
(17.6%) 
1-3 649 
(28.9%) 
422 
(15.7%) 
621 
(20.8%) 
450 
(23.1%) 
4-7 578 
(25.7%) 
904 
(33.7%) 
942 
(31.6%) 
540 
(27.7%) 
8-19 469 
(20.9%) 
1002 
(37.4%) 
893 
(30.0%) 
578 
(29.6%) 
>20 40 (1.8%) 36 (1.3%) 38 (1.3%) 38 (1.9%) 
 Polypharmacy1 at index-
date (Using substances) 
 
No. of valid 
values 
2249 2681 2980 1950 
Mean (SD) 4.35 
(4.50) 
6.45 
(4.51) 
5.54 
(4.49) 
5.42 
(4.81) 
Median [0.0 ; 
28.0] 
[0.0 ; 
25.0] 
[0.0 ; 
28.0] 
[0.0 ; 
26.0] 
Min-Max 3 6 5 5 
Q1-Q3 [1.0 ; 7.0] [3.0 ; 9.0] [2.0 ; 8.0] [1.0 ; 8.0] 
Polypharmacy1 at index-
date (Using substances) 
 
  
Valid values 2249 2681 2980 1950 
0 533 
(23.7%) 
319 
(11.9%) 
497 
(16.7%) 
355 
(18.2%) 
1-3 655 
(29.1%) 
432 
(16.1%) 
626 
(21.0%) 
461 
(23.6%) 
4-7 605 
(26.9%) 
931 
(34.7%) 
975 
(32.7%) 
561 
(28.8%) 
8-19 437 
(19.4%) 
982 
(36.6%) 
865 
(29.0%) 
554 
(28.4%) 
>20 19 (0.8%) 17 (0.6%) 17 (0.6%) 19 (1.0%) 
ACB score2 
  
No. of valid 
values 
2249 2681 2980 1950 
Mean (SD) 6.20 (5.79) 6.58 (5.27) 6.29 (5.29) 6.59 (5.85) 
Median [0.0 ; 69.0] [0.0 ; 66.0] [0.0 ; 64.0] [0.0 ; 69.0] 
Min-Max 5 6 6 6 
Q1-Q3 [3.0 ; 8.0] [3.0 ; 8.0] [3.0 ; 8.0] [3.0 ; 8.0] 
Number of patients on 
anticholinergic drugs 
within the 12-month pre-
index period 
No. of valid 
values 
2249 2681 2980 1950 
0 1545 
(68.7%) 
2071 
(77.2%) 
2246 
(75.4%) 
1370 
(70.3%) 
1 321 
(14.3%) 
253 (9.4%) 334 
(11.2%) 
240 
(12.3%) 
2 163 (7.2%) 127 (4.7%) 149 (5.0%) 141 
(7.2%) 
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3 84 (3.7%) 59 (2.2%) 81 (2.7%) 62 (3.2%) 
4+ 136 (6.0%) 171 (6.4%) 170 (5.7%) 137 (7.0%) 
SD, standard deviation, ACB, Anticholinergic Cognitive Burden; BNF, British National Formulary; QoF, 
Quality Outcomes Framework 
1Polypharmacy was defined as the number of distinct BNF headers/ drug substances (including non-
NGB/OAB drugs) in the therapy dataset 
2The ACB score was calculated within 1 month before and after the first OAB/NGB diagnosis or OAB 
prescription date (date 'd'). For patients with no anticholinergic prescriptions between 1 month 
before/after date 'd': ACB score=0 
 
 
7.7.3 Drug Utilisation  
The results for the SA drug utilisation are presented in Table 7.42 and 7.43. the results are 
similar to the BC findings.  
 The number of OAB prescriptions in the SA were 6.3 which is comparable to the BC 
where it was 6.9. 
 The cumulative days’ supply in the SA was 187.91, which is slightly less than the BC 
result, where the days’ supply was 202.9. 
 Combination use was slightly lower in the SA (7.6%) compared to the BC (8%) 
 The average number of UTI and 5-ARI or α-blockers prescriptions were very similar 
in the SA (2.2 and 2.6 respectively) compared to the BC (2.2 and 2.9 respectively). 
 
 
Table 7.42 Drug utilisation within 12 months after the first OAB/NGB diagnosis or OAB 
prescription date, overall and by underlying conditions sub-cohorts – Sensitivity analysis  
Characteristics 
Definitiv
e 
 NGB 
n=365 
PD 
Cohort 
n=927 
MS 
Cohort 
n=1175 
STK 
Cohort 
n=2370 
SCI 
Cohort 
n=48 
SB 
Cohort 
n=181 
All 
n=4930 
Number of 
OAB 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
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prescription
s 
Mean 
(SD) 
1.61 
(3.54) 
6.88 
(7.55) 
6.87 
(7.13) 
6.44 
(8.24) 
8.10 
(5.90) 
4.98 
(6.28) 
6.32 
(7.69) 
Min-
Max 
[0.0 ; 
21.0] 
[0.0 ; 
55.0] 
[0.0 ; 
64.0] 
[0.0 ; 
104.0] 
[0.0 ; 
24.0] 
[0.0 ; 
52.0] 
[0.0 ; 
104.0] 
Media
n 
0 5 6 4 8.5 3 4 
Q1-Q3 
[0.0 ; 
1.0] 
[1.0 ; 
11.0] 
[2.0 ; 
10.0] 
[1.0 ; 
9.0] 
[1.0 ; 
13.0] 
[1.0 ; 
8.0] 
[1.0 ; 
10.0] 
Number of 
OAB 
prescription
s 
Valid 
values 
365 927 1175 2370 48 181 4930 
0 
255 
(69.9%) 
14 
(1.5%) 
46 
(3.9%) 
46 
(1.9%) 
5 
(10.4%) 
44 
(24.3%) 
339 
(6.9%) 
1-4 
58 
(15.9%) 
442 
(47.7%) 
484 
(41.2%) 
1217 
(51.4%) 
10 
(20.8%) 
64 
(35.4%) 
2244 
(45.5%) 
5-9 
32 
(8.8%) 
200 
(21.6%) 
306 
(26.0%) 
529 
(22.3%) 
13 
(27.1%) 
32 
(17.7%) 
1095 
(22.2%) 
10-14 
14 
(3.8%) 
207 
(22.3%) 
269 
(22.9%) 
419 
(17.7%) 
14 
(29.2%) 
37 
(20.4%) 
947 
(19.2%) 
15-44 
6 (1.6%) 54 
(5.8%) 
58 
(4.9%) 
129 
(5.4%) 
6 
(12.5%) 
3 (1.7%) 252 
(5.1%) 
45+ 
0 (0.0%) 10 
(1.1%) 
12 
(1.0%) 
30 
(1.3%) 
0 (0.0%) 1 (0.6%) 53 
(1.1%) 
Cumulative 
numbers of 
days’ 
supply of 
OAB drugs 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
51.84 
(113.99) 
203.39 
(193.12) 
216.51 
(186.20) 
184.62 
(212.85) 
245.77 
(168.12) 
155.11 
(155.18) 
187.91 
(200.09) 
Min-
Max 
[0.0 ; 
637.7] 
[0.0 ; 
3392.0] 
[0.0 ; 
3177.0] 
[0.0 ; 
6956.0] 
[0.0 ; 
532.0] 
[0.0 ; 
447.6] 
[0.0 ; 
6956.0] 
Media
n 
0 168 196 120 312 90 121.3 
Q1-Q3 
[0.0 ; 
30.0] 
[42.0 ; 
360.0] 
[56.0 ; 
364.0] 
[30.0 ; 
336.0] 
[43.0 ; 
392.0] 
[28.0 ; 
330.0] 
[30.0 ; 
336.0] 
Cumulative 
numbers of 
Valid 
values 
365 927 1175 2370 48 181 4930 
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days’ 
supply of 
OAB drugs 
0-29 
272 
(74.5%) 
148 
(16.0%) 
189 
(16.1%) 
459 
(19.4%) 
9 
(18.8%) 
66 
(36.5%) 
1063 
(21.6%) 
30-119 
40 
(11.0%) 
275 
(29.7%) 
290 
(24.7%) 
725 
(30.6%) 
6 
(12.5%) 
34 
(18.8%) 
1351 
(27.4%) 
120-
349 
33 
(9.0%) 
253 
(27.3%) 
359 
(30.6%) 
656 
(27.7%) 
15 
(31.3%) 
45 
(24.9%) 
1341 
(27.2%) 
350-
549 
19 
(5.2%) 
238 
(25.7%) 
320 
(27.2%) 
505 
(21.3%) 
18 
(37.5%) 
36 
(19.9%) 
1119 
(22.7%) 
>550 
1 (0.3%) 13 
(1.4%) 
17 
(1.4%) 
25 
(1.1%) 
0 (0.0%) 0 (0.0%) 56 
(1.1%) 
OAB 
combinatio
n use 
(yes/no) 
Yes: n 
(%) 
12 
(3.3%) 
71 
(7.7%) 
122 
(10.4%) 
161 
(6.8%) 
2 (4.2%) 11 
(6.1%) 
373 
(7.6%) 
Number of 
antibiotics 
prescription
s for UTI 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
2.70 
(4.24) 
1.67 
(3.28) 
2.33 
(4.17) 
2.10 
(3.84) 
3.04 
(4.61) 
3.13 
(6.20) 
2.15 
(3.97) 
Min-
Max 
[0.0 ; 
24.0] 
[0.0 ; 
44.0] 
[0.0 ; 
36.0] 
[0.0 ; 
46.0] 
[0.0 ; 
18.0] 
[0.0 ; 
59.0] 
[0.0 ; 
59.0] 
Media
n 
1 0 1 1 0 1 1 
Q1-Q3 
[0.0 ; 
4.0] 
[0.0 ; 
2.0] 
[0.0 ; 
3.0] 
[0.0 ; 
2.0] 
[0.0 ; 
6.0] 
[0.0 ; 
4.0] 
[0.0 ; 
2.0] 
Number of 
α-blockers 
or 5-ARI’s 
prescription
s 
No. of 
valid 
values 
365 927 1175 2370 48 181 4930 
Mean 
(SD) 
0.84 
(2.86) 
4.10 
(9.33) 
0.57 
(2.48) 
3.67 
(8.51) 
0.54 
(3.47) 
0.63 
(2.69) 
2.75 
(7.47) 
Min-
Max 
[0.0 ; 
25.0] 
[0.0 ; 
106.0] 
[0.0 ; 
29.0] 
[0.0 ; 
108.0] 
[0.0 ; 
24.0] 
[0.0 ; 
23.0] 
[0.0 ; 
108.0] 
Media
n 
0 0 0 0 0 0 0 
Q1-Q3 
[0.0 ; 
0.0] 
[0.0 ; 
6.0] 
[0.0 ; 
0.0] 
[0.0 ; 
5.0] 
[0.0 ; 
0.0] 
[0.0 ; 
0.0] 
[0.0 ; 
1.0] 
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NGB, neurogenic bladder; PD, Parkinson’s disease; MS, multiple sclerosis; STK, stroke; SCI, spinal cord 
injuries; SB, spina bifida; SD, standard deviation; OAB, overactive bladder; UTI, urinary tract infection; 5-
ARI, 5α-reductase inhibitors 
 
7.8 Chapter Summary  
Results from an epidemiological study, designed to characterise the NGB patient 
population using data from the CPRD database were presented in this chapter. The results, 
which were purely descriptive, provided a concise overview on many pertinent aspects of 
NGB. 
The age of patients was varied and there were slightly more individuals aged between 19-
65, as well as more men (59.6%). The mean comorbidity was 8.6 BNF headers over 12 
months. The average polypharmacy was described by an average of 5.2 BNF headers per 
patient and the average ACB score was 6.6. Solifenacin, oxybutynin and tolterodrine were 
the most prescribed drugs at index date. Around 54% of the population were prescribed 
antibiotics for UTI, as well as 25.5% of patients prescribed 5-ARI’s or α ‐ a d r e n e r g i c 
antagonists . The most frequent form of HRU was outpatient physician visits (mean 67.4 
visits a year), and the highest cost was for hospitalisations (mean=£6256.39 
[SD=£13472.85], median=£2589.9). The next chapter will discuss these results in more 
detail, contextualising these findings with evidence from the literature.  
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8) Chapter Eight – Clinical Practice Research Datalink Study – Discussion 
8.1 Introduction 
The previous chapter presented the results from a descriptive, retrospective study, with 
the aim of characterising patients with neurogenic bladder (NGB), their drug utilisation 
patterns and the economic burden of their condition using data from the Clinical Practice 
Research Datalink (CPRD) database in the UK. This chapter will discuss the results, providing 
interpretation in the context of other relevant literature as well as comparing the results 
to the recommendations in the prominent clinical guidelines (CGs) for NGB, namely those 
from the National Institute for Health and Care Excellence (NICE), the European Association 
of Urology (EAU) and the International Consultation on Incontinence (ICI). Due to the lack 
of comparison data in NGB, estimates from the overactive bladder (OAB) population are 
occasionally used to contextualise the findings, although it should always be kept in mind 
that these are two distinct disease areas. 
8.2 Sub-Optimal Diagnosis/Coding of Neurogenic Bladder 
Diagnosis error is defined as ‘the failure to (a) establish an accurate and timely explanation 
of the patient's health problem(s) or (b) communicate that explanation to the patient’ 
(Institute of Medicine [IOM], 2015: 4). The first and perhaps one of the most critical findings 
from the CPRD study is the exceptionally high rates of potential diagnosis error (type a) in 
NGB. Between 1st January 2004 and 31st December 2015, only 967 patients with a Read 
coded diagnosis of NGB were identified (Section 6.3.6).  
In light of the high prevalence of NGB documented in the literature (Section 2.2.3), it 
seemed improbable that 967 patients were truly representative of the UK NGB population, 
especially considering the wide twelve-year search window that was employed in this 
study. For example, in the UK, 126,893 individuals were diagnosed with Parkinson’s disease 
(PD) in 2009 and estimates suggest that 27-63.9% of this population experience bladder 
dysfunction (Parkinson’s UK, 2009; Ruffion et al., 2013). By conducting a very crude 
estimate, at the least there were 34,261 individuals with NGB secondary to PD in 2009, and 
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this is just one segment of the broader NGB population. Moreover, a study using the 
General Practice Research Database (GPRD) database also identified a low frequency of 
NGB patients (69 patients between the years of 1987 to 2004), further compounding the 
suspicion that there could be an intrinsic problem in the diagnosis of NGB in the UK 
(Odeyemi et al., 2006).  
A lack of clear diagnosis adds ambiguity to patient characterisation, treatment pathways 
and complicates future research endevours. Therefore, it is not infeasible to suggest that 
inadequate diagnosis in NGB could be associated to the high rates of polypharmacy, 
anticholinergic burden and healthcare resource utilisation (HRU) rates observed in the 
study, as most patients were identified via a proxy measure, thus may not be managed 
through the correct care pathways. A correct diagnosis is essential for patients to access 
appropriate services and the right medical treatments, which subsequently improves their 
chances of optimal health outcomes as well as reducing healthcare costs. 
Diagnosis error is a common occurrence but woefully understudied, partly because there 
are few valid and reliable techniques that can enable identification of delayed or missed 
diagnosis (Balogh, 2015). Sub-optimal diagnosis has been identified in multiple chronic 
disease areas, including in lung cancer, ovarian and cervical cancer, type 2 diabetes 
mellitus, meningitis and ischaemic heart disease via methods such as retrospective analysis 
of lab tests, measuring disease progression versus time of diagnosis and clinician surveys 
(Drivsholm and Olivarius, 2006; Esmail, 2004; Mitchell, 2009; Balogh, 2015). Identifying the 
potential reasons and failures that led to the low diagnosis rates helps to pave the way for 
system improvements, as well as providing essential learning information for those 
accountable in the diagnostic process (Balogh, 2015). Two possible rationalisations for low 
NGB diagnosis rates are explored in more detail within the following sections, these are: 
(1) the coding of NGB is inadequate, and (2) diagnosis of NGB is insufficient in UK clinical 
practice.  
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Reasons 
for sub-
optimal 
diagnosis 
of NGB
Coding of NGB is 
inadequate
Complexity of 
symptoms
NGB is not part of 
the QoF
Accomodation of 
urological 
symptoms/Lack of 
help seeking 
behaviour
Low awareness of 
urological symptoms 
amongst 
neurologists/primary 
care physicians
CGs are not typically 
followed -
individualised 
diagnosis pathway
8.2.1 Methods 
Two methods were used to interpret the rates of NGB diagnosis uncovered from the 
feasibility analysis and ascertain possible rationalisations. Firstly, two urological experts 
were invited to participate in short interviews where they were asked to contextualise the 
NGB patient counts, using their experiential knowledge of working in clinical practice. 
Secondly, the information provided by the experts was supplemented with evidence from 
the literature. Further possible information relating to NGB diagnosis pathways was also 
sought from the literature in order to ascertain other possible reasons that lead to 
diagnosis error. The themes emerging from the literature and the expert interviews are 
displayed in Figure 8.1. A central theme emerged regarding a lack of concern and/or 
understanding of urological dysfunction amongst non-urologist healthcare professionals 
(HCPs).  
 
 
 
 
 
 
 
 
QoF, Quality Outcomes Framework; NGB, neurogenic bladder; CGs, clinical guidelines 
Figure 8.1 Reasons for sub-optimal diagnosis of neurogenic bladder patients in the UK 
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8.2.1.1 Coding of Neurogenic Bladder Diagnosis is Inadequate 
The Read code system is a medical terminology used in UK clinical practice. There are a 
multitude of different reasons for missing codes in a patient’s record, and the absence of a 
Read code should not always be interpreted as absence of the disease itself (Section 
6.2.1.1.2). There are three separate Read codes relating to NGB that were identified in this 
study: neurogenic bladder, neuropathic bladder and neuromuscular bladder. No patients 
were found to have a Read code of neuromuscular bladder, which may be because newer 
terms have replaced its use (Section 6.3.6). 
Disparate medical terminologies can make communicating and aggregating clinical 
information in a meaningful way across different levels of the healthcare sector challenging 
(Castle-Clarke, 2015). The Read code system was developed from the view of the general 
practitioner (GP), which has made implementation into secondary care difficult (Meek, 
2015). This is because work activities and organisational structures tend to differ between 
the care settings, and consequently specialists and consultants typically have differing 
views to primary care HCPs on the nature of healthcare. Some opinion goes so far as to 
suggest that ‘Read Codes have failed time after time in secondary care’ (Meek, 2015: 
online). As a result of this ineffectuality, even if a specialist such as urologist or 
gynaecologist has diagnosed a patient with NGB, the information may not be Read coded. 
As opposed to Read codes in primary care, a distinct coding system named the International 
Statistical Classification of Diseases and Related Health Problem 10th revision (ICD-10) is 
applied within UK secondary care. 
8.2.1.2 Low Awareness of Urological Symptoms amongst Non-Urologists and Lack 
of Referrals to Urologists  
The extensive second organ effects that characterise neurological conditions renders a 
simple one-to-one physician-patient relationship insufficient for optimal care. In order to 
improve the overall Quality of Life (QoL) of multiple sclerosis (MS) and PD patients, NICE 
recommend their needs are met through a multidisciplinary team of HCPs, including GPs, 
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speech and language therapists, dieticians, neurologists, and psychologists (NICE, 2014a; 
NICE, 2018d). The composition of the care team depends on the patient’s symptomology, 
disease severity and progression, as well as their social and psychological wellbeing.  
Their superior expertise in bladder dysfunction positions urologists as pre-eminent in the 
diagnosis and management of NGB, however, they are only included in the 
multidisciplinary team, based on their perceived necessity. For example, if urological 
symptoms are not severe, conservative management techniques such as the 
administration of OAB drugs and introducing patients to catheterisation is easily performed 
in primary care. Although resources are saved by confining management to primary care, 
this practice runs the risk of NGB patients remaining undiagnosed, because the awareness 
of urological symptoms amongst GPs is notoriously low. A report into continence care in 
the UK found that physicians do not routinely query ‘at risk’ individuals about their 
continence issues (Wagg, 2010). Some of the common reasons for this include a fear of 
being unable to match patient expectations, lack of understanding of urological symptoms, 
lack of confidence in treating OAB symptoms, and embarrassment in discussing OAB (Smith 
et al., 2011). All of these factors mean GPs are less likely to conduct the appropriate data 
gathering necessary to make a timely and accurate diagnosis of any type of bladder 
dysfunction, let alone NGB, which is considerably more complex. This also indicates that 
they are more susceptible to making cognitive errors in diagnosis (Balogh, 2015). 
Assigning a diagnosis is rarely a straightforward task, often proving challenging, especially 
in primary care. This particularly holds true in NGB, where symptomology can differ vastly 
between patients, making it difficult to uniformly apply diagnostic recommendations from 
CGs (Apostolidis et al., 2017). The temporal nature of NGB also complicates the process 
because symptoms tend to present later than occurrence of neurological disease, making 
assigning of causation difficult (Apostolidis et al., 2017). Moreover, there is a large degree 
of symptom overlap with idiopathic OAB, which can make distinguishing these conditions 
difficult for the untrained professional, thus patients could be incorrectly diagnosed with 
OAB rather than NGB. Given the diffuse and often severer nature of NGB, it is important 
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that the distinction between these conditions is made (Tapia et al., 2013). Further than this, 
the recommendations for diagnostic practices in the CGs may also be an influencing factor 
in diagnosis error. The NICE CGs differ from the EAU and ICI CGs in that they only 
recommend urodynamic investigations in individuals at high risk of renal complications, 
rather than in all possible NGB cases (NICE, 2012; Apostolidis et al., 2017; Bloc et al., 2017). 
Although urodynamic investigations are not imperative for diagnosis, the highly specific 
patient population advocated for testing by NICE may limit diagnosis rates and 
characterisation of a patient’s particular manifestation of NGB. The low rates of 
urodynamic tests are reflected in the CPRD study (2.5%). 
Diagnosis tends to be a team-based and iterative process, which increases the chances of 
error (Balogh 2015). NICE highlight that there is inadequate correspondence to patients 
regarding care providers and specialist services, which means patients are less likely to be 
routed to the correct care pathways (Gallacher et al., 2014; NICE, 2012). This issue is 
exacerbated by the fragmented healthcare service, where many HCPs are involved in the 
care of an NGB patient, leading to ambiguity over responsibilities and a potential disregard 
of CGs and policies (Barth et al., 2016). In most areas of the UK, neurological specialist 
nurses play an instrumental role in streamlining care from multiple care-providers to create 
an individualised management pathway for patients with neurological disorders 
(Bhidayasiri et al., 2016; MacMahon, 1999). However, in the current climate of austerity, 
the number of nurse specialists working within the community are progressively declining, 
therefore patients may have to rely on their GP, who, as established have limited 
awareness of urological symptoms and thus are less likely to be able to diagnose NGB or 
refer patients to a urologist (Christodoulou, 2012).  
In the present CPRD study, 61.3% of the original source cohort did not receive a referral to 
a urologist (Section 7.2). The Urology Trade Association (UTA) obtained figures from 
national healthcare service (NHS) England, which revealed that between 2014-2016, there 
was a decrease in the number of individuals with bladder dysfunction that were referred 
to a specialist. The UTA postulates that this dip in referrals does not necessarily mean that 
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less patients were experiencing incontinence issues during these years. They suggest that 
adequate referrals have not been taking place, and district and practice staff, who lack the 
necessary skills and training to deal with incontinence issues, may have been managing 
these patients instead (Ford, 2017). There is unlikely to be any quick solutions to this issue 
because sub-optimal referrals are observed across innumerable conditions including 
transient ischaemic attacks and several forms of cancer, indicating this may be a cultural 
issue necessitating dedicated interventions across the spectra of disease (Foot, 2010).  
8.2.1.3 Applicability of Current Neurogenic Bladder Clinical Guidelines 
The ICI and EAU CGs scored 53% and 64% respectively in the applicability domain of the 
AGREE II instrument (Section 3.6.5.6.2). The low scores indicate that these CGs are less 
likely to be routinely applied for diagnosing patients in clinical practice, owing to a lack of 
attention the developers devoted to overcoming barriers to implementation. According to 
the AGREE II appraisal, the NICE CGs were highly applicable (90%), however, given the lack 
of uptake data, whether this is translated into their actual use in clinical practice is unknown 
(which is also true for the EAU and ICI) (Section 3.6.5.6.2).  
One of the most limiting factors in NGB CG development was the exclusion of a wide variety 
of stakeholders, in particular of neurologists (all CGs) and GPs (EAU and ICI) (Section 
3.6.5.3). This can propagate a lack of application in clinical practice by these HCPs due to 
the sense their views and opinions have not been incorporated into the recommendations.  
8.2.1.4 The Quality Outcomes Framework  
The Quality Outcomes Framework (QoF) was set up in the UK in 2004 as a pay-for-
performance (P4P) scheme, linking financial incentives to the quality of care, measured 
against a set of clinical activity indicators (Doran et al., 2008; Quint, 2014). The scheme 
focused on ten key chronic conditions predominantly managed in primary care that cause 
significant morbidity and mortality (Gillam et al., 2012; Forbes, 2016). Completeness for 
many of the data points in these conditions improved in the years subsequent to the 
introduction of the QoF (Quint, 2014).  
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The QoF does not include common neurological conditions such as PD, MS or spinal cord 
injuries (SCI), nor does it include NGB. It is therefore apt to assume that the reporting of 
these conditions is not to the same standard as those covered by the scheme. A study by 
Doran et al (2011) found that improvements related to the QoF came at the cost of small 
deleterious effects to conditions not incentivised under the scheme. If neurological 
conditions or NGB were included into the QoF, due to the increased incentive for recording, 
there could be an increase in diagnoses/coding. 
8.2.1.5 Perception of Bladder Symptoms by Patients 
Patients with neurological disorders experience life-altering symptoms such as loss of 
mobility, problems with coordination, memory loss and severe pain (Guy, 2017). In contrast 
to their incapacitating symptoms, patients may not view their urological dysfunction as 
severe (i.e. an accommodation of symptoms occurs), which can result in a lack of help 
seeking behaviour (Tapia et al., 2013; Balogh, 2015). Other reasons for avoiding HCP 
contact include; embarrassment around OAB, lack of faith in treatments and self-
management of symptoms (Diokno et al., 2006). A study in idiopathic OAB revealed only 
25% of patients visited their doctor for bladder problems (Tubaro, 2004). Ultimately, if 
patients are not forthcoming with their symptoms, they cannot receive a diagnosis and 
hence, appropriate treatment. 
8.2.2  Implications of Low Diagnosis Rates and How This Trend can be 
Improved  
For optimal patient management in NGB, closing the current diagnosis lacuna is essential. 
Deprived of a diagnosis, patients will face an up-hill battle in gaining access to services and 
appropriate medications. This increases the chances of unpredicted situations, secondary 
conditions and hospitalisations, which places an additional strain on the NHS, an institution 
that is already over-stretched and under-funded (Vize, 2011). The issue of health inequity 
also arises, as those most affected will be in areas of the UK experiencing severe 
underfunding and cuts in specialist nurses, the key facilitators of the NGB care pathway.  
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There is a gradual migration underway in UK clinical practice from the use of Read codes to 
the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT), with the aim of 
full replacement by April 2020 (Meek, 2015; Spencer, 2016). SNOMED CT can be cross-
mapped to other international standards and classifications, thus it has been described as 
the ‘most comprehensive and precise’ clinical terminology in the world (SNOMED, 2018: 
online). It is envisioned that implementation of SNOMED CT in UK clinical practice will 
improve the channel of communication between primary and secondary care (Spencer, 
2016). It will be of value to assess whether the diagnosis of NGB, and indeed other 
conditions perceived to be underdiagnosed improves after full implementation is 
complete. 
This analysis revealed that a lack of awareness amongst GPs could be a modulating factor 
in low rates of NGB diagnosis. Cognitive task and work analysis through in-depth interviews 
with GPs as well as other important HCPs such as neurologists would be useful in 
ascertaining the cognitive skill necessary for diagnosis. As cognitive error is closely linked 
to diagnosis error this method is likely to highlight the specific sources of diagnosis error 
and thus where interventions will have the most impact (Balogh, 2015).  
An intervention that has proved useful in other disease areas are national awareness 
campaigns to enhance the visibility of disease. In NGB specifically targeting non-urologist 
HCPs, patients and carers would be especially impactful. In particular, campaigns 
highlighting the fact that urological symptoms emanating from neurological conditions are 
very common would be instrumental in changing perceptions and attitudes amongst these 
stakeholders. Lessons can be learnt from the multiple successful campaigns carried out in 
the field of idiopathic OAB. One example is the campaign launched by the American 
Urological Association (AUA), entitled ‘It’s Time to Talk About OAB’, which aimed to 
alleviate the stigma surrounding talking to a physician about OAB symptoms, and equip 
patients with a better understanding of their condition. The campaign consisted of a 
website featuring patient education materials and a ‘Voices of OAB’ contest, where 
patients shared testimonials of the way the disease impacts their daily life (AUA, 2012). It 
  
 
 
 
288 
is also important to consider that NGB can often be non-specific in presentation, thus 
distinguishing it from idiopathic OAB can be challenging for GPs and in some cases for 
specialists. Campaigns targeted towards GPs and neurologists should focus on the distinct 
manifestations of these conditions and the different ways these two patient groups should 
be managed. Another possible solution to improve awareness is to involve neurologists and 
GPs in NGB CG development. This fosters an increased sense of ownership over the CGs 
and can encourage active participation of those working in clinical practice in the care and 
referral of NGB patients to urological specialist care services, ultimately increasing the 
chances of receiving an accurate diagnosis and subsequently receiving appropriate clinical 
care.  
The QoF has proved to be a successful intervention in improving the referral rates of 
patients with transient ischaemic attacks (Wright et al., 2006). This indicates that 
incentivised targets have a direct effect on behaviour in clinical practice. As an alternative 
to incentivising increased diagnosis within primary care, the NHS could offer financial 
incentives to GPs for referrals to a urologist. Health economic analysis into the cost-
effectiveness of encouraging referrals over management in primary care would be 
necessary to ensure the efficacy of introducing such a measure. Some evidence suggests 
that financial incentives alone are not enough to change deep rooted cultural and technical 
barriers, thus this type of intervention should be introduced alongside other measures 
(Foot, 2010). 
The applicability of the EAU and ICI CGs are low, and the real-life application rates of the 
NICE CGs for NGB in clinical practice are unknown, which could have implications for the 
application of diagnostic recommendations in clinical practice. Amongst the possible 
measures that could be introduced to enhance applicability and thus implementation and 
dissemination are Clinical Decision Support Systems (CDSS), which represent a 
sophisticated computational means by which CGs can be integrated into clinical practice 
(O’Sullivan et al., 2014). CDSS should be capitalised upon to assist GPs with any diagnostic 
uncertainty that exists around NGB. Some recent systematic reviews (SRs) have 
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demonstrated promising results; however, some conflicting reviews conclude there is a 
lack of data demonstrating benefit for patient outcomes (Hemens et al., 2011; Fillmore et 
al., 2013). Moreover, there are several challenges that have impeded successful 
implementation on a broad scale across healthcare systems, this includes the necessity of 
large volumes of high-quality data and the limitations of information technology (IT) 
infrastructure (O’Sullivan et al., 2014). Ultimately however, the use of IT and artificial 
intelligence alone is not sufficient, not only because there is uncertainty around the use of 
CDSS but because relationship-centred care such as the doctor-patient relationship as well 
as inter-professional relationships between HCPs remain the cornerstone of good-quality 
care (Goold and Lipkin, 1999; Aguirre-Duarte, 2015). Nurturing better doctor-patient 
relationships will allow patients feel comfortable sharing their symptoms with their doctor, 
and for doctors to attune to their patients’ requirements and expectations (Ha and 
Longnecker, 2010). Additionally, because at present much of patient management is 
confined to primary care, strengthening the channels of communication between doctors 
and specialists is fundamental in facilitating information exchange and creating learning 
opportunities for GPs so to enhance their ability to detect and diagnose NGB.  
8.2.3 Limitations 
This is by no means an exhaustive analysis of the potential reasons for low NGB diagnosis 
rates in the UK population, and additional research into the way NGB patients are managed 
in UK clinical care and the resultant patient outcomes is necessary to further contextualise 
the low diagnosis rates. For example, the possible clinical shortcomings in current 
diagnostic practices were not explored. Another limitation is that some of this discussion 
resides on the assumption that urologists are consistently able to differentiate and 
diagnose NGB adequately, however there is no objective evidence for this, and it is possible 
the capabilities amongst urologists will vary.  
Furthermore, the determinants of referrals should be deciphered through other means. 
The CPRD database could be used to conduct correlation studies against rates of diagnosis 
and factors such as socio-economics, sex, and comorbidity (Benjamin and Austin, 2003; 
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Zielinski et al., 2013). Simulated patients described by case vignettes could also be used to 
measure variation in clinicians' approaches to diagnosis and treatment (Peabody et al., 
2000; Bachmann et al., 2008). In this study, the insight of urologists was used to understand 
diagnosis error in NGB, an alternative and perhaps more apt method would have been to 
administer surveys or conduct interviews with GPs as a means by which to understand the 
way cognitive error can lead to diagnosis error (Balogh, 2015). 
8.2.4 Conclusions  
Diagnosis and referrals directly impact the patient experience and are important cost 
drivers in the healthcare system. Improving the diagnosis rates of NGB in the UK will allow 
appropriate provision of care and services to patients, as well as guiding apposite 
management choices. Measures such as improving the interoperability between primary 
and secondary care databases, educational campaigns, financial incentives, CDSS, and 
fostering better relationships between important stakeholders can help improve the 
diagnosis rates. Ultimately, this will enhance health outcomes and facilitate efficient 
resource allocation for NGB patients. Further research into the possible reasons of low 
diagnosis rates and exploration of the region-level differences that may exist is important 
to gain further insight into this phenomenon and encourage initiatives to reverse this trend.  
8.3 Demographics and duration between diagnosis of the Neurogenic 
Bladder Population in the UK 
Most patients included into this study were male (59.6%). As expected, in the heterogenous 
disease area of NGB, the age of individuals varied substantially. The mean age of the overall 
study population was 61.7 (SD=16.3) years. NGB is distinct from idiopathic OAB in that 
prevalence does not necessarily increase with age; it is instead related to the onset and 
progression of neurological symptoms (Ginsberg, 2013). Spina bifida is a congenital 
condition and an alternative selection method was used to identify these patients, 
therefore the cohort was younger than the other subgroups (mean=36.1 [SD=11.9]). The 
average age of onset of PD is 60, and similarly stroke patients also tend to be older (Ostwald 
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et al., 2006). Conversely, the average age of patients with conditions like MS and SCI is 
much lower (Lunde et al., 2017; McCaughey et al., 2016). Given this variability, one would 
perhaps expect the mean age of this study population to rest in the middle age, however it 
is somewhat higher than expected. The mean age of NGB patients identified in the SR 
(Chapter 5) was much younger at 42.8. 
In this study, the mean number of days between the diagnosis of any neurological condition 
and OAB or OAB drug prescription was 1140.1. This number was inflated by the spina bifida 
(SB) cohort (mean=4149.4), where the inclusion criteria allowed the diagnosis of SB to 
occur from any time within the start of follow-up within CPRD to the time of OAB diagnosis. 
The mean duration in the PD cohort was 1034 (days), which is much lower than another 
study which demonstrated the time between PD diagnosis and onset of urinary 
incontinence (UI) was 144 months (12 years) (although lower urinary tract dysfunction 
(LUTD) was cited as starting a lot earlier) (Rana et al., 2014). The mean duration in the MS 
cohort was recorded as 1095.9, which again is a lot shorter than estimates in the literature, 
which valuate the onset of urinary symptoms as 6-8 years after MS diagnosis (Aharony et 
al., 2017). The duration between diagnoses was shortest in the SCI cohort (mean=457.8). 
This is longer than would typically be expected in traumatic SCI where OAB symptoms tend 
to occur a few days to months after injury (Schurch, 2015). Limitations intrinsic to the 
collection of data for this variable are discussed in Section 8.8.2.  
8.3.1 Comorbidity and Polypharmacy in Neurogenic Bladder Patients 
A high level of comorbidity and polypharmacy was observed in this study, indicating there 
is great clinical complexity within NGB, making patient management more challenging and 
contributing towards a larger healthcare burden. Patients with high polypharmacy and 
comorbidity tend to exhibit poorer health outcomes leading to increased medical 
encounters, adverse events (AEs) and HRU (Tolentino, 2017). Specifically, in this patient 
group, comorbidity and polypharmacy has the ability to influence the underlying 
neurological condition and exacerbate urological symptoms (Stawicki et al., 2015). 
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Corresponding cost are also high, therefore, from a payer perspective, effectively managing 
comorbidity and reducing polypharmacy is essential.  
In the present study, the QoF count did not demonstrate an accurate depiction of 
comorbidity (Section 7.6.5). Conversely, the British National Formulary (BNF) headers 
proved a much more reliable proxy indicator, revealing a significant level of comorbidity in 
NGB patients (average of 8.6 comorbidities per individual). NGB patients can experience a 
wide range of comorbidities that may be directly related to their neurological condition (for 
example, depression) (Siegert and Abernethy, 2005; Marsh, 2013), due to urological 
dysfunction (for example, urinary tract infection (UTI)) (Poisson et al., 2010) or can exist 
completely independently of the primary and secondary conditions (for example, a chronic 
heart condition).  
Comorbidities were highest in the SB cohort (10.97). This result was unexpected as 
comorbidities tend to increase with age and SB was the youngest cohort (mean age=36.1) 
(Divo et al., 2014). In accordance with this logic, PD, as the oldest subgroup (mean 
age=70.7), should have had the highest rate of comorbidities, however the mean number 
of BNF headers over the 12-month period was lower than in SB (9.1). Nonetheless, given 
that the rate of comorbidities was close in range, this difference could be considered not 
significant. Furthermore, SB patients do still tend to experience a wide range of 
comorbidities including issues with digestion, vision, sex, mood, obesity and depression 
(Centre for Disease Control, 2017). MS patients had the lowest rate of comorbidities (6.5) 
in this study. The condition is related to a wide range of co-morbidities, the most common 
being depression, anxiety, hypertension, hyperlipidemia, and chronic lung disease (Marrie 
and Horwitz, 2010).  
Comorbidities have a negative impact throughout the spectrum of neurological disease, 
thus it is critical their management is optimised. Due to masking of symptoms, 
comorbidities have been found to cause a diagnostic delay between the onset of MS 
symptomology and diagnosis, potentially impeding the timely provision of essential 
services and resources (Marrie and Horwitz, 2010). They also have the ability to alter the 
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phenotype and disease progression in PD, affect health-related quality of life (HRQoL) in SB 
(Bakanienė and Prasauskienė, 2018) and increase chances of hospitalisation in PD and 
stroke patients (Martignoni et al., 2004; Johansen et al., 2006). 
Polypharmacy in the overall NGB population was also considerable. Patients were receiving 
on average 5.6 medications concomitantly. The extent of polypharmacy may in part be due 
to the complexity of the underlying neurological disease, which necessitates various 
medications for symptom control. For example, in PD, a combination of three or more 
medications are required to control motor symptoms alone, supplementary to other 
medications for numerous other secondary symptoms such as mood disorders and 
psychosis (McLean et al., 2017).  
When used efficiently, medicines are a cost-effective solution to managing patients. 
Inappropriate and excessive prescriptions of drugs however lead to unpredicted drug-
disease and drug-drug interactions. For example, patients with progressive neurological 
conditions such as PD and MS may experience worsening of pre-existing delirium and 
baseline cognitive impairment (Kuzuhara, 2001; Thelen et al., 2014). Polypharmacy can also 
negatively impact the rehabilitation of stroke patients, causing poorer functional outcomes 
and increased medical complications (Kose et al., 2016). Moreover, polypharmacy has the 
ability to impact urinary function. One common example is the use of corticosteroids, which 
are utilised to increase the speed of recovery from a relapse in MS (Myhr and Mellgren, 
2009). These drugs can cause electrolyte imbalances, fluid retention and nocturnal or 
postural draining. Furthermore, their immunosuppressive effects increase the likelihood of 
UTI (Denys et al., 2006). In turn, when UTI is not managed adequately, the progression of 
MS also deteriorates (Mahadeva et al., 2014). 
At present, the care provided to neurological patients is typically centred in neurological 
disease specific clinics, guided by CGs that are purely focused on a single disease. This care 
model can lead to a dangerous cascade of events because using multiple CGs for each single 
disease a patient is diagnosed with can become a driver of polypharmacy (Austad et al., 
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2016). Drug-drug interactions arising as a result of polypharmacy then further contribute 
to comorbid conditions and the number of drugs prescribed (Marengoni and Onder, 2015). 
Key therapeutic topics by NICE are designed to ‘summarise the evidence-base on topics 
identified to support medicines’ (NICE, 2018a: online). Stand-alone key therapeutic topic 
about multimorbidity and polypharmacy are currently available for use in clinical practice 
(NICE, 2017). Although these documents are useful, inclusion of the most important and 
likely drug-drug interactions and comorbidities within the NGB-specific CGs are arguably 
more beneficial to avoid harm to this particular patient population. For example, focusing 
on issues such as the common but potentially harmful co-administration of cholinesterase 
inhibitors and anticholinergic drugs, and the significance and likelihood of anticholinergic 
burden in PD patients (because patients main form of medication to manage both PD and 
urological symptoms are anticholinergics). NICE recognise the current situation of only 
considering one disease in isolation is not effective and are looking into ways their guidance 
can be updated to better reflect patient complexity (Duerden, 2013).  
Further than this, the current care pathway of patients with neurological conditions is 
fragmented, with evident communication deficiency between care providers (Section 
8.2.1.2). Increased collaboration between HCPs is vital to in order to streamline 
management and decrease the risk of duplication of care. The changes to CGs described 
above in concurrence with improved communication should enhance recognition of 
potential issues in patient management and encourage clinicians to conduct 
comprehensive assessments of comorbidities and structured medication reviews at 
relevant intervals so that comorbidity and polypharmacy can be sufficiently managed 
(Blenkinsopp et al., 2012). 
8.4 Complications Related to Neurogenic Bladder   
UTI was one of the most frequent complications in the present study, with 14% of 
individuals experiencing at least one episode. Indwelling catheterisation (IndUC) is a 
particular risk factor for UTI but is often necessary in NGB patients because they are more 
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likely to have limited manual dexterity (Manack et al., 2011). Section 2.4 and 2.8.4.1 
explicate the clinical and economic burden of UTI in some detail.  
Although 14% of patients had a Read coded diagnosis of UTI, 53.9% of the study population 
were prescribed UTI-specific antibiotics, indicating that the actual prevalence may have 
been considerably higher. Another similar study using a US claims database reported 33% 
of NGB patients with UTI (Manack et al., 2011). A much higher percentage was reported in 
a study of NGB patients presenting to the emergency department (ED) (87.6%) (Sood et al., 
2017). Given that these patients presented in the ED, the higher instance of UTI could be 
due to the likely severer nature of their disease.  
The average number of antibiotic prescriptions over the 12-month follow-up period was 
similar between the neurological disease subgroups and ranged between two and three 
prescriptions over 12 months. In a self-administered survey conducted in five countries 
(Germany, Switzerland, Poland, Russia and Italy), women with history of UTI reported a 
similar number of mean prescriptions, ranging from 2.17 (Poland) to 3.36 (Germany) per 
person, per year (Wagenlehner et al., 2018). Antibiotic overuse can lead to resistance 
amongst bacteria, which has devastating consequences for wider societal health and the 
economy (Section 2.4 and 2.8.4.1) (Fatima and Mussaed, 2018). The NHS currently 
prioritises a policy of infection prevention and control in order to minimise this risk. This 
includes measures such as aseptic technique and limiting the use of IndUC whilst 
encouraging IC use (Mantle, 2015). The widespread use of antibiotics in this study could 
indicate that reviewing the application of these policies may be necessary, and that further 
interventions and additional resources may be necessary to control UTI rates in NGB and 
subsequently lessen the threat of antimicrobial resistance (AMR). This includes education, 
antimicrobial stewardship, and extra due diligence in monitoring patients practicing 
catheterisation (Cheung et al., 2017; Bartoletti et al., 2016). Furthermore, NGB HCPs 
adherence to UTI good practice guidelines may also be an important area of further 
research. 
Fourteen percent of patients were diagnosed with incontinence; however, this cannot be 
used as a proxy to neurogenic detrusor overactivity (NDO). It is likely that a larger 
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proportion of the population suffered from incontinence but as it is not a commonly coded 
term, the true prevalence cannot be determined. Incontinence has a negative impact on 
both patient health, QoL and economic outcomes (Section 2.7 and Section 2.8.4.1).  
A similar spectrum of complications that were sought in this study were also documented 
in a large US claims database study of patients with NGB, albeit at much higher frequencies 
(Manack et al., 2011). For example, urinary retention and sepsis/septicaemia were 
reported in 14% and 4% of patients in the US study respectively, compared with 2% and 1% 
in this study. As key design features, including duration of follow-up, were similar between 
studies, the reason for the marked disparity between reporting rates is unknown, although 
could be linked to the differences in healthcare systems (USA vs UK). In particular the low 
rates of urinary retention in our study are surprising given this is a common complication 
in NGB (Sayed, 2008). 
8.5 Drug utilisation in Neurogenic Bladder  
8.5.1 Anticholinergic Burden Score and the Use of Bladder Muscarinics in 
Neurogenic Bladder   
The detrimental impact of high anticholinergic burden, in particular the potential harm it 
can cause in patients with neurological conditions was discussed in Section 2.5. The average 
Anticholinergic Cognitive Burden (ACB) score in this study was exceptionally high (6.5). 
Most strikingly, the score was high for the progressive neurological conditions MS (6) and 
PD (6.8). Considering that a score of 3 or more can cause delirium (Table 6.12), these scores 
are concerning. Moreover, the ACB score in the post-index period (36.7) was much higher 
than in the pre-index period (15.7), indicating that the addition of a bladder muscarinic 
significantly increases exposure. However, as cumulative score was not taken into account, 
these results should be interpreted with caution (Section 8.8.4). This study also releveled 
that one in five patients were prescribed oxybutynin, which is considered one of the more 
toxic bladder muscarinics (Section 2.5.2). Undoubtedly, the ACB score is not only increased 
by use of bladder muscarinics, for example, anti-Parkinson’s drugs are a common arbiter of 
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anticholinergic burden elevation in patients with PD (Richardson et al., 2018). These 
findings suggest that NGB patients are at particular risk for experiencing adverse effects 
related to anticholinergic medications.  
The efficacy of bladder muscarinics has often proved comparable, however little work has 
been done to differentiate them on the basis of important variances in their potency 
(Section 2.5) (Buser et al., 2012). The current NGB CGs do not recommend one bladder 
muscarinic over the other. Furthermore, the most commonly used tools to measure 
anticholinergic burden, the ACB scale and the Beer’s criteria, regard all bladder muscarinics 
as equally potent (American Geriatrics Society, 2015). Newer scales such as the 
anticholinergic effect on cognition (AEC) scale help to better discern these differences, 
however it is yet to be validated and has not been extensively applied in research or clinical 
practice (Section 6.4.12.2.7).  
Due to the perceived similarity of bladder muscarinics, many Health Technology 
Assessment (HTA)/reimbursement agencies in Europe still recommend the use of generic 
drugs as first line treatment choice. This decision is normally based on drug acquisition cost 
alone, as generic medicines can help conserve resources whilst typically avoiding 
compromising standards of care (SOC) (Godman, 2012). Therefore, as oxybutynin is one of 
the oldest and cheapest bladder muscarinics, it tends to be the most frequently prescribed. 
It is also one of the only bladder muscarinics (along with trospium) that has a licensed 
indication for NGB, and typically, other medicines are not supplied where licensed 
alternatives exist (Dodds-Smith, 2017). However, in this study, tolterodine and solifenacin 
were frequently prescribed, despite having no licensed indication. Additionally, the 
prescription of trospium in the study was scarce, despite having a licensed indication and 
potentially causing less central nervous system (CNS) side effects than other bladder 
muscarinics (Chughtai et al., 2008) (Section 2.5.2). This indicates that physicians tend to act 
on their personal preferences and are more likely to adhere to established norms when 
prescribing bladder muscarinics.  
  
 
 
 
298 
It is important to eradicate the common school of thought that all bladder muscarinics are 
identical, and effort should be made to differentiate bladder muscarinics by taking into 
consideration their varying pharmacokinetic characteristics and potential harm to patients 
(Cornu, 2012). Specifically, due to the growing concern related to anticholinergic burden in 
those with neurological conditions and the associated risk of mild cognitive impairment 
(MCI) and dementia, payers and clinicians alike should be cognisant that there are 
alternative options available for this vulnerable population. The economic burden of 
dementia has been well characterised, and current figures indicate the total cost to the UK 
economy is around £26.3 billion a year. The condition is also related to a higher rate of 
hospitalisations (Phelan et al., 2012) and visits to the GP (Ydstebø et al., 2015). Thus, from 
a payer perspective avoiding anticholinergic burden in NGB patients, not only improves 
outcomes but also saves on the downstream costs of managing MCI and dementia. A study 
conducted in New Zealand demonstrated a reduction in the ACB score of a group of 691 
at-risk individuals by implementing a form of medication review (He and Ball, 2013). Careful 
review of all prescribed medications conducted at regular intervals is an essential practice 
to ensure rates of polypharmacy and anticholinergic burden are minimised, and thus 
should be encouraged in the NGB CGs. 
The β3-adrenoceptor agonist, mirabegron is able to bypass the cognitive effects of bladder 
muscarinics. It is currently second line treatment for OAB, however unlike most of the NGB 
treatment pathway that mirrors the one for OAB, mirabegron is not a licensed or 
recommended treatment option for NGB patients. Scarce data has been published on its 
use in this population (Cameron, 2016), and consequently the drug is not recommended by 
any of the prominent NGB CGs (Chapter 4). This could constitute a reason for the low 
numbers of mirabegron prescriptions in this study (1.2%). The low p rescr ip t ion s  for 
mirabegron will also likely reflect that the drug was introduced in the UK towards the end 
of the study selection period. 
Comparative effectiveness research (CER) is essential to identify to achieve optimal clinical 
utility as well as relative value in an economic sense (Chang and Winkelmayer, 2012). The 
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process involves comparing two or more interventions in an environment that is 
representative of the real world, essentially, carefully balancing of the side effect profile 
with proven efficacy and cost. Sophisticated measures of economic analyses assist payers 
in making their reimbursement decisions as well as inform the recommendations made in 
CGs (Chapter 2). A recent cost-effectiveness analysis (CEA) conducted in OAB patients 
deemed mirabegron 50mg to be cost-effective when compared to the most widely used 
bladder muscarinics in the UK. The base-case incremental cost-effectiveness ratios 
(difference in cost between two possible interventions, divided by the difference in their 
effect) ranged from £367 (vs. solifenacin 10 mg) to £15,593 (vs. oxybutynin IR 10 mg) per 
Quality-Adjusted-Life-Year (QALY) gained (Nazir et al., 2015). This study clearly 
demonstrates the cost-effectiveness of mirabegron, however given the complexity of NGB 
in comparison to OAB; it would be unwise for payers to apply economic data across these 
diseases, thus specific CER in NGB is necessary to quantify the value of healthcare 
interventions in NGB, and subsequently improve uptake of important alternatives. 
8.5.2 Combination Use of Overactive Bladder Drugs  
A combination of bladder muscarinic drugs is recommended in the current EAU CGs. The 
EAU and ICI CGs also suggest that combination therapy between mirabegron and a bladder 
muscarinic could be a viable management strategy in the future, provided further research 
into the efficacy and safety is conducted (Section 4.6.2). Research in the idiopathic OAB 
population suggests this is an efficacious practice, and can provide comparable efficacy to 
bladder muscarinics alone, whilst reducing intolerable AEs (Abrams et al., 2015). 
This study observed a low instance of combination use (8%), suggesting that this practice 
is not well established in clinical practice. Manack et al (2011) reported a very similar level 
of combination use (8.7%) amongst NGB patients. Some patients in this study and the study 
by Manack et (2011) reported more than two bladder muscarinics being prescribed, 
demonstrating deviation from the NGB CGs. Furthermore, the most common combinations 
were included solifenacin, tolterodine, and oxybutynin, whereas the ICI CGs state that 
research only exists for oxybutynin, tolterodine and trospium. Section 7.6.6 describes the 
  
 
 
 
300 
possible limitations surrounding the lack of sensitivity analyses; a higher rate of 
combination use may have been observed if an alternative definition was employed.   
8.5.3 Use of α-Adrenergic Antagonists and 5-Alpha Reductase Inhibitors 
Approximately one-quarter of patients had prescriptions for α‐adrenergic antagonists or 5‐
alpha reductase inhibitors (5‐ARIs), which are traditionally utilised for benign prostatic 
hyperplasia (BPH) in males (Vaughan, 2003; Lepor, 2007). A small number of these 
prescriptions were for women (n=47, 0.32%), α-adrenergic antagonists and 5‐ARIs could 
also be used to treat voiding dysfunction unrelated to BPH, which makes them a plausible 
choice for women with specific types of voiding dysfunction (Nitti, 2005).  
α‐adrenergic antagonists for bladder outlet resistance in NGB are recommended by the ICI 
and EAU but not by NICE (Section 4.6.2). Presumably because despite multiple accounts on 
the use of α-adrenergic antagonists in the management of NGB, evidence primarily comes 
from small, uncontrolled trials (Nitti, 2005; McCrery and Appell, 2006). The SR described in 
Chapter 5 found that α‐adrenergic antagonists were administered to SCI patients with 
marked bladder outlet obstruction (BOO), as well as being the most prevalent drugs 
amongst SCI patients with NDO in another study. Expert opinion suggests that α-adrenergic 
antagonists are probably rarely used in NGB, where BPH is not a concomitant presence, and 
are only administered as a last‐report option (Drake and de Ridder, 2017). 
8.5.4 Cumulative Number of Days Supply of Overactive Bladder Drugs 
The average cumulative number of days’ supply of OAB drugs (including mirabegron) was 
202.86 days. This is exactly the same number of days that Mannack et al (2011) derived 
from their research in a US population (although their calculation included bladder 
muscarinics only) (Manack et al., 2011). The rates of discontinuation were not sought in 
this study, but previous research suggests that less than one third of patients remain 
continuous on their medication (Manack et al., 2011). If patients properly adhered to their 
medications, the median time for therapeutic response in idiopathic OAB is around three 
months but may be longer in NGB given the severity of the condition (Hsiao et al., 2015).  
  
 
 
 
301 
8.6 Healthcare Resource Utilisation in Neurogenic Bladder and Associated 
Costs  
The healthcare burden of NGB was significant in many aspects. The most noteworthy 
observation was the high number of GP visits, where patients visited or made contact with 
their GP an average of 68 times over a 12-month period. Patients with stroke or SCI visited 
their GP more often (76.3 and 75.5, respectively) than other cohorts (range, 49.9 to 69.7). 
The high frequency of visits was likely due to the inclusion of all-cause visits and because 
multiple visits to the GP in a day were recorded. A similar number of primary care visits was 
reported in a UK study of patients with idiopathic OAB (70.3 visits over 12 months) 
(Odeyemi, 2006). Mannack and colleagues in the US observed a much lower frequency of 
visits in patients with NGB (16.1 visits over 12 months) (Manack et al., 2011). This 
discrepancy could be due to differing definitions of what accounted for a ‘visit’ and the 
different economic structures of the UK and US healthcare systems. Furthermore, whether 
visits were all-cause or NGB related was not delineated in the study by Manack et al (2011), 
and multiple visits on same day were counted only once. The estimated overall mean cost 
of GP consultations was £1,448 (median=£1243.6) per individual, proving much costlier 
than idiopathic OAB. One large-scale study determined GP visits in idiopathic OAB to cost 
€281 (£245.27) per patient, per year in the UK (Irwin et al., 2009).  
Although all patients included into this study were referred to a urologist or gynaecologist 
(inclusion criteria), around half of the cohort were recorded making at least one visit to a 
specialist over the 12-month follow up period. This could mean that despite being referred, 
patients did not end up visiting a specialist. Two of the most common reasons cited for 
patients (with various diseases) not following up with specialist appointments include a lack 
of time or resolution of symptoms (Forrest et al., 2007). Another possible rationalisation 
for this phenomenon could be issues with coding, that fail to adequately represent the 
number of patients visiting their specialist after referral (Forrest et al., 2007). 
Notwithstanding these potential issues, the frequency of specialist visits could still be 
considered high, which is to be expected, as the symptoms of NGB are often too severe to 
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be solely managed in primary care. Mannack et al (2011) showed a similar trend, albeit at 
a slightly lower frequency, with 39% of patients with NGB visiting a urologist within one 
year.  
Patients in the present study made a mean number of 2.3 visits per year to the specialist. 
This represented a notable cost component, with a mean cost of £253 (median=£218.8) 
per individual. In a self-reported survey of OAB patients, individuals reported 0.4 to 1.1 
visits to the urologist and 0.1 to 0.9 visits to the urogynaecologists/gynaecologists 
(incumbent upon incontinence severity level), over a six-month period (Jimenez-Cidre et 
al., 2014). This indicates that severer cases of idiopathic OAB have a similar rate of specialist 
visits as NGB patients observed in this study. Most visits in this study (90.8%) were to a 
urologist rather than a gynaecologist, this is important to highlight, because visits to the 
gynaecologist may not necessarily be because of NGB and could instead be related to other 
issues in women’s sexual and reproductive health (Shaw and Faúndes, 2006).  
Only 14 patients (0.4%) in the study cohort were prescribed incontinence pads with a low 
mean annual cost of £40.56 (median=£14) per individual. This is at odds with the reporting 
rate for UI (14%) in this study. A study using 2010 UK costs determined the yearly cost of 
incontinence pads in OAB patients to be slightly higher at $72.97 (£56.23) (Irwin et al., 
2009). Incontinence pads typically represent an ongoing out-of-pocket expense for patients 
in the UK, thus would not typically appear on electronic healthcare records (EHRs), 
providing a possible explanation for the low instance of use in this study. To determine 
eligibility for prescription pads in the UK, the local NHS organisations assess the severity of 
incontinence by asking patients keeping a bladder diary for three days, a process that can 
be time-consuming and difficult for those with disabilities. This could ultimately impede 
access to pads, thus introducing inequalities (NHS, 2015a). If a private care database was 
used for this research, a higher frequency of pad use would have probably been observed. 
Interestingly, in an economic model, focusing on five of European countries, 63% of the 
annual per patient cost of idiopathic OAB management constituted of incontinence pads 
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(Reeves et al., 2006). This is explained by the fact that Italy and Sweden were included in 
this analysis, where incontinence pads are reimbursable. 
Overall, 2.5% of the study cohort had more than one urodynamic test (£179, 
median=£126), 8.8% underwent cystoscopy (£171, median=£146), and 2.1% had urology-
related imaging (£101, median=£144). There are two possible rationalisations for the low 
instance of urodynamic testing. Firstly, NICE do not recommend urodynamic investigations 
in patients with a low risk of renal complications, who are being adequately managed with 
conservative techniques (NICE, 2012). Therefore, if these CGs are being applied in clinical 
practice, it is unlikely that many patients included into this study underwent urodynamic 
testing. The most common time urodynamic testing is carried out is to determine optimal 
management or before surgery in stress urinary incontinence (SUI) (Agro et al., 2017). The 
rate of urodynamics was higher (6.1%) in a study amongst idiopathic UI patients in the UK 
and Ireland. Imaging was also carried out at a higher rate (4.9%), however, cystoscopy was 
carried out at a much lower rate (1.8%) than the present study (Papanicolaou et al., 2005).  
The two main cost drivers of this study were surgical interventions or procedures and 
hospitalisations. Surgical procedures are most commonly considered a last‐resort option if 
conservative measures fail. At least one procedure or surgical intervention was performed 
in 5.7% of the study cohort at a mean cost of £2,285 (median=£1123) per individual. 
Hospitalisations cost £6,256 (median=£2590) per individual and overall, 11.0% of the 
study cohort were hospitalised (urology related) at least once, for an average duration of 
12.5 days during the 12‐month follow‐up period. Furthermore, 17.4% (75 of 431) of 
hospitalised patients were admitted following renal failure. The average length of stay was 
higher than the overall average inpatient stay in the UK, which is 7 days (NHSConfederation, 
2017). Hospital admissions were more common in the definitive NGB and SCI cohorts 
(20.1% and 19.5%, respectively) compared to other cohorts (range=6.7 to 12.0%) but were 
similar between age and sex subgroups.  NGB patients have previously shown to have a 
higher than average stay at hospital in comparison to other urological patients, 
consequently putting them at increased risk for contracting nosocomial UTI’s, and thus 
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increased associated costs (Sauerwein, 2002). A long length of stay (LOS) has also been 
implicated in an increased risk of falls and fractures, episodes of delirium and loss of muscle 
strength (NHS Improvement, 2018). It is however important to consider that short inpatient 
stay does not necessarily equate to better outcomes, for example if adequate rehabilitative 
provisions are not in place, shortened inpatient stays could precipitate further functional 
decline (Vliet et al., 2017).  
The mean total overall costs for NGB patients was £2395.03 (median=£1458.2). The highest 
cost was in the NGB cohort £3378.92 (median=£1308). A systematic review found that 
costs of idiopathic OAB across five Western countries was €269 to €706 per patient per 
year, proving much lower than NGB (Reeves et al., 2006). The considerably high rates of 
polypharmacy, comorbidity, anticholinergic burden and complications are all factors 
related to the growth of HRU. From an economic perspective, targeting these aspects 
through interventions such as medication review, modifications to the NGB CGs, improved 
cross-communication between HCPs as well as between doctors and patients, is essential 
to lower the burden. Furthermore, investing more resources to improve the currently sub-
optimal diagnosis and referral rates in NGB could also help to reduce the overall costs.  
8.7 Strengths of the Study  
8.7.1 Patient Selection Process  
As is common in database analyses, it was necessary to employ a proxy measure 
(neurological condition diagnosis + OAB diagnosis/OAB drug prescription) to identify 
probable NGB patients. Although there is no certainty that these patients definitely have 
NGB, this method of selection was validated by experts and deemed to be the most specific 
way to identify additional subjects. A similar approach to patient inclusion was taken by an 
epidemiological study in the USA (Manack et al., 2011). The use of this proxy measure 
increased the sample size. 
Furthermore, the sensitivity analyses, which involved including patients with any order of 
diagnoses (OAB diagnosis/drug prescription could come before diagnosis of neurological 
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condition) proved an excellent way to confirm the selection process, affirming the notion 
that altering the selection process in this way had no significant impact on results, as 
patient demographics, drug utilisation patterns were very similar between the base case 
and sensitivity analysis. 
8.7.2 Use of Sub-Cohorts 
Another strength of this study was the separation of results by individual neurological 
condition. Considering all neurological conditions that cause NGB as singular, and 
transferring evidence from one condition to another is often inappropriate because they 
are incredibly heterogenous in nature. By incorporating sub-cohorts into the study design, 
it was possible to understand important factors such as the differences in general patient 
characteristics, determining which conditions had the highest ACB score and which cost the 
most to the healthcare system. The results were also split by age and sex. When considering 
sex, the NICE CGs make some sex-specific recommendations, reinforcing that it is an 
important factor to consider when making management decisions. Age is also an important 
influencing factor, for example in this study, older patients had a higher frequency of 
outpatient physician visits, which could warrant further inquiry and interventions in this 
specific population. 
8.7.3 Use of Electronic Healthcare Records 
EHRs present an unprecedented opportunity to detect and analyse real world clinical 
manifestations and subsequently inform health practice. However, far too often, non-
interoperable databases severely limit potential insight that could be derived (De Moor et 
al., 2015). Fortunately, in this study, there existed an opportunity to link a subset of NGB 
patients that were included from the CPRD database to the Hospital Episode Statistics (HES) 
data. Valuable insight of a much larger portion of the patient journey was derived with the 
collection of several different outcomes related to HRU that would not have been possible 
without database linkage. 
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Using EHRs to determine treatment patterns is also useful in circumventing the issue of 
recall bias. Recall bias is a classic form of information bias, referring to systematic error as 
a result of inaccuracies or incompleteness of recollections by study participants of past 
events. Although recall bias typically focuses on differences between subjects in one group 
compared to the other, the inaccurate reporting of past events can also impact descriptive 
studies (Althubaiti, 2016). With EHRs, the exact time a patient was prescribed their 
medications can be specified without having to rely on the patients’ memory as an aid, thus 
improving the internal validity of the study (Casey et al., 2016).  
Another important strength of this study, through virtue of the longitudinal nature of the 
data, was the ability to measure time dependent measures, in particular the cumulative 
dose of OAB drug.  
8.8 Limitations/Biases of the Study  
Bias relates to the systematic error that is introduced in the collection or analysis of data 
and is an important consideration when weighing the accuracy of results (Malone et al., 
2014). Several intrinsic biases and limitations with the study design were identified, which 
are discussed in further detail below. The general limitations associated with HRU studies 
were discussed in Section 2.8.2. 
8.8.1 Limitations in Patient Selection Process 
As mentioned previously in this chapter, the 967 Read coded NGB patients that were 
identified from the CPRD database in a preliminary count do not provide a representative 
picture of NGB patients in the UK (Section 8.1). A proxy measure was employed to identify 
further NGB patients, which is both a strength and limitation of this study, as whilst it was 
deemed a reliable method by experts, there remains uncertainty regarding the NGB status 
of these individuals, due to the lack of definitive diagnosis. Suboptimal diagnoses/coding 
of conditions in UK clinical practice may extend further than NGB, evidenced by the 
discrepancy between the numbers of patients with a UTI diagnosis versus those with a 
prescription of antibiotics.  
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Another limitation pertaining to cohort definition was around the Read codes used to 
identify SCI and SB patients, which could have been improved. In order to capture the 
largest pool of SCI patients, additional search terms should have been employed to identify 
relevant Read codes. This includes search terms: triplegia, tetraplegia and paraplegia, 
which represent distinct injuries in SCI. Similarly, when searching for patients with SB, codes 
for meningocele and myelomeningocele should have been included. In SCI, the projected 
number of patients from the sample size calculation was 384, signifying that the 41 patients 
included into this study was not enough to reach reliable conclusions. These improvements 
were identified after execution of the study and since then, access to the analysis platform 
was lost thus these rectifications to patient cohort definition could not be implemented.  
8.8.2 Limitations in Calculating Time Between Diagnosis of Neurological 
Condition and Overactive Bladder  
When considering the probable NGB cohort, only patients diagnosed with both a 
neurological condition and OAB/OAB drug prescription within the 12-year study period 
were included. It is well established that urological symptoms tend to worsen with 
increasing severity of the underlying disease (Jost, 2013). Slow neurological disease 
progression would result in the time between diagnosis of neurological condition and 
occurrence of OAB symptoms for many NGB patients to be longer than the 12-year period 
employed in this study, thus excluding a large number of potential subjects. Furthermore, 
the neurological diagnosis date that was used to calculate this duration is the most recent 
diagnosis before the OAB diagnosis/prescription. Patients could have been diagnosed prior 
to this date, and if the first date was utilised, longer durations would be observed.  
It is also important to consider that the way diagnoses are recorded in CPRD biases this 
variable. Patients can be transferred in and out of CPRD practices which means they may 
have been diagnosed with a neurological condition in secondary care (not captured in the 
data of this study) therefore underestimating the duration.  
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8.8.3 Limitations of Prescription Data  
 Accurate drug taking behaviour is difficult to ascertain, and EHR data such as the CPRD 
database does not provide information around whether the prescribed medications were 
actually picked up by the patient and adhered to. Conversely, claims data shows every 
fill/refill of a prescription, contains information about the actual drug that was dispensed, 
the amount that was dispensed, and the number of days the prescription lasted for (Wilson, 
2012). This type of data is available in countries that have insurance-based healthcare 
systems, and thus could not have been utilised for characterising the UK NGB population 
(van Heuckelum et al., 2017).  
Patients may opt for complementary and alternative medicine (CAM) to manage their 
underlying neurological condition or their urological dysfunction if they (or in some cases 
their doctor) feel conventional therapies are not sufficient enough to control symptoms 
(Haughn, 2010). Over-the-counter (OTC) medications such as CAM are not included in the 
CPRD database; therefore, polypharmacy was likely underestimated in this study.   
8.8.4 Limitations of Anticholinergic Cognitive Burden Scale  
The ACB scale takes into account the age-related pathophysiological changes that occur in 
the brain to determine the impact of prescribing anticholinergic medications to elderly 
patients (Campbell et al., 2016). The scale has not been designed with the purpose of 
application to younger individuals, potentially threatens the reliability of the ACB score 
results in the present study, which included patients under the age of 65. Moreover, the 
structural brain changes that accompany neurological disease are often different to that 
which occur in the aged brain. Changes also differ across the various neurological 
conditions as a result of the distinct severity and progression rates (Hindle, 2010). The ACB 
scale is not designed to take into account these specificities of neurological conditions, thus 
the reliability of use in this patient population is questionable.  
Bladder muscarinics vary in their ability to interact with the M1 and M2 receptors in the 
brain, owing to differing pharmacological properties such as degree of lipophilicity and 
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molecular size, which modulate the ability to move across the blood-brain-barrier (BBB) 
(Section 2.5). Although the developers of the ACB scale claim that these properties are 
taken into account, it is clear that this is not the case, instead all bladder muscarinics are 
categorised as highly potent (ACB score 3). This constitutes a major limitation of this scale. 
A positive modification to the study design would be to employ a sensitivity analysis, 
utilising an alternative scale to calculate the anticholinergic burden and determine whether 
this would have any impact on the results. The AEC scale was developed by two reviewers 
who identified the main drug classes and medicines commonly used amongst older people 
in the UK. Electronic searches were performed to determine which drugs were associated 
with cognitive functioning, and which had known anticholinergic activity. For those drugs 
with reported anticholinergic activity, the reviewers independently assigned scores of 0, 1, 
2, or 3 based on the bladder muscarinic potency, specificity to receptor subtypes, BBB 
penetration ability, and reports of associated cognitive impairment. Any discrepancy was 
mediated by a third reviewer. A total of 60 drugs were found to have some anticholinergic 
activity. The AEC scale is superior to many other scales as it takes into account the differing 
pharmacological properties of anticholinergics. In contrast to the ACB scale, it 
differentiates between the bladder muscarinics; for example, oxybutynin is scored a ‘3’ and 
darifenacin is scored a ‘1’, accurately reflecting their differing abilities to cause cognitive 
impairment (Bishara et al., 2017).  
Increased duration of use and higher doses can result in a greater anticholinergic burden 
and augment risk of cognitive impairment. The calculation of anticholinergic burden in this 
study does not take these factors into account, thus the burden may have been over or 
underestimated. Measures such as the total standardised daily dose (TSDD), which 
standardises conversion of doses of different anticholinergic medications into a single 
exposure measure (Gray et al., 2015), or the mean total daily ACB score, which creates a 
weighted average ACB score for each patient, could have been employed to strengthen the 
calculation. 
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Common OTC drugs such as cough and allergy medications possess anticholinergic 
properties; however, this data is not collected in the CPRD database, and therefore was not 
included in the ACB score (Gray et al., 2015). Subsequently, there is a good chance that the 
ACB score calculated in this study for NGB patients is an underestimation.  
8.8.5 Limitations in using the Quality Outcomes Framework for Measuring 
Comorbidity 
Using the QoF to measure comorbidity offers benefits in data completeness because data 
recording is linked to GP rewards. Despite this, the QoF score did not prove to be a reliable 
indicator of comorbidity in this study, as patients across all subgroups were deemed to 
have 0-1 comorbidities, which does not seem likely given the numerous comorbidities 
mentioned in the literature that are associated with neurological conditions.  
Frequent comorbidities such as renal disease and psychological disturbances are not 
included in the QoF hence the true prevalence of comorbidity remains uncharacterised 
(Salisbury et al., 2011). In addition to this, the one-year follow up employed in this study 
may have not been long enough to pick up many of the long-term conditions listed in the 
QoF.  
8.8.6 Limitation in Sensitivity Analyses of Combination Use  
Combination use was defined as two or more overlapping prescriptions for an OAB drug 
within a 30-day period. There is no agreement on what constitutes combination use, thus 
there are a number of definitions that could have been employed. Sensitivity analyses by 
using alternative definitions of combination use would have been useful to understand 
whether rates changed according to definition. 
Some possible sensitivity analyses that could have been employed include: 
 Those prescribed a second OAB drug within the intended prescription interval of 
the first 
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 Where the second OAB drug is prescribed within 1.5x the intended prescription 
interval of the first drug 
 Where both OAB drugs were prescribed on the same day 
 Where the second OAB drug is prescribed within six months of the intended 
prescription interval of the first 
 Both drugs continue to be prescribed for >90 days from combination index date, to 
distinguish between combination patients and switchers. 
8.8.7 Limitations in Filling Data Gaps 
Although progress has indubitably been made towards collecting and reporting many 
previously undescribed variables relating to the NGB population, data gaps remain. For 
example, further detail on drug taking behaviour such as sequencing and switching, 
measurements on the usage of cholinesterase inhibitors and a deeper delve into antibiotic 
use and associated outcomes all could have enriched the results. In addition, resource use 
and cost data could have been enhanced by taking a wider societal perspective, i.e. 
understanding the costs borne by the patient, their carer or society. Reporting this data 
would have offered a more complete picture of the NGB population and provide further 
direction for hypothesis driven research.  
Of course, it is impossible to include all potential variables of interest; however, given these 
limitations and considering the broad number of variables that could have been collected 
and described, the results from this study should be considered as only part of the picture 
on drug utilisation behaviour, and the minimum likely financial costs to the UK healthcare 
system of the NGB population.  
8.9 Generalisability  
It is important that study results are generalisable because they are often used to justify 
practices and draw conclusions for all patients in wider society (Kukull and Ganguli, 2012). 
This study used data from the CPRD database, which is the largest EHR in the UK, therefore 
patients included into the database are considered representative of the population at 
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large (Section 6.2.1.1.1). Given that the selection process is well-designed (albeit with some 
unavoidable limitations), the sample cohort can be considered representative of the UK 
NGB population, however it is important to consider that employing too many criteria can 
threaten the external validity. In this study, patients with missing data for age and sex, 
those with inadequate follow up, without a referral to a urologist and those with a diagnosis 
of dementia were excluded. This may have introduced selection bias, which shrinks the 
study population and limits the generalisability of results to the wider NGB population. 
The treatment patterns observed this study would most likely not be generalisable to other 
countries. The NHS is the sole administrator of healthcare policies and provider of medical 
care in the UK. Accordingly, drug choices are overwhelmingly influenced by NICE, who 
stipulate which drugs must be made available to patients through compulsory placement 
of positively recommended drugs on the formulary (Hill, 2013). In countries without a 
government-funded healthcare system, healthcare providers have a lot more autonomy in 
the choice of prescribing, with insurers making many important formulary decisions 
(Regnier, 2014). Additionally, all UK practising physicians are expected to consider the NICE 
CGs. In other countries, drug choices in NGB might be influenced more so by the EAU, ICI, 
or local/disease specific CGs.  
8.10   Conclusions 
The findings from this study suggest that NGB may be under-recognised among primary 
care providers, which has led to a low rate of diagnosis in the UK. It is important that efforts 
are focused on improving this trend through measures such as increased interoperability 
between primary and secondary care databases, educational campaigns, financial 
incentives, CDSS and fostering of better relationships between important stakeholders. An 
improvement in diagnosis rates will be instrumental to the accurate characterisation of 
patients that will further enhance effective individual treatment pathways and resource 
allocation.  
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This study also demonstrated that the burden of illness, healthcare needs and associated 
costs in this patient population were considerable. Patients had a high rate of 
polypharmacy, anticholinergic burden, UTI, incontinence and visited their GP and 
specialists frequently. The total mean per-patient costs for HRU was £2,395. All of these 
factors indicate that management may be sub-optimal in the UK NGB population, and 
highlight the need for interventions to improve the treatment landscape. This includes 
measures such as better infection control measures to lessen the impact of UTI and 
increased CER for the selection of optimal treatments that can provide the most benefit 
and avoid harm in the NGB population. Furthermore, modifications to the NGB CGs to 
include information on polypharmacy, comorbidity and anticholinergic burden are 
essential to strengthen awareness and knowledge amongst key stakeholders. Hypothesis 
driven research is crucial to understanding the drivers of HRU, specifically determining the 
association of NGB and HRU and further investigate the association of anticholinergic 
burden and cognitive dysfunction in patients with neurological disorders. 
8.11   Chapter Summary 
The SR conducted in Chapter Five revealed a lack of drug utilisation research (DUR) in NGB. 
Furthermore, the literature review in Section 2.8.3 established a lack of HRU evidence in 
this disease area. The CPRD study presented in this thesis fill a very important gap in our 
understanding of these important topics in a UK population. This study should help payers 
and policy makers shift their focus onto these pertinent aspects of NGB management when 
making reimbursement and policy decisions and encourage modifications in the current 
NGB CGs. 
The next chapter will discuss the results from the CPRD study in conjunction with the rest 
of the research presented in this thesis to formulate overall conclusions, implications for 
clinical practice and recommendations for further research. 
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9) Chapter Nine – Summary, Recommendations, Further Research and 
Conclusions 
9.1 Introduction 
The overall aim of this research was to raise an awareness and greater understanding of 
the neurogenic bladder (NGB) population, as well as providing recommendations on how 
to improve the management of this important patient group. The final chapter presents a 
summary of findings from the research presented in this thesis and explores the potential 
implications for both theory and practice. Considerations for further, more advanced 
research in this field are also explored. 
9.2  Outcomes Related to Research Aims 
The outcomes and findings in relation to the overall aims of this research that were 
presented in Chapter One, are presented below:  
Primary aims: 
1)  Enhance the understanding of the current treatment landscape in NGB 
2) Enhance the understanding of the current burden of disease in NGB 
Outcomes: 
1)  The quality of the NGB clinical guidelines (CGs) developed by the National Institute 
for Health and Care Excellence (NICE), European Association of Urology (EAU) and 
International Consultation on Incontinence (ICI) was assessed using the Appraisal of 
Guidelines Research and Evaluation (AGREE) II instrument. The study revealed that 
amongst many areas of improvement, one of the most important was in the 
applicability and incorporation of comparative effectiveness research (CER), which 
is crucial to ensure uptake in clinical practice.  
2) A comparison of treatment recommendations between the NGB CGs was 
conducted. When considering the results in conjunction with the AGREE II study, it 
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is clear that the CGs place differing emphasis on costs and expert opinion, which 
translated in notably different recommendations. It is imperative that the evidence 
base on which the recommendations were made is strengthened in order to guide 
more robust and consistent recommendations in future publications.  
3) A UK-wide retrospective observational study was conducted using the Clinical 
Practice Research Datalink (CPRD) database. The study uncovered that the rate of 
diagnosis error in NGB is high. This has implications for accurate patient 
characterisation, optimal treatment pathways and resource allocation.  
4) The CPRD study revealed that drug-prescribing patterns are consistent with the 
symptoms and complications of NGB, however interventions are necessary to 
manage the high levels of comorbidity, polypharmacy, anticholinergic burden and 
healthcare resource utilisation (HRU). 
9.3 Recommendations 
The following recommendations pertain to ways in which the management of NGB patients 
can be improved in light of the findings from the CG assessment and the CPRD study. A 
particular focus is placed on possible alterations to CGs and their development, which are 
one of the cornerstones of patient management (Hoesing, 2016).  
9.3.1 Improve Management of Polypharmacy and Comorbidity Neurogenic 
Bladder  
Results from the CPRD study revealed a high level of comorbidity and polypharmacy in NGB 
patients, which poses a major clinical and economic burden (Section 8.2.1 and Section 
8.4.1). The CG quality appraisal highlighted that the NGB CGs eschew all information 
regarding polypharmacy; generally failing to make clear when or how to stop drugs (Section 
4.4.2). They also do not include information on how to manage patients with comorbid 
conditions. Reducing the rates of polypharmacy and managing comorbidities in NGB 
patients is more challenging without the inclusion of supporting information and guidance 
in the standard CGs.  
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Furthermore, it is also important to consider that CGs for a single disease are notoriously 
difficult to implement in patients with multiple morbidities and the cumulative impact of 
applying treatment recommendations from various CGs can result in unnecessarily 
complex drug regimen (Austad et al., 2016). This situation is only exacerbated in NGB 
because patients may be managed in specific neurological care centres, and 
communication between the different levels of care often proves sub-optimal.  
There are many important aspects of polypharmacy and comorbidity that are specific to 
NGB patients, such as the risk of anticholinergic burden in PD patients, the problematic 
concurrent use of cholinesterase inhibitors and anticholinergics, and exacerbation of 
urological symptoms by MS medications. Inclusion of this information in NGB CGs are 
essential for the optimisation of care. Moreover, increased communication and 
collaboration between the multidisciplinary team managing these patients is imperative to 
ensure appropriate practices are followed and to avoid the duplication of care. 
9.3.2 Improve Diagnosis Rates of Neurogenic Bladder  
The high rate of diagnosis error in NGB evidenced by the CPRD study has implications for 
patient characterisation and thus the proper planning and provision of healthcare and 
services. Inadequate diagnosis is also related to treatment insufficiency, which can lead to 
increased rates of anticholinergic burden, polypharmacy and HRU, all of which were 
prominent in the CPRD study. 
There are a number of ways in which this trend can be modified, including improving the 
interoperability between primary and secondary care so that diagnostic information is fed 
back effectively, educational campaigns targeted towards both HCPs and patients to 
improve the awareness and understanding of NGB, financial incentives for diagnosis and/or 
referrals, and fostering better relationships between important stakeholders across 
healthcare settings. 
Deficits in applicability of NGB CGs were also touted as a potential reason for low NGB 
diagnoses rates. The CGs are less likely to be routinely applied for diagnosing patients in 
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clinical practice owing to a lack of attention devoted towards overcoming barriers to 
implementation and a paucity of cost-effectiveness analyses (CEA). Improving the 
applicability should come through measures such as educational training of HCPs, 
increased incorporation of comparative effectiveness research (CER), better assessment of 
local barriers to implementation, CDSS, better monitoring of uptake and raising the profile 
and understanding of NGB. The CPRD study presented in this thesis paves the way for 
raising awareness of NGB.   
9.3.3 Improving Efficiency of Care in Neurogenic Bladder 
The CPRD study highlighted a number of resource-intensive components of the NGB 
patient journey; this included the high frequency of general practitioner (GP) and specialist 
visits, the substantial associated costs and a high level of complications. This information 
demonstrates the scale and scope of the burden and should guide the attention of policy 
makers towards recognising NGB as a health priority and supporting new policies and 
interventions in this disease area.  
More than half of NGB patients were prescribed antibiotics for urinary tract infection (UTI), 
which is concerning given the significant costs related to managing UTI as well as the threat 
of antimicrobial resistance (AMR). Policy makers should focus on prevention of catheter 
associated UTI (CAUTI), through enhancing awareness of basic infection control measures 
and introducing targeted interventions (Trautner et al., 2005). 
In order to improve efficiencies in NGB, CER should be incorporated into all CG 
recommendations. The CPRD study in this thesis provides fundamental data that could be 
used to inform economic models. Through a consideration of local budgets and the 
promotion of cost-effective treatments, treatment pathways can be enhanced, costs and 
resources saved and variation in care reduced. In particular, because of the associated risk 
of dementia, it is essential to objectively assess the benefits and harms of using alternatives 
to bladder muscarinics in NGB.  
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Although the incorporation of health economics is essential, there are some barriers that 
must first be overcome. Due to their broad country remits and lack of resources, CER is not 
feasible in the EAU and ICI CGs. Although the national scope makes economic analysis 
possible in the NICE CGs, complete de novo analysis is not realistic given the infeasibility of 
acquiring resources for such a monumental task. Increased collaboration between these 
institutions could encourage better integration of health economics in the CGs.  
Moreover, there may be resistance to adopting cost-effective recommendations because 
of clinicians’ distrust of health economics (Wailoo et al., 2004; Gupta et al., 2017). One 
example of this is the potential resistance to the NICE recommendation which suggests 
conducting bladder augmentation before Onabotulinum-A in patients likely to benefit from 
treatment for more than 10 years because surgical intervention is potentially curative, 
possibly resulting in a net cost savings. Clinicians should be educated on the importance of 
health economics to ensure that once CER is integrated into recommendations, they are 
genuinely applied in practice.  
9.4 Further Research 
9.4.1 Enhance the Research Efforts in Neurogenic Bladder Through 
Modification of the Evidence-Based-Medicine Hierarchy  
All NGB CGs were created with the utmost methodological rigour (Section 3.6.5.4) 
however, in the absence of high-quality research, the developers had no choice but to rely 
upon expert opinion for the formation of certain recommendations (Chapter 4). Research 
efforts need to be amplified in order to strengthen the recommendations and thus 
encourage evidence-based care in clinical practice.  
Real-World Evidence (RWE) is essential in filling the evidence gap that currently exists in 
NGB. Given that CGs are designed for application in real-world clinical practice, the notion 
that RWE is inherently less valuable than randomised controlled trials (RCTs) seems illogical 
(Kim et al., 2018). External validity should be emphasised and held up in greater steed 
because observational studies ensure that recommendations can be applied to different 
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persons, settings and times, which is especially important in this heterogenous patient 
population (Fernandez et al., 2015). Moreover, RCTs are largely infeasible to conduct in 
NGB populations due to difficult patient populations and the apparent self-evident nature 
of interventions (Buckley and Grant, 2009).  
Descriptive epidemiology such as the research presented in this thesis is an important 
preliminary step to generate hypotheses in under-researched disease areas such as NGB; 
however, the causes of any trends observed and discussed are purely speculative. Analytic 
studies are paramount for the evaluation of factors associated with observed trends. 
Accordingly, pharmacoepidemiological studies utilising electronic healthcare records 
(EHRs), pragmatic trials and disease registries at centres managing a diverse range of 
neurological conditions should be prioritised in bridging the gap between efficiency and 
real-world effectiveness. This will strengthen the recommendations in NGB CGs, encourage 
increased CER and lead to tangible improvements in the management of patients and 
lowering of the excessive HRU burden (Ford and Norrie, 2016). In order for RWE to be 
readily accepted, the linear model of evidence-based medicine (EBM) needs to be 
revolutionised so that it takes into account the complexity of knowledge and the ability of 
different study designs to complement each other (Fernandez et al., 2015). 
9.4.2 Epidemiological Research in Other Countries  
This research consisted of an epidemiological study which provided insight into the UK NGB 
population and a quality assessment of the CGs that are most typically utilised in the UK 
and Europe. Although the evidence could be beneficial in other countries for purposes of 
improved awareness of the disease, the findings are primarily relevant for the UK, because 
patient populations, healthcare systems and clinical practice norms differ between 
countries.  
The research should incentivise additional epidemiological studies to characterise the NGB 
patient population in other countries, as the first step in reducing the burden of disease 
worldwide. This will be particularly useful in developing nations where resources are 
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significantly stretched and consequently, urological care is of lower quality (Przydacz et al., 
2017). It will also aid in cross-comparison between countries, allowing insight into the 
possible disparities that exist in treatment patterns and quality of care. It is however 
important to consider that limited access to high quality data from real world data (RWD) 
and poor IT infrastructure may impair the ability to apply RWE in these countries (Luna et 
al., 2014). 
9.4.3 Qualitative Research  
The research in this thesis provided valuable insight into the NGB population through 
critical analysis of the most prominent CGs and observational research using EHR data. The 
evidence generated does however fall short of truly understanding the patient experience. 
The healthcare environment is becoming increasingly patient centric in nature, with patient 
insight sought at multiples points of the healthcare journey, including during CG 
development, from health technology assessment (HTA)/payers during reimbursement 
discussions, from regulators, and in the improvement of services (du Plessis et al., 2017). 
This insight helps prescribers and policy makers understand patient needs when selecting 
and advocating optimal management techniques (Fraser et al., 2006). Furthermore, 
through more progressive models of EBM, qualitative research could help to improve the 
recommendations in CGs to adopt a more patient-centric approach. 
Despite the shift in environment, there has been very little progress in the way of 
understanding NGB from the perspective of patients (Patel et al., 2016). The CPRD provide 
a research service which allows the recruitment of patients into interventional studies, 
presenting a unique opportunity for the same or a similar cohort that was enrolled in the 
present CPRD retrospective study to be also be followed up prospectively. Patient Reported 
Outcomes (PROs), measure several subjective and objective dimensions of health through 
the perspective of the patient (Bonniaud et al., 2008; Megari, 2013) and can be completed 
electronically in the CPRD research services platform, thus saving the typical hassle and 
burden of administering paper-based or iPad versions (Valentine, 2018). Patients can also 
be asked to participate in interviews pertaining to their condition. Qualitative research such 
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as patient interviews are an excellent way to broaden the evidence base, as QoL measures 
often prove insufficient to capture the complexity of the patient experience. Interviews can 
be semi-structured, where open ended questions are posed to the patient in a bid to 
explore their experiences and viewpoints. Alternatively, interviews may be in-depth, where 
there is the opportunity to uncover issues or concerns that may not have even been 
considered by the researchers (Pope et al., 2002). Meta-synthesis, the process of 
qualitative meta-analysis is still scarcely conducted, which could make understanding these 
prospective results difficult in the context of other research in this area (Levitt, 2018).  
The CPRD interventional research service can also be utilised to administer clinician 
surveys. Clinicians play a central role in the care of NGB patients and possess unique insight 
on several key aspects of the patient journey. Surveys are excellent way to access this 
information and achieve a better understanding of their personal practices and opinions 
(Chen et al., 2016). As a continuation from the epidemiological CPRD study presented in 
this thesis, doctors could be probed on the rationale for their prescribing decisions 
including the reasons for their use of certain combinations of drugs, the prescription of 5-
ARI’s and α-adrenergic antagonists in women, querying their knowledge on the dangers of 
anticholinergic burden in NGB, as well as understanding their general attitudes and 
knowledge of NGB. 
The cognitive errors that lead to diagnosis error can also be explored through surveys. One 
of the potential rationalisations for low NGB diagnosis rates was the lack of referrals by 
HCPs to a urologist (60% of the original NGB source cohort were not referred to a urologist). 
It is however important to remember that this, and the other reasons detailed in Section 
8.2 remain purely speculative. Through the physician surveys, the rationale for not regularly 
referring patients to a urologist could be uncovered. More nuanced questions can be also 
be asked, such as whether patients with certain neurological conditions are referred faster.  
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9.4.4 Research into Anticholinergic Burden in Patients with Neurological 
Conditions  
There is a pronounced lack of attention given to anticholinergic burden in the three 
prominent NGB CGs, leaving clinicians without easily accessible guidance on the safe use 
of these drugs in this patient population. This may provide, at least in part, some 
explanation for the high ACB score, coupled with the high frequency of oxybutynin use 
observed in the CPRD study. Moreover, payers do not seem to differentiate between the 
different bladder muscarinics, despite important differences in pharmacokinetic profiles, 
translating in differing abilities to cause cognitive deficit. 
To date, little research has been conducted to determine the risk anticholinergics pose to 
patients with neurological disorders. The evidence that does exist suggests their use can be 
problematic because they can precipitate cognitive dysfunction and increase morbidity 
(Crispo et al., 2016; Cruce et al., 2012). There are several possible alternatives which can 
avoid the associated cognitive adverse events related to bladder muscarinics. One option 
is the β3-adrenoceptor agonist, mirabegron, which is the only other oral pharmacotherapy 
available on the market for symptoms of OAB. Management methods such as behavioural 
techniques are encouraged in the NGB CGs despite the objective lack of evidence 
supporting their use (Section 4.4.1). The evidence base for mirabegron is also small, 
however it is not advocated in the same way. It was approved by NICE in 2013 for OAB, 
considerably later than many other treatments, which could indicate a lack of prescribing 
experience amongst clinicians, and consequently a reluctance to advocate it (Chapple et 
al., 2017; MIMS, 2013). The low frequency of use in real world practice is evidenced in the 
CPRD study (1.2% of overall OAB drug use).  
Practitioners will inevitably begin to accumulate more experience of using mirabegron in 
NGB over the coming years. This needs to be accompanied by an increased drive towards 
CER, considering the various alternatives strategies to bladder muscarinics. This research is 
imperative to bolster the recommendations for mirabegron and other safer alternatives 
(including less potent bladder muscarinics) in the NGB CGs. Furthermore, to remedy the 
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dearth in evidence and quantify the extent of harm to patients, longitudinal real-world 
studies, monitoring cognitive function in patients with neurological conditions receiving 
anticholinergics are of great interest. This may be what is needed to influence prescribers 
and payers to improve the NGB treatment pathway and subsequently avoid the 
downstream costs of managing MCI and dementia associated with bladder muscarinics.  
9.5 Conclusions 
This thesis presents entirely novel research into the area of NGB, filling a crucial knowledge 
gap that currently exists in this disease area and highlighting this disease area as a health 
priority. 
The comprehensive CG quality appraisal and comparison provides a wealth of information 
on both the advantages and disadvantages of the current NGB CGs, providing insight into 
how well-equipped practitioners are to manage patients. The assessment revealed that the 
evidence base on which recommendations are constructed is weak. The CPRD study is the 
first stepping stone into improving the understanding of the real-world population. A 
culture-shift on the notion of RCTs as the highest form of evidence is necessary for any 
additional epidemiological research to be readily accepted and integrated into 
recommendations. Increased collaboration between NICE, EAU and ICI are essential for the 
creation of harmonious recommendations and improving the economic applicability across 
countries.    
The UK-wide epidemiological study significantly enhanced the understanding of the UK 
NGB population. The results demonstrated that the polypharmacy, anticholinergic burden 
and rate of comorbidities were high, and the healthcare burden was significant. The study 
also illuminated the issue of diagnosis error in NGB. By introducing modifications in CG 
development many of these issues could be improved and/or managed more effectively. 
Furthermore, it is evident that increased awareness of NGB amongst neurologists, payers, 
patients and GPs is imperative to further raise the profile of this disease and encourage 
improvements in health policy and management
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Appendix 6: Individual Neurogenic Bladder Clinical Guidelines AGREE II 
Appraisal Result 
National Institute for Health and Care Excellence - Urinary Incontinence in Neurological 
Disease: Management of Lower Urinary Tract Dysfunction in Neurological Disease 
Section Item Appraiser 1 Appraiser 2 
Scope and Purpose 1 6 5 
Scope and Purpose 2 7 6 
Scope and Purpose 3 7 6 
Stakeholder Involvement 4 6 6 
Stakeholder Involvement 5 7 7 
Stakeholder Involvement 6 7 7 
Rigour of Development 7 7 6 
Rigour of Development 8 7 6 
Rigour of Development 9 7 5 
Rigour of Development 10 7 5 
Rigour of Development 11 7 6 
Rigour of Development 12 7 6 
Rigour of Development 13 6 6 
Rigour of Development 14 7 6 
Clarity of Presentation 15 7 6 
Clarity of Presentation 16 5 5 
Clarity of Presentation 17 7 7 
Applicability 18 6 6 
Applicability 19 7 7 
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Applicability 20 7 7 
Applicability 21 5 6 
Editorial Independence 22 7 5 
Editorial Independence 23 7 6 
Overall Assessment OA1 7 6 
Overall Assessment OA2 Yes Yes, with modifications 
 
European Association of Urology - Clinical Guidelines on Neuro-Urology  
Section Item Appraiser 1 Appraiser 2 
Scope and Purpose 1 7 6 
Scope and Purpose 2 5 5 
Scope and Purpose 3 7 6 
Stakeholder Involvement 4 5 5 
Stakeholder Involvement 5 5 6 
Stakeholder Involvement 6 7 6 
Rigour of Development 7 6 5 
Rigour of Development 8 6 6 
Rigour of Development 9 7 6 
Rigour of Development 10 4 4 
Rigour of Development 11 7 6 
Rigour of Development 12 6 6 
Rigour of Development 13 5 5 
Rigour of Development 14 7 6 
Clarity of Presentation 15 6 6 
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Clarity of Presentation 16 6 6 
Clarity of Presentation 17 7 7 
Applicability 18 5 5 
Applicability 19 7 7 
Applicability 20 5 5 
Applicability 21 2 2 
Editorial Independence 22 6 6 
Editorial Independence 23 7 6 
Overall Assessment OA1 6 6 
Overall Assessment OA2 Yes, with modifications Yes, with modifications 
 
International Consultation on Incontinence - Neurologic Urinary and Faecal Incontinence 
Section Item Appraiser 2 Appraiser 6 
Scope and Purpose 1 7 6 
Scope and Purpose 2 6 6 
Scope and Purpose 3 7 6 
Stakeholder Involvement 4 5 5 
Stakeholder Involvement 5 4 2 
Stakeholder Involvement 6 7 7 
Rigour of Development 7 5 6 
Rigour of Development 8 7 5 
Rigour of Development 9 7 5 
Rigour of Development 10 5 5 
Rigour of Development 11 7 6 
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Rigour of Development 12 7 6 
Rigour of Development 13 3 3 
Rigour of Development 14 7 6 
Clarity of Presentation 15 7 6 
Clarity of Presentation 16 7 6 
Clarity of Presentation 17 7 7 
Applicability 18 5 5 
Applicability 19 5 5 
Applicability 20 5 5 
Applicability 21 2 2 
Editorial Independence 22 6 4 
Editorial Independence 23 7 6 
Overall Assessment OA1 6 5 
Overall Assessment OA2 Yes, with modifications Yes, with modifications 
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Appendix 7: Search strategy performed in ProQuest Dialog® to identify real 
world evidence studies relating to treatment patterns in neurogenic bladder 
Set # Searched for Results 
S5 ((S1 AND S2) AND S3) and (pd(19960101-20171231)) 116° 
S4 (S1 AND S2) AND S3 128° 
S3 ((treatment pattern*) OR (standard near/2 (treatment OR therapy OR care))) 
OR MESH.EXACT.EXPLODE("Standard of Care") OR 
EMB.EXACT.EXPLODE("health care quality") OR EMB.EXACT.EXPLODE("health 
care utilization") 
870350* 
S2 ((epidemiolog* stud*) OR (case control) OR (cohort NEAR/1 (stud* OR 
analy*)) OR (observational stud*) OR (longitudinal) OR ((retrospective OR 
prospective) near/3 (stud* OR analy*)) OR (cross sectional) OR (chart review) 
OR (medical record review)) OR EMB.EXACT("epidemiology") OR 
EMB.EXACT.EXPLODE("case control study") OR 
EMB.EXACT.EXPLODE(“prospective study”) OR EMB.EXACT.EXPLODE("cross-
sectional study") or EMB.EXACT.EXPLODE("cohort analysis") OR 
EMB.EXACT.EXPLODE("observational study") OR 
EMB.EXACT.EXPLODE("longitudinal study") OR 
EMB.EXACT.EXPLODE("retrospective study") or 
EMB.EXACT.EXPLODE("medical record review") OR 
MESH.EXACT.EXPLODE("Epidemiologic Studies") OR 
MESH.EXACT.EXPLODE("Observational Study") 
7643028* 
S1 ti,ab,if(((bladder OR detrusor) near/3 dyssnergia) OR (neurogenic near/3 
detrusor near/3 overactiv*) OR ((neurogenic OR neuropathic) near/3 
bladder)) OR EMB.EXACT.EXPLODE("neurogenic bladder") OR 
MESH.EXACT.EXPLODE("Urinary Bladder, Neurogenic") 
20227* 
*Duplicates are removed from the search but included in the result count. 
° Duplicates are removed from the search and from the result count 
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Appendix 8: Pilot data extraction form for systematic literature review 
Study 
author and 
year 
Study 
design 
Patient 
characteristi
cs 
Type of NGB (NDO, 
underactive) 
Neurogenic 
condition 
Treatment 
patterns 
Drake et al 
2005 
Prospec
tive  
57.4 years 
mean age 
(range 43-
81), 171 
(86%) male 
One 
hundred 
and ninety 
six people 
post injury 
(YPI) 33 
 
SCI (for at 
least 20 
years) 
BMM options 
differ in respect of 
prevalence and 
incidence of 
complications. At 
a late stage post 
injury there 
remains a high 
probability of 
change in BMM. 
Drake et al 
2005 
Prospec
tive  
57.4 years 
mean age 
(range 43-
81), 171 
(86%) male 
One 
hundred 
and ninety 
six people 
post injury 
(YPI) 33 
 
SCI (for at 
least 20 
years) 
 
Drake et al 
2005 
Prospec
tive  
57.4 years 
mean age 
(range 43-
81), 171 
(86%) male 
One 
hundred 
and ninety 
six people 
post injury 
(YPI) 33 
 
SCI (for at 
least 20 
years) 
IDUC/SPC IC 
Strain RV Normal 
Incomplete (n) 0 7 
4 7 19 
Para ABC (n) 29 
16 11 40 0 
Tetra ABC (n) 16 4 
7 34 0 
Mean age (years) 
61.2 (0.03) 58.2 
(0.69) 57.3 (0.90) 
54.8 (0.0003) 58.2 
(0.68) 
MeanYPI (years) 
35.9 (0.007) 35.3 
(0.04) 33.2 (0.90) 
31.2 (0.0004) 30.7 
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(0.06 
Gender: M/F 40/5 
(0.3) 19/8 (0.35) 
13/11 (0.60) 80/1 
(0.0001) 18/1 
(0.23) 
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI All patients used 
more than one 
method of 
management at 
different times, 
particularly 
towards old age. 
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI Phase 1- Before 
admission to MSCI 
- All patients were 
initially managed 
with IndUC. 38 
patients (32%) did 
not have their 
method of urine 
drainage 
documented. Of 
the remaining 81 
patients, 56 (69%) 
had IndUC, 22 
(27%) had ACIC, 
and in 3 other 
patients RV 
and/or bladder 
expression were 
used before 
admission to 
MSCI. one patient 
with a C4 frankel 
injury had an 
initial IndUC had a 
sphincterotomy 
before admission 
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in order to 
achieve RV.  
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI Phase 2 - During 
hospitalisation to 
MCSI - In those 
with and without 
complications, the 
overwhelming 
method of 
bladder 
management was 
four hourly 
intermittent 
catheterisation  
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI Patients without 
complications at 
phase 2                                                       
No intervention 4 
Intermittent 
catheterisation 
with or without 
oral medicinea 41 
Intermittent 
catheterisation+s
phincterotomy 5 
Intermittent 
catheterisation-
suprapubic 
catheterization                        
2 
Intermittent 
catheterisation-
sphincterotomy -
reflex voiding               
1 
Intermittent 
catheterisation-
reflex voiding                                        
3 
Indwelling 
urethral 
catheterisation 3 
Indwelling 
urethral 
catheterisation-
intermittent 
catheterisation             
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9 
 Indwelling 
urethral 
catheterisation-
intermittent 
catheterisation             
2 
-reflex voiding 
  
Reflex voiding 4 
Total 74 
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI Patients with 
complications at 
phase 2                                                                 
No intervention 1 
Intermittent 
catheterisation 
with or without 
oral medicinea 10 
Intermittent 
catheterisation-
sphincterotomy 
11 
Intermittent 
catheterisation-
reflex voiding 4 
Intermittent 
catheterisation-
suprapubic 
catheterisation 2 
Intermittent 
catheterisation-
suprapubic 
catheterisation 1 
- sphincterotomy-
reflex voiding 
Intermittent 
catheterisation -
sphincterotomy -
reflex voiding 2 
Intermittent 
catheterisation-
indwelling 
urethral 
catheterisation 1 
Intermittent 
catheterisation-
indwelling 
urethral 
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catheterisation 
-sphincterotomy-
reflex voiding 
1 
Indwelling 
catheterisation 3 
Indwelling 
catheterisation-
intermittent 
catheterisation 2 
Indwelling 
catheterisation-
intermittent 
catheterisation 
-sphincterotomy 
2 
Indwelling 
catheterisation-
intermittent 
catheterisation 
-reflex voiding 
1 
Indwelling 
catheterisation-
suprapubic 
catheterisation 1 
Reflex voiding 1 
Reflex voiding-
sphincterotomy 2 
Total 45 
El-Masri et 
al 2012 
Retrosp
ective, 
longitud
inal 
Traumatic 
SCI, Frankel 
grade A-D, 
admission 
within 6 
weeks post 
injury. 99 
males and 
20 females 
(5:1), age at 
time of 
injury 16-63 
(mean 29) 
69 paraplegic, 50 
tetraplegic. 
SCI Bladder 
management 
after discharge 
from MCSI  Phase 
3 -                                                        
Without 
intervention 
Complication - 21 
No complication - 
3 Total - 24 
Intermittent 
catheterization 
(also 
sphincterotomy) 4 
14 (1) 18 (1) 
Indwelling 
catheterisation 
(also 
sphincterotomy) 1 
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9 (3) 10 (3) 
Reflex voiding 
(also 
sphincterotomy) 
19 (3) 40 (24) 59 
(27) 
Expression 1 2 3 
Suprapubic 
catheterisation 
(also 
sphincterotomy) 0 
5 (3) 5 (3) 
Total number of 
patients (also 
sphincterotomy) 
46 (3) 73 (31) 119 
(34) 
  
Lemelle et al 
2006 
Multice
ntre 
retrospe
ctive 
cohort 
of 
medical 
charts 
421 
patients, 
230 (55%) 
male and 
191 (45%) 
female. 
Mean 
patient age 
was 22.1 
years (range 
10-47.5). 
140 aged 
10-18 and 
281 aged 
over 18.  
 
Spina bifida A total of 191 
patients (45%) 
were medically 
treated for 
urinary 
continence 
management. 
Mean age was 
21.7 years. Clean 
intermittment 
catheter 
performed in 116 
(61%), including 
69 males and 47 
females of whom 
53 (46%) used 
oxybutnin reg. 
Remaning 35 
wore diapers 
without any 
method for 
bladder emptying. 
Urisheath reg 
used by 4 patients 
and 1 had a 
permanent 
suprapubic 
catheter 
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Lemelle et al 
2006 
Multice
ntre 
retrospe
ctive 
cohort 
of 
medical 
charts 
421 
patients, 
230 (55%) 
male and 
191 (45%) 
female. 
Mean 
patient age 
was 22.1 
years (range 
10-47.5). 
140 aged 
10-18 and 
281 aged 
over 18.  
 
Spina bifida Of the patients 23 
underwent 
noncontinent 
urinary diversion, 
that is a Bricker 
procedure in 19 
and vesicostomy 
in 
4. There were 
missing data on 
the surgical 
procedure in 2 
cases. The 
description of 
surgical 
management and 
urinary 
continence was 
relevant in 205 
cases. Mean age 
at first 
operation for 
urinary 
incontinence was 
12.8 _ 5.3 years. 
(range 3 to 29.). 
Mean followup 
after initial 
surgery was 9.25 
years. A total of 
184 patients 
(90%) used to 
perform clean 
intermittent 
catheterization 
through the 
urethra (112 or 
61%) and through 
a continent 
neoconduit on the 
abdominal 
wall (72 or 39%). 
Intestinal bladder 
augmentation 
was done 
in 148 cases 
(72%), including 
the sigmoid in 95 
(64%), the 
ileum in 47 (32%), 
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the stomach in 5 
(3%) and the 
ileumcecum 
in 1 (1%). Bladder 
auto-
augmentation 
with 
detrusorotomy 
without any other 
subsequent 
bladder 
enlargement 
was performed in 
4 cases (2%). 
Procedures on the 
bladder 
neck were 
numerous, 
including mainly 
bladder neck 
closure, 
a urinary AMS800 
artificial sphincter 
(American 
Medical 
Systems, 
Minnetonka, 
Minnesota), a 
sling or cinch 
procedure, 
a Kropp, 
PippiSalle or 
Young-Dees 
procedure, or 
biomaterial 
injection 
endoscopically or 
at open surgery. 
Manack et 
al 2009  
Retrosp
ective 
analysis 
of a 
claims 
databas
e 
46,271 
patients 
(9.9% of 
overall OAB 
patients), 
2.9% (1,323) 
were 
pediatric 12 
years old or 
younger. 
 
MS, SCI, PD, 
Paralytic 
syndrome or 
CP 
33,100 (71.5%) of 
total 46,271, 
NOAB patients 
were on one or 
more OAB drug 
during the one 
year post index 
period.1 drug 
(62.8%), 2 drugs 
(8.3%), 3 drugs 
(0.4%), 11 
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patients on 4 or 
more drugs. 
Manack et 
al 2009  
Retrosp
ective 
analysis 
of a 
claims 
databas
e 
46,271 
patients 
(9.9% of 
overall OAB 
patients), 
2.9% (1,323) 
were 
pediatric 12 
years old or 
younger. 
 
MS, SCI, PD, 
Paralytic 
syndrome or 
CP 
Mean number of 
days on drug 
therapy on this 
group was 201.87 
(SD 120.59) 
median - 218 
Manack et 
al 2009  
Retrosp
ective 
analysis 
of a 
claims 
databas
e 
46,271 
patients 
(9.9% of 
overall OAB 
patients), 
2.9% (1,323) 
were 
pediatric 12 
years old or 
younger. 
 
MS, SCI, PD, 
Paralytic 
syndrome or 
CP 
10,110 NOAB 
(22% of 46,271) 
dicontinued OAB 
oral therapy and 
did not restart, 
7782 (17%) 
continued, 9,030 
(20%) stopped 
and restarted oral 
therapy. 1,033 
(2%) neither 
stopped 
continued not 
restarted oral 
therapy. 18,316 
(36%) did not 
initiate oral 
therapy.  
Manack et 
al 2009  
Retrosp
ective 
analysis 
of a 
claims 
databas
e 
46,271 
patients 
(9.9% of 
overall OAB 
patients), 
2.9% (1,323) 
were 
pediatric 12 
years old or 
younger. 
 
MS, SCI, PD, 
Paralytic 
syndrome or 
CP 
5 most common 
meds were 
oxybutynin 
(39.0%), 
tolterodine 
(36.9%), 
acetaminophen/h
ydeocodone 
biltartate (25.4%), 
ciproflaxin 
(21.9%), 
levoflaxacin 
(20.9%). 
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Manack et 
al 2009  
Retrosp
ective 
analysis 
of a 
claims 
databas
e 
46,271 
patients 
(9.9% of 
overall OAB 
patients), 
2.9% (1,323) 
were 
pediatric 12 
years old or 
younger. 
 
MS, SCI, PD, 
Paralytic 
syndrome or 
CP 
real world rates of 
second and third 
line therapies - 
vast majority had 
aumentation 
cystoplasty (0.2%) 
and interstim 
therapy (0.4%) 
Anson & 
Shepard 
1996 
Data 
was 
collecte
d in 
outpatie
nt 
clinics 
when 
patients 
retured 
for 
routine 
follow 
up 
examina
tions 
348 
patients.                                       
(Table 1) 
36.2% had 
neurological levels 
of injury between C4 
and C8, C5 (19%), 
(Table 2). 
post-actute 
SCI 
two of the most 
freq use were IC 
(n=106, 30.5%) 
and reflex 
(n=87.25%). 
Combination of IC 
and reflex (n=40, 
11.5%), indwelling 
UC (n=34, 9.8%), 
suprapubic 
catheter (n=11, 
3.2%). 57 (16.4%) 
were self voiding 
and 13 (3.7%) 
were using some 
combination of 
those 
programmes.  
Weld & 
Dmochowsk
i 2000 
retrospe
ctively 
reviewe
d the 
medical 
records, 
upper 
tract 
imaging 
and 
video 
urodyna
mics of  
316 
posttraumat
ic spinal 
cord injured 
patients. 
Mean 
followup 
plus or 
minus 
standard 
deviation 
since injury 
was 18.3 6 
12.4 years. 
(Table 1 ) 
(Table 1) posttraumatic 
spinal cord 
injured 
patients 
chronic urethral 
catheterization, 
clean intermittent 
catheterization, 
spontaneous 
voiding and 
suprapubic 
catheterization in 
114, 92, 74 and 
36, 
respectively. 
Manack et 
al 2011  
Medical 
and 
pharma
cy 
46,271 
patients in 
the 
Neurogenic 
Patients with lower 
urinary tract 
dysfunctions related 
to urinary 
NGB 33,100 (71.5%) 
neurogenic 
bladder patients 
were taking one 
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claims 
were 
retrospe
ctively 
analyze
d from 
April 1, 
2002 to 
March 
31, 
2007 
bladder 
cohort, and 
9,315 and 
4,168 
patients in 
Multiple 
Sclerosis 
(MS) and 
Spinal Cord 
Injury (SCI) 
subcohorts. 
The mean 
age (SD) of 
the 
neurogenic 
bladder 
cohort was 
62.5 
(19.6) years, 
and the 
mean ages 
in the MS 
and SCI 
subcohorts 
were 53.2 
(12.0) and 
61.9 (20.5) 
years, 
respectively 
(table 1) 
incontinence (e.g., 
hypertonic bladder, 
detrusor sphincter 
dyssynergia, bladder 
paralysis, urinary 
frequency) due to 
neurologic disease 
or injury. MS; SCI 
(including 
paraplegia, 
quadriplegia, 
tetraplegia); spina 
bifida; Parkinson's 
disease; cerebral 
palsy; and specified 
paralytic 
syndromes(hemiple
gia/hemiparesis, 
late effects of 
stroke, other 
specified paralytic 
syndromes, and 
neoplasm of the 
spinal cord). Two 
predefined 
subcohorts, SCI and 
MS, were also 
selected based on 
an ICD-9-CM 
diagnosis code 
during the eligibility 
period. 
or more OAB oral 
drugs. 
Oxybutynin 
(39.0%) and 
tolterodine 
(36.9%) were the 
most frequently 
used medications. 
Manack et 
al 2011  
Medical 
and 
pharma
cy 
claims 
were 
retrospe
ctively 
analyze
d from 
April 1, 
2002 to 
March 
31, 
2007 
46,271 
patients in 
the 
Neurogenic 
bladder 
cohort, and 
9,315 and 
4,168 
patients in 
Multiple 
Sclerosis 
(MS) and 
Spinal Cord 
Injury (SCI) 
subcohorts. 
The mean 
age (SD) of 
Patients with lower 
urinary tract 
dysfunctions related 
to urinary 
incontinence (e.g., 
hypertonic bladder, 
detrusor sphincter 
dyssynergia, bladder 
paralysis, urinary 
frequency) due to 
neurologic disease 
or injury. MS; SCI 
(including 
paraplegia, 
quadriplegia, 
tetraplegia); spina 
bifida; Parkinson's 
NGB The mean number 
of days (SD; 
median) on OAB 
drug was 201.9 
days (120.6; 218). 
This included 
8,075 patients 
(86.7%) in the MS 
subcohort and 
3,372 patients 
(80.9%) in the SCI 
subcohort who 
were taking ≥1 
OAB oral drugs 
during the 1-year 
post-index period.  
  
 
 
 
444 
the 
neurogenic 
bladder 
cohort was 
62.5 
(19.6) years, 
and the 
mean ages 
in the MS 
and SCI 
subcohorts 
were 53.2 
(12.0) and 
61.9 (20.5) 
years, 
respectively 
(table 1) 
disease; cerebral 
palsy; and specified 
paralytic 
syndromes(hemiple
gia/hemiparesis, 
late effects of 
stroke, other 
specified paralytic 
syndromes, and 
neoplasm of the 
spinal cord). Two 
predefined 
subcohorts, SCI and 
MS, were also 
selected based on 
an ICD-9-CM 
diagnosis code 
during the eligibility 
period. 
Manack et 
al 2011  
Medical 
and 
pharma
cy 
claims 
were 
retrospe
ctively 
analyze
d from 
April 1, 
2002 to 
March 
31, 
2007 
46,271 
patients in 
the 
Neurogenic 
bladder 
cohort, and 
9,315 and 
4,168 
patients in 
Multiple 
Sclerosis 
(MS) and 
Spinal Cord 
Injury (SCI) 
subcohorts. 
The mean 
age (SD) of 
the 
neurogenic 
bladder 
cohort was 
62.5 
(19.6) years, 
and the 
mean ages 
in the MS 
and SCI 
subcohorts 
were 53.2 
(12.0) and 
Patients with lower 
urinary tract 
dysfunctions related 
to urinary 
incontinence (e.g., 
hypertonic bladder, 
detrusor sphincter 
dyssynergia, bladder 
paralysis, urinary 
frequency) due to 
neurologic disease 
or injury. MS; SCI 
(including 
paraplegia, 
quadriplegia, 
tetraplegia); spina 
bifida; Parkinson's 
disease; cerebral 
palsy; and specified 
paralytic 
syndromes(hemiple
gia/hemiparesis, 
late effects of 
stroke, other 
specified paralytic 
syndromes, and 
neoplasm of the 
spinal cord). Two 
predefined 
subcohorts, SCI and 
NGB The average 
length of time 
(SD; median) on 
drug was 209.1 
days (121.8; 238) 
for the MS 
subcohort and 
195.5 days (121.5; 
206) for the SCI 
subcohort. 
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61.9 (20.5) 
years, 
respectively 
(table 1) 
MS, were also 
selected based on 
an ICD-9-CM 
diagnosis code 
during the eligibility 
period. 
Manack et 
al 2011  
Medical 
and 
pharma
cy 
claims 
were 
retrospe
ctively 
analyze
d from 
April 1, 
2002 to 
March 
31, 
2007 
46,271 
patients in 
the 
Neurogenic 
bladder 
cohort, and 
9,315 and 
4,168 
patients in 
Multiple 
Sclerosis 
(MS) and 
Spinal Cord 
Injury (SCI) 
subcohorts. 
The mean 
age (SD) of 
the 
neurogenic 
bladder 
cohort was 
62.5 
(19.6) years, 
and the 
mean ages 
in the MS 
and SCI 
subcohorts 
were 53.2 
(12.0) and 
61.9 (20.5) 
years, 
Patients with lower 
urinary tract 
dysfunctions related 
to urinary 
incontinence (e.g., 
hypertonic bladder, 
detrusor sphincter 
dyssynergia, bladder 
paralysis, urinary 
frequency) due to 
neurologic disease 
or injury. MS; SCI 
(including 
paraplegia, 
quadriplegia, 
tetraplegia); spina 
bifida; Parkinson's 
disease; cerebral 
palsy; and specified 
paralytic 
syndromes(hemiple
gia/hemiparesis, 
late effects of 
stroke, other 
specified paralytic 
syndromes, and 
neoplasm of the 
spinal cord). Two 
predefined 
subcohorts, SCI and 
MS, were also 
selected based on 
NGB Most patients 
were on only one 
OAB drug (Table 
II). Eleven 
patients were 
receiving ≥4 OAB 
drugs, and two of 
those patients 
belonged to the 
MS subcohort. No 
patients were 
on >3 drugs in the 
SCI subcohort 
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respectively 
(table 1) 
an ICD-9-CM 
diagnosis code 
during the eligibility 
period. 
Manack et 
al 2011  
Medical 
and 
pharma
cy 
claims 
were 
retrospe
ctively 
analyze
d from 
April 1, 
2002 to 
March 
31, 
2007 
46,271 
patients in 
the 
Neurogenic 
bladder 
cohort, and 
9,315 and 
4,168 
patients in 
Multiple 
Sclerosis 
(MS) and 
Spinal Cord 
Injury (SCI) 
subcohorts. 
The mean 
age (SD) of 
the 
neurogenic 
bladder 
cohort was 
62.5 
(19.6) years, 
and the 
mean ages 
in the MS 
and SCI 
subcohorts 
were 53.2 
(12.0) and 
61.9 (20.5) 
years, 
respectively 
(table 1) 
Patients with lower 
urinary tract 
dysfunctions related 
to urinary 
incontinence (e.g., 
hypertonic bladder, 
detrusor sphincter 
dyssynergia, bladder 
paralysis, urinary 
frequency) due to 
neurologic disease 
or injury. MS; SCI 
(including 
paraplegia, 
quadriplegia, 
tetraplegia); spina 
bifida; Parkinson's 
disease; cerebral 
palsy; and specified 
paralytic 
syndromes(hemiple
gia/hemiparesis, 
late effects of 
stroke, other 
specified paralytic 
syndromes, and 
neoplasm of the 
spinal cord). Two 
predefined 
subcohorts, SCI and 
MS, were also 
selected based on 
an ICD-9-CM 
diagnosis code 
during the eligibility 
period. 
 
Most received 
alpha blockers 
(33%), 
antimuscarinic 
agents (26%) and 
cholinergic agents 
(15%). 67% 
received urinary 
catheterisations.  
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Chia-Cheng 
et al 2012 
Cross-
sectiona
l 
Patients 
with 
emergency 
department 
visits or 
hospitalisati
ons for SCI. 
941 
patients, 
165(17.5%) 
NDO with a 
mean age of 
54, 64% 
male.  
NDO SCI Most received 
alpha blockers 
(33%), 
antimuscarinic 
agents (26%) and 
cholinergic agents 
(15%). 67% 
received urinary 
catheterisations.  
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Appendix 9: Strengths and limitations of the CPRD and HES databases 
Strengths of the Clinical Practice Research Database GOLD 
The aim of this research is to build a comprehensive image of the NGB population in the 
UK, therefore, it is a logical choice to utilise the largest longitudinal EHR available, that is 
broadly representative of the UK population. This ensures that the greatest possible 
number of NGB patients will be captured thus enhancing the generalisability of results.  
Contributing GP practices receive guidelines from the CPRD to encourage high quality 
recording of data. In addition, upon receipt of the data, the CPRD provide feedback and 
work with the practices to rectify any inconsistences that remain. If the practices are not 
able to address data quality issues and ultimately fail meet the pre-specified quality criteria, 
then they are not marked as ‘up-to-standard (UTS)’ and are no longer included in the 
dataset (Boston University, N.D). The data is usually considered unacceptable if a surgery 
has had too large of a gap between uploads, (unless, for example, there is a valid reason 
like a bank holiday) or if death recording falls below a pre-defined threshold. In addition to 
UTS quality criteria, individual patients are coded as being ‘research acceptable’ 
(acceptable=1 or unacceptable=0), to specify whether their data points are complete and 
do not contain outliers. Both of these measures enhance data-usability. Only patients with 
UTS and of research acceptable status were enrolled into this study.  
The CPRD contains granular patient level data, and in particular, prescription data is 
extremely detailed, which allows an accurate and comprehensive description of drug 
utilisation. Information on drug dose, strength and brand is available. Furthermore, all 
information is computer generated and recorded simultaneously, reducing the rates of 
error which typically come with handwritten notes. 
Every patient in England and Wales who are registered with the NHS have a unique 
identifier known as their ‘NHS number’. This number is common to multiple datasets in the 
UK, allowing information on individuals from disparate sources to be linked. The CPRD 
database can be linked to the hospital episode statistics (HES) database, which allows 
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longitudinal data capture of the patient journey from primary through to secondary care. 
This provides more complete information on outcomes such as hospitalisations as well as 
enrichment of patients’ medical and therapeutic histories. 
Limitations of the Clinical Practice Research Database GOLD 
Despite being the superior choice for this research, there are a number of inherent 
weaknesses of the CPRD, those most relevant to this study are highlighted in this section.  
Although the CPRD is considered broadly representative of the UK population, there are 
some individuals in the UK who are less likely to not be registered with their GP this 
includes, prisoners, the homeless, members of the armed forces and asylum seekers. 
Furthermore, males are less likely to the registered than females due to differences in 
health-seeking behaviour between the genders (Herrett, 2015). 
Another issue is the potential underestimation of disease prevalence as a consequence of 
the absence of Read codes, which can be misinterpreted as absence of the disease itself. In 
reality, missing Read codes could reflect inadequate diagnoses, failure of the patient to 
present to the GP or inconsistencies in coding between primary and secondary care 
(Herrett, 2015). This concept is explored further in Section 8.2.   
The ability to accurately describe drug-taking behaviour from the CPRD is impeded by a few 
factors. Firstly, despite a wealth of information existing for drugs that are prescribed in 
clinical practice, information on over-the-counter (OTC) drugs does not appear in the 
database. Secondly, although a prescription has been issued, it is impossible to know 
whether patients took their medication as per the prescriber’s instructions (i.e. whether 
they adhered to their medication). Thus, what is observed in the CPRD can be considered 
only part of the patients’ drug taking behaviour. 
Strengths of Hospital Episode Statistics Admitted Patient Care and Outpatient  
The HES data is assessed for completeness and consistency, with a data quality report 
published annually. Generally, the completeness of recording admissions is very high. The 
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diagnostic accuracy in HES has proven adequate (80.3%), as well as the accuracy of 
procedure coding (84.2%) (Burns et al., 2012). Furthermore, because the GP is the 
gatekeeper of healthcare, acting as the first point of contact for all non-emergency care by 
coordinating referrals to specialists, any diagnoses or treatments given in secondary care 
is fed back to primary care. Information is entered into the electronic patient record to 
ensure full transparency and facilitation of the appropriate delivery of health care services 
(Herrett, 2015; La Rocca and Hoholm, 2017).  
The data in HES is comprehensive, which posits the database as an excellent resource for 
research purposes; it includes information on patient and clinical characteristics and 
administrative information (NHS Digital, 2018). Overall, there are 270 variables available in 
the core dataset (Herbert, 2017). The universal coverage of HES and possibility to link to 
patients in the CPRD database provides excellent longitudinal data capture across the 
patient’s entire health journey allowing for the detailed evaluation of factors related to 
HRU. Furthermore, each episode in the HES can be linked to a Healthcare Resource Group 
(HRG) code and thus a unit cost, allowing the quantification of burden of disease (Meacock 
et al., 2015).  
Limitations of Hospital Episode Statistics Admitted Patient Care and Outpatient  
Although in recent years the coding accuracy in HES has improved, errors in diagnostic, 
procedure codes and administrative codes are still likely to be present. The instance of 
errors varies between hospitals, which means there is inconsistency in data quality (Slavin, 
2012). Another factor affecting data quality is the payment by results (PbR). This scheme 
incentivises the accurate coding of data points in order to reimburse hospitals for the care 
they provide. The scheme was introduced in 2003 and has subsequently expanded to 60% 
of hospital activity in the UK (Marshall, 2014). Although in itself the scheme has steadily 
improved the quality of coding of the years, it proves an issue when analysing data over a 
long period. Consequently, the quality of data points was varied over the period of this 
study (2004-2016) (Herbert, 2017).  
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It is important to consider that only a subset of CPRD practices have consented to HES 
linkage, furthermore HES is only available in the English NHS. This means there was an 
invariably smaller cohort available to analyse for the secondary objective of this study. This 
limitation was perhaps less impactful given the descriptive nature of this research.  
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Appendix 11: Independent Scientific Approval Committee (ISAC) protocol 
number 17_207R  
 
ISAC EVALUATION OF PROTOCOLS FOR RESEARCH INVOLVING CPRD DATA 
FEEDBACK TO APPLICANTS 
CONFIDENTIAL                                                                       by e-mail 
PROTOCOL NO: 17_207 
PROTOCOL TITLE:  Drug Utilisation Patterns and Healthcare Resource Use in Patients With 
Neurogenic Bladder (NGB): A descriptive study using electronic health 
records from the UK 
APPLICANT:  Dr. Jameel Nazir, HEOR Director. 
APPROVED  
 
  
APPROVED WITH COMMENTS  
(resubmission not required)  
  
REVISION/ RESUBMISSION 
REQUESTED  
  
REJECTED 
  
 
 
INSTRUCTIONS: 
Please include your response/s to the Reviewer’s feedback below only if you are required 
to Revise/ Resubmit your protocol.  
Protocols with an outcome of ‘Approved’ or ‘Approved with comments’ do not require 
resubmission to the ISAC. 
DATE OF ISAC FEEDBACK: 29/09/2017 
DATE OF APPLICANT FEEDBACK: 25/09/2017 
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Appendix 12: Read codes for neurogenic bladder and probable neurogenic 
bladder patients 
Codes for Neurogenic Bladder and Overactive Bladder 
Disease Key words  Read terms Read 
codes 
Neurogenic  
bladder 
*neurogenic* Neurogenic bladder K16V011 
Neurogenic bladder F246112 
*neuropathic bladder* Neuropathic bladder K16V00 
Neuropathic bladder F246113 
Reflex neuropathic bladder, not elsewhere 
classified 
K16W.00 
Uninhibited neuropathic bladder, NEC K16X.00 
*neuromuscular*bladder* [X]Other neuromuscular dysfunction of 
bladder 
Kyu5200 
[X]Neuromuscular dysfunction of bladder, 
unspecified  
Kyu5E00 
Neuromuscular dysfunction of bladder, 
unspecified  
K16V.00 
Overactive  
Bladder 
*overactive*  K16V100 
*detrusor* detrusor instability K165300 
detrusor instability K16y411 
unstable bladder K165400 
unstable bladder K16y412 
 
Codes for Stroke 
Read terms Read codes 
Intracerebral haemorrhage G61..00 
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Cortical haemorrhage G610.00 
Internal capsule haemorrhage G611.00 
CVA - cerebrovascular accid due to intracerebral haemorrhage G61..11 
Stroke due to intracerebral haemorrhage G61..12 
Basal nucleus haemorrhage G612.00 
Cerebellar haemorrhage G613.00 
Pontine haemorrhage G614.00 
Bulbar haemorrhage G615.00 
External capsule haemorrhage G616.00 
Intracerebral haemorrhage; multiple localized G618.00 
Intracerebral haemorrhage in hemisphere; unspecified G61X.00 
Left sided intracerebral haemorrhage; unspecified G61X000 
Right sided intracerebral haemorrhage; unspecified G61X100 
Intracerebral haemorrhage NOS G61z.00 
Cerebral infarct due to thrombosis of precerebral arteries G63y000 
Cerebral infarction due to embolism of precerebral arteries G63y100 
Cerebral arterial occlusion G64..00 
Cerebral thrombosis G640.00 
Cerebral infarction due to thrombosis of cerebral arteries G640000 
Cerebral embolism G641.00 
Cerebral infarction due to embolism of cerebral arteries G641000 
CVA - cerebral artery occlusion G64..11 
Cerebral embolus G641.11 
Infarction - cerebral G64..12 
Stroke due to cerebral arterial occlusion G64..13 
  
456 
 
Cerebral infarction NOS G64z.00 
Brainstem infarction G64z000 
Wallenberg syndrome G64z100 
Brainstem infarction NOS G64z.11 
Lateral medullary syndrome G64z111 
Cerebellar infarction G64z.12 
Left sided cerebral infarction G64z200 
Right sided cerebral infarction G64z300 
Infarction of basal ganglia G64z400 
Carotid artery syndrome hemispheric G653.00 
Stroke and cerebrovascular accident unspecified G66..00 
Middle cerebral artery syndrome G660.00 
Anterior cerebral artery syndrome G661.00 
CVA unspecified G66..11 
Stroke unspecified G66..12 
CVA - Cerebrovascular accident unspecified G66..13 
Posterior cerebral artery syndrome G662.00 
Brain stem stroke syndrome G663.00 
Cerebellar stroke syndrome G664.00 
Pure motor lacunar syndrome G665.00 
Pure sensory lacunar syndrome G666.00 
Left sided CVA G667.00 
Right sided CVA G668.00 
Cereb infarct due unsp occlus/stenos precerebr arteries G6W..00 
Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs G6X..00 
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[X]Other intracerebral haemorrhage Gyu6200 
[X]Cerebrl infarctn due/unspcf occlusn or sten/cerebrl artrs Gyu6300 
[X]Other cerebral infarction Gyu6400 
[X]Occlusion and stenosis of other precerebral arteries Gyu6500 
[X]Occlusion and stenosis of other cerebral arteries Gyu6600 
[X]Cereb infarct due unsp occlus/stenos precerebr arteries Gyu6G00 
CVA - cerebrovascular accident in the puerperium L440.11 
Stroke in the puerperium L440.12 
STROKE WITH HYPERTENSION 4360B 
CVA (CEREBROVASCULAR ACCIDENT) 4369A 
CEREBROVASCULAR ACCIDENT LEFT 4369AL 
CEREBROVASCULAR ACCIDENT RIGHT 4369AR 
STROKE 4369B 
SYNDROME STROKE 4369BN 
 
Codes for spinal cord injuries  
Read terms Read codes 
Open fracture of sacrum with other spinal cord injury  S117300 
Delivery of rehabilitation for spinal cord injury  7P21100 
Late effect of spinal cord injury SC22.00 
Frankel grading system for spinal cord injury  ZRBy.00 
Spine of spinal cord injury due to birth trauma Q204.00 
Spine of spinal cord injury due to birth trauma NOS Q204z00 
spinal cord injury without spinal bone injury NOS SJ2z.00 
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Nerve and spinal cord injuries SJ…00 
Nerve and spinal cord injury NOS SJz..00 
spinal cord injury multiple site without spinal bone injury SJ2x.00 
spinal cord injury without evidence of spinal bone injury SJ2..00 
spinal cord injuries SJ…13 
 
Codes for multiple sclerosis  
Read terms Read codes 
Benign multiple sclerosis F204.00 
Generalised multiple sclerosis F202.00 
Multiple sclerosis of the spinal cord F201.00 
Multiple sclerosis of the brain stem F200.00 
Relapsing and remitting multiple sclerosis F207.00 
Multiple sclerosis NOS F20z.00 
Multiple sclerosis F20..00 
Exacerbation of multiple sclerosis F203.00 
Secondary progressive multiple sclerosis F208.00 
Primary progressive multiple sclerosis F206.00 
Disseminated sclerosis F20..11 
 
Codes for Parkinson’s disease  
Read terms Read codes 
Paralysis agitans F120.00 
Parkinson's disease F12..00 
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Parkinsonism with orthostatic hypotension F130300 
Parkinson's disease NOS F12z.00 
Cerebral degeneration in Parkinson's disease F11x900 
 
Codes for spina bifida  
Read terms Read codes 
Spina bifida P1...00 
Spina bifida occulta PG17.00 
FH: Spina bifida 12J2.00 
Spina bifida with hydrocephalus, unspecified P100000 
Spina bifida NOS P1z..00 
Repair of spina bifida 7043.00 
Spina bifida with hydrocephalus P10..00 
Spina bifida without mention of hydrocephalus P11..00 
Spina bifida with hydrocephalus - open NOS P102z00 
Suspect fetal spina bifida L250.13 
Closed spina bifida with Arnold-Chiari malformation P101.11 
Spina bifida with hydrocephalus NOS P10z.00 
Dandy - Walker syndrome with spina bifida P10y000 
Spina bifida with stenosis of aqueduct of Sylvius P105.00 
Repair of spina bifida NOS 7043z00 
Unspecified spina bifida with hydrocephalus P100.00 
Lumbar spina bifida without mention of hydrocephalus P110300 
Sacral spina bifida without hydrocephalus - closed P118400 
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Lumbar spina bifida without hydrocephalus - closed P118300 
Lumbar spina bifida with hydrocephalus P100300 
Other specified repair of spina bifida 7043y00 
Spina bifida without hydrocephalus - closed P118.00 
Sacral spina bifida without hydrocephalus - open P117400 
Spina bifida without mention of hydrocephalus NOS P11z.00 
Sacral spina bifida with hydrocephalus - open P102400 
Thoracic spina bifida without mention of hydrocephalus P110200 
Spina bifida with hydrocephalus - closed P103.00 
Other specified spina bifida without hydrocephalus P11y.00 
Unspecified spina bifida without hydrocephalus NOS P110z00 
Cervical spina bifida without mention of hydrocephalus P110100 
Insertion of Halber valve for spina bifida 7010111 
Thoracic spina bifida with hydrocephalus - open P102200 
Spina bifida with hydrocephalus of late onset P104.00 
Spina bifida without hydrocephalus - open P117.00 
Unspecified spina bifida without hydrocephalus - closed P118000 
Spina bifida without hydrocephalus - open NOS P117z00 
Thoracolumbar spina bifida with hydrocephalus - closed P103z11 
Thoracic spina bifida with hydrocephalus P100200 
Lumbar spina bifida with hydrocephalus - open P102300 
Spina bifida without hydrocephalus, site unspecified P110000 
Sacral spina bifida with hydrocephalus - closed P103400 
Spina bifida without hydrocephalus - closed NOS P118z00 
Cervical spina bifida with hydrocephalus P100100 
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Spina bifida with hydrocephalus NOS P100z00 
Lumbar spina bifida with hydrocephalus - closed P103300 
Spina bifida with hydrocephalus - open P102.00 
Other specified spina bifida with hydrocephalus P10y.00 
[X]Unspecified spina bifida with hydrocephalus Pyu0400 
Thoracic spina bifida without hydrocephalus - open P117200 
Lumbar spina bifida without hydrocephalus - open P117300 
Cervical spina bifida without hydrocephalus - closed P118100 
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Appendix 13: Product list codes for OAB drugs 
Drug 
class 
Substance Pro
d 
cod
e 
Product name  Strength Formulatio
n 
Rout
e 
AM Oxybutynin 
hydrochlori
de 
355 Oxybutynin 2.5mg tablets 2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
130
4 
Oxybutynin 5mg tablets 5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
133
9 
Ditropan 5mg tablets (Sanofi) 5mg Tablet Oral 
AM Flavoxate 
hydrochlori
de 
151
7 
Urispas 200mg Tablet (Shire 
Pharmaceuticals Ltd) 
200mg Tablet Oral 
AM Flavoxate 
hydrochlori
de 
235
8 
Flavoxate 200mg tablets 200mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
252
4 
Ditropan 2.5mg tablets (Sanofi) 2.5mg Tablet Oral 
AM Tolterodine 
tartrate 
252
9 
Tolterodine 1mg tablets 1mg Tablet Oral 
AM Tolterodine 
tartrate 
264
0 
Detrusitol 2mg tablets (Pfizer Ltd) 2mg Tablet Oral 
AM Tolterodine 
tartrate 
328
3 
Tolterodine 2mg tablets 2mg Tablet Oral 
AM Propiverine 
hydrochlori
de 
328
4 
Propiverine 15mg tablets 15mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
343
0 
Oxybutynin 2.5mg/5ml oral 
solution 
500micr
ogram/1
ml 
Oral 
solution 
Oral 
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AM Terodiline 
Hydrochlori
de 
350
0 
Terodiline 12.5mg tablets 12.5mg Tablets Oral 
AM Tolterodine 
tartrate 
392
2 
Detrusitol 1mg tablets (Pfizer Ltd) 1mg Tablet Oral 
AM Terodiline 
Hydrochlori
de 
399
1 
Micturin 25mg Tablet (Pharmacia 
Ltd) 
25mg Tablet Oral 
AM Propiverine 
hydrochlori
de 
483
6 
Detrunorm 15mg tablets (AMCo) 15mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
515
5 
Ditropan xl 5mg Tablet (Sanofi-
Synthelabo Ltd) 
5mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
539
9 
Oxybutynin 10mg modified-release 
tablets 
10mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
553
7 
Ditropan xl 10mg Tablet (Sanofi-
Synthelabo Ltd) 
10mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
557
3 
Oxybutynin 5mg modified-release 
tablets 
5mg Modified-
release 
tablet 
Oral 
AM Tolterodine 
tartrate 
559
5 
Detrusitol xl 4mg Capsule 
(Pharmacia Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
564
1 
Tolterodine 4mg modified-release 
capsules 
4mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
578
8 
Ditropan 2.5mg/5ml elixir (Sanofi) 500micr
ogram/1
ml 
Oral 
solution 
Oral 
AM Oxybutynin 
Hydrochlori
de 
592
2 
Oxybutynin 5mg/5ml oral solution 
sugar free 
5mg/5m
l 
Solution 
Sugar-free 
Oral 
AM Oxybutynin 
hydrochlori
de 
601
0 
Ditropan XL 5mg tablets (Janssen-
Cilag Ltd) 
5mg Modified-
release 
tablet 
Oral 
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AM Trospium 
chloride 
664
1 
Trospium chloride 20mg tablets 20mg Tablet Oral 
AM Solifenacin 
succinate 
690
2 
Solifenacin 5mg tablets 5mg Tablet Oral 
AM Solifenacin 
succinate 
692
9 
Vesicare 5mg tablets (Astellas 
Pharma Ltd) 
5mg Tablet Oral 
AM Solifenacin 
succinate 
702
6 
Solifenacin 10mg tablets 10mg Tablet Oral 
AM Trospium 
chloride 
723
4 
Regurin 20mg tablets (Speciality 
European Pharma Ltd) 
20mg Tablet Oral 
AM Flavoxate 
Hydrochlori
de 
767
0 
Urispas 100mg Tablet (Shire 
Pharmaceuticals Ltd) 
100mg Tablet Oral 
AM Flavoxate 
Hydrochlori
de 
767
1 
Flavoxate 100mg Tablet 100mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
783
8 
Cystrin 3mg tablets (Sanofi) 3mg Tablet Oral 
AM Terodiline 
Hydrochlori
de 
789
3 
Micturin 12.5mg Tablet (Pharmacia 
Ltd) 
12.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
809
0 
Oxybutynin 3mg tablets 3mg Tablet Oral 
AM Oxybutynin 101
43 
Oxybutynin 3.9mg/24hours 
transdermal patches 
3.9mg/2
4hour 
Transderm
al patch 
Trans
derm
al 
AM Solifenacin 
succinate 
101
71 
Vesicare 10mg tablets (Astellas 
Pharma Ltd) 
10mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
106
33 
Cystrin 5mg tablets (Zentiva) 5mg Tablet Oral 
AM Oxybutynin 117
90 
Kentera 3.9mg/24hours patches 
(Orion Pharma (UK) Ltd) 
3.9mg/2
4hour 
Transderm
al patch 
Trans
derm
al 
  
465 
 
AM Oxybutynin 
hydrochlori
de 
130
12 
Ditropan XL 10mg tablets (Janssen-
Cilag Ltd) 
10mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
148
95 
Lyrinel XL 5mg tablets (Janssen-
Cilag Ltd) 
5mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
160
16 
Lyrinel XL 10mg tablets (Janssen-
Cilag Ltd) 
10mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
hydrochlori
de 
219
14 
Promictuline 2.5mg Tablet 
(Ashbourne Pharmaceuticals Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
219
93 
Promictuline 5mg Tablet 
(Ashbourne Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
262
23 
Contimin 2.5mg Tablet (Berk 
Pharmaceuticals Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
262
50 
Contimin 5mg Tablet (Berk 
Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
267
18 
Urimin 5mg Tablet (Opus 
Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Propiverine 
hydrochlori
de 
283
57 
Propiverine 30mg modified-release 
capsules 
30mg Modified-
release 
capsule 
Oral 
AM Propiverine 
hydrochlori
de 
286
69 
Detrunorm XL 30mg capsules 
(AMCo) 
30mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
307
76 
Oxybutynin 5mg tablets (Sterwin 
Medicines) 
5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
312
22 
Oxybutynin 5mg tablets (Actavis 
UK Ltd) 
5mg Tablet Oral 
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AM Oxybutynin 
hydrochlori
de 
344
58 
Oxybutynin 2.5mg tablets (Actavis 
UK Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
345
29 
Oxybutynin 2.5mg tablets (Mylan 
Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
345
30 
Oxybutynin 2.5mg tablets (A A H 
Pharmaceuticals Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
346
74 
Oxybutynin 2.5mg tablets 
(Approved Prescription Services 
Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
347
80 
Oxybutynin 5mg tablets (A A H 
Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Darifenacin 
hydrobromi
de 
351
21 
Darifenacin 7.5mg modified-
release tablets 
7.5mg Modified-
release 
tablet 
Oral 
AM Darifenacin 
hydrobromi
de 
351
40 
Darifenacin 15mg modified-release 
tablets 
15mg Modified-
release 
tablet 
Oral 
AM Oxybutynin 
Hydrochlori
de 
357
91 
Oxybutynin 5mg/5ml oral solution 
sugar free (Rosemont 
Pharmaceuticals Ltd) 
5mg/5m
l 
Oral 
Solution 
Oral 
AM Darifenacin 
hydrobromi
de 
358
38 
Emselex 7.5mg modified-release 
tablets (Merus Labs Luxco S.a R.L.) 
7.5mg Modified-
release 
tablet 
Oral 
AM Darifenacin 
hydrobromi
de 
361
60 
Emselex 15mg modified-release 
tablets (Merus Labs Luxco S.a R.L.) 
15mg Modified-
release 
tablet 
Oral 
AM Fesoterodin
e fumarate 
381
97 
Fesoterodine 4mg modified-
release tablets 
4mg Modified-
release 
tablet 
Oral 
AM Fesoterodin
e fumarate 
382
35 
Toviaz 4mg modified-release 
tablets (Pfizer Ltd) 
4mg Modified-
release 
tablet 
Oral 
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AM Flavoxate 
hydrochlori
de 
382
52 
Urispas 200 tablets (Recordati 
Pharmaceuticals Ltd) 
200mg Tablet Oral 
AM Fesoterodin
e fumarate 
382
91 
Fesoterodine 8mg modified-
release tablets 
8mg Modified-
release 
tablet 
Oral 
AM Fesoterodin
e fumarate 
384
67 
Toviaz 8mg modified-release 
tablets (Pfizer Ltd) 
8mg Modified-
release 
tablet 
Oral 
AM Tolterodine 
tartrate 
388
16 
Detrusitol XL 4mg capsules (Pfizer 
Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
400
96 
Oxybutynin 2.5mg tablets (Strides 
Shasun (UK) Ltd) 
2.5mg Tablet Oral 
AM Trospium 
chloride 
407
97 
Trospium chloride 60mg modified-
release capsules 
60mg Modified-
release 
capsule 
Oral 
AM Trospium 
chloride 
409
62 
Regurin XL 60mg capsules 
(Speciality European Pharma Ltd) 
60mg Modified-
release 
capsule 
Oral 
AM Trospium 
chloride 
414
29 
Flotros 20mg tablets (Galen Ltd) 20mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
415
80 
Oxybutynin 5mg tablets (Teva UK 
Ltd) 
5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
416
43 
Oxybutynin 2.5mg tablets (Teva UK 
Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
416
49 
Oxybutynin 2.5mg tablets (Sterwin 
Medicines) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
435
59 
Oxybutynin 2.5mg Tablet 
(Pharmacia Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
461
77 
Oxybutynin 2.5mg tablets (Almus 
Pharmaceuticals Ltd) 
2.5mg Tablet Oral 
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AM Oxybutynin 
hydrochlori
de 
493
65 
Oxybutynin 5mg/5ml oral 
suspension 
1mg/1m
l 
Oral 
suspension 
Oral 
AM Tolterodine 
tartrate 
494
14 
Detrusitol 1mg tablets (DE 
Pharmaceuticals) 
1mg Tablet Oral 
AM Tolterodine 
tartrate 
501
26 
Detrusitol XL 4mg capsules 
(Mawdsley-Brooks & Company Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
502
62 
Oxybutynin 5mg/5ml oral solution 1mg/1m
l 
Oral 
solution 
Oral 
AM Fesoterodin
e fumarate 
505
96 
Toviaz 8mg modified-release 
tablets (Mawdsley-Brooks & 
Company Ltd) 
8mg Modified-
release 
tablet 
Oral 
AM Tolterodine 
tartrate 
510
25 
Detrusitol XL 4mg capsules 
(Necessity Supplies Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
518
68 
Detrusitol 1mg tablets (Necessity 
Supplies Ltd) 
1mg Tablet Oral 
AM Tolterodine 
tartrate 
519
22 
Tolterodine 2mg tablets (Actavis 
UK Ltd) 
2mg Tablet Oral 
AM Tolterodine 
tartrate 
519
29 
Tolterodine 1mg tablets (A A H 
Pharmaceuticals Ltd) 
1mg Tablet Oral 
AM Trospium 
chloride 
522
66 
Regurin XL 60mg capsules (Lexon 
(UK) Ltd) 
60mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
524
01 
Detrusitol XL 4mg capsules (Sigma 
Pharmaceuticals Plc) 
4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
524
21 
Detrusitol 1mg tablets (Waymade 
Healthcare Plc) 
1mg Tablet Oral 
AM Trospium 
chloride 
524
22 
Regurin 20mg tablets (DE 
Pharmaceuticals) 
20mg Tablet Oral 
AM Trospium 
chloride 
526
67 
Uraplex 20mg tablets (Speciality 
European Pharma Ltd) 
20mg Tablet Oral 
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AM Trospium 
chloride 
527
53 
Trospium chloride 20mg tablets 
(Teva UK Ltd) 
20mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
536
94 
Oxybutynin 2.5mg tablets 
(Tillomed Laboratories Ltd) 
2.5mg Tablet Oral 
AM Tolterodine 
tartrate 
539
54 
Tolterodine 1mg tablets (Pfizer Ltd) 1mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
546
53 
Oxybutynin 5mg tablets (Tillomed 
Laboratories Ltd) 
5mg Tablet Oral 
AM Tolterodine 
tartrate 
551
08 
Mariosea XL 4mg capsules (Teva 
UK Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
556
88 
Efflosomyl XL 4mg capsules (Mylan 
Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
559
34 
Neditol XL 4mg capsules (Aspire 
Pharma Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Trospium 
chloride 
565
17 
Regurin XL 60mg capsules (DE 
Pharmaceuticals) 
60mg Modified-
release 
capsule 
Oral 
AM Trospium 
chloride 
596
93 
Trospium chloride 20mg tablets (A 
A H Pharmaceuticals Ltd) 
20mg Tablet Oral 
AM Tolterodine 
tartrate 
600
90 
Blerone XL 4mg capsules (Zentiva) 4mg Modified-
release 
capsule 
Oral 
AM Tolterodine 
tartrate 
614
66 
Tolterodine 2mg tablets (Sandoz 
Ltd) 
2mg Tablet Oral 
AM Tolterodine 
tartrate 
619
56 
Preblacon XL 4mg capsules (Actavis 
UK Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Propiverine 
hydrochlori
de 
624
03 
Detrunorm XL 45mg capsules 
(AMCo) 
45mg Modified-
release 
capsule 
Oral 
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AM Tolterodine 
Tartrate 
626
34 
Tolterodine tartrate (roi) 2mg 
Modified-release capsule 
2mg Modified-
release 
Capsule 
NULL 
AM Tolterodine 
tartrate 
633
29 
Tolterodine 2mg tablets (Teva UK 
Ltd) 
2mg Tablet Oral 
AM Propiverine 
hydrochlori
de 
638
28 
Propiverine 45mg modified-release 
capsules 
45mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
639
84 
Oxybutynin 2.5mg/5ml oral 
solution sugar free 
500micr
ogram/1
ml 
Oral 
solution 
Oral 
AM Tolterodine 
tartrate 
642
57 
Inconex XL 4mg capsules (Sandoz 
Ltd) 
4mg Modified-
release 
capsule 
Oral 
AM Solifenacin 
succinate 
644
73 
Vesicare 5mg tablets (DE 
Pharmaceuticals) 
5mg Tablet Oral 
AM Trospium 
chloride 
645
31 
Regurin XL 60mg capsules 
(Waymade Healthcare Plc) 
60mg Modified-
release 
capsule 
Oral 
AM Oxybutynin 
hydrochlori
de 
649
34 
Oxybutynin 5mg tablets (Kent 
Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Tolterodine 
tartrate 
649
55 
Tolterodine 1mg/5ml oral solution 200micr
ogram/1
ml 
Oral 
solution 
Oral 
AM Oxybutynin 
hydrochlori
de 
653
00 
Oxybutynin 2.5mg tablets (Alliance 
Healthcare (Distribution) Ltd) 
2.5mg Tablet Oral 
AM Oxybutynin 
hydrochlori
de 
666
68 
Oxybutynin 5mg tablets (Almus 
Pharmaceuticals Ltd) 
5mg Tablet Oral 
AM Trospium 
chloride 
679
32 
Trospium chloride 20mg tablets 
(DE Pharmaceuticals) 
20mg Tablet Oral 
MIRA
BEGR
ON 
Mirabegron 549
23 
Mirabegron 50mg modified-release 
tablets 
50mg Modified-
release 
tablet 
Oral 
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MIRA
BEGR
ON 
Mirabegron 551
31 
Mirabegron 25mg modified-release 
tablets 
25mg Modified-
release 
tablet 
Oral 
MIRA
BEGR
ON 
Mirabegron 551
52 
Betmiga 50mg modified-release 
tablets (Astellas Pharma Ltd) 
50mg Modified-
release 
tablet 
Oral 
MIRA
BEGR
ON 
Mirabegron 553
80 
Betmiga 25mg modified-release 
tablets (Astellas Pharma Ltd) 
25mg Modified-
release 
tablet 
Oral 
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Appendix 14: Read codes for dementia (exclusion criteria) 
Code Coding system Description 
3AE..00 Read Global deterioration scale: assessment of prim deg dementia 
66h..00 Read Dementia monitoring 
6AB..00 Read Dementia annual review 
E00..00 Read Senile and presenile organic psychotic conditions 
e000.00 Read Uncomplicated senile dementia 
E000.00 Read Uncomplicated senile dementia 
E001.00 Read Presenile dementia 
E001000 Read Uncomplicated presenile dementia 
E00..11 Read Senile dementia 
E001100 Read Presenile dementia with delirium 
E00..12 Read Senile/presenile dementia 
E001200 Read Presenile dementia with paranoia 
E001300 Read Presenile dementia with depression 
E001z00 Read Presenile dementia NOS 
E002.00 Read Senile dementia with depressive or paranoid features 
E002000 Read Senile dementia with paranoia 
E002100 Read Senile dementia with depression 
E002z00 Read Senile dementia with depressive or paranoid features NOS 
E003.00 Read Senile dementia with delirium 
E004.00 Read Arteriosclerotic dementia 
E004000 Read Uncomplicated arteriosclerotic dementia 
E004100 Read Arteriosclerotic dementia with delirium 
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E004.11 Read Multi infarct dementia 
E004200 Read Arteriosclerotic dementia with paranoia 
E004300 Read Arteriosclerotic dementia with depression 
E004z00 Read Arteriosclerotic dementia NOS 
E00y.00 Read Other senile and presenile organic psychoses 
E00y.11 Read Presbyophrenic psychosis 
E00z.00 Read Senile or presenile psychoses NOS 
E012.00 Read Other alcoholic dementia 
E012000 Read Chronic alcoholic brain syndrome 
E012.11 Read Alcoholic dementia NOS 
E041.00 Read Dementia in conditions EC 
Eu00.00 Read [X]Dementia in Alzheimer's disease 
Eu00000 Read [X]Dementia in Alzheimer's disease with early onset 
Eu00011 Read [X]Presenile dementia;Alzheimer's type 
Eu00012 Read [X]Primary degen dementia; Alzheimer's type; presenile onset 
Eu00013 Read [X]Alzheimer's disease type 2 
Eu00100 Read [X]Dementia in Alzheimer's disease with late onset 
Eu00111 Read [X]Alzheimer's disease type 1 
Eu00112 Read [X]Senile dementia;Alzheimer's type 
Eu00113 Read [X]Primary degen dementia of Alzheimer's type; senile onset 
Eu00200 Read [X]Dementia in Alzheimer's dis; atypical or mixed type 
Eu00z00 Read [X]Dementia in Alzheimer's disease; unspecified 
Eu00z11 Read [X]Alzheimer's dementia unspec 
Eu01.00 Read [X]Vascular dementia 
Eu01000 Read [X]Vascular dementia of acute onset 
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Eu01100 Read [X]Multi-infarct dementia 
Eu01.11 Read [X]Arteriosclerotic dementia 
Eu01111 Read [X]Predominantly cortical dementia 
Eu01200 Read [X]Subcortical vascular dementia 
Eu01300 Read [X]Mixed cortical and subcortical vascular dementia 
Eu01y00 Read [X]Other vascular dementia 
Eu01z00 Read [X]Vascular dementia; unspecified 
Eu02.00 Read [X]Dementia in other diseases classified elsewhere 
Eu02000 Read [X]Dementia in Pick's disease 
Eu02100 Read [X]Dementia in Creutzfeldt-Jakob disease 
Eu02200 Read [X]Dementia in Huntington's disease 
Eu02300 Read [X]Dementia in Parkinson's disease 
Eu02400 Read [X]Dementia in human immunodef virus [HIV] disease 
Eu02500 Read [X]Lewy body dementia 
Eu02y00 Read [X]Dementia in other specified diseases classif elsewhere 
Eu02z00 Read [X] Unspecified dementia 
Eu02z11 Read [X] Presenile dementia NOS 
Eu02z12 Read [X] Presenile psychosis NOS 
Eu02z13 Read [X] Primary degenerative dementia NOS 
Eu02z14 Read [X] Senile dementia NOS 
Eu02z15 Read [X] Senile psychosis NOS 
Eu02z16 Read [X] Senile dementia; depressed or paranoid type 
Eu04100 Read [X]Delirium superimposed on dementia 
Eu10711 Read [X]Alcoholic dementia NOS 
F110.00 Read Alzheimer's disease 
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F110000 Read Alzheimer's disease with early onset 
F110100 Read Alzheimer's disease with late onset 
F111.00 Read Pick's disease 
F112.00 Read Senile degeneration of brain 
F116.00 Read Lewy body disease 
Fyu3000 Read [X]Other Alzheimer's disease 
ZR1K.00 Read Alzheimer's disease assessment scale 
ZR1K.11 Read ADAS - Alzheimer's disease assessment scale 
ZR2X.12 Read BDRS - Blessed dementia rating scale 
ZR3V.00 Read Clinical dementia rating scale 
ZR3V.11 Read DRS - Clinical dementia rating scale 
ZR3V.12 Read CDR - Clinical dementia rating scale 
ZR3V.13 Read Dementia rating scale 
ZS7C500 Read Language disorder of dementia 
2900 OXMIS SENILE DEMENTIA 
2901A OXMIS PRESENILE DEMENTIA 
2901B OXMIS ALZHEIMER'S DISEASE 
2901D OXMIS JACOB- CREUZFELDT DISEASE WITH DEMENTIA 
2919 OXMIS DEMENTIA ALCOHOLIC 
2930 OXMIS DEMENTIA ARTERIOSCLEROTIC 
299 B OXMIS DEMENTIA 
299 G OXMIS DEMENTIA AGGRESSIVE 
Y0601JS OXMIS DEMENTIA CLINIC ATTENDANCE 
Y060 JS OXMIS DEMENTIA CLINIC 
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Appendix 15: QoF Business Rules Read Codes 
Condition Cluster 
Name  
Description  Read V2  CTV3  
Asthma AST_COD  Asthma diagnosis 
codes  
H33* (excluding 
H333.*);H3120;H3
B*;173A* 
H33* (excluding 
H44*;H441*;H440*;X1
025*;X1023*;XaKdk*;X
aJFG*;Xa1hD*);X1020;
Xac33  
Atrial 
Fibrillation 
AFIB_COD  Atrial fibrillation 
codes  
G573*  G5730*;G573.*;G5731
*  
Cancer CAN_COD  Codes for 
relevant 
malignancies  
B0*-B32z.;B34*-
B6z0. (excluding 
B677.);Byu*-
Byu41;Byu5.-
ByuE0;K1323;K01
w1;68W24;C184.  
XaabR*;B62y.*;X78ef* 
(excluding 
B937W*;Byu5A*;Byu4
3*;Byu4.*;ByuHD*;Byu
42*;B5820*;B582z*;B5
826*;B5821*;B5825*;
B5822*;B5823*;B5824
*;Xa0Sh*;XaB49*;X00Z
9*;XE1yx*;Xa3eJ*;X78
hl*;XM1ML*;X20FX*;X
00ZC*;XaFrS*;X78h0*;
B331.*;B332z*;B33y.*;
B333.*;B334.*;B3320*
;B3321*;B3330*;B332.
*;B337.*;B330.*;B335.
*;B336.*;X78RP*;XaEG
W*;XaEGV*;XaCKx*;B3
3z.*;B33**;Xa0KC*;X7
8hS*;X00Z6;X78gs;Xa3
BF*;Xa0SJ*;XaB46*;Xa
YiK*;Xa0SY;D41y1*;XE
1vh*;C332.*;Xa0l6*;B9
34.*;Xa0Se*;Xa0Sg*;X
a0Sf*;XaYv2*;X00ZA*;
X00Z8*;C3330*;X78ha;
X78hm;X78hn;Xa0EY;X
a34C;Xa34D)  
Coronary 
heart 
disease 
CHD_COD  Coronary heart 
disease codes  
G3*-G309.;G30B.-
G330z (excluding 
G310.);G33z.-
G3401;G342.-
G35X.;G38*-
G3z*;Gyu3.* 
(excluding Gyu31)  
XE2uV* (excluding 
Xa07j*;G341.*;X200B*
;X200c;G363.;Gyu31;X
200d;X200e);Ua1eH;X
a1dP*;XaYYq;XM0rN  
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Chronic 
Kidney 
Disease 
CKD_COD  Chronic kidney 
disease codes 3-5  
1Z12.;1Z13.;1Z14.;
1Z15.;1Z16.;1Z1B.-
1Z1L.;K053.;K054.;
K055.;1Z1T.;1Z1V.;
1Z1W.;1Z1X.;1Z1Y.
;1Z1Z.;1Z1a.;1Z1b.;
1Z1c.;1Z1d.;1Z1e.;
1Z1f.  
XaLHI*;XaLHJ*;XaLHK*
;XacAM*;XacAN*;XacA
O*;XacAV*;XacAW*;Xa
cAX*;XacAb*;XacAd*;X
acAe*;XacAf*;XacAh*;
XacAi* 
  CKD1AND2_
COD  
Chronic kidney 
disease codes 1-2  
1Z10*;1Z11*;1Z17.
-
1Z1A.;K051*;K052
*;1Z1M*;1Z1Q*;1Z
1N*;1Z1P*;1Z1R*;
1Z1S*  
XaLHH*;XaLHG*;Xac9y
*;XacA4*;Xac9z*;XacA
2*;XacA6*;XacA9* 
COPD COPD_COD  COPD codes  H3*;H31*(excludin
g 
H3101;H31y0;H31
22);H32*;H36*-
H3z* (excluding 
H3y0.;H3y1.);H583
2*;H4640*;H4641
*;Hyu30*;Hyu31* 
H31*;H32* (excluding 
XaIQg;H582.);H3* 
(excluding 
H3122*);Xaa7C*;Xac3
3*;H3120* 
Dementia DEM_COD  Codes for 
Dementia  
Eu02*;E00*;Eu01*
;E02y1*;E012*;Eu0
0*;E041*;Eu041*;F
110.-
F112.;F116*;F118*
;F21y2*;A410*;A4
11*;Eu107*;F11x7
* 
X002w* (excluding 
X003E;X003F;X001T);E
u02*;XE1Xt*;E00z*;E0
2y1*;XE1Xu*;E0120*;E
u041*;F112*;X00Rk* 
Depression DEPR_COD  Depression 
diagnosis codes  
E0013*;E0021*;E1
12*;E113*;E118*;
E11y2*;E11z2*;E1
30*;E135*;E2003*
;E291*;E2B*;E2B1
*;Eu204*;Eu251*;
Eu32* (excluding 
Eu32A;Eu32B;Eu32
9);Eu33*;Eu341*;E
u412* 
X00Sb*;X00SO* 
(excluding 
62T1.*;E2B0.;XaCHo;X
aX54;XaX53;XaY2C);E0
013*;E0021* 
Diabetes DM_COD  Codes for 
diabetes  
C10*;C109J*;C109
K*;C10C*;C10D*;C
10E*;C10F* 
(excluding 
C10F8);C10G*;C10
H*;C10M*;C10N*;
PKyP*;C10P*;C10
Q* 
C10*;XaOPu*;XaOPt*;
X40J4* (excluding 
L1805);X40J5* 
(excluding 
L1806);X40J6*;X40JA* 
(excluding 
XSETI*;C11y0*);X40JG
* (excluding 
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X40JK);C1010*;C1011*
;C1030*;C1031*;XaIrf*
;X40JZ*;XSETp*;XM1X
k*;X008t*;Xaagd*;XSE
Te*  
Epilepsy EPIL_COD  Epilepsy 
diagnosis codes  
F25* (excluding 
F2501;F2504;F251
1;F2516;F256.*;F2
58.-
F25A.;F25y4;F25G.
;F25H.);F1321*;SC
200* 
F25*(excluding 
X005r*;X005p*;X005q
*;X005o*;X005t*;Q48
0.*;X005s*;XaBM2*;X0
06G*;Xa0lJ;XaOZG*;X0
05w*;X006n*)  
Heart failure HF_COD  Heart failure 
codes  
G58*;G1yz1*;662f.
-662i.  
G58*(excluding 
G5y4.*)  
Hypertensio
n 
HYP_COD  Hypertension 
diagnosis codes  
G2*;G20*;G24*-
G2z* (excluding 
G24z1;G2400;G24
10;G27*);Gyu2*;G
yu20* 
XE0Ub*;XE0Uc*;G24*(
excluding 
61462;G2400;G2410;G
24z1;Gyu21;L1282;Xa0
kX);G2*;Xa0Cs*;XSDSb
*;G202*;Xa3fQ*;XaZW
n*;XaZbz*;XaZWm*;Xa
b9M*;Xab9L* 
Learning 
disability 
LD_COD  Learning 
Disability codes  
E3*;Eu7*;Eu814*;
Eu815*;Eu816*;Eu
817*;Eu81z*;918e
*;Eu818* 
E3*;XaQZ4*;XaQZ3*;X
aKYb*;XaREt*;XaREu*;
Eu81z*;XaaiS*;Xabk1* 
Mental 
Health 
MH_COD  Psychosis; 
schizophrenia + 
bipolar affective 
disease codes  
E10*;E110*;E111*
;E1124*;E1134*;E
114.-E117z;E11y* 
(excluding 
E11y2);E11z*;E11z
0*;E11zz*;E12*;E1
3*(excluding 
E135.);E2122*;Eu2
*;Eu30*;Eu31*;Eu
323*;Eu328*;Eu33
3*;Eu32A*;Eu329* 
X00S6* (excluding 
Xa9B0*;E14**);X00SL*
;X00SM*;X00SJ*;XSGo
n*;E11z*;E11z0*;E11zz
*;XE1ZZ*;XE1Ze*;XaX5
4*;XaX53*;E130*;E112
4*;E1134*;XagU1* 
Obesity BMI30_COD  BMI codes – 
without an 
associated BMI 
value  
22K5*;22K7*;22KC
*;22KD*;22KE* 
22K5*;XaJJH*;XabHx*;
XabHy*;XabHz* 
  BMIVAL_CO
D  
BMI codes – with 
an associated 
BMI value  
22K*  22K*;X76CO* 
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Osteoporosi
s 
OSTEO_COD  Osteoporosis 
codes  
N330* (excluding 
N3308;N3309);N3
312*;N3313*;N33
16*;N3318–
N331B;N331H–
N331M;NyuB0*;N
yuB1*;NyuB8*;N3
314*;N3315*;N37
46*;NyuB2*  
Xa0AZ* (excluding 
X70Au);XE1GA*;N330*
;N3300*;N3304*;N330
B*;N330z*;X70CK*;N3
313*;N3316*;N331B*;
XaD4K*;XaD4J*;XaD4I
*;NyuB0*;NyuB1*;Nyu
B8*;XaIIp*;XaC12*;N3
307*;N330A*;N3314*;
N3315*;N3746;X70Av
*;NyuB2* 
Peripheral 
Arterial 
Disease 
PAD_COD  PAD diagnostic 
codes  
G73*;G73z* 
(excluding 
G73z1);Gyu74*;G7
34*;G73y* 
Xa0lV*;XE0VP*;G73z*;
XE0VR*;Gyu74*;XaZJa
* 
Palliative 
Care 
PALCARE_C
OD  
Palliative care 
codes  
1Z01*;2JE*;2Jf*;38
VY*;38Vb*;38Vd*;
38Ve*;38Vf*;38Vg
*;38Vh*;38Vi*;8B
A2*;8BAP*;8BAS*;
8BAT*;8BAe*;8BJ1
*;8CM1* 
(excluding 
8CM15);8CM4*;8C
ME*;8CMj*;8CMk
*;8H6A*;8H7L*;8H
7g*;8HH7*;8IEE*;9
EB5*;9Ng7*;ZV57C
*;8CMQ*;9NgD*;9
G8*;9c0P*;9c0N*;
8CMW3*;9K9*;93
67*;9c0L0*;9c0M*
;9NNd*;8CMb*;8B
2a*;9NNf0*;38QH
*;38QK*;8CMg*;2J
g*; 
9NNq*;9NNr*;9NN
s* 
1Z01*;XaQg1*;8BA2*;
XaIse* (excluding 
XaIsf);XaIpI*;XaMhi*;X
aJv2* (excluding 
XaZb7);8H6A*;8H7L*;X
aAex*;XaIlk*;XaAg6*;X
aAT5*;XaEJE*;XaAWN
*;XaAPW*;XaRFG*;Xa
RFF*;9EB5*;ZV57C*;Xa
XUG*;XaXoP*;XaXoW*
;XaYRB*;XaYRD*;XaYR
y*;XaYpV*;XaZmb*;Xa
Zcg*;XaZPo*;XaZe1*;X
aZLA*;XaZbi*;XaZZe*;X
aZPX*;XaZPn*;XaZhw*
;XaaIR*;XaaD3*;Xab0s
*;Xab1a*;Xab1h*;Xab1
f*;Xab1e*;Xab1g*;Xab
q2*;XacFk*;XacdB*;Xa
eCv*;XaeED*;XaeTh*;X
aeWb*;XaeWg*;XaeW
v*;XaeWw*;XaeWx*;X
aeWy*;XaeXv*;XaeYr*;
XaeYs*;XaeYt* 
Rheumatoid 
Arthritis 
RARTH_COD  Rheumatoid 
arthritis codes  
N040.*;N041.;N04
2.* (excluding 
N0420);N047.;N04
X.;N04y0;N04y2;N
yu11;Nyu12;Nyu1
G;Nyu10;G5yA.;G5
y8.  
N040.*;XE1DU;X705I;G
5y8.  
Stroke TIA_COD  TIA codes  G65*-
G654.;G656.-
XE0VK* (excluding 
F4236;G660.;G661.;G6
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G65zz;ZV12D*;Fyu
55* 
62.);XaX16*;G65z0*;G
65z1* 
  OSTR_COD  Non-
haemorrhagic 
stroke codes  
G63y0-
G63y1;G64**;G66
5.;G666.;G6760;G6
W*;G6X*;Gyu63-
Gyu66;Gyu6G  
Xa0kZ* (excluding 
XE1Xs*);G640.* 
(excluding 
G663.;G664.);X00D3;G
641.;Gyu65;Gyu66  
  STRK_COD  Stroke diagnosis 
codes  
G61* (excluding 
G617*);G63y0*;G6
3y1*;G64*;G66* 
(excluding 
G669*);G6760;G6
W*;G6X*;Gyu62*;
Gyu66*;Gyu6F*;G
yu6G* 
X00D1* (excluding 
XE1Xs*;F21y2*);G660*
;G661*;G662*;Gyu6F*
;G641*;Xa6YV*;Gyu62
*;Gyu65*;Gyu66* 
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Appendix 16: Read codes for complications 
Read codes for urinary tract infection  
Medcode Readcode Read term 
99759 14D7.00 History of recurrent urinary tract infection 
9378 1AG..00 Recurrent urinary tract infections 
106661 8CMWE00 On urinary tract infection care pathway 
1289 K190.00 Urinary tract infection, site not specified 
1572 K190.11 Recurrent urinary tract infection 
12570 K190200 Post operative urinary tract infection 
10515 K190300 Recurrent urinary tract infection 
97002 K190500 Urinary tract infection 
150 K190z00 Urinary tract infection, site not specified NOS 
107568 SP07Q00 Catheter-associated urinary tract infection 
 
Read codes for sepsis/septicaemia  
Medcode Readcode Read term 
54077 H5y0100 Tracheostomy sepsis 
106405 1JN0.00 Suspected sepsis 
104141 K190600 Urosepsis 
104294 A396.00 Sepsis due to Actinomyces 
110225 A3C1z00 Sepsis due to staphylococcus NOS 
104492 A3C1000 Sepsis due to Staphylococcus aureus 
104260 A3Cz.00 Sepsis NOS 
108045 A3C3.11 Sepsis due to Gram negative organisms 
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105423 A3C0.00 Sepsis due to Streptococcus 
37043 Q404z00 Umbilical sepsis NOS 
105716 A3C0z00 Streptococcal sepsis, unspecified 
110263 A3C1y00 Sepsis due to other specified staphylococcus 
104633 A3C2.11 Sepsis due to anaerobes 
105075 A3C3.00 Sepsis due to Gram negative bacteria 
104577 A3C1.00 Sepsis due to Staphylococcus 
104900 A3C0y00 Other streptococcal sepsis 
104189 A3C0100 Sepsis due to Streptococcus group B 
105102 A3C2.00 Sepsis due to anaerobic bacteria 
104028 A3C..00 Sepsis 
104150 A3Cy.00 Other specified sepsis 
105053 A3C3y00 Sepsis due to other Gram negative organisms 
2136 A38z.11 Sepsis 
104731 A3C0000 Sepsis due to Streptococcus group A 
53182 A38y.00 Other specified septicaemias 
101759 Ayu3E00 [X]Other streptococcal septicaemia 
12578 A380400 Septicaemia due to enterococcus 
49590 A380500 Vancomycin resistant enterococcal septicaemia 
31706 A383.00 Septicaemia due to anaerobes 
54534 A384400 Serratia septicaemia 
16104 A381.00 Staphylococcal septicaemia 
15229 A380.00 Streptococcal septicaemia 
10978 A380100 Septicaemia due to streptococcus, group B 
35232 A384.00 Septicaemia due to other gram negative organisms 
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42825 A381100 Septicaemia due to coagulase-negative staphylococcus 
29950 A380000 Septicaemia due to streptococcus, group A 
53762 Ayu3J00 [X]Septicaemia, unspecified 
12400 A384300 Pseudomonas septicaemia 
72876 A384z00 Other gram negative septicaemia NOS 
18809 A021.00 Salmonella septicaemia 
72881 Ayu3G00 [X]Septicaemia due to other gram-negative organisms 
30102 A381000 Septicaemia due to Staphylococcus aureus 
72106 Ayu3H00 [X]Other specified septicaemia 
98545 Ayu3F00 [X]Streptococcal septicaemia, unspecified 
31517 A384000 Gram negative septicaemia NOS 
885 A38..00 Septicaemia 
33765 A38z.00 Septicaemia NOS 
 
Read codes for Urinary Retention 
Medcode Readcode Read term 
6158 R082400 [D]Retention of urine unspecified 
5375 1A32.00 Cannot pass urine - retention 
5039 R082000 [D]Clot retention of urine 
1052 R082.00 [D]Retention of urine 
28017 R082300 [D]Chronic retention of urine 
3002 R082200 [D]Acute retention of urine 
 
Read codes for Obstructive Uropathy 
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Medcode Readcode Read term 
10880 K19C.00 Other obstructive and reflux uropathy 
105941 Kyu1300 [X]Obstructive and reflux uropathy, unspecified 
107866 Kyu1200 [X]Other obstructive and reflux uropathy 
12095 K196.11 Obstructive uropathy, unspecified 
12123 K19X.00 Obstructive and reflux uropathy, unspecified 
 
Read codes for renal failure 
Medcode Readcode Read term 
61930 Kyu2.00 [X]Renal failure 
35235 K04y.00 Other acute renal failure 
108103 K043100 Acute renal failure induced by aminoglycoside 
64636 7L1Az00 Compensation for renal failure NOS 
11773 7L1A.11 Dialysis for renal failure 
59194 7L1By00 Placement ambulatory apparatus- compensate renal failure OS 
56760 7L1B.00 Placement ambulatory apparatus compensation renal failure 
65089 7L1Cz00 Placement other apparatus- compensate for renal failure NOS 
16929 D215.00 Anaemia secondary to renal failure 
53940 Kyu2100 [X]Other chronic renal failure 
53852 K05..12 End stage renal failure 
100205 K0E..00 Acute-on-chronic renal failure 
350 K06..00 Renal failure unspecified 
107901 7L1Cy00 Placement other apparatus- compensate for renal failure OS 
53945 Kyu2000 [X]Other acute renal failure 
2266 K04..00 Acute renal failure 
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512 K05..00 Chronic renal failure 
48022 7L1Ay00 Other specified compensation for renal failure 
109215 K043300 Acute renal failure induced by cyclosporin A 
25582 K04z.00 Acute renal failure NOS 
97198 K044.00 Acute renal failure due to urinary obstruction 
105739 K04..11 ARF - Acute renal failure 
106860 C353600 Renal failure-associated hyperphosphataemia 
11554 SP15400 Renal failure as a complication of care 
6712 K050.00 End stage renal failure 
31549 7L1A.00 Compensation for renal failure 
83513 7L1C.00 Placement other apparatus for compensation for renal failure 
 
Read codes for Hyrdonephrosis 
Medcode Readcode Read term 
8522 K113.11 Hydronephrosis with pelviureteric junction obstruction 
27302 K11z.00 Hydronephrosis NOS 
98067 Kyu1F00 [X]Hydronephrosis with ureteral stricture NEC 
10410 K113.00 Hydronephrosis with ureteropelvic junction obstruction 
28159 K11X.00 Hydronephrosis with ureteral stricture NEC 
3277 K11..00 Hydronephrosis 
72621 Kyu1100 [X]Other and unspecified hydronephrosis 
27592 K112.00 Hydronephrosis with renal and ureteral calculous obstruction 
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Appendix 17: Product list codes for 5-ARI’s and alpha-blockers 
Drug 
class 
Substance Prod 
code 
Product name  Strength Formulat
ion 
Rou
te 
5ARI Finasteride 711 Finasteride 1mg 
tablets 
1mg Tablet Oral 
5ARI Finasteride 1360 Proscar 5mg 
tablets (Merck 
Sharp & Dohme 
Ltd) 
5mg Tablet Oral 
5ARI Finasteride 1361 Finasteride 5mg 
tablets 
5mg Tablet Oral 
5ARI Finasteride 5993 Propecia 1mg 
tablets (Merck 
Sharp & Dohme 
Ltd) 
1mg Tablet Oral 
5ARI Dutasteride 6387 Dutasteride 
500microgram 
capsules 
500microgram Capsule Oral 
5ARI Dutasteride 16128 Avodart 
500microgram 
capsules 
(GlaxoSmithKline 
UK Ltd) 
500microgram Capsule Oral 
5ARI Finasteride 49525 Propecia 1mg 
tablets (Lexon 
(UK) Ltd) 
1mg Tablet Oral 
5ARI Finasteride 52223 Finasteride 5mg 
tablets (Pfizer Ltd) 
5mg Tablet Oral 
5ARI Dutasteride 53080 Avodart 
500microgram 
capsules (DE 
Pharmaceuticals) 
500microgram Capsule Oral 
5ARI Finasteride 59905 Finasteride 
5mg/5ml oral 
suspension 
1mg/1ml Oral 
suspensi
on 
Oral 
5ARI Finasteride 60337 Finasteride 5mg 
tablets (A A H 
5mg Tablet Oral 
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Pharmaceuticals 
Ltd) 
5ARI Finasteride 63265 Aindeem 1mg 
tablet (Actavis UK 
Ltd) 
1mg Tablet Oral 
5ARI Finasteride 65407 Finasteride 1mg 
tablets (Accord 
Healthcare Ltd) 
1mg Tablet Oral 
5ARI Finasteride 67718 Finasteride 1mg 
tablets (Ennogen 
Healthcare Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 119 Doxazosin 1mg 
tablets 
1mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
460 Flomax MR 
400microgram 
capsules (Astellas 
Pharma Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 493 Doxazosin 2mg 
tablets 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 582 Doxazosin 4mg 
modified-release 
tablets 
4mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
634 Tamsulosin 
400microgram 
modified-release 
capsules 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 755 Cardura XL 4mg 
tablets (Pfizer Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 1294 Doxazosin 4mg 
tablets 
4mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
2088 Alfuzosin 2.5mg 
tablets 
2.5mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
2120 Alfuzosin 5mg 
modified-release 
tablets 
5mg Modified
-release 
tablet 
Oral 
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ALPHA Terazosin 
hydrochloride 
2346 Hytrin 5mg Tablet 
(Abbott 
Laboratories Ltd) 
5mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
2347 Hytrin 10mg 
Tablet (Abbott 
Laboratories Ltd) 
10mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
2348 Hytrin bph 10mg 
Tablet 
(Amdipharm Plc) 
10mg Tablet Oral 
ALPHA Terazosine 3470 Terazosin 1mg 
tablets 
1mg Tablets Oral 
ALPHA Terazosine 3923 Terazosin BPH 
starter pack 
7x1mg with 
14x2mg with 
7x5mg 
7 X 1mg + 14 X 
2mg + 7 X 5mg 
Starter 
Pack 
Oral 
ALPHA Terazosin 
hydrochloride 
3924 Terazosin 5mg 
tablets 
5mg Tablet Oral 
ALPHA Doxazosin mesilate 4449 Cardura 1mg 
tablets (Pfizer Ltd) 
1mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
4637 Terazosin 2mg 
tablets 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 4802 Cardura 2mg 
tablets (Pfizer Ltd) 
2mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
4875 Terazosin 10mg 
tablets 
10mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
5179 Xatral XL 10mg 
tablets (Sanofi) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Terazosin 
hydrochloride 
5337 Hytrin bph 5mg 
Tablet 
(Amdipharm Plc) 
5mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
5485 Alfuzosin 10mg 
modified-release 
tablets 
10mg Modified
-release 
tablet 
Oral 
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ALPHA Doxazosin mesilate 5496 Doxazosin 8mg 
modified-release 
tablets 
8mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 5618 Cardura XL 8mg 
tablets (Pfizer Ltd) 
8mg Modified
-release 
tablet 
Oral 
ALPHA Alfuzosin 
hydrochloride 
5624 Xatral 2.5mg 
tablets (Sanofi) 
2.5mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
6008 Omnic 
400microgram 
Modified-release 
capsule (Paines & 
Byrne Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
Hydrochloride 
7056 Tamsulosin 
400microgram 
modified-release 
tablets 
400microgram
s 
Modified 
Release 
Tablet 
Oral 
ALPHA Doxazosin mesilate 7547 Doxadura 2mg 
tablets (Discovery 
Pharmaceuticals) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 7549 Doxadura 1mg 
tablets (Discovery 
Pharmaceuticals) 
1mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
8077 Hytrin 2mg Tablet 
(Abbott 
Laboratories Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 8086 Cardura 4mg 
Tablet (Pfizer Ltd) 
4mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
9422 Xatral sr 5mg 
Tablet (Sanofi-
Synthelabo Ltd) 
5mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 10088 Doxadura 4mg 
tablets (Discovery 
Pharmaceuticals) 
4mg Tablet Oral 
ALPHA Tamsulosin 
Hydrochloride 
10134 Flomaxtra XL 
400microgram 
tablets (Astellas 
Pharma Ltd) 
400microgram
s 
Modified 
Release 
Tablet 
Oral 
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ALPHA Tamsulosin 
hydrochloride 
14932 Tabphyn MR 
400microgram 
capsules (Kyowa 
Kirin Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Terazosin 
hydrochloride 
16201 Hytrin bph 2mg 
Tablet 
(Amdipharm Plc) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 19193 Doxazosin 2mg 
tablets (Teva UK 
Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 19216 Doxazosin 4mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 20369 Doxazosin 
1mg/5ml oral 
suspension 
200microgram
/1ml 
Oral 
suspensi
on 
Oral 
ALPHA Tamsulosin 
hydrochloride 
24369 Petyme 
400microgram 
MR capsules 
(Teva UK Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 25487 Cascor 2mg 
tablets (Ranbaxy 
(UK) Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 25551 Cascor 4mg 
tablets (Ranbaxy 
(UK) Ltd) 
4mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
27403 Omnic MR 
400microgram 
capsules (Astellas 
Pharma Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
hydrochloride 
28441 Pamsvax XL 
400microgram 
capsules (Actavis 
UK Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
hydrochloride 
31109 Prosurin XL 
400microgram 
capsules (Mylan 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
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ALPHA Doxazosin mesilate 33094 Doxazosin 2mg 
tablets (Mylan 
Ltd) 
2mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
34080 Stronazon 
400microgram 
MR capsules 
(Actavis UK Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 34342 Doxazosin 1mg 
tablets (Teva UK 
Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 34553 Doxazosin 4mg 
tablets (Mylan 
Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 34601 Doxazosin 1mg 
tablets (Mylan 
Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 34625 Doxazosin 2mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 34715 Doxazosin 1mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
1mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
35058 Diffundox XL 
400microgram 
capsules (Zentiva) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 35272 Doxadura XL 4mg 
tablets (Discovery 
Pharmaceuticals) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
35312 Bazetham MR 
400microgram 
capsules (Teva UK 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
hydrochloride 
35466 Alphacard MR 
400microgram 
capsules 
(Ratiopharm UK 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
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ALPHA Doxazosin mesilate 35603 Doxazosin 
4mg/5ml oral 
suspension 
800microgram
/1ml 
Oral 
suspensi
on 
Oral 
ALPHA Alfuzosin 
hydrochloride 
35639 Besavar XL 10mg 
tablets (Zentiva) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
35925 Contiflo XL 
400microgram 
capsules (Ranbaxy 
(UK) Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 36023 Cardozin xl 4mg 
Tablet (Hillcross 
Pharmaceuticals 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
36282 Morvesin XL 
400microgram 
capsules (Sandoz 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Alfuzosin 
hydrochloride 
36439 Zufal XL 10mg 
tablets (Teva UK 
Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Terazosin 
hydrochloride 
36649 Hytrin 2mg 
tablets (AMCo) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 36740 Slocinx XL 4mg 
tablets (Zentiva) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Terazosin 
hydrochloride 
36780 Hytrin 5mg 
tablets (AMCo) 
5mg Tablet Oral 
ALPHA Doxazosin mesilate 37243 Cardozin xl 4mg 
Tablet (Teva UK 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Terazosin 
hydrochloride 
37428 Hytrin 10mg 
tablets (AMCo) 
10mg Tablet Oral 
ALPHA Doxazosin mesilate 38461 Cardozin XL 4mg 
tablets (Arrow 
Generics Ltd) 
4mg Modified
-release 
tablet 
Oral 
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ALPHA Alfuzosin 
hydrochloride 
39373 Fuzatal XL 10mg 
tablets (Teva UK 
Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 40678 Doxazosin 4mg 
tablets (Teva UK 
Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 40891 Doxazosin 2mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 41543 Doxazosin 1mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
1mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
42462 Kirtacap mr 
400microgram 
Capsule 
(Consilient Health 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Alfuzosin 
hydrochloride 
42820 Alfuzosin xl 10mg 
Tablet (Hillcross 
Pharmaceuticals 
Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
42936 Flomax Relief MR 
400microgram 
capsules 
(Boehringer 
Ingelheim Self-
Medication 
Division) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
Hydrochloride/dutas
teride 
43458 Tamsulosin 
400microgram / 
Dutasteride 
500microgram 
capsules 
0.5mg + 0.4mg Capsules Oral 
ALPHA Tamsulosin 
Hydrochloride/dutas
teride 
43567 Combodart 
0.5mg/0.4mg 
capsules 
(GlaxoSmithKline 
UK Ltd) 
NULL Capsules Oral 
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ALPHA Doxazosin mesilate 43695 Colixil XL 4mg 
tablets (Sandoz 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Alfuzosin 
hydrochloride 
44268 Vasran XL 10mg 
tablets (Ranbaxy 
(UK) Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
44553 Pinexel PR 
400microgram 
capsules 
(Wockhardt UK 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 45040 Larbex XL 4mg 
tablets (Teva UK 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 45265 Doxazosin sr 4mg 
Tablet (Generics 
(UK) Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 45328 Doxazosin 1mg 
tablets (Sandoz 
Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 45342 Doxazosin 4mg 
tablets (Sandoz 
Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 45583 Doxazosin 2mg 
tablets (Dexcel-
Pharma Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 46066 Cardozin XL 4mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
46206 Pamsvax XL 
400microgram 
capsules (Almus 
Pharmaceuticals 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 46526 Raporsin XL 4mg 
tablets (Actavis 
UK Ltd) 
4mg Modified
-release 
tablet 
Oral 
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ALPHA Alfuzosin 
hydrochloride 
47563 Besavar XL 10mg 
tablets (Actavis 
UK Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 47807 Doxazosin xl 4mg 
Tablet (Hillcross 
Pharmaceuticals 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 48150 Doxazosin 1mg 
tablets (Actavis 
UK Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 50467 Doxazosin 2mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
2mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
51665 Tamurex 
400microgram 
modified-release 
capsules (Somex 
Pharma) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 51685 Doxazosin 4mg 
tablets (Actavis 
UK Ltd) 
4mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
52055 Tamsulosin 
400microgram 
oral powder 
sachets 
400microgram Powder Oral 
ALPHA Tamsulosin 
hydrochloride 
52159 Tamsulosin 
400microgram 
modified-release 
capsules (Focus 
Pharmaceuticals 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 53033 Doxzogen XL 4mg 
tablets (Mylan 
Ltd) 
4mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 53322 Doxazosin 4mg 
tablets (Bristol 
Laboratories Ltd) 
4mg Tablet Oral 
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ALPHA Tamsulosin 
hydrochloride 
53964 Tamsulosin 
400microgram 
modified-release 
capsules (A A H 
Pharmaceuticals 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Tamsulosin 
hydrochloride 
54497 Galebon 
400microgram 
modified-release 
capsules 
(Consilient Health 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 54785 Doxazosin 4mg 
tablets (Medreich 
Plc) 
4mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
55005 Kelanu XL 10mg 
tablets (Pfizer Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 55906 Doxazosin 1mg 
tablets (Dexcel-
Pharma Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 55916 Doxazosin 1mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 56145 Doxazosin 2mg 
tablets (Actavis 
UK Ltd) 
2mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
56793 Alfuzosin 2.5mg 
tablets (Teva UK 
Ltd) 
2.5mg Tablet Oral 
ALPHA Doxazosin mesilate 57074 Doxazosin 2mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
2mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
57145 Terazosin 2mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 57448 Doxazosin 4mg 
tablets (A A H 
4mg Tablet Oral 
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Pharmaceuticals 
Ltd) 
ALPHA Alfuzosin 
hydrochloride 
57549 Xatral 2.5mg 
tablets (Necessity 
Supplies Ltd) 
2.5mg Tablet Oral 
ALPHA Doxazosin mesilate 57784 Doxazosin 
2mg/5ml oral 
suspension 
400microgram
/1ml 
Oral 
suspensi
on 
Oral 
ALPHA Doxazosin mesilate 58276 Doxazosin 2mg 
tablets (Medreich 
Plc) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 58325 Doxazosin 4mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
4mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
58985 Xatral SR 5mg 
tablets (Sanofi-
Synthelabo Ltd) 
5mg Modified
-release 
tablet 
Oral 
ALPHA Doxazosin mesilate 59209 Doxazosin 1mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 59862 Doxazosin 4mg 
tablets (Dexcel-
Pharma Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 60200 Doxazosin 4mg 
tablets (DE 
Pharmaceuticals) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 60319 Doxazosin 1mg 
tablets (Bristol 
Laboratories Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 61066 Doxazosin 2mg 
tablets (Bristol 
Laboratories Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 61283 Doxazosin 4mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
4mg Tablet Oral 
  
498 
 
ALPHA Doxazosin mesilate 62019 Doxazosin 1mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 62158 Doxazosin 4mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 62351 Doxazosin 2mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
2mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
62539 Alfuzosin 10mg 
modified-release 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
10mg Modified
-release 
tablet 
Oral 
ALPHA Tamsulosin 
hydrochloride 
62553 Tamsulosin 
400microgram 
modified-release 
capsules (Alliance 
Healthcare 
(Distribution) Ltd) 
400microgram Modified
-release 
capsule 
Oral 
ALPHA Doxazosin mesilate 63158 Doxazosin 2mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 63314 Doxazosin 1mg 
tablets (Sovereign 
Medical Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 64233 Doxazosin 1mg 
tablets (Waymade 
Healthcare Plc) 
1mg Tablet Oral 
ALPHA Alfuzosin 
hydrochloride 
64443 Alfuzosin 2.5mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
2.5mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
65124 Tamsulosin 
400micrograms/5
ml oral solution 
80microgram/
1ml 
Oral 
solution 
Oral 
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ALPHA Doxazosin mesilate 65159 Doxazosin 4mg 
tablets (Waymade 
Healthcare Plc) 
4mg Tablet Oral 
ALPHA Terazosin 
hydrochloride 
65442 Terazosin 5mg 
tablets (Mylan 
Ltd) 
5mg Tablet Oral 
ALPHA Doxazosin mesilate 65853 Doxazosin 1mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
1mg Tablet Oral 
ALPHA Doxazosin mesilate 66065 Doxazosin 2mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
2mg Tablet Oral 
ALPHA Doxazosin mesilate 68022 Doxazosin 4mg 
tablets (Sovereign 
Medical Ltd) 
4mg Tablet Oral 
ALPHA Doxazosin mesilate 68161 Doxazosin 4mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
4mg Tablet Oral 
ALPHA Tamsulosin 
hydrochloride 
68584 Tabphyn MR 
400microgram 
capsules (Genus 
Pharmaceuticals 
Ltd) 
400microgram Modified
-release 
capsule 
Oral 
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Appendix 18: Antibiotics for UTI  
 
Prodcode Product Name Substance Stregnth Formulation 
45757 Trimethoprim 
with 
sulfamethoxazole 
16mg + 80mg/ml 
Concentrate for 
solution for 
infusion 
Sulfamethoxazole
/Trimethoprim 
16mg + 80mg/ml Concentrate For 
Solution For 
Infusion 
51510 Trimethoprim 
200mg tablets 
(Bristol 
Laboratories Ltd) 
Trimethoprim 200mg Tablet 
34542 Trimethoprim 
100mg tablets 
(Teva UK Ltd) 
Trimethoprim 100mg Tablet 
41967 Co-trimoxazole 
240mg/5ml Oral 
suspension 
(Hillcross 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
9100 Co-trimoxazole 
(trimethoprim 
and 
sulfamethoxazole
) 160mg+800mg 
Sulfamethoxazole
/Trimethoprim 
160mg+800mg Dispersible Tablet 
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dispersible 
tablets 
57981 Trimethoprim 
200mg tablets 
(Waymade 
Healthcare Plc) 
Trimethoprim 200mg Tablet 
13325 Monotrim 100mg 
tablets (Abbott 
Healthcare 
Products Ltd) 
Trimethoprim 100mg Tablet 
31477 Laratrim Liquid 
(Lagap) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
42517 Co-trimoxazole 
40mg+200mg 
Liquid (Celltech 
Pharma Europe 
Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
34252 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (A A H 
Pharmaceuticals 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
7421 Bactrim adult 
480mg/5ml 
Liquid (Roche 
Products Ltd) 
Trimethoprim/Sul
famethoxazole 
16mg/1ml + 
80mg/1ml 
Oral suspension 
29907 Comox Tablet 
(IVAX 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
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Pharmaceuticals 
UK Ltd) 
8073 Trimethoprim 
300mg Tablet 
Trimethoprim 300mg Tablet 
34727 Co-trimoxazole 
80mg/400mg 
tablets (Actavis 
UK Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
60216 Bactrim 96mg/ml 
Infusion (Roche 
Products Ltd) 
Sulfamethoxazole
/Trimethoprim 
96mg/ml Infusion 
53828 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Actavis UK 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
43509 Sulfadiazine 
500mg tablets 
(Wockhardt UK 
Ltd) 
Sulfadiazine 500mg Tablet 
34488 Trimethoprim 
100mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Trimethoprim 100mg Tablet 
37 Trimethoprim 
200mg tablets 
Trimethoprim 200mg Tablet 
34878 Trimethoprim 
100mg Tablet (C 
Trimethoprim 100mg Tablet 
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P 
Pharmaceuticals 
Ltd) 
606 Co-trimoxazole 
80mg/400mg 
tablets 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
53284 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Sigma 
Pharmaceuticals 
Plc) 
Trimethoprim 10mg/1ml Oral suspension 
52198 Co-trimoxazole 
80mg/400mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
44075 Septrin tablets 
(Aspen Pharma 
Trading Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
1604 Septrin paediatric 
Oral suspension 
sugar free 
(Wellcome 
Medical Division) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
67596 Trimethoprim 
100mg tablets 
(DE 
Pharmaceuticals) 
Trimethoprim 100mg Tablet 
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55121 Sulfadiazine 
500mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Sulfadiazine 500mg Tablet 
67613 Co-trimoxazole 
80mg+400mg 
Dispersible tablet 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Sulfamethoxazole
/Trimethoprim 
80mg+400mg Dispersible Tablet 
128 Sulfametopyrazin
e 2g tablet 
Sulfametopyrazin
e 
2g Tablets 
32908 Trimethoprim 
200mg tablets 
(Teva UK Ltd) 
Trimethoprim 200mg Tablet 
68225 Trimethoprim 
100mg tablets 
(Crescent Pharma 
Ltd) 
Trimethoprim 100mg Tablet 
1634 Septrin paediatric 
Dispersible tablet 
(Wellcome 
Medical Division) 
Sulfamethoxazole
/Trimethoprim 
 
Dispersible Tablet 
33997 Trimethoprim 
200mg tablets 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Trimethoprim 200mg Tablet 
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25497 Syraprim 100mg 
Tablet (Wellcome 
Medical Division) 
Trimethoprim 100mg Tablet 
303 Co-trimoxazole 
16mg with 
80mg/ml 
concentrate 
solution for 
infusion 
Sulfamethoxazole
/Trimethoprim 
16mg + 80mg/ml Concentrate For 
Solution For 
Infusion 
41544 Trimethoprim 
100mg Tablet 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Trimethoprim 100mg Tablet 
10745 Bactrim double 
strength 
160mg+800mg 
Tablet (Roche 
Products Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
29800 Phthalylsulfathiaz
ole 500mg tablet 
Phthalylsulfathiaz
ole 
500mg Tablets 
56267 Trimethoprim 
100mg tablets 
(Bristol 
Laboratories Ltd) 
Trimethoprim 100mg Tablet 
68726 Co-trimoxazole 
80mg/400mg 
tablets (Sigma 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
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Pharmaceuticals 
Plc) 
27921 Laratrim forte 
Tablet (Lagap) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
33987 Sulfamethoxazole 
800mg with 
trimethoprim 
160mg/5ml 
concentrate 
solution for 
infusion 
Sulfamethoxazole
/Trimethoprim 
800mg + 
160mg/10ml 
Concentrate For 
Solution For 
Infusion 
25269 Bactrim im 
320mg/ml 
intramuscular 
injection (Roche 
Products Ltd) 
Sulfamethoxazole
/Trimethoprim 
320mg/ml Intramuscular 
Injection 
7616 Trimopan 
50mg/5ml Liquid 
(Berk 
Pharmaceuticals 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
43505 Trimethoprim 
200mg Tablet 
(Numark 
Management Ltd) 
Trimethoprim 200mg Tablet 
3660 Septrin 
Dispersible tablet 
(Wellcome 
Medical Division) 
Sulfamethoxazole
/Trimethoprim 
 
Dispersible Tablet 
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54166 Sulfadiazine oral 
solution 
Sulfadiazine 
  
29351 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Teva UK Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
45246 Trimethoprim 
100mg tablets 
(Sandoz Ltd) 
Trimethoprim 100mg Tablet 
2460 Septrin Forte 
160mg/800mg 
tablets (Aspen 
Pharma Trading 
Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
32906 Trimethoprim 
100mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Trimethoprim 100mg Tablet 
29357 Sulphadimethoxi
ne 500mg tablet 
Sulphadimethoxi
ne 
500mg Tablets 
14367 Ipral 50mg/5ml 
Liquid (E R Squibb 
and Sons Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
29532 Trimogal 100mg 
Tablet (Lagap) 
Trimethoprim 100mg Tablet 
24856 Sulphamezathine 
333mg/ml 
Sulfadimidine 333mg/ml Injection 
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Injection 
(AstraZeneca UK 
Ltd) 
21805 Triprimix 200 
Tablet 
(Ashbourne 
Pharmaceuticals 
Ltd) 
Trimethoprim 200mg Tablet 
28004 Co-trimoxazole 
(trimethoprim 
and 
sulfamethoxazole
) 20mg+100mg 
paediatric tablets 
Sulfamethoxazole
/Trimethoprim 
20mg+100mg Tablets 
131 Septrin for 
Infusion 
80mg/400mg/5m
l solution for 
infusion 
ampoules (Aspen 
Pharma Trading 
Ltd) 
Sulfamethoxazole
/Trimethoprim 
80mg/1ml + 
16mg/1ml 
Solution for 
infusion 
340 Trimethoprim 
100mg tablets 
Trimethoprim 100mg Tablet 
68990 Comox forte 
Tablet (IVAX 
Pharmaceuticals 
UK Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
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33794 Sulfamethoxazole 
400mg with 
trimethoprim 
80mg/5ml oral 
suspension 
Sulfamethoxazole
/Trimethoprim 
400mg + 
80mg/5ml 
Oral Suspension 
20368 Sulfamethoxazole 
400mg with 
trimethoprim 
80mg/5ml 
concentrate 
solution for 
infusion 
Sulfamethoxazole
/Trimethoprim 
400mg + 
80mg/5ml 
Concentrate For 
Solution For 
Infusion 
67361 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Phoenix 
Healthcare 
Distribution Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
46663 Bactrim 
paediatric tablets 
(Roche Products 
Ltd) 
Sulfamethoxazole
/Trimethoprim 
 
Tablet 
403 Sulfadiazine 
500mg tablets 
Sulfadiazine 500mg Tablet 
15988 Trimethoprim 
with 
sulfamethoxazole 
80mg+400mg 
Tablet 
Sulfamethoxazole
/Trimethoprim 
80mg+400mg Tablet 
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65497 Trimethoprim 
200mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Trimethoprim 200mg Tablet 
2658 Co-trimoxazole 
80mg/400mg/5m
l oral suspension 
Trimethoprim/Sul
famethoxazole 
16mg/1ml + 
80mg/1ml 
Oral suspension 
41991 Co-trimoxazole 
80mg+400mg 
Dispersible tablet 
(Approved 
Prescription 
Services Ltd) 
Sulfamethoxazole
/Trimethoprim 
80mg+400mg Dispersible Tablet 
44241 Fectrim 
Dispersible tablet 
(DDSA 
Pharmaceuticals 
Ltd) 
Sulfamethoxazole
/Trimethoprim 
 
Dispersible Tablet 
34379 Trimethoprim 
200mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Trimethoprim 200mg Tablet 
34392 Trimethoprim 
200mg tablets 
(Actavis UK Ltd) 
Trimethoprim 200mg Tablet 
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7420 Bactrim 480mg 
Tablet (Roche 
Products Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
43545 Trimethoprim 
100mg tablets 
(Actavis UK Ltd) 
Trimethoprim 100mg Tablet 
21037 Uromide Tablet 
(Consolidated 
Chemicals (UK) 
Ltd) 
Sulfacarbamide/p
henazopyridine 
Hydrochloride 
 
Tablet 
24324 Trimogal 200mg 
Tablet (Lagap) 
Trimethoprim 200mg Tablet 
20126 Trimethoprim 
with 
sulfamethoxazole 
160mg+800mg 
Tablet 
Sulfamethoxazole
/Trimethoprim 
160mg+800mg Tablet 
10046 Trimopan 200mg 
tablets (Teva UK 
Ltd) 
Trimethoprim 200mg Tablet 
58490 Trimethoprim 
100mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Trimethoprim 100mg Tablet 
21809 Comixco 
80mg+400mg 
Tablet 
(Ashbourne 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
  
512 
 
Pharmaceuticals 
Ltd) 
10308 Sulfamethoxazole 
400mg with 
trimethoprim 
80mg tablet 
Sulfamethoxazole
/Trimethoprim 
400mg + 80mg Tablets 
34455 Trimethoprim 
200mg Tablet (C 
P 
Pharmaceuticals 
Ltd) 
Trimethoprim 200mg Tablet 
39933 Trimethoprim 
200mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Trimethoprim 200mg Tablet 
52669 Trimethoprim 
200mg/5ml oral 
solution 
   
10301 Sulfadimidine 
500mg/5ml 
paediatric 
mixture 
Sulfadimidine 500mg/5ml Mixture 
50120 Trimethoprim 
200mg tablets 
(Accord 
Healthcare Ltd) 
Trimethoprim 200mg Tablet 
31227 Trimethoprim 
200mg Tablet 
Trimethoprim 200mg Tablet 
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(Regent 
Laboratories Ltd) 
53275 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Alliance 
Healthcare 
(Distribution) Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
27048 Syraprim 300mg 
Tablet (Wellcome 
Medical Division) 
Trimethoprim 300mg Tablet 
31484 Laratrim adult 
480mg/5ml 
Liquid (Lagap) 
Trimethoprim/Sul
famethoxazole 
16mg/1ml + 
80mg/1ml 
Oral suspension 
17729 Sulfadimidine 
500mg tablet 
Sulfadimidine 500mg Tablets 
29994 Sulfaguanidine 
500mg tablet 
Sulfaguanidine 500mg Tablets 
8561 Bactrim 
paediatric sugar 
free oral solution 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
53946 Sulfadiazine 
500mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Sulfadiazine 500mg Tablet 
61714 Trimethoprim 
50mg/5ml oral 
suspension sugar 
Trimethoprim 10mg/1ml Oral suspension 
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free (Pinewood 
Healthcare) 
41978 Co-trimoxazole 
240mg/5ml Oral 
suspension 
(Approved 
Prescription 
Services Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
14998 Ipral 200mg 
Tablet (E R 
Squibb and Sons 
Ltd) 
Trimethoprim 200mg Tablet 
53276 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Kent 
Pharmaceuticals 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
30614 Sulfamethoxazole 
200mg with 
trimethoprim 
40mg/5ml oral 
suspension 
Sulfamethoxazole
/Trimethoprim 
200mg + 
40mg/5ml 
Oral Suspension 
31905 Trimethoprim 
with 
sulfamethoxazole 
80mg + 
400mg/5ml 
Concentrate for 
Sulfamethoxazole
/Trimethoprim 
80mg + 
400mg/5ml 
Concentrate For 
Solution For 
Infusion 
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solution for 
infusion 
60448 Co-trimoxazole 
80mg/400mg/5m
l solution for 
infusion 
ampoules 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Sulfamethoxazole
/Trimethoprim 
80mg/1ml + 
16mg/1ml 
Solution for 
infusion 
30201 Co-trimoxazole 
240mg/5ml 
Paediatric 
mixture (Lagap) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
8171 Monotrim 200mg 
tablets (Abbott 
Healthcare 
Products Ltd) 
Trimethoprim 200mg Tablet 
67147 Trimethoprim 
100mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Trimethoprim 100mg Tablet 
8286 Co-trimoxazole 
(trimethoprim 
and 
sulfamethoxazole
) 80mg+400mg 
dispersible 
tablets 
Sulfamethoxazole
/Trimethoprim 
80mg+400mg Dispersible Tablet 
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51725 Trimethoprim 
20mg/5ml oral 
suspension 
   
44286 Septrin Paediatric 
40mg/200mg/5m
l oral suspension 
(Aspen Pharma 
Trading Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
135 Septrin Tablet 
(Wellcome 
Medical Division) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
68101 Co-trimoxazole 
40mg/200mg/5m
l oral suspension 
sugar free (Aspen 
Pharma Trading 
Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
38090 Co-trimoxazole 
480mg/5ml Adult 
Mixture (Lagap) 
Trimethoprim/Sul
famethoxazole 
16mg/1ml + 
80mg/1ml 
Oral suspension 
43262 Co-trimoxazole 
240mg/5ml Oral 
suspension (C P 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
1199 Co-trimoxazole 
40mg/200mg/5m
l oral suspension 
sugar free 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
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50797 Trimethoprim 
200mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Trimethoprim 200mg Tablet 
298 Sulfadimidine 
333mg/ml 
injection 
Sulfadimidine 333mg/ml Injection 
63733 Co-trimoxazole 
80mg/400mg 
tablets (Essential 
Generics Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
65343 Co-trimoxazole 
160mg/800mg 
tablets (Tillomed 
Laboratories Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
27418 Trimethoprim 
with 
sulfamethoxazole 
40mg + 
200mg/5ml Oral 
suspension 
Sulfamethoxazole
/Trimethoprim 
40mg + 
200mg/5ml 
Oral Suspension 
43537 Trimethoprim 
200mg Tablet 
(Celltech Pharma 
Europe Ltd) 
Trimethoprim 200mg Tablet 
28562 Enteromide 
500mg Tablet 
(Consolidated 
Calcium 500mg Tablet 
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Chemicals (UK) 
Ltd) 
8741 Bactrim 
Dispersible tablet 
(Roche Products 
Ltd) 
Sulfamethoxazole
/Trimethoprim 
 
Dispersible Tablet 
287 Co-trimoxazole 
(trimethoprim 
with 
sulfamethoxazole
) 320mg/ml IM 
injection 
Sulfamethoxazole
/Trimethoprim 
320mg/ml Im Injection 
58282 Co-trimoxazole 
80mg/400mg 
tablets 
(Waymade 
Healthcare Plc) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
22991 Chemotrim Liquid 
(Rosemont 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
8mg/1ml + 
40mg/1ml 
Oral suspension 
1467 Co-trimoxazole 
160mg/800mg 
tablets 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
15081 Ipral 100mg 
Tablet (E R 
Squibb and Sons 
Ltd) 
Trimethoprim 100mg Tablet 
  
519 
 
68826 Co-trimoxazole 
160mg/800mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
59444 Co-trimoxazole 
80mg/400mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
68027 Co-trimoxazole 
160mg+800mg 
Tablet (C P 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
160mg + 800mg Tablet 
10318 Sulfamethoxazole 
80mg with 
trimethoprim 
16mg/5ml 
concentrate 
solution for 
infusion 
Sulfamethoxazole
/Trimethoprim 
80mg + 16mg/ml Concentrate For 
Solution For 
Infusion 
41579 Co-trimoxazole 
80mg/400mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
27445 Trimethoprim 
with 
sulfamethoxazole 
160mg + 
Sulfamethoxazole
/Trimethoprim 
160mg + 
800mg/10ml 
Concentrate For 
Solution For 
Infusion 
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800mg/10ml 
Concentrate for 
solution for 
infusion 
109 Septrin Adult 
80mg/400mg/5m
l oral suspension 
(Aspen Pharma 
Trading Ltd) 
Trimethoprim/Sul
famethoxazole 
16mg/1ml + 
80mg/1ml 
Oral suspension 
20920 Trimethoprim 
with 
sulfamethoxazole 
80mg + 
400mg/5ml Oral 
suspension 
Sulfamethoxazole
/Trimethoprim 
80mg + 
400mg/5ml 
Oral Suspension 
64028 Trimethoprim 
200mg tablets 
(Crescent Pharma 
Ltd) 
Trimethoprim 200mg Tablet 
27417 Sulphafurazole 
500mg tablet 
Sulfafurazole 
Acetyl 
500mg Tablets 
57080 Trimethoprim 
100mg tablets 
(Waymade 
Healthcare Plc) 
Trimethoprim 100mg Tablet 
65487 Trimethoprim 
200mg tablets 
(DE 
Pharmaceuticals) 
Trimethoprim 200mg Tablet 
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60808 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Almus 
Pharmaceuticals 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
7962 Kelfizine w 2g 
Tablet 
(Pharmacia Ltd) 
Sulfametopyrazin
e 
2g Tablet 
27255 Trimethoprim 
200mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Trimethoprim 200mg Tablet 
477 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free 
Trimethoprim 10mg/1ml Oral suspension 
57642 Trimethoprim 
20mg/5ml oral 
solution 
Trimethoprim 4mg/1ml Oral solution 
56259 Trimethoprim 
100mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Trimethoprim 100mg Tablet 
57116 Trimethoprim 
50mg/5ml oral 
suspension sugar 
Trimethoprim 10mg/1ml Oral suspension 
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free (Waymade 
Healthcare Plc) 
54914 Co-trimoxazole 
80mg/400mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
Trimethoprim/Sul
famethoxazole 
80mg + 400mg Tablet 
260 Sulphafurazole 
500mg/5ml oral 
solution 
Sulfafurazole 
Acetyl 
500mg/5ml Syrup 
53599 Trimethoprim 
200mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Trimethoprim 200mg Tablet 
280 Monotrim 
50mg/5ml Liquid 
(Solvay 
Healthcare) 
Trimethoprim 10mg/1ml Oral suspension 
62630 Trimethoprim 
200mg tablets 
(Ranbaxy (UK) 
Ltd) 
Trimethoprim 200mg Tablet 
53720 Trimethoprim 
100mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Trimethoprim 100mg Tablet 
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36622 Monotrim 
50mg/5ml oral 
suspension 
(Chemidex 
Pharma Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
21640 Trimopan 100mg 
tablets (Teva UK 
Ltd) 
Trimethoprim 100mg Tablet 
25908 Sulfamethoxazole 
800mg with 
trimethoprim 
160mg tablet 
Sulfamethoxazole
/Trimethoprim 
800mg + 160mg Tablets 
16620 Co-trimoxazole 
80mg/400mg/5m
l solution for 
infusion 
ampoules 
Sulfamethoxazole
/Trimethoprim 
80mg/1ml + 
16mg/1ml 
Solution for 
infusion 
55986 Trimethoprim 
200mg/5ml oral 
suspension 
Trimethoprim 40mg/1ml Oral suspension 
20523 Thalazole 500mg 
Tablet (May and 
Baker) 
Phthalylsulfathiaz
ole 
500mg Tablet 
49592 Trimethoprim 
100mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Trimethoprim 100mg Tablet 
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34633 Trimethoprim 
200mg tablets 
(Sandoz Ltd) 
Trimethoprim 200mg Tablet 
15973 Polymyxin B 
10,000units/g / 
Trimethoprim 
5mg/g eye 
ointment 
Polymyxin B 
sulfate/Trimetho
prim 
10000unit/1gram 
+ 5mg/1gram 
Eye ointment 
8309 Polytrim eye 
drops (PLIVA 
Pharma Ltd) 
Polymyxin B 
sulfate/Trimetho
prim 
10000unit/1ml + 
1mg/1ml 
Eye drops 
53793 Trimethoprim 
50mg/5ml oral 
suspension sugar 
free (Almus 
Pharmaceuticals 
Ltd) 
Trimethoprim 10mg/1ml Oral suspension 
153 Trimethoprim 
100mg/5ml 
solution for 
injection 
ampoules 
Trimethoprim 20mg/1ml Solution for 
injection 
12465 Polytrim 
ophthalmic 
ointment (PLIVA 
Pharma Ltd) 
Polymyxin B 
sulfate/Trimetho
prim 
10000unit/1gram 
+ 5mg/1gram 
Eye ointment 
31463 Co-trimoxazole 
160mg/800mg/1
0ml solution for 
Sulfamethoxazole
/Trimethoprim 
80mg/1ml + 
16mg/1ml 
Solution for 
infusion 
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infusion 
ampoules 
13306 Monotrim 
100mg/5ml 
solution for 
injection 
ampoules (Abbott 
Healthcare 
Products Ltd) 
Trimethoprim 20mg/1ml Solution for 
injection 
15972 Polymyxin B 
10,000units/ml / 
Trimethoprim 
1mg/ml eye 
drops 
Polymyxin B 
sulfate/Trimetho
prim 
10000unit/1ml + 
1mg/1ml 
Eye drops 
54393 Ciprofloxacin 
250mg tablets 
(Arrow Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
49839 Ciproxin 500mg 
tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
32388 Ciproxin 
200mg/100ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
200mg/100ml Infusion 
51537 Ciprofloxacin 
250mg tablets 
(Alliance 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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Healthcare 
(Distribution) Ltd) 
14233 Ciprofloxacin 
3mg/g eye 
ointment 
Ciprofloxacin 
hydrochloride 
3mg/1gram Eye ointment 
47785 Ciprofloxacin 
400mg/200ml 
infusion bags 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
34494 Ciprofloxacin 
500mg tablets 
(Wockhardt UK 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
50601 Ciprofloxacin 
250mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
43517 Ciprofloxacin 
750mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
61302 Ciprofloxacin 
100mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
7752 Ciproxin 750mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
  
527 
 
54663 Ciproxin Infusion 
200mg/100ml 
solution for 
infusion bottles 
(Bayer Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
58246 Ciprofloxacin 
400mg/200ml 
infusion bags 
(Hospira UK Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
53878 Ciprofloxacin 
500mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
728 Ciproxin 500mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
58235 Ciprofloxacin 
250mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
56789 Ciprofloxacin 
500mg tablets 
(APC 
Pharmaceuticals 
& Chemicals 
(Europe) Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
59653 Ciproxin Infusion 
400mg/200ml 
solution for 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
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infusion bottles 
(Bayer Plc) 
34322 Ciprofloxacin 
500mg Tablet 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
1837 Ciprofloxacin 
750mg tablets 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
50141 Ciprofloxacin 
0.2% eye drops 
preservative free 
Ciprofloxacin 
hydrochloride 
2mg/1ml Eye drops 
34973 Ciprofloxacin 
750mg Tablet 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
66214 Ciprofloxacin 
250mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
29343 Ciprofloxacin 
250mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
45341 Ciprofloxacin 
500mg Tablet 
(Neo Laboratories 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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66727 Ciprofloxacin 
500mg/5ml oral 
suspension 
Ciprofloxacin 100mg/1ml Oral suspension 
63501 Ciprofloxacin 
750mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
50055 Ciprofloxacin 
500mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
66971 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials (A A 
H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
34605 Ciprofloxacin 
500mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
45285 Ciprofloxacin 
500mg tablets 
(Teva UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
42174 Ciprofloxacin 
500mg tablets 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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5631 Ciloxan 0.3% eye 
drops (Alcon 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
3mg/1ml Eye drops 
52309 Ciprofloxacin 
100mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
56856 Ciprofloxacin 
750mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
57960 Ciprofloxacin 
500mg tablets 
(Tillomed 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
52099 Ciprofloxacin 
750mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
34308 Ciprofloxacin 
250mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
52353 Ciproxin 250mg 
tablets (DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
163 Ciproxin 
250mg/5ml oral 
Ciprofloxacin 50mg/1ml Oral suspension 
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suspension 
(Bayer Plc) 
34448 Ciprofloxacin 
250mg tablets 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
57703 Ciprofloxacin 
200mg/100ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
53519 Ciproxin 250mg 
tablets (Lexon 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
498 Ciprofloxacin 
100mg tablets 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
60436 Ciprofloxacin 
250mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
61783 Ciprofloxacin 
250mg tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
56381 Ciprofloxacin 
250mg tablets 
(Strides Shasun 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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65896 Ciproxin 250mg 
tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
52177 Ciproxin 500mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
1202 Ciproxin 250mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
34647 Ciprofloxacin 
250mg Tablet 
(Neo Laboratories 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
64814 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials 
(Genus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
53641 Ciprofloxacin 
500mg tablets 
(Strides Shasun 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
55917 Ciprofloxacin 
500mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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58955 Ciprofloxacin 
100mg/50ml 
solution for 
infusion vials (A A 
H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
26840 Ciprofloxacin 
100mg/50ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
59572 Ciprofloxacin 
500mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
33215 Ciprofloxacin 
200mg/100ml in 
sodium chloride 
0.9% infusion 
Ciprofloxacin 
Lactate 
200mg/100ml Infusion 
30707 Ciprofloxacin 
500mg tablets 
(Mylan Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
58021 Ciprofloxacin 
100mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
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54302 Ciprofloxacin 
250mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
11883 Ciprofloxacin 
100mg/50ml 
solution for 
infusion vials 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
54555 Ciprofloxacin 
100mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
39913 Ciprofloxacin 
100mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
38171 Ciprofloxacin 
200mg/100ml 
infusion bags 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
33989 Ciprofloxacin 
250mg tablets 
(Mylan Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
14376 Ciproxin 2mg/ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
4091 Ciprofloxacin 
250mg/5ml oral 
suspension 
Ciprofloxacin 50mg/1ml Oral suspension 
34655 Ciprofloxacin 
250mg tablets 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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(Wockhardt UK 
Ltd) 
43557 Ciprofloxacin 
500mg tablets 
(PLIVA Pharma 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
29472 Ciprofloxacin 
750mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
48031 Ciprofloxacin 
100mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
67154 Cilodex ear drops 
(Alcon 
Laboratories (UK) 
Ltd) 
Dexamethasone/
Ciprofloxacin 
hydrochloride 
1mg/1ml + 
3mg/1ml 
Ear drops 
34694 Ciprofloxacin 
250mg tablets 
(PLIVA Pharma 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
68409 Ciprofloxacin 
750mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
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68274 Ciproxin 500mg 
tablets (DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
281 Ciprofloxacin 
250mg tablets 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
34478 Ciprofloxacin 
250mg tablets 
(Teva UK Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
64446 Ciprofloxacin 
250mg tablets 
(Tillomed 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
49445 Ciprofloxacin 
500mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
43814 Ciprofloxacin 
250mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
61869 Ciproxin 
250mg/5ml oral 
suspension 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 50mg/1ml Oral suspension 
28544 Ciprofloxaxin 
400mg/200ml in 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
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glucose 5% 
infusion 
29507 Ciprofloxacin 
400mg/200ml in 
sodium chloride 
0.9% infusion 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
58608 Ciprofloxacin 
100mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
42507 Ciprofloxacin 
100mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
59937 Ciprofloxacin 
750mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
21812 Ciproxin Infusion 
100mg/50ml 
solution for 
infusion bottles 
(Bayer Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
43797 Ciprofloxacin 
500mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
19512 Ciloxan 3mg/g 
eye ointment 
Ciprofloxacin 
hydrochloride 
3mg/1gram Eye ointment 
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(Alcon 
Laboratories (UK) 
Ltd) 
9154 Ciproxin 100mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
54674 Ciprofloxacin 
100mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
38006 Ciproxin 
400mg/200ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
583 Ciprofloxacin 
500mg tablets 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
32530 Ciproxin iv 
flexibag 
400mg/200ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
53088 Ciprofloxacin 
500mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
54701 Ciprofloxacin 
250mg tablets 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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(Bristol 
Laboratories Ltd) 
67656 Ciprofloxacin 
500mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
52501 Ciprofloxacin 
500mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
41561 Ciprofloxacin 
250mg tablets 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
58074 Ciprofloxacin 
400mg/200ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
52807 Ciproxin 500mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
34559 Ciprofloxacin 
250mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
58323 Ciprofloxacin 
100mg tablets 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
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(Alliance 
Healthcare 
(Distribution) Ltd) 
66483 Ciprofloxacin 
170mg/5ml oral 
suspension 
Ciprofloxacin 34mg/1ml Oral suspension 
10304 Ciprofloxacin 
2mg/ml infusion 
Ciprofloxacin 
Lactate 
2mg/ml Infusion 
52616 Ciprofloxacin 
500mg tablets 
(Arrow Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
64301 Ciprofloxacin 
500mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
528 Ciprofloxacin 
0.3% eye drops 
Ciprofloxacin 
hydrochloride 
3mg/1ml Eye drops 
29458 Ciprofloxacin 
500mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
57118 Ciprofloxacin 
250mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
  
541 
 
54993 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
65115 Ciprofloxacin 
0.3% / 
Dexamethasone 
0.1% ear drops 
Dexamethasone/
Ciprofloxacin 
hydrochloride 
1mg/1ml + 
3mg/1ml 
Ear drops 
51726 Nitrofurantoin 
40mg/5ml oral 
suspension 
Nitrofurantoin 8mg/1ml Oral suspension 
35673 Nitrofurantoin 
25mg/5ml oral 
suspension sugar 
free (AMCo) 
Nitrofurantoin 5mg/1ml Oral suspension 
2023 Furadantin 50mg 
tablets (AMCo) 
Nitrofurantoin 50mg Tablet 
61907 Nitrofurantoin 
50mg capsules 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Nitrofurantoin 50mg Capsule 
6370 Nitrofurantoin 
100mg modified-
release capsules 
Nitrofurantoin 100mg Modified-release 
capsule 
53094 Nitrofurantoin 
50mg tablets (A A 
H 
Nitrofurantoin 50mg Tablet 
  
542 
 
Pharmaceuticals 
Ltd) 
54325 Nitrofurantoin 
50mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Nitrofurantoin 50mg Tablet 
1825 Macrodantin 
50mg capsules 
(AMCo) 
Nitrofurantoin 50mg Capsule 
60713 Nitrofurantoin 
100mg capsules 
(AMCo) 
Nitrofurantoin 100mg Capsule 
64389 Nitrofurantoin 
30mg/5ml oral 
solution 
Nitrofurantoin 6mg/1ml Oral solution 
67759 Nitrofurantoin 
50mg tablets 
(Mylan Ltd) 
Nitrofurantoin 50mg Tablet 
16284 Urantoin 100mg 
tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Nitrofurantoin 100mg Tablet 
2198 Nitrofurantoin 
25mg/5ml Oral 
suspension 
Nitrofurantoin 25mg/5ml Oral Suspension 
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60252 Nitrofurantoin 
50mg capsules 
(AMCo) 
Nitrofurantoin 50mg Capsule 
41397 Nitrofurantoin 
100mg tablets 
(Actavis UK Ltd) 
Nitrofurantoin 100mg Tablet 
58469 Nitrofurantoin 
5mg/5ml oral 
solution 
Nitrofurantoin 1mg/1ml Oral solution 
53638 Nitrofurantoin 
100mg tablets 
(Teva UK Ltd) 
Nitrofurantoin 100mg Tablet 
56621 Nitrofurantoin 
25mg/5ml oral 
solution 
Nitrofurantoin 5mg/1ml Oral solution 
65207 Nitrofurantoin 
24mg/5ml oral 
suspension 
Nitrofurantoin 4.8mg/1ml Oral suspension 
35850 Nitrofurantoin 
100mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Nitrofurantoin 100mg Tablet 
210 Nitrofurantoin 
50mg capsules 
Nitrofurantoin 50mg Capsule 
57669 Nitrofurantoin 
50mg tablets 
(Genesis 
Nitrofurantoin 50mg Tablet 
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Pharmaceuticals 
Ltd) 
2541 Furadantin 
100mg tablets 
(AMCo) 
Nitrofurantoin 100mg Tablet 
466 Nitrofurantoin 
100mg capsules 
Nitrofurantoin 100mg Capsule 
2036 Macrodantin 
100mg capsules 
(AMCo) 
Nitrofurantoin 100mg Capsule 
778 Nitrofurantoin 
50mg tablets 
Nitrofurantoin 50mg Tablet 
2887 Nitrofurantoin 
100mg tablets 
Nitrofurantoin 100mg Tablet 
40164 Nitrofurantoin 
50mg tablets 
(Actavis UK Ltd) 
Nitrofurantoin 50mg Tablet 
65803 Macrobid 100mg 
modified-release 
capsules 
(Waymade 
Healthcare Plc) 
Nitrofurantoin 100mg Modified-release 
capsule 
53659 Nitrofurantoin 
25mg/5ml oral 
suspension 
Nitrofurantoin 5mg/1ml Oral suspension 
48353 Nitrofurantoin 
25mg/5ml oral 
Nitrofurantoin 5mg/1ml Oral suspension 
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suspension sugar 
free 
53171 Nitrofurantoin 
50mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Nitrofurantoin 50mg Tablet 
62647 Nitrofurantoin 
50mg Tablet 
(Biorex 
Laboratories Ltd) 
Nitrofurantoin 50mg Tablet 
272 Furadantin 
25mg/5ml oral 
suspension 
(Mercury Pharma 
Group Ltd) 
Nitrofurantoin 5mg/1ml Oral suspension 
57779 Nitrofurantoin 
50mg tablets 
(Waymade 
Healthcare Plc) 
Nitrofurantoin 50mg Tablet 
61642 Nitrofurantoin 
100mg capsules 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Nitrofurantoin 100mg Capsule 
67981 Genfura 100mg 
tablets (Genesis 
Pharmaceuticals 
Ltd) 
Nitrofurantoin 100mg Tablet 
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51959 Nitrofurantoin 
50mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Nitrofurantoin 50mg Tablet 
64690 Nitrofurantoin 
100mg/5ml oral 
solution 
Nitrofurantoin 20mg/1ml Oral solution 
65251 Macrodantin 
50mg capsules 
(Waymade 
Healthcare Plc) 
Nitrofurantoin 50mg Capsule 
63588 Nitrofurantoin 
50mg capsules (A 
A H 
Pharmaceuticals 
Ltd) 
Nitrofurantoin 50mg Capsule 
67762 Nitrofurantoin 
100mg tablets 
(Mylan Ltd) 
Nitrofurantoin 100mg Tablet 
7525 Macrobid 100mg 
modified-release 
capsules (AMCo) 
Nitrofurantoin 100mg Modified-release 
capsule 
66013 Nitrofurantoin 
50mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Nitrofurantoin 50mg Tablet 
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17181 Pivampicillin 
175mg sachet 
Pivampicillin 175mg Sachets 
28701 Ampicillin 50mg / 
Cloxacillin 
25mg/vial 
injection 
Cloxacillin/Ampici
llin 
50mg + 25mg/vial Injection 
46175 Ampicillin 
125mg/5ml Oral 
suspension 
(Hillcross 
Pharmaceuticals 
Ltd) 
Ampicillin 
Trihydrate 
125mg/5ml Oral Suspension 
8680 Talpen 
125mg/5ml Oral 
solution 
(Beecham 
Research 
Laboratories) 
Talampicillin 
Hydrochloride 
125mg/5ml Oral Solution 
308 Magnapen 
250mg/250mg 
capsules 
(Wockhardt UK 
Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
951 Flucloxacillin with 
ampicillin 
125mg+125mg 
Liquid 
Ampicillin 
Trihydrate/Fluclo
xacillin 
Magnesium 
125mg+125mg Liquid 
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2246 Pondocillin 
500mg Tablet 
(LEO Pharma) 
Pivampicillin 500mg Tablet 
857 Ampicillin 
125mg/5ml oral 
suspension 
Ampicillin 25mg/1ml Oral suspension 
67787 Ampicillin 
250mg/5ml oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Ampicillin 50mg/1ml Oral suspension 
45237 Co-fluampicil 
500mg with 
500mg injection 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
500mg+500mg Injection 
28919 Ampicillin 250mg 
/ Cloxacillin 
250mg/vial 
injection 
Cloxacillin/Ampici
llin 
250mg + 
250mg/vial 
Injection 
7570 Pivampicillin 
500mg tablet 
Pivampicillin 500mg Tablets 
31156 Ampitrin 250mg 
Capsule (OPD 
Pharm) 
Ampicillin 250mg Capsule 
26356 Amfipen 500mg 
Capsule 
(Yamanouchi 
Pharma Ltd) 
Ampicillin 500mg Capsule 
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54471 Ampicillin 250mg 
capsules (Kent 
Pharmaceuticals 
Ltd) 
Ampicillin 250mg Capsule 
34228 Ampicillin 250mg 
capsules (A A H 
Pharmaceuticals 
Ltd) 
Ampicillin 250mg Capsule 
25570 Co-fluampicil 
250mg/250mg 
capsules (Sandoz 
Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
21967 Vidopen 500mg 
Capsule (Berk 
Pharmaceuticals 
Ltd) 
Ampicillin 500mg Capsule 
57997 Ampicillin 250mg 
capsules 
(Waymade 
Healthcare Plc) 
Ampicillin 250mg Capsule 
204 Penbritin 250mg 
Capsule 
(Beecham 
Research 
Laboratories) 
Ampicillin 250mg Capsule 
4318 Penbritin 
250mg/5ml Oral 
solution 
(Beecham 
Ampicillin 50mg/1ml Oral suspension 
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Research 
Laboratories) 
31154 Ampitrin 500mg 
Capsule (OPD 
Pharm) 
Ampicillin 500mg Capsule 
2377 Pondocillin 
175mg/5ml Oral 
suspension sugar 
free (LEO 
Pharma) 
Pivampicillin 175mg/5ml Oral Suspension 
41744 Ampicillin 
125mg/5ml oral 
suspension (A A H 
Pharmaceuticals 
Ltd) 
Ampicillin 25mg/1ml Oral suspension 
12540 Pivampicillin 
250mg with 
pivmecillinam 
200mg tablet 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
250mg + 200mg Tablets 
13438 Magnapen 
1g/vial Injection 
(C P 
Pharmaceuticals 
Ltd) 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
1g/vial Injection 
900 Ampicillin 
125mg/5ml sugar 
free suspension 
Ampicillin 
Trihydrate 
125mg/5ml Suspension 
Sugar-free 
10369 Ampicillin 125mg 
/ Flucloxacillin 
Ampicillin 
Trihydrate/Fluclo
125mg+125mg Syrup 
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125mg oral 
solution 
xacillin 
Magnesium 
25832 Pivampicillin 
125mg with 
pivmecillinam100
mg tablet 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
125mg + 100mg Tablets 
31669 Pondocillin 
120mg Sachets 
(LEO Pharma) 
Pivampicillin 120mg Sachets 
37485 Penbritin 
125mg/5ml syrup 
(Chemidex 
Pharma Ltd) 
Ampicillin 25mg/1ml Oral suspension 
10603 Penbritin 
125mg/5ml Oral 
solution 
(Beecham 
Research 
Laboratories) 
Ampicillin 25mg/1ml Oral suspension 
31471 Vidopen 
250mg/5ml Oral 
solution (Berk 
Pharmaceuticals 
Ltd) 
Ampicillin 50mg/1ml Oral suspension 
926 Ampicillin 500mg 
capsules 
Ampicillin 500mg Capsule 
18934 Penbritin 
125mg/1.25ml 
Liquid (Beecham 
Ampicillin 
Trihydrate 
125mg/1.25ml Liquid 
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Research 
Laboratories) 
12083 Ampiclox 
neonatal 
90mg/0.6ml Oral 
suspension 
(Beecham 
Research 
Laboratories) 
Cloxacillin/Ampici
llin Sodium 
90mg/0.6ml Oral Suspension 
41646 Ampicillin 250mg 
Capsule (Berk 
Pharmaceuticals 
Ltd) 
Ampicillin 250mg Capsule 
21926 Amfipen 
500mg/vial 
Injection 
(Yamanouchi 
Pharma Ltd) 
Ampicillin sodium 500mg Powder for 
solution for 
injection 
41415 Co-fluampicil 
250mg/250mg 
capsules (Kent 
Pharmaceuticals 
Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
21345 Bacampicillin HCl 
400mg tablets 
Bacampicillin 400mg Tablets 
106 Ampicillin 
250mg/5ml oral 
suspension 
Ampicillin 50mg/1ml Oral suspension 
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14485 Ampicillin 500mg 
powder for 
solution for 
injection vials 
Ampicillin sodium 500mg Powder for 
solution for 
injection 
20516 Miraxid Liquid 
(Rpr / Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Liquid 
15039 Penbritin 500mg 
Capsule 
(Beecham 
Research 
Laboratories) 
Ampicillin 500mg Capsule 
30630 Penbritin 
250mg/vial 
Injection 
(Beecham 
Research 
Laboratories) 
Ampicillin Sodium 250mg/vial Injection 
26174 Ampicillin 500mg 
capsules (A A H 
Pharmaceuticals 
Ltd) 
Ampicillin 500mg Capsule 
52340 Cloxacillin 30mg 
with Ampicillin 
60mg/0.6ml 
suspension 
Cloxacillin/Ampici
llin Sodium 
  
30764 Co-fluampicil 
250mg/250mg 
capsules (IVAX 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
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Pharmaceuticals 
UK Ltd) 
9242 Flucloxacillin with 
ampicillin 
250mg+250mg 
Capsule 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
250mg+250mg Capsule 
8960 Pondocillin plus 
Tablet (Edwin 
Burgess Ltd) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Tablet 
16167 Ampicillin 
250mg/5ml sugar 
free suspension 
Ampicillin 
Trihydrate 
250mg/5ml Suspension 
Sugar-free 
58520 Ampicillin 250mg 
capsules (Alliance 
Healthcare 
(Distribution) Ltd) 
Ampicillin 250mg Capsule 
34358 Co-fluampicil 
250mg/250mg 
capsules (Mylan 
Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
20007 Talampicillin 
250mg tablets 
Talampicillin 
Hydrochloride 
250mg Tablets 
1450 Ampicillin 250mg 
/ Flucloxacillin 
250mg capsules 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
250mg+250mg Capsules 
21029 Miraxid 450 
Tablet (Rpr / 
Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Tablet 
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34380 Co-fluampicil 
250mg/250mg 
capsules (Actavis 
UK Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
32760 Ampitrin 
125mg/5ml 
Liquid (OPD 
Pharm) 
Ampicillin 25mg/1ml Oral suspension 
24483 Penbritin 250mg 
capsules 
(Chemidex 
Pharma Ltd) 
Ampicillin 250mg Capsule 
13531 Magnapen 
500mg powder 
for solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Ampicillin 
sodium/Flucloxac
illin sodium 
250mg + 250mg Powder for 
solution for 
injection 
10685 Ampicillin 250mg 
injection 
Ampicillin Sodium 250mg Injection 
23485 Flu-amp 500mg 
Capsule (Generics 
(UK) Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
38091 Penbritin Forte 
250mg/5ml syrup 
(Chemidex 
Pharma Ltd) 
Ampicillin 50mg/1ml Oral suspension 
16589 Talampicillin 
125mg/5ml syrup 
Talampicillin 
Hydrochloride 
125mg/5ml Syrup 
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12382 Ampiclox 500mg 
Capsule 
(Beecham 
Research 
Laboratories) 
Cloxacillin/Ampici
llin 
500mg Capsule 
14484 Ampicillin / 
Cloxacillin 500mg 
capsules 
Cloxacillin/Ampici
llin 
500mg Capsules 
9473 Co-fluampicil 
125mg/125mg/5
ml oral 
suspension 
Flucloxacillin 
magnesium/Ampi
cillin trihydrate 
25mg/1ml + 
25mg/1ml 
Oral suspension 
54907 Cloxacillin 250mg 
with Ampicillin 
250mg injection 
Cloxacillin/Ampici
llin Sodium 
  
8209 Ampicillin 
125mg/5ml 
paediatric oral 
suspension 
Ampicillin 
Trihydrate 
125mg/1.25ml Suspension 
55846 Ampicillin 
125mg/5ml 
Liquid (C P 
Pharmaceuticals 
Ltd) 
Ampicillin 25mg/1ml Oral suspension 
7531 Penbritin 500mg 
powder for 
solution for 
injection vials 
Ampicillin sodium 500mg Powder for 
solution for 
injection 
  
557 
 
(Chemidex 
Pharma Ltd) 
2874 Magnapen syrup 
(Wockhardt UK 
Ltd) 
Flucloxacillin 
magnesium/Ampi
cillin trihydrate 
25mg/1ml + 
25mg/1ml 
Oral suspension 
12489 Ambaxin 400mg 
Tablet 
(Pharmacia Ltd) 
Bacampicillin 400mg Tablet 
10755 Ampiciilin 60mg / 
Cloxacillin 
30mg/0.6ml 
sugar free oral 
suspension 
Cloxacillin/Ampici
llin Sodium 
60mg + 
30mg/0.6ml 
Suspension 
Sugar-free 
10795 Ampiclox 
250mg/5ml Oral 
solution 
(Beecham 
Research 
Laboratories) 
Cloxacillin/Ampici
llin 
250mg/5ml Oral Solution 
115 Ampicillin 250mg 
capsules 
Ampicillin 250mg Capsule 
17161 Miraxid Tablet 
(Rpr / Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Tablet 
31281 Penbritin 500mg 
capsules 
(Chemidex 
Pharma Ltd) 
Ampicillin 500mg Capsule 
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21801 Vidopen 250mg 
Capsule (Berk 
Pharmaceuticals 
Ltd) 
Ampicillin 250mg Capsule 
20869 Flucloxacillin with 
ampicillin 
250mg+250mg 
Injection 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
250mg+250mg Injection 
24847 Ampicillin 500mg 
/ Flucloxacillin 
500mg injection 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
500mg+500mg Injection 
5454 Co-fluampicil 
250mg/250mg 
capsules 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
11954 Talpen 250mg 
Tablet (Beecham 
Research 
Laboratories) 
Talampicillin 
Hydrochloride 
250mg Tablet 
41647 Ampicillin 500mg 
capsules (Actavis 
UK Ltd) 
Ampicillin 500mg Capsule 
32148 Amfipen forte 
250mg/5ml Oral 
solution 
(Yamanouchi 
Pharma Ltd) 
Ampicillin 50mg/1ml Oral suspension 
20531 Amfipen 250mg 
Capsule 
Ampicillin 250mg Capsule 
  
559 
 
(Yamanouchi 
Pharma Ltd) 
10538 Ampiclox 
neonatal 
75mg/vial 
Injection 
(Beecham 
Research 
Laboratories) 
Cloxacillin/Ampici
llin 
75mg/vial Injection 
26510 Ampicillin 250mg 
/ Flucloxacillin 
250mg injection 
Ampicillin 
Trihydrate/Fluclo
xacillin Sodium 
250mg+250mg Injection 
8614 Pivampicillin 
175mg/5ml oral 
solution 
Pivampicillin 175mg/5ml Suspension 
19648 Co-fluampicil 
250mg/250mg 
capsules (A A H 
Pharmaceuticals 
Ltd) 
Flucloxacillin 
sodium/Ampicilli
n trihydrate 
250mg + 250mg Capsule 
31473 Vidopen 
250mg/vial 
Injection (Berk 
Pharmaceuticals 
Ltd) 
Ampicillin Sodium 250mg/vial Injection 
23186 Vidopen 
125mg/5ml Oral 
solution (Berk 
Ampicillin 25mg/1ml Oral suspension 
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Pharmaceuticals 
Ltd) 
26329 Co-fluampicil 
250mg/250mg 
powder for 
solution for 
injection vials 
Ampicillin 
sodium/Flucloxac
illin sodium 
250mg + 250mg Powder for 
solution for 
injection 
22452 Britcin 250mg 
Capsule (DDSA 
Pharmaceuticals 
Ltd) 
Ampicillin 250mg Capsule 
32347 Amfipen 
125mg/5ml Oral 
solution 
(Yamanouchi 
Pharma Ltd) 
Ampicillin 25mg/1ml Oral suspension 
7519 Norfloxacin 
400mg tablets 
Norfloxacin 400mg Tablet 
32112 Norfloxacin 
400mg tablets 
(Genus 
Pharmaceuticals 
Ltd) 
Norfloxacin 400mg Tablet 
26586 Noroxin 0.30% 
Eye drops (MSD 
Thomas Morson 
Pharmaceuticals) 
Norfloxacin 0.30% Eye Drops 
20187 Norfloxacin 0.3% 
Eye drops 
Norfloxacin 0.30% Eye Drops 
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2253 Utinor 400mg 
tablets (Merck 
Sharp & Dohme 
Ltd) 
Norfloxacin 400mg Tablet 
26101 Pivmecillinam 
100mg/sachet 
Pivmecillinam 
Hydrochloride 
100mg/sachet Suspension 
12014 Pivmecillinam 
200mg tablets 
Pivmecillinam 
hydrochloride 
200mg Tablet 
12540 Pivampicillin 
250mg with 
pivmecillinam 
200mg tablet 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
250mg + 200mg Tablets 
25832 Pivampicillin 
125mg with 
pivmecillinam100
mg tablet 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
125mg + 100mg Tablets 
20516 Miraxid Liquid 
(Rpr / Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Liquid 
8960 Pondocillin plus 
Tablet (Edwin 
Burgess Ltd) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Tablet 
21029 Miraxid 450 
Tablet (Rpr / 
Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
 
Tablet 
12015 Selexid 
100mg/sachet 
Pivmecillinam 
Hydrochloride 
100mg/sachet Liquid 
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Liquid (Edwin 
Burgess Ltd) 
9601 Selexid 200mg 
tablets (LEO 
Pharma) 
Pivmecillinam 
hydrochloride 
200mg Tablet 
17161 Miraxid Tablet 
(Rpr / Fisons) 
Pivampicillin/Piv
mecillinam 
Hydrochloride 
  Tablet 
12277 Cinoxacin 500mg 
capsules 
Cinoxacin 500mg Capsules 
54393 Ciprofloxacin 
250mg tablets 
(Arrow Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
49839 Ciproxin 500mg 
tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
32388 Ciproxin 
200mg/100ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
200mg/100ml Infusion 
51537 Ciprofloxacin 
250mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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47785 Ciprofloxacin 
400mg/200ml 
infusion bags 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
34494 Ciprofloxacin 
500mg tablets 
(Wockhardt UK 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
50601 Ciprofloxacin 
250mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
30877 Tarivid 2mg/ml 
Infusion (Aventis 
Pharma) 
Ofloxacin 
Hydrochloride 
2mg/ml Infusion 
43517 Ciprofloxacin 
750mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
61302 Ciprofloxacin 
100mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
7519 Norfloxacin 
400mg tablets 
Norfloxacin 400mg Tablet 
7752 Ciproxin 750mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
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54663 Ciproxin Infusion 
200mg/100ml 
solution for 
infusion bottles 
(Bayer Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
58246 Ciprofloxacin 
400mg/200ml 
infusion bags 
(Hospira UK Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
10567 Cinobac 500mg 
Capsule (Eli Lilly 
and Company 
Ltd) 
Cinoxacin 500mg Capsule 
17693 Tavanic 250mg 
tablets (Sanofi) 
Levofloxacin 
hemihydrate 
250mg Tablet 
53878 Ciprofloxacin 
500mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
728 Ciproxin 500mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
58235 Ciprofloxacin 
250mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
56789 Ciprofloxacin 
500mg tablets 
(APC 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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Pharmaceuticals 
& Chemicals 
(Europe) Ltd) 
59653 Ciproxin Infusion 
400mg/200ml 
solution for 
infusion bottles 
(Bayer Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
34322 Ciprofloxacin 
500mg Tablet 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
1837 Ciprofloxacin 
750mg tablets 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
34523 Ofloxacin 200mg 
tablets (Sandoz 
Ltd) 
Ofloxacin 200mg Tablet 
34973 Ciprofloxacin 
750mg Tablet 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
66214 Ciprofloxacin 
250mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
29343 Ciprofloxacin 
250mg tablets (A 
A H 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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Pharmaceuticals 
Ltd) 
10319 Levofloxacin 
500mg/100ml 
Intravenous 
infusion 
Levofloxacin 500mg/100ml Intravenous 
Infusion 
45341 Ciprofloxacin 
500mg Tablet 
(Neo Laboratories 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
47995 Avelox 
400mg/250ml 
solution for 
infusion bottles 
(Bayer Plc) 
Moxifloxacin 
hydrochloride 
1.6mg/1ml Solution for 
infusion 
14389 Comprecin 
200mg Tablet 
(Parke-davis 
Research 
Laboratories) 
Enoxacin 200mg Tablet 
6206 Tavanic 500mg 
tablets (Sanofi) 
Levofloxacin 
hemihydrate 
500mg Tablet 
66727 Ciprofloxacin 
500mg/5ml oral 
suspension 
Ciprofloxacin 100mg/1ml Oral suspension 
56012 Levofloxacin 
250mg tablets (Dr 
Reddy's 
Levofloxacin 
hemihydrate 
250mg Tablet 
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Laboratories (UK) 
Ltd) 
66317 Tarivid 
200mg/100ml 
solution for 
infusion bottles 
(Sanofi) 
Ofloxacin 
hydrochloride 
2mg/1ml Solution for 
infusion 
63501 Ciprofloxacin 
750mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
34819 Ofloxacin 400mg 
tablets (Mylan 
Ltd) 
Ofloxacin 400mg Tablet 
32112 Norfloxacin 
400mg tablets 
(Genus 
Pharmaceuticals 
Ltd) 
Norfloxacin 400mg Tablet 
50055 Ciprofloxacin 
500mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
53673 Levofloxacin 
500mg/100ml 
infusion bags 
   
24373 Tavanic 
500mg/100ml 
solution for 
Levofloxacin 
hemihydrate 
5mg/1ml Solution for 
infusion 
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infusion vials 
(Sanofi) 
66971 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials (A A 
H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
34605 Ciprofloxacin 
500mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
55708 Levofloxacin 
250mg tablets 
(Actavis UK Ltd) 
Levofloxacin 
hemihydrate 
250mg Tablet 
45285 Ciprofloxacin 
500mg tablets 
(Teva UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
42174 Ciprofloxacin 
500mg tablets 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
52309 Ciprofloxacin 
100mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
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66211 Levofloxacin 
500mg/100ml solution 
for infusion bottles 
  
2726 Tarivid 400mg 
tablets (Sanofi) 
Ofloxacin 400mg Tablet 
40252 Ofloxacin 
200mg/100ml 
solution for 
infusion bottles 
Ofloxacin 
hydrochloride 
2mg/1ml Solution for 
infusion 
56856 Ciprofloxacin 
750mg tablets 
(Ranbaxy (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
57960 Ciprofloxacin 
500mg tablets 
(Tillomed 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
5238 Levofloxacin 
500mg tablets 
Levofloxacin 
hemihydrate 
500mg Tablet 
52099 Ciprofloxacin 
750mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
34308 Ciprofloxacin 
250mg tablets 
(Actavis UK Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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52353 Ciproxin 250mg 
tablets (DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
65885 Levofloxacin 
500mg tablets 
(Waymade 
Healthcare Plc) 
Levofloxacin 
hemihydrate 
500mg Tablet 
163 Ciproxin 
250mg/5ml oral 
suspension 
(Bayer Plc) 
Ciprofloxacin 50mg/1ml Oral suspension 
34448 Ciprofloxacin 
250mg tablets 
(Niche Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
57703 Ciprofloxacin 
200mg/100ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
53519 Ciproxin 250mg 
tablets (Lexon 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
498 Ciprofloxacin 
100mg tablets 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
60436 Ciprofloxacin 
250mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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58345 Levofloxacin 
250mg tablets 
(Mylan Ltd) 
Levofloxacin 
hemihydrate 
250mg Tablet 
61783 Ciprofloxacin 
250mg tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
56381 Ciprofloxacin 
250mg tablets 
(Strides Shasun 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
48200 Grepafloxacin 
400mg Tablet 
Grepafloxacin 400mg Tablet 
65896 Ciproxin 250mg 
tablets 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
25901 Sparfloxacin 
200mg tablet 
Sparfloxacin 200mg Tablets 
58940 Levofloxacin 
250mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Levofloxacin 
hemihydrate 
250mg Tablet 
52177 Ciproxin 500mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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34391 Ofloxacin 400mg 
tablets (Sandoz 
Ltd) 
Ofloxacin 400mg Tablet 
1202 Ciproxin 250mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
25127 Avelox 400mg 
tablets (Bayer 
Plc) 
Moxifloxacin 
hydrochloride 
400mg Tablet 
34647 Ciprofloxacin 
250mg Tablet 
(Neo Laboratories 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
64814 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials 
(Genus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
53641 Ciprofloxacin 
500mg tablets 
(Strides Shasun 
(UK) Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
372 Nalidixic acid 
300mg/5ml oral 
suspension 
Nalidixic acid 60mg/1ml Oral suspension 
64991 Levofloxacin 
500mg tablets 
Levofloxacin 
hemihydrate 
500mg Tablet 
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(Accord 
Healthcare Ltd) 
55917 Ciprofloxacin 
500mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
58955 Ciprofloxacin 
100mg/50ml 
solution for 
infusion vials (A A 
H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
561 Ofloxacin 200mg 
tablets 
Ofloxacin 200mg Tablet 
26840 Ciprofloxacin 
100mg/50ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
59572 Ciprofloxacin 
500mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
33707 Ofloxacin 400mg 
tablets (Teva UK 
Ltd) 
Ofloxacin 400mg Tablet 
33215 Ciprofloxacin 
200mg/100ml in 
Ciprofloxacin 
Lactate 
200mg/100ml Infusion 
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sodium chloride 
0.9% infusion 
6295 Levofloxacin 
250mg tablets 
Levofloxacin 
hemihydrate 
250mg Tablet 
30707 Ciprofloxacin 
500mg tablets 
(Mylan Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
58021 Ciprofloxacin 
100mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
54302 Ciprofloxacin 
250mg tablets 
(Medreich Plc) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
11883 Ciprofloxacin 
100mg/50ml 
solution for 
infusion vials 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
21147 Uriben 
300mg/5ml oral 
suspension 
(Rosemont 
Pharmaceuticals 
Ltd) 
Nalidixic acid 60mg/1ml Oral suspension 
54555 Ciprofloxacin 
100mg tablets 
(DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
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39913 Ciprofloxacin 
100mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
38171 Ciprofloxacin 
200mg/100ml 
infusion bags 
Ciprofloxacin 
lactate 
2mg/1ml Infusion 
33989 Ciprofloxacin 
250mg tablets 
(Mylan Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
14376 Ciproxin 2mg/ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
4091 Ciprofloxacin 
250mg/5ml oral 
suspension 
Ciprofloxacin 50mg/1ml Oral suspension 
34655 Ciprofloxacin 
250mg tablets 
(Wockhardt UK 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
9073 Nalidixic acid 
with sodium 
citrate 660mg + 
3750mg Sachets 
Nalidixic 
Acid/Sodium 
Citrate 
660mg + 3750mg Sachets 
43557 Ciprofloxacin 
500mg tablets 
(PLIVA Pharma 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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29472 Ciprofloxacin 
750mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
45263 Ofloxacin 400mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Ofloxacin 400mg Tablet 
34694 Ciprofloxacin 
250mg tablets 
(PLIVA Pharma 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
68409 Ciprofloxacin 
750mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
52945 Ciprofloxacin 
200mg/100ml solution 
for infusion vials 
  
68274 Ciproxin 500mg 
tablets (DE 
Pharmaceuticals) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
281 Ciprofloxacin 
250mg tablets 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
67572 Levofloxacin 
250mg tablets 
Levofloxacin 
hemihydrate 
250mg Tablet 
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(Accord 
Healthcare Ltd) 
34478 Ciprofloxacin 
250mg tablets 
(Teva UK Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
64446 Ciprofloxacin 
250mg tablets 
(Tillomed 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
17272 Teflox 300mg 
Tablet (Abbott 
Laboratories Ltd) 
Temafloxacin 300mg Tablet 
49445 Ciprofloxacin 
500mg tablets 
(Almus 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
43814 Ciprofloxacin 
250mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
61869 Ciproxin 
250mg/5ml oral 
suspension 
(Waymade 
Healthcare Plc) 
Ciprofloxacin 50mg/1ml Oral suspension 
4513 Tarivid 200mg 
tablets (Sanofi) 
Ofloxacin 200mg Tablet 
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28544 Ciprofloxaxin 
400mg/200ml in 
glucose 5% 
infusion 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
29507 Ciprofloxacin 
400mg/200ml in 
sodium chloride 
0.9% infusion 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
58608 Ciprofloxacin 
100mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
60817 Levofloxacin 
500mg tablets 
(Actavis UK Ltd) 
Levofloxacin 
hemihydrate 
500mg Tablet 
42507 Ciprofloxacin 
100mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
17890 Eradacin 150mg 
Capsule (Sanofi-
Synthelabo Ltd) 
Rosoxacin 150mg Capsule 
59937 Ciprofloxacin 
750mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
750mg Tablet 
21812 Ciproxin Infusion 
100mg/50ml 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
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solution for 
infusion bottles 
(Bayer Plc) 
43797 Ciprofloxacin 
500mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
9154 Ciproxin 100mg 
tablets (Bayer 
Plc) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
17749 Teflox 400mg 
Tablet (Abbott 
Laboratories Ltd) 
Temafloxacin 400mg Tablet 
56439 Ciprofloxacin 
200mg/100ml solution 
for infusion vials (A A 
H Pharmaceuticals Ltd) 
  
54674 Ciprofloxacin 
100mg tablets 
(Phoenix 
Healthcare 
Distribution Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
38006 Ciproxin 
400mg/200ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
583 Ciprofloxacin 
500mg tablets 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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32530 Ciproxin iv 
flexibag 
400mg/200ml 
Infusion (Bayer 
Plc) 
Ciprofloxacin 
Lactate 
400mg/200ml Infusion 
53088 Ciprofloxacin 
500mg tablets (Dr 
Reddy's 
Laboratories (UK) 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
54701 Ciprofloxacin 
250mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
67656 Ciprofloxacin 
500mg tablets 
(Bristol 
Laboratories Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
52501 Ciprofloxacin 
500mg tablets 
(Accord 
Healthcare Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
23666 Grepafloxacin 
600mg Tablet 
Grepafloxacin 600mg Tablet 
29280 Ofloxacin 2mg/ml 
Infusion 
Ofloxacin 
Hydrochloride 
2mg/ml Infusion 
41561 Ciprofloxacin 
250mg tablets 
(IVAX 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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Pharmaceuticals 
UK Ltd) 
34541 Ofloxacin 200mg 
tablets (Teva UK 
Ltd) 
Ofloxacin 200mg Tablet 
2253 Utinor 400mg 
tablets (Merck 
Sharp & Dohme 
Ltd) 
Norfloxacin 400mg Tablet 
566 Ofloxacin 400mg 
tablets 
Ofloxacin 400mg Tablet 
58074 Ciprofloxacin 
400mg/200ml 
solution for 
infusion bottles 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
35777 Rosoxacin 150mg 
capsule 
Rosoxacin 150mg Capsules 
12428 Enoxacin 200mg 
tablets 
Enoxacin 200mg Tablets 
52807 Ciproxin 500mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
34559 Ciprofloxacin 
250mg tablets 
(Sandoz Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
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58323 Ciprofloxacin 
100mg tablets 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Ciprofloxacin 
hydrochloride 
100mg Tablet 
66483 Ciprofloxacin 
170mg/5ml oral 
suspension 
Ciprofloxacin 34mg/1ml Oral suspension 
18661 Temafloxacin 
400mg tablets 
Temafloxacin 400mg Tablets 
10304 Ciprofloxacin 
2mg/ml infusion 
Ciprofloxacin 
Lactate 
2mg/ml Infusion 
52616 Ciprofloxacin 
500mg tablets 
(Arrow Generics 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
56075 Levofloxacin 
500mg/100ml 
solution for 
infusion vials 
Levofloxacin 
hemihydrate 
5mg/1ml Solution for 
infusion 
64301 Ciprofloxacin 
500mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
29458 Ciprofloxacin 
500mg tablets (A 
A H 
Ciprofloxacin 
hydrochloride 
500mg Tablet 
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Pharmaceuticals 
Ltd) 
57118 Ciprofloxacin 
250mg tablets 
(Kent 
Pharmaceuticals 
Ltd) 
Ciprofloxacin 
hydrochloride 
250mg Tablet 
54993 Ciprofloxacin 
400mg/200ml 
solution for 
infusion vials 
Ciprofloxacin 
lactate 
2mg/1ml Solution for 
infusion 
43123 Moxifloxacin 
400mg/250ml 
solution for 
infusion bottles 
Moxifloxacin 
hydrochloride 
1.6mg/1ml Solution for 
infusion 
61850 Levofloxacin 
500mg tablets (A 
A H 
Pharmaceuticals 
Ltd) 
Levofloxacin 
hemihydrate 
500mg Tablet 
6306 Moxifloxacin 
400mg tablets 
Moxifloxacin 
hydrochloride 
400mg Tablet 
21487 Fosfomycin 3g 
granules sachets 
Fosfomycin 
Trometamol 
3g Sachets 
27986 Monuril 2g 
Paediatric sachet 
(Pharmax Ltd) 
Fosfomycin 2g Paediatric Sachet 
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12379 Monuril 3g 
Sachets (Pharmax 
Ltd) 
Fosfomycin 3g Sachets 
26113 Fosfomycin 2g 
Sachets 
Fosfomycin 2g Sachets 
46915 Co-amoxiclav 
250mg/125mg 
tablets (Zentiva) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
65056 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
54796 Amoxicillin 
250mg capsules 
(Boston 
Healthcare Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
2174 Amoxil 3g oral 
powder sachets 
sucrose free 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
3gram Powder 
34679 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Actavis UK 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
1140 Amoxicillin 3g 
oral powder 
Amoxicillin 
trihydrate 
3gram Powder 
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sachets sugar 
free 
40243 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Actavis UK 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
829 Co-amoxiclav 
250mg/125mg 
dispersible 
tablets sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Dispersible tablet 
29337 Amoxicillin 
125mg/5ml Oral 
solution (Neo 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
55394 Amoxicillin 
500mg capsules 
(Wockhardt UK 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
50742 Co-amoxiclav 
500mg/125mg 
tablets (Actavis 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
28882 Amoxicillin 
250mg Capsule 
(Crosspharma 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
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641 Co-amoxiclav 
500mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
68545 Amoxicillin 1g 
powder for 
solution for 
injection vials (A 
A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
sodium 
1gram Powder for 
solution for 
injection 
33706 Amoxicillin 
500mg capsules 
(Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
17746 Amoxicillin 
375mg soluble 
tablets 
Amoxicillin 
Trihydrate 
375mg Soluble Tablet 
53627 Amoxicillin 
500mg capsules 
(Accord 
Healthcare Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
24396 Flemoxin 750mg 
Soluble tablet 
(Paines & Byrne 
Ltd) 
Amoxicillin 
Trihydrate 
750mg Soluble Tablet 
49321 Augmentin 
625mg tablets 
(Sigma 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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Pharmaceuticals 
Plc) 
59588 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
54808 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
44154 Co-amoxiclav 
500mg/125mg 
tablets (Zentiva) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
52820 Amoxicillin 
500mg capsules 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
42227 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
36054 Amoxicillin 
125mg/5ml oral 
suspension sugar 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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free (Almus 
Pharmaceuticals 
Ltd) 
2171 Amoxil 
125mg/1.25ml 
paediatric oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
100mg/1ml Oral suspension 
22438 Amoram 
250mg/5ml oral 
suspension (LPC 
Medical (UK) Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
59481 Amoxicillin 
250mg capsules 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
58494 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Colorama 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
44854 Amoxicillin 
500mg Capsule 
(Lagap) 
Amoxicillin 
trihydrate 
500mg Capsule 
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42809 Amoxicillin 
250mg Capsule (C 
P 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
59112 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
14386 Galenamox 
125mg/5ml oral 
suspension 
(Galen Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
63911 Amoxicillin 
250mg capsules 
(Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
54591 Co-amoxiclav 
500mg/125mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
17509 Amoxicillin 1g 
powder for 
solution for 
injection vials 
Amoxicillin 
sodium 
1gram Powder for 
solution for 
injection 
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24005 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
60134 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
35191 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials 
(Teva UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
38684 Amoxicillin 
500mg Capsule (C 
P 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
585 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
41090 Amoxicillin 
250mg/5ml oral 
suspension 
(Almus 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
  
591 
 
Pharmaceuticals 
Ltd) 
20432 Clavulanic acid 
57mg with 
amoxicillin 
400mg/5ml sugar 
free suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
57mg + 
400mg/5ml 
Suspension 
Sugar-free 
64986 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials (A 
A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
27725 Amoxicillin 
250mg/5ml oral 
suspension (Teva 
UK Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
25370 Ranclav 375mg 
tablets (Ranbaxy 
(UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
51536 Amoxicillin 
250mg capsules 
(Milpharm Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
33699 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (IVAX 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
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Pharmaceuticals 
UK Ltd) 
63063 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
30783 Co-amoxiclav 
250mg/125mg 
tablets (Ranbaxy 
(UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
34885 Amoxicillin 
500mg Capsule 
(DDSA 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
56591 Augmentin-Duo 
400/57 oral 
suspension 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
33840 Amoxicillin 
500mg powder 
for solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium 
500mg Powder for 
solution for 
injection 
31801 Amoxicillin 
500mg capsules 
(Sandoz Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
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30743 Amoxicillin 
250mg capsules 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
52666 Augmentin 
250/62 SF oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
34232 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
11613 Amix 250 
capsules 
(Ashbourne 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
29356 Co-amoxiclav 
500mg/125mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
13239 Clavulanic acid 
125mg with 
Amoxicillin 
500mg tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
125mg+500mg Tablets 
  
594 
 
30786 Co-amoxiclav 
250mg/125mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
54271 Amoxicillin 
250mg capsules 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
37755 Amoxicillin 
250mg/5ml Oral 
suspension 
(Sandoz Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
54780 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
17121 Clavulanic acid 
100mg with 
amoxicillin 
500mg/vial 
injection 
Potassium 
Clavulanate/Amo
xicillin Sodium 
100mg + 
500mg/vial 
Injection 
31014 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Mylan Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
  
595 
 
5341 Augmentin-Duo 
400/57 oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
33110 Amrit 250mg/5ml 
Liquid (BHR 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
47184 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
29474 Amoxicillin 
1000mg with 
clavulanic acid 
100mg/vial 
injection 
Potassium 
Clavulanate/Amo
xicillin Sodium 
1g + 200mg/vial Injection 
51194 Augmentin-Duo 
400/57 oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
51678 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Almus 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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Pharmaceuticals 
Ltd) 
61207 Amoxicillin 
125mg/5ml oral 
suspension 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
24819 Amoxil 500mg 
powder for 
solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium 
500mg Powder for 
solution for 
injection 
439 Amoxicillin with 
Clavulanic acid 
dispersible 
tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
 
Dispersible Tablet 
6687 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
62 Amoxicillin 
125mg/5ml oral 
suspension 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
13285 Amoxicillin 
125mg / 
Clavulanic acid 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
125mg + 
31mg/5ml 
Oral Suspension 
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31mg/5ml oral 
suspension 
49683 Augmentin 
625mg tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
47640 Amoxicillin 
500mg capsules 
(Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
13216 Amoxicillin 
500mg / 
Clavulanic acid 
125mg tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
500mg+125mg Tablets 
63452 Co-amoxiclav 
875mg/125mg 
tablets (Creo 
Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
875mg + 125mg Tablet 
25484 Amoxicillin 
250mg capsules 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
29353 Co-amoxiclav 
500mg/125mg 
tablets (Teva UK 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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65958 Amoxicillin 
500mg capsules 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
500mg Capsule 
33165 Amoxicillin 
250mg/5ml oral 
suspension (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
29858 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Sandoz Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
54222 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
64355 Amoxicillin 
125mg/5ml oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
16612 Clavulanic acid 
62mg with 
amoxicillin 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
62mg + 
250mg/5ml 
Suspension 
Sugar-free 
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250mg/5ml sugar 
free suspension 
33701 Co-amoxiclav 
500mg/125mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
34638 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Teva UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
14396 Galenamox 
500mg capsules 
(Galen Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
62686 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Pharma-z Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
51637 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
55312 Co-amoxiclav 
250mg/125mg 
tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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15290 Lansoprazole 
with amoxicillin 
and 
clarithromycin 
30mg + 500mg + 
500mg Triple 
pack 
Amoxicillin 
Trihydrate/Lanso
prazole/Clarithro
mycin 
30mg + 500mg + 
500mg 
Triple Pack 
4582 Amoxicillin 
750mg soluble 
tablets 
Amoxicillin 
Trihydrate 
750mg Soluble Tablet 
524 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
54185 Amoxicillin 
250mg capsules 
(Wockhardt UK 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
42815 Amoxicillin 
250mg/5ml 
Mixture (Celltech 
Pharma Europe 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
49656 Augmentin 
625mg tablets 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
33109 Amrit 125mg/5ml 
Liquid (BHR 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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Pharmaceuticals 
Ltd) 
15148 Amoxil 500mg 
Dispersible tablet 
(SmithKline 
Beecham Plc) 
Amoxicillin 
Trihydrate 
500mg Dispersible Tablet 
17282 Almodan 
125mg/5ml syrup 
(Teva UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
55626 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
43548 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
509 Augmentin 
625mg tablets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
28874 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (IVAX 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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Pharmaceuticals 
UK Ltd) 
53942 Amoxicillin 
125mg / 
Clavulanic acid 
62.5mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
  
34734 Co-amoxiclav 
250mg/125mg 
tablets (Teva UK 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
45317 Amoxicillin 
250mg/5ml Oral 
solution (Neo 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
34775 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Teva UK Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
17711 Amopen 500mg 
Capsule 
(Yorkshire 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
59042 Amoxicillin 
250mg capsules 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
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32910 Co-amoxiclav 
500mg/125mg 
tablets (Sandoz 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
59592 Amoxicillin 
500mg capsules 
(Pfizer Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
23967 Amoxicillin 
250mg capsules 
(Teva UK Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
58771 Amoxicillin 
250mg capsules 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate 
250mg Capsule 
4010 Amoxil 750mg 
Sachets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
Trihydrate 
750mg Sachets 
12378 Amoram 
125mg/5ml oral 
suspension (LPC 
Medical (UK) Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
1746 Amoxicillin 
500mg powder 
for solution for 
injection vials 
Amoxicillin 
sodium 
500mg Powder for 
solution for 
injection 
54324 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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sugar free 
(Actavis UK Ltd) 
34297 Co-amoxiclav 
250mg/125mg 
tablets (Mylan 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
3669 Amoxymed 
250mg Capsule 
(Medipharma 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
54452 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
30705 Co-amoxiclav 
500mg/125mg 
tablets (Mylan 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
13848 Amoxicillin 
125mg sugar free 
powder 
Amoxicillin 
Trihydrate 
125mg Powder Sugar-
free 
569 Augmentin 
250/62 SF oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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52122 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
23740 Amoxicillin 
500mg capsules 
(Mylan Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
34680 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
34238 Amoxicillin 1g 
powder for 
solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium 
1gram Powder for 
solution for 
injection 
58205 Amoxicillin 
500mg powder 
for solution for 
injection vials (A 
A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
sodium 
500mg Powder for 
solution for 
injection 
577 Co-amoxiclav 
500mg/100mg 
powder for 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
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solution for 
injection vials 
50279 Augmentin 
625mg tablets 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
49374 Augmentin 
375mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
7364 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
50446 Co-amoxiclav 
250mg/125mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
24150 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
28592 Amoxicillin 
500mg with 
clavulanic acid 
Potassium 
Clavulanate/Amo
xicillin Sodium 
500mg + 
100mg/vial 
Injection 
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100mg/vial 
injection 
51164 Augmentin 
125/31 SF oral 
suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
59879 Amoxicillin 
500mg capsules 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate 
500mg Capsule 
42545 Amoxicillin 
125mg/5ml oral 
suspension 
(Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
52771 Amoxicillin 
500mg capsules 
(Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
55527 Amoxicillin 
500mg capsules 
(Boston 
Healthcare Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
485 Amoxicillin 
125mg/1.25ml 
oral suspension 
paediatric 
Amoxicillin 
trihydrate 
100mg/1ml Oral suspension 
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18786 Amix 500 
capsules 
(Ashbourne 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
26262 Zoxycil 500mg 
Capsule (Trinity 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
40168 Amoxicillin 3g 
oral powder 
sachets sugar 
free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
3gram Powder 
61407 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Colorama 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
2153 Amoxil 
125mg/5ml syrup 
sucrose free 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
48038 Amoxicillin 
125mg/5ml oral 
suspension (Kent 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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Pharmaceuticals 
Ltd) 
51623 Co-amoxiclav 
250mg/125mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
4154 Amoxil fiztab 
125mg Tablet 
(Bencard) 
Amoxicillin 
Trihydrate 
125mg Tablet 
22415 Amoram 500mg 
capsules (LPC 
Medical (UK) Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
22016 Almodan 
125mg/5ml Oral 
solution (Berk 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
46918 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
48683 Augmentin 
375mg tablets 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
62332 Co-amoxiclav 
875mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
875mg + 125mg Tablet 
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58057 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Sandoz Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
37304 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
51382 Amoxicillin 
250mg/5ml oral 
suspension 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
14407 Galenamox 
250mg/5ml oral 
suspension 
(Galen Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
49610 Co-amoxiclav 
500mg/125mg 
tablets (Medreich 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
28870 Amoxicillin 
125mg/5ml oral 
suspension (Teva 
UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
  
611 
 
32622 Amoxicillin 
125mg/5ml oral 
suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
49065 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
32872 Amoxicillin 
250mg Capsule 
(Mepra-Pharm) 
Amoxicillin 
trihydrate 
250mg Capsule 
67466 Co-amoxiclav 
500mg/125mg 
tablets (Brown & 
Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
33383 Amoxicillin 3g 
oral powder 
sachets sugar 
free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
3gram Powder 
49063 Augmentin 
375mg tablets 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
11634 Amix 125 oral 
suspension 
(Ashbourne 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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Pharmaceuticals 
Ltd) 
33690 Amoxicillin 
125mg/5ml oral 
suspension (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
847 Amoxil 500mg 
capsules 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
21829 Zoxycil 250mg 
Capsule (Trinity 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
28871 Co-amoxiclav 
250mg/125mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
65215 Co-amoxiclav 
250mg/125mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
42732 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Almus 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
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Pharmaceuticals 
Ltd) 
57833 Amoxil 500mg 
capsules 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
500mg Capsule 
870 Amoxicillin 
250mg sugar free 
chewable tablets 
Amoxicillin 
Trihydrate 
250mg Chewable Tablets 
Sugar-free 
33696 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
55018 Amoxicillin 
250mg/5ml oral 
suspension 
(Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
48147 Co-amoxiclav 
250mg/125mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
2507 Augmentin 
375mg 
dispersible 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Dispersible tablet 
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(GlaxoSmithKline 
UK Ltd) 
40148 Co-amoxiclav 
500mg/125mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
56578 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
598 Amoxicillin 
250mg powder 
for solution for 
injection vials 
Amoxicillin 
sodium 
250mg Powder for 
solution for 
injection 
399 Augmentin 
375mg tablets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
503 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
1391 Amoxicillin 
250mg / 
Clavulanic acid 
125mg tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
250mg + 125mg Tablets 
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34855 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
43229 Amoxicillin 
125mg/5ml Oral 
suspension 
(Sandoz Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
31286 Amoxymed 
125mg/5ml Oral 
solution 
(Medipharma 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
58097 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
53609 Co-amoxiclav 
500mg/125mg 
tablets (APC 
Pharmaceuticals 
& Chemicals 
(Europe) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
60034 Co-amoxiclav 
250mg/125mg 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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tablets (DE 
Pharmaceuticals) 
9925 Clavulanic acid 
125mg with 
Amoxicillin 
250mg tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
125mg + 250mg Tablets 
7737 Amoxil fiztab 
500mg Tablet 
(Bencard) 
Amoxicillin 
Trihydrate 
500mg Tablet 
30745 Amoxicillin 
250mg capsules 
(Mylan Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
34384 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
62786 Amoxicillin 
250mg powder 
for solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium 
250mg Powder for 
solution for 
injection 
68408 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free (Brown 
& Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
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65031 Amoxicillin 
250mg/5ml oral 
suspension 
(Crescent Pharma 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
24203 Respillin 250mg 
Capsule (OPD 
Pharm) 
Amoxicillin 
trihydrate 
250mg Capsule 
52857 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
32640 Amoxicillin 
250mg/5ml oral 
suspension (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
33343 Amoxicillin 
250mg capsules 
(Actavis UK Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
34857 Amoxicillin 
125mg/5ml oral 
suspension 
(Actavis UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
34001 Amoxicillin 
500mg capsules 
(Teva UK Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
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42822 Amoxicillin 
125mg/5ml 
Mixture (Celltech 
Pharma Europe 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
34972 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
19209 Co-amoxiclav 
250mg/125mg 
tablets (Actavis 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
1722 Amoxicillin 
500mg 
dispersible 
tablets 
Amoxicillin 
Trihydrate 
500mg Dispersible Tablet 
31535 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Mylan Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
40320 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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59153 Amoxicillin 
250mg capsules 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
250mg Capsule 
2281 Amoxicillin 
500mg sugar free 
chewable tablets 
Amoxicillin 
Trihydrate 
500mg Chewable Tablets 
Sugar-free 
56884 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
33570 Amoxicillin 
250mg/5ml 
Mixture 
(Crosspharma 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
67694 Co-amoxiclav 
250mg/125mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
62597 Augmentin-Duo 
400/57 oral 
suspension 
(Mawdsley-
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
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Brooks & 
Company Ltd) 
7636 Amoxicillin 
250mg / 
Clavulanic acid 
62mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
250mg + 
62mg/5ml 
Suspension 
427 Amoxicillin 
250mg/5ml oral 
suspension 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
42485 Clavulanic acid 
62mg with 
amoxicillin 
250mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
62mg + 
250mg/5ml 
Oral Suspension 
61906 Amoxicillin 
500mg capsules 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
35570 Amoxicillin 
500mg Capsule 
(Crosspharma 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
29697 Amopen 
125mg/5ml 
Liquid (Yorkshire 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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21963 Almodan 
250mg/5ml Oral 
solution (Berk 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
17099 Amoxil 1g 
powder for 
solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium 
1gram Powder for 
solution for 
injection 
30528 Amoxicillin 
250mg capsules 
(Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
1812 Amoxil 
250mg/5ml syrup 
sucrose free 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
59432 Amoxicillin 
250mg capsules 
(Accord 
Healthcare Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
57178 Amoxicillin 3g 
oral powder 
sachets sugar 
free (Mawdsley-
Amoxicillin 
trihydrate 
3gram Powder 
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Brooks & 
Company Ltd) 
53078 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
68416 Amoxicillin 
500mg capsules 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
50002 Amoxicillin 
125mg/5ml oral 
suspension 
(Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
34760 Amoxicillin 
250mg/5ml oral 
suspension 
(Actavis UK Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
1638 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
62377 Co-amoxiclav 
500mg/125mg 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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tablets (Creo 
Pharma Ltd) 
61299 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
51436 Amoxil 500mg 
capsules 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
33692 Amoxicillin 
500mg capsules 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
52207 Augmentin 
625mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
28875 Amoxicillin 
125mg/5ml oral 
suspension 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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52058 Amoxicillin 
500mg capsules 
(Medreich Plc) 
Amoxicillin 
trihydrate 
500mg Capsule 
10771 Amoxil 250mg 
powder for 
solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium 
250mg Powder for 
solution for 
injection 
62102 Amoxicillin 
250mg/5ml oral 
suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
5662 Amoxicillin 
500mg / 
Clarithromycin 
500mg / 
Lansoprazole 
30mg triple pack 
Amoxicillin 
Trihydrate/Lanso
prazole/Clarithro
mycin 
500mg + 500mg + 
30mg 
Triple Pack 
58803 Co-amoxiclav 
250mg/125mg 
tablets (APC 
Pharmaceuticals 
& Chemicals 
(Europe) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
9343 Amoxicillin 
750mg sugar free 
powder 
Amoxicillin 
Trihydrate 
750mg Powder Sugar-
free 
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33693 Co-amoxiclav 
250mg/125mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
49048 Augmentin 
375mg tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
41835 Amoxicillin 
125mg Powder 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
Trihydrate 
125mg Powder 
65095 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
11433 Clarithromycin 
500mg with 
lansoprazole 
30mg and 
amoxicillin 
500mg triple pack 
Amoxicillin 
Trihydrate/Lanso
prazole/Clarithro
mycin 
500mg + 30mg + 
500mg 
Triple Pack 
415 Augmentin 
125/31 SF oral 
suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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(GlaxoSmithKline 
UK Ltd) 
66650 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
34042 Amoxicillin 
250mg capsules 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
54708 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
49590 Amoxil 500mg 
capsules (Lexon 
(UK) Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
27714 Amrit 250mg 
Capsule (BHR 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
33112 Amrit 500mg 
Capsule (BHR 
Amoxicillin 
trihydrate 
500mg Capsule 
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Pharmaceuticals 
Ltd) 
8906 Amoxicillin 
125mg / 
Clavulanic acid 
31mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
125mg + 
31mg/5ml 
Suspension 
34493 Co-amoxiclav 
500mg/125mg 
tablets (Ranbaxy 
(UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
22015 Respillin 
125mg/5ml Oral 
solution (OPD 
Pharm) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
34435 Amoxicillin 
250mg Capsule 
(DDSA 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
18930 Flemoxin 375mg 
Soluble tablet 
(Paines & Byrne 
Ltd) 
Amoxicillin 
Trihydrate 
375mg Soluble Tablet 
48 Amoxicillin 
500mg capsules 
Amoxicillin 
trihydrate 
500mg Capsule 
10200 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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545 Co-amoxiclav 
250mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
59740 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
66905 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
21775 Clavulanic acid 
31mg with 
amoxicillin 
125mg/5ml sugar 
free oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
31mg + 
125mg/5ml 
Suspension 
Sugar-free 
59908 Co-amoxiclav 
500mg/125mg 
tablets (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
55047 Amoxicillin 
125mg/5ml oral 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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suspension 
(Sandoz Ltd) 
65533 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(CST Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
24093 Clavulanic acid 
with amoxicillin 
dispersible 
tablets 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
 
Dispersible Tablet 
21845 Almodan 
250mg/5ml Oral 
solution (Berk 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
54491 Amoxicillin 
250mg capsules 
(Bristol 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
1637 Amoxil fiztab 
250mg Tablet 
(Bencard) 
Amoxicillin 
Trihydrate 
250mg Tablet 
62762 Amoxicillin 
250mg/5ml oral 
suspension (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
21799 Almodan 250mg 
Capsule (Berk 
Amoxicillin 
trihydrate 
250mg Capsule 
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Pharmaceuticals 
Ltd) 
24200 Respillin 500mg 
Capsule (OPD 
Pharm) 
Amoxicillin 
trihydrate 
500mg Capsule 
54725 Amoxicillin 
500mg capsules 
(Milpharm Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
62074 Amoxicillin 
250mg/5ml oral 
suspension 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
63582 Amoxicillin 
125mg/5ml oral 
suspension 
(Crescent Pharma 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
53924 Amoxicillin 
250mg/5ml oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
50595 Augmentin 
125/31 SF oral 
suspension 
(Mawdsley-
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
  
631 
 
Brooks & 
Company Ltd) 
15192 Amoxicillin 
400mg / 
Clavulanic acid 
57mg/5ml sugar 
free oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
400mg + 
57mg/5ml 
Suspension 
Sugar-free 
21844 Amix 250 oral 
suspension 
(Ashbourne 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
68476 Amoxil 500mg 
capsules (Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
500mg Capsule 
31661 Amoxicillin 
250mg Capsule 
(Co-Pharma Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
34234 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Teva 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
28872 Amoxicillin 
125mg/5ml 
Mixture 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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(Crosspharma 
Ltd) 
34714 Amoxicillin 
250mg Capsule 
(Neo Laboratories 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
64794 Amoxicillin 
250mg capsules 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate 
250mg Capsule 
42240 Amoxicillin 
125mg/5ml Oral 
solution (Co-
Pharma Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
31423 Amopen 
250mg/5ml 
Liquid (Yorkshire 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
60281 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(CST Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
41818 Amoxicillin 
125mg/5ml Oral 
solution (Berk 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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67771 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
(PLIVA Pharma 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
64357 Amoxicillin 
500mg capsules 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
500mg Capsule 
3742 Amoxicillin 
125mg sugar free 
chewable tablets 
Amoxicillin 
Trihydrate 
125mg Chewable Tablets 
Sugar-free 
26157 Amoxicillin 
500mg capsules 
(Actavis UK Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
66062 Amoxicillin 
125mg/5ml oral 
suspension sugar 
free (Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
41734 Amoxicillin 3g 
Powder (Actavis 
UK Ltd) 
Amoxicillin 
trihydrate 
3gram Powder 
60027 Amoxicillin 
250mg/5ml oral 
suspension sugar 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
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free (DE 
Pharmaceuticals) 
34852 Amoxicillin 
500mg capsules 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
133 Amoxil 250mg 
capsules 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
24006 Clavulanic acid 
31mg with 
amoxcillin 
125mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
31mg + 
125mg/5ml 
Oral Suspension 
55499 Amoxicillin 
250mg/5ml oral 
suspension 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
45267 Amoxicillin 
250mg Capsule 
(Regent 
Laboratories Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
33222 Amoxicillin 
250mg Capsule 
(Lagap) 
Amoxicillin 
trihydrate 
250mg Capsule 
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19414 Co-amoxiclav 
250mg/125mg 
tablets (Sandoz 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
27681 Ranclav 
125mg/31mg/5m
l SF oral 
suspension 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
21827 Almodan 500mg 
Capsule (Berk 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
56561 Amoxicillin 
125mg/5ml oral 
suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
57081 Co-amoxiclav 
500mg/125mg 
tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
22017 Respillin 
125mg/5ml Oral 
solution (OPD 
Pharm) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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17852 Augmentin 
Intravenous 
600mg powder 
for solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
54732 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
56223 Amoxicillin 
250mg/5ml oral 
suspension 
(Sandoz Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
53996 Co-amoxiclav 
500mg/125mg 
tablets 
(Aurobindo 
Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
60267 Amoxicillin 
250mg/5ml oral 
suspension (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
59391 Amoxicillin 
125mg/5ml oral 
suspension (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
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58053 Amoxicillin 
250mg/5ml oral 
suspension sugar 
free (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
54052 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
56700 Amoxil 500mg 
capsules 
(Necessity 
Supplies Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
52685 Amoxicillin 
125mg/5ml oral 
suspension 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
57966 Amoxicillin 
250mg capsules 
(Medreich Plc) 
Amoxicillin 
trihydrate 
250mg Capsule 
66747 Co-amoxiclav 
250mg/125mg 
tablets (Brown & 
Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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244 Augmentin 
Intravenous 1.2g 
powder for 
solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
57886 Amoxil 500mg 
capsules (Stephar 
(U.K.) Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
34912 Amoxicillin 
500mg Capsule 
(Neo Laboratories 
Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
28130 Amoxicillin 3g 
oral powder 
sachets sugar 
free (Teva UK Ltd) 
Amoxicillin 
trihydrate 
3gram Powder 
14371 Galenamox 
250mg capsules 
(Galen Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
30498 Amopen 250mg 
Capsule 
(Yorkshire 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
22029 Amiclav 
250mg/125mg 
tablets 
(Ashbourne 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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Pharmaceuticals 
Ltd) 
33689 Amoxicillin 
250mg/5ml oral 
suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
40238 Amoxicillin 
250mg/5ml 
Mixture (Mepra-
Pharm) 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
9243 Amoram 250mg 
capsules (LPC 
Medical (UK) Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
48006 Amoxicillin 
250mg capsules 
(Sandoz Ltd) 
Amoxicillin 
trihydrate 
250mg Capsule 
50341 Co-amoxiclav 
500mg/125mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
23238 Amoxicillin 
125mg/5ml oral 
suspension (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate 
25mg/1ml Oral suspension 
62442 Amoxicillin 
250mg/5ml oral 
suspension sugar 
Amoxicillin 
trihydrate 
50mg/1ml Oral suspension 
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free (Waymade 
Healthcare Plc) 
9 Amoxicillin 
250mg capsules 
Amoxicillin 
trihydrate 
250mg Capsule 
29463 Amoxicillin 
500mg capsules 
(IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate 
500mg Capsule 
13262 Amoxicillin 
250mg / 
Clavulanic acid 
62mg/5ml oral 
suspension 
Amoxicillin 
Trihydrate/Potass
ium Clavulanate 
250mg + 
62mg/5ml 
Oral Suspension 
46915 Co-amoxiclav 
250mg/125mg 
tablets (Zentiva) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
65056 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
829 Co-amoxiclav 
250mg/125mg 
dispersible 
tablets sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Dispersible tablet 
50742 Co-amoxiclav 
500mg/125mg 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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tablets (Actavis 
UK Ltd) 
641 Co-amoxiclav 
500mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
59588 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
54808 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
44154 Co-amoxiclav 
500mg/125mg 
tablets (Zentiva) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
42227 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
58494 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Colorama 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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Pharmaceuticals 
Ltd) 
54591 Co-amoxiclav 
500mg/125mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
24005 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
60134 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
35191 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials 
(Teva UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
64986 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials (A 
A H 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
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Pharmaceuticals 
Ltd) 
63063 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
30783 Co-amoxiclav 
250mg/125mg 
tablets (Ranbaxy 
(UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
29356 Co-amoxiclav 
500mg/125mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
30786 Co-amoxiclav 
250mg/125mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
54780 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
47184 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
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(Wockhardt UK 
Ltd) 
51678 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
6687 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
63452 Co-amoxiclav 
875mg/125mg 
tablets (Creo 
Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
875mg + 125mg Tablet 
29353 Co-amoxiclav 
500mg/125mg 
tablets (Teva UK 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
33701 Co-amoxiclav 
500mg/125mg 
tablets (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
62686 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Pharma-z Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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51637 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
55312 Co-amoxiclav 
250mg/125mg 
tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
524 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
43548 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
28874 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
34734 Co-amoxiclav 
250mg/125mg 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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tablets (Teva UK 
Ltd) 
32910 Co-amoxiclav 
500mg/125mg 
tablets (Sandoz 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
54324 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Actavis UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
34297 Co-amoxiclav 
250mg/125mg 
tablets (Mylan 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
54452 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
30705 Co-amoxiclav 
500mg/125mg 
tablets (Mylan 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
34680 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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(Ranbaxy (UK) 
Ltd) 
577 Co-amoxiclav 
500mg/100mg 
powder for 
solution for 
injection vials 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
7364 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
50446 Co-amoxiclav 
250mg/125mg 
tablets (Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
61407 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Colorama 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
51623 Co-amoxiclav 
250mg/125mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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46918 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
62332 Co-amoxiclav 
875mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
875mg + 125mg Tablet 
37304 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
49610 Co-amoxiclav 
500mg/125mg 
tablets (Medreich 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
67466 Co-amoxiclav 
500mg/125mg 
tablets (Brown & 
Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
28871 Co-amoxiclav 
250mg/125mg 
tablets (IVAX 
Pharmaceuticals 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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65215 Co-amoxiclav 
250mg/125mg 
tablets (Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
48147 Co-amoxiclav 
250mg/125mg 
tablets (Almus 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
40148 Co-amoxiclav 
500mg/125mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
56578 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
58097 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
53609 Co-amoxiclav 
500mg/125mg 
tablets (APC 
Pharmaceuticals 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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& Chemicals 
(Europe) Ltd) 
60034 Co-amoxiclav 
250mg/125mg 
tablets (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
68408 Co-amoxiclav 
400mg/57mg/5m
l oral suspension 
sugar free (Brown 
& Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
34972 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Sandoz Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
19209 Co-amoxiclav 
250mg/125mg 
tablets (Actavis 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
40320 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Ranbaxy (UK) 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
56884 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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(Phoenix 
Healthcare 
Distribution Ltd) 
67694 Co-amoxiclav 
250mg/125mg 
tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
1638 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
62377 Co-amoxiclav 
500mg/125mg 
tablets (Creo 
Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
61299 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
58803 Co-amoxiclav 
250mg/125mg 
tablets (APC 
Pharmaceuticals 
& Chemicals 
(Europe) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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33693 Co-amoxiclav 
250mg/125mg 
tablets (Kent 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
66650 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
sugar free 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
54708 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
34493 Co-amoxiclav 
500mg/125mg 
tablets (Ranbaxy 
(UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
10200 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
545 Co-amoxiclav 
250mg/125mg 
tablets 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
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59740 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free 
(Phoenix 
Healthcare 
Distribution Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
66905 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
(Wockhardt UK 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
59908 Co-amoxiclav 
500mg/125mg 
tablets (DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
65533 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
(CST Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
34234 Co-amoxiclav 
250mg/62mg/5m
l oral suspension 
sugar free (Teva 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
60281 Co-amoxiclav 
125mg/31mg/5m
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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l oral suspension 
(CST Pharma Ltd) 
67771 Co-amoxiclav 
1000mg/200mg 
powder for 
solution for 
injection vials 
(PLIVA Pharma 
Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
19414 Co-amoxiclav 
250mg/125mg 
tablets (Sandoz 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
57081 Co-amoxiclav 
500mg/125mg 
tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
54732 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(Mylan Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
53996 Co-amoxiclav 
500mg/125mg 
tablets 
(Aurobindo 
Pharma Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
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54052 Co-amoxiclav 
125mg/31mg/5m
l oral suspension 
(A A H 
Pharmaceuticals 
Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
66747 Co-amoxiclav 
250mg/125mg 
tablets (Brown & 
Burk UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
50341 Co-amoxiclav 
500mg/125mg 
tablets (Alliance 
Healthcare 
(Distribution) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
49321 Augmentin 
625mg tablets 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
56591 Augmentin-Duo 
400/57 oral 
suspension 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
52666 Augmentin 
250/62 SF oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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5341 Augmentin-Duo 
400/57 oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
51194 Augmentin-Duo 
400/57 oral 
suspension 
(Sigma 
Pharmaceuticals 
Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
49683 Augmentin 
625mg tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
49656 Augmentin 
625mg tablets 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
509 Augmentin 
625mg tablets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
569 Augmentin 
250/62 SF oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
50mg/1ml + 
12.5mg/1ml 
Oral suspension 
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50279 Augmentin 
625mg tablets 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
49374 Augmentin 
375mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
51164 Augmentin 
125/31 SF oral 
suspension 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
48683 Augmentin 
375mg tablets 
(Lexon (UK) Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
49063 Augmentin 
375mg tablets 
(DE 
Pharmaceuticals) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
2507 Augmentin 
375mg 
dispersible 
tablets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Dispersible tablet 
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399 Augmentin 
375mg tablets 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
62597 Augmentin-Duo 
400/57 oral 
suspension 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
80mg/1ml + 
11.4mg/1ml 
Oral suspension 
52207 Augmentin 
625mg tablets 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
500mg + 125mg Tablet 
49048 Augmentin 
375mg tablets 
(Waymade 
Healthcare Plc) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
250mg + 125mg Tablet 
415 Augmentin 
125/31 SF oral 
suspension 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
50595 Augmentin 
125/31 SF oral 
suspension 
(Mawdsley-
Brooks & 
Company Ltd) 
Amoxicillin 
trihydrate/Potassi
um clavulanate 
25mg/1ml + 
6.25mg/1ml 
Oral suspension 
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17852 Augmentin 
Intravenous 
600mg powder 
for solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
500mg + 100mg Powder for 
solution for 
injection 
26658 AUGMENTIN 
DISPERSIBLE 
250/125 
   
244 Augmentin 
Intravenous 1.2g 
powder for 
solution for 
injection vials 
(GlaxoSmithKline 
UK Ltd) 
Amoxicillin 
sodium/Potassiu
m clavulanate 
1000mg + 200mg Powder for 
solution for 
injection 
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Appendix 19: Anticholinergic burden scale drug list 
 
ACB Score Drugs 
ACB 1 Alimemazine, Alprazolam, Alverine, Aripiprazole, 
Aesapine, Atenolol, Bupropion, Captopril, 
Cetrizine, Chlorathildon, Cimetidine, Clidinium, 
Clorazepate, Codeine, Colchicine, Desloratadine, 
Diazepam, Digoxin, Dipyridamole, Disopyramide, 
Fentanyl, Fluvoxamine, Furosemide, Haloperidol, 
Hydralazine, Hydrocortisone, Iioperidone, 
Isosorbide, Levocetirizine, Loperamide, 
Loratadine, Metoprolol, Morphine, Nifedipne, 
Paliperidone, Prednisone, Quinidine, Ranitdine, 
Risperidone, Theophylline, Trazodone, 
Triamterene, Venalfaxine, Warafin 
ACB 2 Amantadine, Belladonna, Carbamazepine, 
Cyclobenaprine, Cyproheptadine, Meperidine, 
Methotrimeprazine, Molindone, Nefopam, 
Pimozide, Loxapine, Oxcarbazepine 
ACB 3 Amitriptyline, Amoxapine, Atropine, 
Benztropine, Brompheniramine, Carbinoxamine, 
Chlorpheniramine, Chlorpromazine, Clemastine, 
Clomipramine, Clozapine, Darifenacin, 
Desparime, Dicyclomine, Dicycloverine, 
Dimenhydrinate, Diphenhydramine, Doxepin, 
Doxylamine, Fesoterodine, Flovaxate, 
Hydroxyzine, Hyoscyamine, Imipramine, 
Meclizine, Methocarbamol, Notriptyline, 
Olanzapine, Orphenadrine, Oxybutynin, 
Paroxetine, Perphenazine, Promethazine, 
Propantheline, Propiverine, Quetiapine, 
Scoplamine Hyoscine, Solifenacin, Thioridazine, 
Tolterodine, Triflluoperazine, Trihexyphidyl, 
Tripramine, Trospium 
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Appendix 20: OPCS-4 codes for urodynamic tests and imaging 
Urodynamic studies 
Medcode Readcode Read term 
2916 317..12 Urodynamic studies 
18036 317C.00 Urinary flow rate 
3411 7065100 Electromyography 
10876 3176 Residual urinary volume 
2622 7B2C600 Cystometry 
6716 317B.00 Other urodynamic tests 
18998 8HR6.00 Refer to Urodynamic studies 
64138 7P14300 Urodynamics NEC 
25001 R141800 [D]Electromyogram (EMG) abnormal 
14451 3117000 EMG - Electromyography normal 
55018 7P14100 Uroflowmetry NEC 
103500 3177 Uroflowmetry 
3632 3173.11 Urodynamic studies normal 
12169 3175 Detrusor reflex testing 
18018 3173000 Cystometry normal 
40731 3174000 Cystometry abnormal 
41472 3174.11 Urodynamic studies abnormal 
17629 7B2B600 Urethral catheterisation for urodynamics 
90890 7B2B700 Urodynamic studies using catheter 
103851 3178 Voided urinary volume 
103674 3179 Average urinary flow rate 
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72105 7B2C611 Cystometrogram 
103913 317F.00 Urinary flow time 
20399 7B45400 Urethral pressure measurement 
103615 317E.00 Urinary voiding total flow time 
104865 317D.00 Time to maximum urinary flow 
105951 317D.11 TQmax - Time to maximum urinary flow rate 
43903 561F.00 Fluoroscopy - urinary tract 
102094 561G.00 Fluoroscopy - female genital 
2916 317..12 Urodynamic studies 
 
Other imaging  
Medcode Read code Read term 
18951 8HQA.00 Referral for DXA scan of hip and spine 
59688 7P02400 Magnetic resonance imaging of spine 
14377 585E.00 US scan of bladder 
69075 7P09.00 Diagnostic imaging of genitourinary system 
89458 7P09z00 Diagnostic imaging of genitourinary system NOS 
89450 58D8.00 US scan of spine 
94660 7P09y00 Other specified diagnostic imaging of genitourinary system 
98923 7P0N.00 Other diagnostic imaging of genitourinary system 
95679 7P0Ny00 Other specified other diagn imaging of genitourinary system 
96882 58DR.00 Ultrasound scan of sacral spine 
100620 7P0Nz00 Other diagnostic imaging of genitourinary system NOS 
12850 7P06.00 Diagnostic imaging of pelvis 
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83486 7P06z00 Diagnostic imaging of pelvis NOS 
97118 7P05600 Ultrasound scan of inguinal region 
12871 7P06100 Ultrasound of pelvis 
49116 7P05.00 Diagnostic imaging of abdomen 
47119 7P05100 Ultrasound of abdomen 
93552 7P09700 Nuclear cystography 
89915 7P06y00 Other specified diagnostic imaging of pelvis 
56048 7P09400 Ultrasound of bladder 
93625 7P05y00 Other specified diagnostic imaging of abdomen 
97243 7P06200 Magnetic resonance imaging of pelvis 
70547 R135z00 [D]Genitourinary x-ray or scan abnormality NOS 
55989 R135.00 [D]Genitourinary x-ray or scan abnormality 
696 5856 U-S pelvic scan 
103473 585m.00 Ultrasound scan of abdomen and pelvis 
14218 567A.00 CAT scan - pelvis 
4754 54E..00 Cystography 
72665 7B2CC00 Micturating cystography 
3726 54E2.00 Cystography normal 
27020 54E7.00 Micturating cystography 
20285 54E3.00 Cystography abnormal 
36254 54EZ.00 Cystography NOS 
55118 57...16 Cystographic isotope studies 
68785 54E5.00 Percutaneous cystography 
60315 54E8.00 Intravenous cystography 
44411 54E1.00 Cystography requested 
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47180 54E4.00 Retrograde cystography 
56625 5736 Isotope static cystography 
89103 7B2CD00 High intensity focused ultrasound of bladder 
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Appendix 21: Read codes for specialist visits 
 
Visits to the urologist 
Medcode Read code Read term 
13644 8HVA.00 Private referral to urologist 
10895 ZL9GR00 Seen by urologist 
2568 8H5B.00 Referred to urologist 
104258 ZL9GR00 Seen by urologist 
22237 ZL1GS00 Under care of urologist 
10313 ZL5GP00 Referral to urologist 
26383 ZLD4M00 Discharge by urologist 
12038 8H2F.00 Admit urology emergency 
98108 9NJp.00 In-house urology discharge 
19726 ZLEQL00 Discharge from urology service 
16762 8HJF.00 Urology self-referral 
51881 9b81.00 Urology 
103547 8Hko.00 Referral to community urology service 
99551 9NJn.00 In-house urology first appointment 
97262 9NJn.00 In-house urology follow-up appointment 
6283 9N1I.00 Seen in urology clinic 
59482 U623.00 [X]Gastroenterol+urology device assoc with adverse incident 
13642 8HTb.00 Referral to male urology clinic 
31926 8H3K.00 Non-urgent urology admission 
30868 8H4W.00 Referral to urology special interest general practitioner 
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58609 ZG44.00 Advice on infective conditions in urology 
28449 8HMR.00 Listed for Urology admission 
 
Visits to the gynaecologist 
Medcode Readcode Read term 
16776 15...00 Gynaecological history 
48342 1J0J.00 Suspected gynaecological cancer 
48014 8H4V.00 Referral to gynaecology special interest GP 
10663 ZL5D200 Referral to gynaecologist 
60028 9NI4.00 Gynaecology outreach clinic 
32517 ZLE8200 Discharge from gynaecology service 
9966 ZL5D.00 Referral to obstetrician and gynaecologist 
99498 9Np4.00 Seen in fast track suspected gynaecological cancer clinic 
30253 159Z.00 H/O:gynaecological problem NOS 
25242 ZLD2X00 Discharge by obstetrician and gynaecologist 
91081 9NJP.00 In-house gynaecology follow-up appointment 
10175 159..00 H/O:gynaecological problem NOS 
19215 8H3B.00 Non-urgent gynaecol.admission 
6606 7E2Az11 Gynaecological examination under anaesthetic 
32693 ZLE8.00 Discharge from obstetrics and gynaecology service 
71562 8HKO.00 Gynaecological D.V. requested 
107526 9NJv.00 In-house gynaecology 
18646 ZLD2Y00 Discharge by gynaecologist 
11377 7H29211 Gynaecological laparoscopy NEC 
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88893 9NJN.00 In-house gynaecology first appointment 
61394 9b9S.00 Obstetrics and gynaecology 
20820 7130700 Subcutaneous mastectomy for gynaecomastia 
8353 K311011 Bilateral gynaecomastia 
35900 7D...11 Gynaecological operations of lower female genital tract 
6508 9N1J.00 Seen in gynaecology clinic 
107988 8T0B.00 Referral to paediatric gynaecology service 
16673 26B2.00 O/E - gynaecomastia 
21340 8HJ6.00 Gynaecological self-referral 
10643 ZL9B100 Seen by gynaecologist 
95358 9Ni7.00 DNA gynaecology special interest general practitioner clinic 
9631 ZL9B.00 Seen by obstetrician and gynaecologist 
16796 ZV72300 [V]Gynaecological examination 
13647 8HV7.00 Private referral to gynaecologist 
102348 26L..00 Gynaecologic examination 
64263 8HLO.00 Gynaecological D.V. done 
3150 K311000 Gynaecomastia 
21718 8L7..00 Gynaecological operation planned 
53711 9b9T.00 Gynaecology 
26012 ZL1C.00 Under care of obstetrician and gynaecologist 
2116 8H58.00 Gynaecological referral 
85845 8Hn1.00 Fast track referral for suspected gynaecological cancer 
107888 9Nic000 DNA fast track suspected gynaecological cancer clinic 
103854 8Hku.00 Referral to community gynaecology service 
43123 15Z..00 Gynaecological history NOS 
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103892 9b9T000 Gynaecological oncology 
2128 K311012 Unilateral gynaecomastia 
55061 4JRK.00 Gynaecology cytology screening test 
94231 9Nk2.00 Seen in urogynaecology clinic 
71064 9NJQ.00 In-house gynaecology discharged from care 
10172 ZL1C100 Under care of gynaecologist 
94652 K311200 Idiopathic gynaecomastia 
45816 7E...11 Gynaecological operations on upper female genital tract 
37793 4M4..00 FIGO staging of gynaecological malignancy 
6109 8H26.00 Admit gynaecological emergency 
  
  
669 
 
Appendix 22: Product code list for incontinence pads 
 
Prodcode Product name BNF code BNF header 
61097 Spring truss back pad sliding 71490300 Spring Truss Back Pad: 
Fixed Or Sliding 
29738 Long flanged plastic bag with foam pad, 
compatible with MK4 urinal system 0821 
32/38mm (S.G.& P.Payne Ltd) 
74130600 Plastic Bag With Foam 
Pads 
31659 Long flanged plastic bag with foam pad, 
compatible with MK4 urinal system 0822 45mm 
(S.G.& P.Payne Ltd) 
74130600 Plastic Bag With Foam 
Pads 
6273 Tena incontinence pad 60cm x 60cm (Molnlycke 
Health Care Ltd) 
74160000 Incontinence Pads 
6308 Tena incontinence pad 40cm x 60cm (Molnlycke 
Health Care Ltd) 
74160000 Incontinence Pads 
21021 Attends Cover Dri Plus incontinence pad 60cm x 
60cm (Procter & Gamble (Health & Beauty Care) 
Ltd) 
74160000 Incontinence Pads 
15806 Attends Cover Dri Super incontinence pad 60cm x 
60cm (Procter & Gamble (Health & Beauty Care) 
Ltd) 
74160000 Incontinence Pads 
9864 Robinson Plus incontinence pad 40cm x 60cm 
(Robinson Healthcare) 
74160000 Incontinence Pads 
19150 Attends Cover Dri Super incontinence pad 60cm x 
90cm (Procter & Gamble (Health & Beauty Care) 
Ltd) 
74160000 Incontinence Pads 
21174 Ecopad incontinence pad 58cm x 60cm (Warden 
Dressings Company) 
74160000 Incontinence Pads 
49019 Dansac Seals 070-30 30mm (Dansac Ltd) 75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
48298 Dansac Seals 070-20 20mm (Dansac Ltd) 75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
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49053 Dansac Seals 070-40 40mm (Dansac Ltd) 75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
50943 Adapt oval convex barrier ring 79602 30mm-
48mm (Hollister Ltd) 
75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
50838 Adapt oval convex barrier ring 79601 22mm-
38mm (Hollister Ltd) 
75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
49221 Dansac Seals 070-50 50mm (Dansac Ltd) 75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
50356 Adapt oval convex barrier ring 79603 38mm-
56mm (Hollister Ltd) 
75190000 Skin Protector 
(wafers,blankets,foam 
Pads,washers) 
28802 Ostomy foam pad WJ275-32-W 76mm diameter, 
32mm opening White (Jade-Euro-Med) 
75190100 Foam Pad 
31861 Ostomy foam pad WJ275-38-K 76mm diameter, 
38mm opening White (Jade-Euro-Med) 
75190100 Foam Pad 
31363 SoftPads skin protector SP101 (SASH) 75190100 Foam Pad 
37654 Ostomy foam pad WJ275-25-A 76mm diameter, 
25mm opening White (Jade-Euro-Med) 
75190100 Foam Pad 
  
  
671 
 
Appendix 23: Procedures and operations performed (HES data) 
 
 OPCS-4 Description 
SNS (Insertion of 
neurostimulator 
electroduces 
into peripheral 
nerve) 
In addition to 
one of the below 
OPCS-4 codes the 
following site 
code would be 
assigned: Z11.2 
Sacral nerve 
 
A70.1 Implantation of neurostimulator into peripheral nerve  
A70.2 Maintenance of neurostimulator in peripheral nerve  
A70.3 Removal of neurostimulator from peripheral nerve  
A70.4 Insertion of neurostimulator electrodes into peripheral 
nerve 
A70.8 Other specified neurostimulation of peripheral nerve 
A70.9 Unspecified neurostimulation of peripheral nerve 
Catheterisation M30.2 Endoscopic catheterisation of ureter 
M38.2 Cystostomy and insertion of suprapubic tube into bladder 
M47.2 Change of urethral catheter into bladder 
M47.3 Removal of urethral catheter from bladder 
M47.5 Maintenance of urethral catheter in bladder 
M47.8 Other specified urethral catheterisation of bladder 
M47.9 Unspecified urethral catheterisation of bladder 
M49.2 Change of suprapubic tube into bladder 
M49.3 Removal of suprapubic tube from bladder 
Other surgical 
procedures 
M51.8 Other specified combined abdominal and vaginal 
operations to support outlet of female bladder 
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M51.9 Unspecified combined abdominal and vaginal operations to 
support outlet of female bladder 
M52.8 Other specified abdominal operations to support outlet of 
female bladder 
M52.9 Unspecified abdominal operations to support outlet of 
female bladder 
M54.8 Other specified open operations on outlet of female 
bladder 
M54.9 Unspecified open operations on outlet of female bladder 
M57.8 Other specified other vaginal operations to support outlet 
of female bladder 
M57.9 Unspecified other vaginal operations to support outlet of 
female bladder 
Sphincter AUS M54.3 Removal of artificial urinary sphincter from outlet of female 
bladder 
M55.2 Implantation of artificial urinary sphincter into outlet of 
female bladder 
M60.3 Removal of artificial urinary sphincter from outlet of male 
bladder 
M64.2 Implantation of artificial urinary sphincter into outlet of 
male bladder 
Sphincterotomy M66.1 Endoscopic sphincterotomy of external sphincter of male 
bladder 
Urinary 
diversion 
M19.1 Construction of ileal conduit 
M19.2 Creation of urinary diversion to intestine NEC 
M19.4 Cutaneous ureterostomy NEC 
M19.8 Other specified urinary diversion 
M19.9 Unspecified urinary diversion 
Surgical 
procedure for 
M361 Caecocystoplasty 
M362 Ileocystoplasty 
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bladder 
enlargement 
M363 Colocystoplasty 
Urodynamics M474 Urodynamic studies using catheter 
U264 Urodynamics NEC 
Botox injection X85.1 (in 
conjuction with 
M43.4) 
Torsion dystonias and other involuntary movements drugs 
Band 1  
M49.5 (in 
conjuction with 
M43.4) 
Injection of therapeutic substance into bladder wall 
M43.4 (in 
conjuction with 
M49.5 or X85.1) 
Endoscopic injection of neurolytic substance into nerve of 
bladder 
Bladder 
Augmentation 
M36.1  Caecocystoplasty 
M36.2 Ileocystoplasty 
M36.3 Colocystoplasty 
M36.8 Other specified enlargement of bladder 
M36.9 Unspecified enlargement of bladder 
Sling Procedures 
/ Mid-urethral 
sling 
M52.1 Suprapubic sling operation 
M53.3 Introduction of tension-free vaginal tape 
M53.5 Partial removal of tension-free vaginal tape 
M53.6 Introduction of transobturator tape 
M55.6 Insertion of retropubic device for female stress urinary 
incontinence NEC 
Artificial Urinary 
Sphincter 
M55.2 Implantation of artificial urinary sphincter into outlet of 
female bladder 
M64.2 Implantation of artificial urinary sphincter into outlet of 
male bladder 
MRI Ultrasound 
Followed by: 
Y53.7 
Q20.6 Focused ultrasound to lesion of uterus 
U08.2 Ultrasound of abdomen 
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U09.2 Ultrasound of pelvis 
X-ray U08.3 Plain x-ray of abdomen 
CT Scan U08.1 Computed tomography of abdomen NEC 
U09.1 Computed tomography of pelvis 
Bulking agents M568 Other specified therapeutic endoscopic operations on 
outlet of female bladder 
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Appendix 24: ICD-10 codes for hospitalisations 
Chapter Description 
A418 Other specified sepsis 
A419 Sepsis, unspecified 
N110 Nonobstructive reflux-associated chronic pyelonephritis 
N111 Chronic obstructive pyelonephritis 
N130 Hydronephrosis with ureteropelvic junction obstruction 
N131 Hydronephrosis with ureteral stricture, not elsewhere classified 
N132 Hydronephrosis with renal and ureteral calculous obstruction 
N133 Other and unspecified hydronephrosis 
N134 Hydroureter 
N136 Pyonephrosis 
N137 Vesicoureteral-reflux-associated uropathy 
N138 Other obstructive and reflux uropathy 
N139 Obstructive and reflux uropathy, unspecified 
N170 Acute renal failure with tubular necrosis 
N171 Acute renal failure with acute cortical necrosis 
N172 Acute renal failure with medullary necrosis 
N178 Other acute renal failure 
N179 Acute renal failure, unspecified 
N181 Chronic kidney disease, stage 1 
N182 Chronic kidney disease, stage 2 
N183 Chronic kidney disease, stage 3 
N184 Chronic kidney disease, stage 4 
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N185 Chronic kidney disease, stage 5 
N189 Chronic kidney disease, unspecified 
N19X Unspecified kidney failure 
N200 Calculus of kidney 
N201 Calculus of ureter 
N202 Calculus of kidney with calculus of ureter 
N209 Urinary calculus, unspecified 
N210 Calculus in bladder 
N211 Calculus in urethra 
N218 Other lower urinary tract calculus 
N219 Calculus of lower urinary tract, unspecified 
N23X Unspecified renal colic 
N300 Acute cystitis 
N301 Interstitial cystitis (chronic) 
N302 Other chronic cystitis 
N308 Other cystitis 
N309 Cystitis, unspecified 
N310 Uninhibited neuropathic bladder, not elsewhere classified 
N311 Reflex neuropathic bladder, not elsewhere classified 
N312 Flaccid neuropathic bladder, not elsewhere classified 
N318 Other neuromuscular dysfunction of bladder 
N319 Neuromuscular dysfunction of bladder, unspecified 
N320 Bladder-neck obstruction 
N323 Diverticulum of bladder 
N324 Rupture of bladder, nontraumatic 
  
677 
 
N328 Other specified disorders of bladder 
N329 Bladder disorder, unspecified 
N341 Nonspecific urethritis 
N342 Other urethritis 
N343 Urethral syndrome, unspecified 
N390 Urinary tract infection, site not specified 
N391 Persistent proteinuria, unspecified 
N392 Orthostatic proteinuria, unspecified 
N393 Stress incontinence 
N394 Other specified urinary incontinence 
N398 Other specified disorders of urinary system 
N399 Disorder of urinary system, unspecified 
R32X Unspecified urinary incontinence 
R33X Retention of urine 
R34X Anuria and oliguria 
R35X Polyuria 
 
 
